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Chronic Obstructive Pulmonary Disease (COPD) is associated with comorbidities. 
Cardiovascular (CV) disease, cognitive impairment, dementia, and depression are 
common comorbidities in patients with COPD, leading to increased morbidity and 
mortality. However, there are considerable gaps in how these comorbidities are 
assessed, while the burden of others remains inadequately researched.  
This PhD applied several methodologies and used different databases to 1) explore 
whether circulating biomarkers from the blood (soluble Receptor for Advanced 
Glycation End-products - sRAGE) and urine (microalbuminuria) might have a role in 
COPD related to prognostication of CV risk (assessed by aortic stiffness and carotid 
intima-media thickness), 2) evaluate the prevalence and incidence of cognitive 
impairment and dementia, 3) examine the incident risk of depression, and 4) assess the 
risks of respiratory-related morbidities associated with antidepressant use in patients 
with COPD.  
Using data from a multisite UK study, sRAGE was not associated with aortic stiffness, 
carotid intima-media thickness, or CV disease in patients with COPD. However,  there 
was a weak direct association between sRAGE and spirometric lung function 
measures. Data from the same cohort also showed that urinary albumin creatinine ratio 
(UACR) was not strongly associated with physiological CV risk measures. 
Nevertheless, patients with COPD and either diabetes, ischaemic heart disease, or 
cerebrovascular disease have increased UACR, compared to patients without these 
comorbidities. Microalbuminuria was also prevalent in all patients with COPD.  
Using a large primary care database, this PhD demonstrates that patients with COPD 
have increased prevalence of cognitive impairment compared to subjects without 
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COPD, matched by age, gender and GP surgery. The incidence of cognitive 
impairment following COPD diagnosis was 23.1 per 1,000 person-years compared to 
16.3 per 1,000 person-years in subjects without COPD. However, the prevalence and 
incidence of dementia were less frequently recorded in patients with COPD compared 
to individuals without COPD, indicating the possibility of underdiagnosis of dementia 
and highlighting the need for systematic assessment. 
The incidence of depression was also greater following COPD diagnosis, compared to 
subjects without COPD, which indicates the need to stay alert and target accordingly. 
Antidepressant use was associated with increased risks of pneumonia and COPD 
exacerbations relative to periods of unexposed to antidepressants in patients with 
COPD, raising the concern of potential side-effects and adverse events.  
This thesis addresses several aspects of COPD comorbidities and contributes new 
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1.1 Definition of Chronic Obstructive Pulmonary Disease (COPD) 
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) defines chronic 
obstructive pulmonary disease (COPD) as “a common, preventable and treatable 
disease that is characterised by persistent respiratory symptoms and airflow limitation 
due to airway and/or alveolar abnormalities, usually caused by significant exposure 
to noxious particles or gases” [1]. The key characteristic of COPD – that is persistent 
airflow limitation - is caused by a mixture of small airway disease and parenchymal 
destruction [1]. COPD is a disabling disease that usually occurs and worsens over time. 
COPD is also associated with comorbidities, which have a significant impact on 
morbidity and mortality [1].  
The heterogeneity of COPD includes both chronic bronchitis and emphysema. Chronic 
bronchitis is defined clinically as the presence of cough and sputum for more than 
three months for two consecutive years, without any other condition causing sputum 
production [2]. Emphysema, meanwhile, is a pathological term refers to permanent 
enlargement of the airspace and destruction of the gas-exchanging surface (alveolar 
wall) distal to terminal bronchioles, leading to irreversible loss of elastic recoil [3].  
1.2 Risk factors for COPD 
Tobacco smoking is the primary environmental factor – especially in low and middle 
income class countries (LMICs) -  which increases the risk of COPD [1]. Compared 
to non-smokers, smokers are associated with increased prevalence of lung function 
abnormalities and a higher rate of COPD mortality [4, 5]. Indeed, tobacco smoking 
induces inflammation in the lung and its airway by provoking inflammatory cytokines 
and macrophages. It is, however, important to mention that less than 50% of smokers 
develop COPD, irrespective of the scale of smoking [6]. This implies that other factors 
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are contributing to the development of COPD [7]. It is evident that non-smokers 
account for a considerable proportion of patients with COPD. The Burden of 
Obstructive Lung Disease (BOLD) study, which collected data from 14 countries, 
indicated that non-smokers (n= 4,291) comprise 28% of all COPD cases, 33% of mild 
COPD, and 23% of moderate COPD and worse [8].  
Occupational exposures, which include fumes, chemicals, and organic/nonorganic 
dust, also contribute to the development of COPD [9, 10]. A recent UK population-
based study (n= 94, 551) identified several occupations (such as sculptors, gardeners, 
and warehouse workers) that were associated with amplified COPD risk among non-
smokers and non-asthmatics [11]. According to US population-based data collected 
from 9,823 subjects, occupational exposures account for 19% of all COPD cases, and 
31% of cases among lifelong non-smokers [12]. However, the risk from occupational 
exposures seems to be much more significant in LMICs. Therefore, it is important to 
take occupational history into account during respiratory assessment.  
Air pollution, which occurs as a result of industrial operations, vehicular traffic, and 
biomass fuels, also increases the risk of developing COPD [13, 14]. A recent large 
population-based study within the UK, including 303,887 subjects aged 40-69, showed 
that higher exposures to ambient air pollution were associated with reduced lung 
function and increased prevalence of COPD [15]. Current literature also suggests that 
about 3 billion people, especially in LMICs, rely on solid fuels (coal and biomass) as 
an energy source (e.g. cooking and/or heating) [16, 17], contributing to higher 
exposure to household air pollution (HAP), and therefore to COPD.  Indeed, in many 
countries, several studies have linked the exposure to solid fuel to increased risk of 
COPD [18-23]. A recent systematic review and meta-analysis involving 35 studies 
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(n=73,122) showed that exposure to HAP from biomass increases the risk of COPD 
by almost 3 times compared to non-biomass fuels [18]. A recent Chinese cohort study 
involving 277,838 people who never smoked demonstrated that solid fuel users were 
at increased risk of COPD compared to clean fuel users [24].  
Women are more likely to be predisposed to COPD through HAP, resulting from solid 
fuels exposures, especially in LMICs [25, 26]. The association – that is the risk of 
COPD - is more significant in women living in rural areas (OR:1.95; CI: 1.54 to 2.37) 
compared to women in urban areas (OR: 1.61; CI: 1.20 to 2.02), given the higher 
exposure to solid fuels [25].  This may be attributed to the considerable exposure to 
smoke from biomass fuels to women living in rural areas [27].     
The socioeconomic status (SES) has been considered as a strong determinant of health 
in a variety of diseases; one of which is COPD [28]. An analysis of three population-
based studies involving 11,042 participants (aged 35–95 years) demonstrated that 
lower SES was associated with higher odds of having COPD, following adjustments 
for confounders [29]. In the UK, primary care data from The Health Improvement 
Network (THIN) has also shown that the prevalence of COPD was greater amongst 
individuals with lower SES, compared to subjects with a higher SES [30].  
Genetic susceptibility to the development of COPD has been reported. Alpha-1 
antitrypsin deficiency is recognised as a cause of COPD [1]. Previous studies indicated 
that a low concentration of alpha-1 antitrypsin, defined as < 11 micromol/L, is 
associated with early onset of emphysema [31]. However, deficiency in alpha-1 
antitrypsin only accounts for a small proportion of COPD [32]; other genetic factors 
also contribute.  
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1.3 COPD symptoms  
Patients with COPD often present with several symptoms, such as dyspnoea 
(breathlessness), cough, sputum production, wheezing, and chest tightness [1]. 
Dyspnoea, either chronic or progressive, is considered the hallmark of COPD, defined 
as “a subjective experience of breathing discomfort that consists of qualitatively 
distinct sensations that vary in intensity” [33]. Dyspnoea is common in all COPD 
stages [34], and has been associated with worse clinical outcomes, including a higher 
risk of COPD exacerbation [34], frequent visit to primary care practice [34], reduced 
physical activity [35], and depression [36].  
A simple, validated method for the measurement of dyspnoea is by using the Medical 
Research Council (MRC) dyspnoea score (1 ─ 5;Table 1-1) [37, 38]. It is a 
unidimensional measure, where patients indicate how their breathlessness impacts on 
their everyday activity.  
Table 1-1. Medical Research Council (MRC) dyspnoea grades [39] 
Grade  Description 
1 Not troubled by breathlessness except on strenuous exercise 
2 Short of breath when hurrying or walking up a slight hill 
3 Walks slower than contemporaries on level ground because of 
breathlessness, or has to stop for breath when walking at own pace 
4 Stops for breath after walking about 100 m or after a few minutes on level 
ground 




1.4 COPD diagnosis  
According to the guideline produced by the National Institute for Health and Care 
Excellence (NICE), a diagnosis of COPD should be suspected in patients who have a 
risk factor (primarily a history of smoking in the high-income countries) and one or 
more of the aforementioned respiratory symptoms [40]. A COPD diagnosis is then 
confirmed by post-bronchodilator spirometry. The post-bronchodilator spirometric 
criterion of the airflow obstruction is defined as the ratio of forced expiratory volume 
in one second (FEV1)/forced vital capacity (FVC) of less than 70% [1, 40]. Spirometry 
is the most reproducible, cost-effective, non-invasive measure for airflow limitation. 
It is noteworthy that good quality spirometry measurements are essential in making a 
diagnosis and assessing disease progression and severity.   
1.4.1 COPD severity 
NICE and GOLD guidelines grade COPD airflow obstruction severity based on the 
reduction in FEV1 in those with the obstruction, and compare it to the individual’s 
reference values: age, sex, and height and ethnicity [1, 40]. The GOLD and NICE 




Table 1-2. GOLD and NICE classification of airflow limitation severity in COPD [1, 40].     
GOLD stage   Severity  FEV1% predicted  
GOLD 1 Mild  • FEV1/FVC < 0.70  
• FEV1 ≥80%  
GOLD 2 Moderate  • FEV1/FVC < 0.70  
• 50% ≤ FEV1<80 %  
GOLD 3 Severe  • FEV1/FVC < 0.70  
• 30% ≤ FEV1<50 %  
GOLD 4 Very severe  • FEV1/FVC < 0.70  
• FEV1 <30%  
FEV1: Forced expiratory volume in one second; FEV1/FVC: the ratio of forced expiratory volume in one second 
to forced vital capacity  
 
1.5 Epidemiology of COPD  
COPD presents a significant public health threat across the world. Its prevalence, 
incidence, as well as associated morbidity and mortality, have increased in recent years 
[41]. It is ranked as the 3rd leading cause of death worldwide [41]. The increased 
burden of COPD, especially in LMICs, is usually associated with the increased 
prevalence of smoking, whereas other factors (e.g. occupational and environmental) 
are common in LMICs [42]. 
1.5.1 Prevalence and Incidence of COPD 
There has been an increasing trend in COPD prevalence over the past decades. 
Adeloye et al. reported that the global prevalence of COPD (defined based on 
spirometry) increased from 10.7% (95% CI: 7.3 to 14.0%) in 1990 to 11.7% (95% CI: 
8.4% to 15%) [43]. The World Health Origination (WHO) reported that there were 
approximately 251 million cases of COPD globally in 2016 [44]. A recent 
geographical study, including population-based studies between 1995 and 2019, 
showed that western and central Europe had the highest mean prevalence of COPD 
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with approximately 14.2% (95% CI: 8.8% to 19.6%), followed by northern and 
southern Europe with 11.5% (95% CI: 8.8% to 14.1%) and 10.8% (95% CI: 7.8% to 
13.8%), respectively [45].   
In the UK, it is estimated that around 3 million people live with COPD; of whom, 2 
million cases are undiagnosed. Statistics also suggest that 2% of the entire UK 
population, and 4-5% of people over the age of 40 in live with COPD [46]. 
Furthermore, the number of individuals who have received COPD diagnosis has 
increased in the last decade by 27%, from 1,600 to 2,000 per 1000,00. This may 
indicate that more people are getting diagnosed with COPD but could also mean that 
the prevalence of COPD is increasing. Indeed, between 2008 and 2012, the prevalence 
of COPD increased by 9%, and the proportion of males living with COPD is higher 
than that relating to females [46]. Data based on the Quality and Outcomes Framework 
(QOF) for general practices (GPs) indicates that the prevalence of COPD in England 
is estimated to be 1.9% [47].   
1.5.2 Morbidity and economic burden of COPD 
COPD imposes significant morbidities (e.g. emergency visits and hospitalisation) with 
a considerable economic burden. Indeed, it has become the 2nd largest cause of hospital 
admission in the UK, with 115,000 emergency admission and over a million bed days 
per year [48]. Available data also show that 43% of patients admitted with COPD were 
readmitted within 90 days after discharge in 2014, with a substantial increase from 
33% in 2008 [49].     
The cost of COPD to the National Health Service (NHS) is estimated to be £1.85 
billion per year and is expected to increase to £2.32 billion by 2030 [50], with the most 
significant costs related to COPD exacerbation and hospitalisation. In addition, COPD 
9 
 
severity is directly related to healthcare cost – that is the direct cost per patient 
increases with the increased number of experienced COPD exacerbations [51]. As 
COPD is a disabling disease, 25% of patients with the condition are prevented from 
working, and the annual cost of lost productivity because of COPD is estimated to be 
£3.8 billion [52].   
1.5.3 Mortality of COPD 
COPD is a major cause of death, accounting for nearly 5% of all deaths worldwide 
[53]. The most significant proportion of COPD deaths occur in low-middle income –
countries (about 90% of all COPD deaths) [44]. The Global Burden of Disease (GBD) 
study reported that there were more than 3 million deaths caused by COPD in 2015; 
an increase of 11.6% compared with the number of deaths recorded in 1990 [54]. By 
2060, COPD and its related conditions are expected to cause more than 5.4 million 
deaths annually [55]. 
Statistics have shown that the UK is one of the top 20 countries in terms of COPD 
mortality, with an age-standardised mortality rate of 210.7 per 1000,000 of the 
population [46]. The British Lung Foundation (BLF) reported that there were 30,000 
deaths from COPD in 2012, and this accounted for 5.3% of all mortality cases, making 
COPD the 5th largest cause of death in the country. The distribution of these deaths is 
slightly greater in men (51.2%; 15,254 deaths) compared to women (48.8%; 14,531 




1.6 Management and treatment of COPD  
As COPD is an irreversible condition, an effective COPD management plan such as 
assessing disease severity and progression, minimising risk factors, and managing 
stable COPD and exacerbations, should be employed. COPD management should, 
therefore, focus on improving patients’ overall health by preserving lung function, and 
reducing symptoms, risk of exacerbation, and disease progression [1, 40].  
Smoking cessation remains the most effective approach for people who smoke [1]. 
Indeed, it has been shown to alter the natural history of COPD and reduce the lung 
function decline [56]. Smoking cessation should be supported by pharmacological 
(e.g. nicotine replacement therapy) and non-pharmacological (e.g. counselling) 
therapies [1, 40].  
Pharmacotherapy (e.g. inhaled medications), such as bronchodilators and 
corticosteroids, is mainly indicated to ameliorate symptoms, reduce the severity of 
COPD exacerbations, and improve exercise limitation and overall health status [1, 40]. 
The latest NICE COPD guidelines have published an algorithm for the selection of 
inhaled therapies based on clinical evidence. Short-acting bronchodilators are 
indicated (as necessary) to relieve shortness of breath and improve exercise limitation. 
Long-acting agents, such as long-acting anti-muscarinic (LAMA) and long-acting β2 
agonist (LABA), in addition to inhaled corticosteroids (ICS), are indicated if 
breathlessness persists, and to improve day to day symptoms and reduce exacerbations 
[1, 40].  Pneumococcal and influenza vaccinations are also recommended [1, 40]. They 
have been shown to reduce the risk of lower respiratory tract infection 
(LRTI)/pneumonia and mortality in patients with COPD [57].   
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An important non-pharmacological therapy is a pulmonary rehabilitation (PR), defined 
as “an individually tailored, multidisciplinary care program for people with COPD, 
which aims to optimize physical and psychological condition through exercise 
training, education, and nutritional, psychological, and behavioural interventions” 
[40]. PR should be considered in a wide range of respiratory diseases, one of which is 
COPD [58]. PR aims to improve symptoms, overall health, exercise limitation, and 
psychological well-being [1, 58].  
1.7 COPD exacerbation 
An acute exacerbation of COPD (AECOPD) is defined as “a sustained worsening of 
the patient’s symptoms from his or her usual stable state that is beyond normal day-
to-day variations and is acute in onset” [1] that requires a change in the treatment [59]. 
The GOLD report recommends managing COPD exacerbation based on the severity 
of the episode. The main goal of treating COPD exacerbation is to minimise the impact 
of the current episode as well as reduce the risk of subsequent/future ones. The 
majority of COPD exacerbation episodes (up to 80%) are managed in outpatient by 
pharmacotherapies such as bronchodilators, corticosteroids (oral), and antibiotics. In 
some cases, where COPD exacerbation cannot be managed by pharmacological 
therapies, hospital admission may be required [1].   
COPD exacerbations are important events in the natural history of COPD and are 
associated with a significant impact on a patients’ health [60]. Even a single 
exacerbation episode can significantly increase the lung function decline rate [61]. 
Also, COPD exacerbation is associated with increased readmission rates as well as in-
hospital and post-discharge mortality [62-64]. Current evidence shows that 
exacerbations are associated with a more significant disease progression (e.g. faster 
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decline in FEV1), and increased risk of a subsequent event [65, 66]. Indeed, 25% of 
COPD exacerbations are followed by a second recurrent episode within eight weeks 
[67].   
1.8 Comorbidities in COPD 
Although COPD mainly affects the lungs, it is commonly associated with other 
comorbid conditions. The term “comorbidity” is widely described as the co-existence 
of other medical conditions alongside the primary disease of interest (e.g. COPD). The 
co-existence of comorbidities does not necessarily imply that these comorbidities are 
directly related to COPD. Some comorbidities may arise independently, while others 
may occur due to common risk factors. Further, it is also possible that one condition 
could amplify the risk of the other. The underlying mechanisms linking COPD to its 
associated comorbidities remain for further investigation [68]. Comorbidities, either 
single or multiple, are common in patients with COPD, impacting on patients’ health 
status, and increasing the risks of exacerbations, readmission, and mortality [69-74]. 
Nevertheless, current guidelines provide limited information on how to identify, 
assess, and manage these comorbidities in patients with COPD [1].  
Current literature suggests that patients with COPD are more likely to suffer from a 
higher proportion of comorbidities, compared to subjects without COPD [75, 76]. 
Further, patients with COPD are more likely to die from non-pulmonary causes [73, 
77]. In a cluster analysis of 213 well-characterised patients with COPD (defined based 
on FEV1 % predicted), 98% had one or more comorbidities, and 53% had at least four 
comorbid conditions [78]. In a previous study, involving 1,969 patients with COPD 
and 316 subjects without COPD, Divo et al. reported that the median number of 
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comorbidities in patients with COPD is 4 (interquartile range; 2–7) compared to 2 
(interquartile range; 0-3) in subjects without COPD [79]. 
The view that a considerable proportion of patients with COPD suffer from multiple 
comorbidities has a significant impact on survival. Almagro et al. demonstrated that 
comorbidities, quantified by Charlson comorbidity index score, was associated with 
23% increased odds of mortality, following adjustment for confounders [80]. In the 
BODE COPD cohort, there was an amplified risk of death with higher values of COPD 
specific comorbidity test (COTE) index (Hazard Ratio (HR): 1.13; 95% CI: 1.08 – 
1.18) [73]. Even the co-existence of a single comorbid condition in patients with 
COPD has a significant impact on survival. Data from the Evaluation of COPD 
Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) study showed 
that the presence of 1 comorbidity was associated with 74% increased odds of 
mortality (compared to no comorbidity), while the co-existence of  ≥ 4 comorbidities 
were associated with a 4-fold increase of death [81]. These observations - that is a 
significant proportion of patients with COPD have comorbidities (86% to 98%) - have 
led researchers to conclude that the co-existence of comorbidities (either single or 
multiple) in COPD is likely to be the rule as opposed to the exception [82].  
Comorbidities are common at/in all COPD severities [83-85]. However, it appears that 
the impact of comorbidities is significantly greater on patients with advanced COPD 
severity [86]. Data from the Atherosclerosis Risk in Communities (ARIC) study of 
20,296 patients showed that worse COPD severity (GOLD stage 3 or 4) was associated 
with increased odds of comorbidities, even after adjusting for common confounders. 
These comorbidities (e.g. diabetes, hypertension, and cardiovascular disease) 
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contributed to worse clinical outcomes such as an increased risk of hospitalisation and 
mortality [87].  
The presence of comorbidities in patients with COPD makes the assessment and 
clinical management more challenging. To explain, some medications that are 
commonly prescribed for patients with COPD can potentially worsen or increase the 
risk of other medical conditions. For instance, bronchodilators may worsen the existing 
CV disease, or increase the risk of subsequent CV event [88]. Current evidence reports 
that more than 50% of patients with COPD take more than 4 medications [82]. This 
may add to the risk of drug interactions, resulting in potential adverse events [89]. In 
addition, clinical decision making is also complicated, as there are no sufficient 
recommendations regarding the management of patients with COPD who have 
comorbidities. The current COPD guidelines (e.g. GOLD and NICE) state that 
comorbidities should be managed according to usual care. However, identifying and 
diagnosing co-existing comorbidities is not always easy. Some comorbidities can be 
asymptomatic, whereas other symptoms (e.g. dyspnoea) may not be specific to COPD. 
Because of this, there needs to be a holistic approach when identifying and treating 
comorbidities in COPD.   
Based on the preceding discussion, it is evident that comorbidities are a common issue 
in patients with COPD, with significant impacts on prognosis and management.  
However, it is noteworthy that studies on the burden of comorbidities (either single or 
multiple) in COPD are largely heterogeneous in data collection methods and in how 
patients with COPD were defined. There is a wide disparity with regards to the burden 
of comorbidities in COPD. This indicates that there is a need for more research to 
understand the broader spectrum of the disease and its associated comorbidities.  There 
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have been many comorbidities recorded in patients with COPD [73, 79]. Nevertheless, 
there is a lack of understanding in some of these comorbidities, while others have not 
been adequately researched. In the following sections, specific comorbidities relevant 
to this thesis are discussed. These include cardiovascular disease, cognitive 
impairment, dementia, and depression. 
1.8.1 Cardiovascular (CV) disease  
1.8.1.1 Cardiovascular disease and lung function  
A large body of evidence has demonstrated an association between impaired lung 
function and cardiovascular (CV) risk, even in the absence of established pulmonary 
disease [90]. Indeed, current evidence demonstrates that reduced lung function (FEV1) 
is a marker of CV mortality, independent of common risk factors (e.g. age, sex, and 
history of smoking) [91]. Reduced lung function is also a predictor of all-cause 
mortality [92]. Even a small reduction in FEV1 has shown to increase the risk of CV 
events.  Recent longitudinal data on 4,761 subjects aged 18-30 years demonstrated that 
a reduction in FEV1 (by 10% of FEV1 percent predicted) and FVC (by 10%  in FVC 
percent predicted) at a younger age, was associated with an 18% (adjusted HR: 1.18; 
95% CI: 1.06 to 1.31) and 19% (adjusted HR: 1.19; 95% CI: 1.06 to 1.33) increased 
risk of CV events, respectively, in middle age, independent of traditional risk factors 
[93]. Agarwal et al. reported an inverse association between heart failure and FEV1 – 
that is increased risk of heart failure with decreased FEV1 even after adjustments for 
confounders [94]. 
There is also an association between CV risk and lung function decline. Analysis from 
the ARIC study on 10,351 subjects free of CV disease, showed that a fast decline in 
lung function (defined as a reduction in FEV1 > 1.9% per year or FVC >2.1% per year) 
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over a 3-year follow-up period, was associated with a greater risk of CV disease, after 
accounting for smoking status and other confounders. The same study also showed 
that a rapid decline in FEV1  in the first year of follow-up was the most prognostic (HR: 
4.22) [95]. Collectively, these findings clearly show that there is an association 
between impaired lung function and CV risk.  
1.8.1.2 Cardiovascular disease and COPD 
Cardiovascular disease (CV) is a very common comorbidity in patients with COPD. 
Both conditions (e.g. COPD and CV disease) share similar risk factors, such as ageing, 
smoking, and unhealthy lifestyle (e.g. physical inactivity and unhealthy diet) [73]. 
Patients with COPD and CV disease, compared to subjects without COPD, are at 
increased risk of hospitalisation [87] and mortality [77, 96]. In addition, it is well-
documented that the observed prevalence of CV disease in patients with COPD is 
independent of age, sex, smoking, and other risk factors [82, 87]. A recent meta-
analysis, including 29 datasets, showed that patients with COPD were at 2 to 5 times 
greater risk of CV diseases (ischaemic heart disease, arrhythmias, heart failure, 
diseases of the pulmonary circulation, and diseases of arteries) [97]. It is clear that 
there is a significant CV risk in patients with COPD, which highlights the importance 
of increasing awareness, and emphases on routine screening/assessment to the CV 
state to increase detection.   
A series of large-scale prospective, population-based studies demonstrated that 
patients with COPD are at increased risk of CV disease, both as a composite outcome 
and as a specific disease. It has been shown that patients with COPD are at increased 
risk of acute CV events, namely myocardial infarction (MI) and stroke [98-100]. In 
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addition, other studies have also reported increased CV disease other than MI and 
stroke (e.g. heart failure and arterial fibrillation)  [96, 101, 102].  
CV disease is also recognised as a significant determinant of survival in patients with 
COPD. Indeed, it has been shown that patients with COPD are more likely to die from 
CV disease than from respiratory causes [103]. Data from the Towards a Revolution 
in COPD Health (TORCH) study showed that CV deaths account for 27% of all deaths 
(n=911) in patients with moderate to severe COPD [77]. In addition, the Lung Health 
Study indicated that, even in patients with mild-moderate COPD, CV disease was also 
a significant cause of death, accounting for 22% of CV mortality [104].   
The exact causes of the increased risk of CV disease in COPD remain poorly 
understood. This may be attributed to common risk factors, such as age, smoking, 
systematic inflammation, sedentary lifestyle, or conditions that can impair the heart 
from lung disease [73, 105]. However, what remains unclear is whether there are 
mechanistic pathways which contribute to the development of CV disease in COPD, 
or vice versa.  
Given the greater burden of CV disease in COPD, healthcare professionals are 
encouraged to manage and treat comorbidities. This implies increasing the detection 
of CV disease in those patients. Thus, it is important to consider simple, easy-to-use, 
sub-clinical biomarkers over and beyond the guideline-recommended diagnostic 
procedures to assist in the detection and recognition of CV disease.  
1.8.2 Cognitive impairment  
Cognitive impairment refers to a condition in which individuals experience a decline 
in their cognitive function (e.g. memory), where deficits do not completely impair 
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independent functioning  [106]. In the UK, the rate of cognitive impairment has been 
increasing. A recent report showed an increasing trend in the prevalence of cognitive 
impairment (without a diagnosis of dementia) in the general population (aged ≥ 65 
years) over the past 2 decades, from 36.8% in 1991 to 40.4% in 2011 [107]. Several 
risk factors are associated with increased risk of cognitive impairment and dementia, 
including advanced ageing, hypoxia [108], systemic inflammation and oxidative stress 
[109], obesity [110], dietary insufficiencies [111] CV disease [112, 113], physical 
inactivity [114], smoking [115], and genetics predispositions [116]. Thus, 
interventions which could reduce the risk or even prevent dementia cases, such as 
childhood education, regular exercise, maintaining social engagement, and managing 
CV risk, and smoking cessation, have been suggested [117]. In addition, efforts have 
also been made to increase awareness and detection of dementia [118]. 
Cognitive impairment has a significant impact on health and is associated with worse 
clinical outcomes [119]. Indeed, the presence of cognitive impairment is recognised as 
a precursor to established dementia [120, 121], despite not all patients with cognitive 
impairment will eventually develop dementia [122]. A previous study showed that 
approximately 30% of patients with confirmed cognitive developed dementia over a 
median of 5-year follow up [122]. Therefore, important to understand the relationship 
between cognitive impairment and dementia and identify any modifiable risk factors. 
What remains unclear, however, is what clinical features might predict the progression 
to dementia. 
Making a diagnosis of dementia is ideally made by a comprehensive cognitive 
test/assessment, which is not often performed in GP practices. Although GP doctors 
have been supported and encouraged to take an independent role in diagnosing 
19 
 
dementia, there is a hesitance in using the term “dementia” [123, 124]. Therefore, it is 
assumed that doctors may use the term “cognitive impairment” in place of the term 
“dementia” more often. This, in turn, may lead to under-or overestimation of the true 
prevalence of cognitive impairment and dementia. Furthermore, determining the 
severity of the cognitive impairment (e.g. mild, moderate, etc) can also be missed if 
no cognitive assessment being performed. This may limit timely appropriate 
interventions, as well as providing services that are structured to meet patients’ needs. 
Although cognitive impairment and COPD have been studied as individual entities, 
current evidence suggests they often co-exist and may also be inter-related. Indeed, 
COPD is associated with hypoxemia, hypercapnia, smoking, and CV disease; all of 
which increase the risk of neuronal injury, and therefore, cognitive impairment and 
subsequent dementia [106]. Other risk factors have also been proposed, which include 
systematic inflammation and oxidative stress [106]. However, it is unlikely these 
factors to fully account for the presence of cognitive impairment and dementia in 
COPD.  
Impaired cognitive function in people with COPD is an important determinant of 
clinical outcomes. A recent observational study, including 157 patients with COPD 
referred to a pulmonary rehabilitation program, showed that patients with COPD and 
co-existing cognitive impairment were less likely to adhere to pulmonary 
rehabilitation, compared to patients without cognitive impairment (23% vs 10%) 
[125]. However, PR was effective for patients who completed the program (even in 
those with cognitive impairment). This suggests that interventions should be taken to 
reduce the drop-out rates in those patients in order to bring greater benefits.  
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Cognitive impairment also has a significant impact on dependency and self-
management in COPD. A systematic review including 13 studies demonstrated that 
patients with COPD and cognitive impairment need more assistance in many aspects 
of daily life activities, and also have improper inhaler technique [126]. Proper inhaler 
use is a major element for effective self-management, and also for optimising drug 
delivery [127]. However, there have been no specific recommendations on inhaler use 
for patients with COPD and co-existing cognitive impairment. Therefore, systematic 
assessment of the cognitive function in patients with COPD is of clinical importance, 
as it can make a clear distinction between patients with poor adherence due to cognitive 
impairment, and those with improper techniques [128].  
Current estimates of cognitive impairment in patients with COPD are largely 
heterogeneous, depending on the study population and methods used to assess 
cognitive function [129]. Establishing accurate epidemiology of cognitive impairment 
in people with COPD has relevant clinical implications. This is because cognitive 
impairment increases the burden of COPD and raises the concern of the increased risk 
of subsequent dementia. A broader understanding of the association between COPD 
and cognitive impairment may; therefore, help identify any modifiable risk factors 
early in the course of the illness, allowing for timely interventions to avoid or at least 
minimise the risk of progressing to clinical dementia. Moreover, it may also help 
reduce the negative impact of cognitive impairment on COPD populations.  
1.8.3 Dementia  
Dementia is a devastating condition, defined as the development of multiple cognitive 
impairments that significantly interfere with social activities and occupational 
functioning. It is a progressive and irreversible disease, which contributes substantially 
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to the health and economic burdens [130]. Currently, there are more than 40 million 
people suffering from dementia around the world, but the prevalence is projected to 
increase to 135 million people by 2050 [131]. In the general population, 5-8% of 
people over 70 years old and 15-60% of people over 80 years old are more likely to 
develop dementia worldwide [132].  
Whereas a growing body of literature has investigated the association between COPD 
and cognitive impairment, studies on dementia in patients with COPD are generally 
lacking. A recent systematic review, including 3 Taiwanese studies, reported that 
patients with COPD were at increased risk of dementia. However, the studies included 
in the latter systematic review are limited by some methodological flaws such as 
including patients with asthma [133], undefined follow-up period [134], and 
inadequate matching group [135]. In addition, another major limitation for the existing 
studies is the methodology used for COPD ascertainment [136-138]. Rusanen et al. 
showed that a diagnosis of COPD in midlife was associated with increased risk of mild 
cognitive impairment/dementia (HR: 1.85, 95% CI: 1.05 to 3.28) [136]. By contrast, a 
COPD diagnosed in later life (> 65 years) was inversely associated (although not 
significant) with dementia (HR: 0.30, 95% CI: 0.08 to 1.24). However, it is important 
to note that the latter study defined COPD based on self-reported history as opposed 
to a COPD diagnosis that is objectively confirmed, which further limit the applicability 
of the findings.  
The findings of the existing studies regarding the association between COPD and 
dementia have also been inconsistent. A recent analysis from the ARIC study, 
including 14,184 subjects aged ≥ 45 years, with a median follow-up of 23 years, 
showed a nonsignificant risk of dementia in patients with COPD (n= 2,490) compared 
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to subjects without COPD (n=6,108) following adjustments for confounders (adjusted 
HR: 1.08; 95% CI: 0.92 to 1.27) [137]. In contrast, a Chinese study, with a short 
follow-up (3 years), showed that a self-reported COPD diagnosis in older subjects 
(mean age: 82.9 years) was associated with an increased risk of dementia (adjusted 
HR: 1.89; 95% CI: 1.07 to 3.33) [138]. Given the heterogeneity in the current 
literature, there is a need to further explore the relationship between COPD with 
cognitive impairment and dementia. Up to date, there are no previous population-based 
studies, which investigated the prevalence and incidence of cognitive impairment and 
dementia in patients with COPD in the UK.   
1.8.4 Depression 
The co-existence of poor mental health in COPD has a significant effect on health and 
prognosis. Depression is among the most common and modifiable comorbidities in 
COPD, contributing to impaired quality of life, poor adherence to medications and 
pulmonary rehabilitation [139, 140], and increased risk of death [141].  
Depression is frequent, even in patients with mild COPD [142]. The reported 
prevalence varies across studies, as a result of differences in terms of the study’s 
population and design. It is estimated that depression affects 27% [143] to 40% [144] 
of patients with stable COPD. The prevalence of depression also increases in line with 
the severity of COPD. Data from the ECLIPSE study showed that patients with more 
severe COPD (defined based on GOLD) had a higher prevalence of depression 
compared with lower COPD stage [145]. Furthermore, older studies indicated that 
patients with COPD are at increased risk of depression [146-148] and that patients 
with severe COPD (defined as oxygen use) are associated with a two-fold higher risk 
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of depression compared with mild COPD (defined as patients who received no drug 
treatment) [147].  
Although the current guidelines recommend recognising depression in patients with 
COPD [40], there has been no evidence that depression is currently part of the standard 
assessment. Depressive symptoms may remain undiagnosed in patients with COPD; 
thus, undertreated [149], ultimately to the detriment of patients. Current evidence 
suggests that more than 60% of patients with COPD and depression receive no 
treatments [150]. Identifying depression as early as possible allows healthcare 
providers to develop appropriate strategies that meet patients’ needs and guide the 
choice of pharmacological and non-pharmacological therapies. Therefore, it is 
important to recognise depression and be vigilant to symptoms to ensure that it is 
appropriately managed alongside COPD. 
The current COPD guidelines (e.g. GOLD) indicate that the management of 
comorbidities in the presence of COPD should be done according to usual care [1]. 
This means that depression (when co-exists with COPD) should be managed using the 
existing guidelines for depression. However, it is important to be cautious when 
managing these patients, especially when prescribing antidepressants. As such, it is 
crucial to guide the choice of pharmacological treatment, as the risk of drug 
interactions may be increased, leading to adverse events. Recent evidence suggests 
that antidepressants are associated with an increased risk of respiratory-related 
morbidities (e.g. pneumonia, emergency visits, and hospitalisations) in patients with 
COPD compared to patients with COPD who do not use antidepressants [151]; 
however, this requires further investigation.  
24 
 
1.9 Circulating Biomarkers 
There has been growing interest in identifying clinically relevant biomarkers in COPD. 
According to the National Institutes of Health, biomarkers are defined as “a 
characteristic that is objectively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes, or pharmacologic responses to a 
therapeutic intervention” [152]. Unlike a physiological measure (FEV1 and FVC), 
biological markers are considered to be substances. The clinical applications of 
biomarkers can include predicting the disease’s course and severity, determining 
prognosis, categorising different clinical phenotypes, monitoring drug response, and 
assessing the pathophysiology of disease [153]. Potential characteristics of a clinically 
useful biomarker are to be safe, precise, reproducible, measurable, inexpensive, and 
easy to implement into clinical practice [152, 154, 155]. However, it is acknowledged 
that new biomarkers development is extremely challenging, as in many cases, 
biomarkers may fail because of poor reproducibility. For the selected biomarkers in 
this thesis, the purpose was not to reproduce previous findings; but rather, to increase 
understanding of the role of simple clinically relevant biomarkers. 
Promoting CV disease prevention or at least minimising low CV risks have been of 
great interest [156]. Although, as previously discussed, there is an increased burden of 
CV disease in patients with COPD, there is inadequate information on how to assess 
the CV state in patients with COPD. There is also uncertainty regarding the optimal 
method for assessing CV risk in patients with COPD.  
The clinical presentation of COPD is largely heterogeneous, making it unlikely for a 
single marker to capture the increased risk of CV abnormalities. Thus, changes in 
patient care are needed, so that the CV risk in patients with COPD are addressed. This 
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implies using a multi-dimensional approach, where other measures should be made 
available to address CV risk as opposed to merely assessing the lung function status in 
patients with COPD [157-159].  
The field of biomarkers in COPD has received great interest. It is indeed of clinical 
importance to assess the CV abnormalities in patients with COPD. Several biomarkers 
have been investigated in the literature, including C-reactive protein (CRP), 
fibrinogen, surfactant protein [160-162]. Indeed, the role of CRP as a CV biomarker 
has been reported in the literature – that is increased CRP level is associated with 
increased risk of CV disease [163, 164]. In the setting of COPD, however, there seems 
to be inconsistency across studies. While some literature suggests that CRP relates to 
CV risk in patients with COPD [165, 166], another suggests otherwise. Findings from 
a recent multicentre study (n= 729) showed that neither CRP nor fibrinogen were 
associated with the non-invasive CV risk measure (as measured by aortic PWV) in 
patients with COPD [167]. It is worth noting that fibrinogen is the only biomarker with 
approval as a drug development tool for COPD [168]. Nevertheless, identifying 
inflammatory comorbidities, such CV disease, by fibrinogen remains not fully 
understood [169]. Therefore, there is a need to identify biomarkers that can help 
improve CV risk detection in patients with COPD. 
Herein, two biological markers that have shown to have a predictive CV risk values in 
other disease groups and in the general population are explored in patients with COPD. 
These include soluble Receptor for Advanced Glycation End-products (sRAGE) and 
Microalbuminuria (MAB). In the following sections, the structure and clinical utility 
of these biomarkers will be briefly highlighted.  
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1.9.1 Advanced Glycation End-products (AGEs) 
Advanced Glycation End-products (AGEs) are a heterogeneous group of compounds, 
which are irreversibly formed by a non-enzymatic glycation and oxidation reactions 
of lipids and proteins. Typically, AGEs are formed at a slow rate and accumulate in 
tissues with chronological ageing. The rate of this process accelerates under oxidative 
and inflammatory stress, leading to increased levels of AGEs; thereby contributing to 
age-related pathogenesis [170-172]. A previous prospective population-based study 
including subjects over the age of 65 years (n=1013) showed that increased AGEs was 
associated with increased risk of CV mortality (HR:1.84; 95% CI: 1.30 – 2.60) 
compared to subjects with lower AGEs [173]. 
1.9.2 Receptor for Advanced Glycation End-products (RAGE)  
The receptor for advanced glycation end-products (RAGE) is a member of the 
immunoglobulin superfamily of cell-surface, and a pattern-recognition receptor that 
interacts with multiple ligands [174]; one of which is AGEs. RAGE is at highest 
baseline level in the lungs, including proximal and distal airways [175, 176]. However, 
it is expressed at a very low or undetectable level in most other body tissues [175]. 
Wheresoever its ligands accumulate, RAGE is overexpressed. This can be seen in 
conditions associated with inflammation, such as CV disease and COPD. 
1.9.3 Soluble Receptor for Advanced Glycation End-products (sRAGE)  
RAGE exists in two isoforms, namely membrane (mRAGE) and soluble (sRAGE). 
The physiological function of sRAGE is not yet fully understood. However, it has been 
suggested that sRAGE can act as a decoy receptor for RAGE ligands by blocking the 
binding of AGEs to RAGE.  
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1.9.3.1 Soluble RAGE and COPD 
The role of AGE and RAGE in both the airways and circulation has been studied in 
COPD. AGEs levels have shown to be significantly elevated in patients with COPD. 
[177]. Ferhani et al. also reported that smokers with COPD have significantly 
increased levels of RAGE, especially in their proximal and distal airways, compared 
to non-smokers and smokers without COPD. In contrast, studies have consistently 
shown that sRAGE levels are reduced in patients with COPD, in comparison to 
subjects without COPD [178-181]. Besides, reduced sRAGE levels are directly 
associated with FEV1 [179, 182-184], and inversely associated with GOLD severity 
[181]. A weak association between lower sRAGE levels and FEV1/FVC decline over 
4 years has also been reported [178].  
1.9.3.2 Soluble RAGE and CV disease  
Studies on the associations between sRAGE and CV events are largely heterogeneous, 
with some studies showing inverse associations between sRAGE with CV disease 
[172, 185, 186], while others are showing positive associations [187, 188]. The 
discrepancies across studies are attributed to different study designs and populations. 
A recent 3-year longitudinal study, involving 933 patients with CV disease 
demonstrated that increased sRAGE was associated with a new CV event [189]. 
Furthermore, Nin et al. indicated that elevated sRAGE at baseline in subjects with type 
1 diabetes (n= 339) free of CV disease was associated with increased risk of incident 
CV disease and all-cause mortality [170]. It is worth noting, though, that this 
association has also been shown in subjects without diabetes [190, 191]. Whether 
sRAGE is related to the CV status in patients with COPD remains unknown.  
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1.9.4 Microalbuminuria (MAB) 
Microalbuminuria (MAB) is defined as a moderate increase in urinary albumin 
(protein) above the normoalbuminuria range. The clinical threshold, which defines 
MAB, is based on increased urinary albumin creatinine ratio (UACR) of 2.5 mg/mmol 
in males and 3.5 mg/mmol in females. Increased UACR above the level of MAB is 
termed “macroalbuminuria (UACR > 30 mg/mmol)”, and it is likely to be associated 
with both significant kidney damage and CV disease.  
1.9.4.1 Microalbuminuria and CV disease 
Microalbuminuria is considered the hallmark of early kidney damage in individuals 
with diabetes [192], independent of the overall measure of kidney function the 
estimated glomerular filtration rate (eGFR) [193]. In addition, MAB is is an indicator 
of increased CV risk and a predictor for mortality in the general population [194-197]. 
MAB has also been related to arterial stiffness – a non-invasive physiological CV 
measure and a predictor of CV events (assessed by pulse wave velocity) – in 
individuals with diabetes, hypertension, and in subjects from the general population 
[198-200].  Furthermore, even a small increase in UACR within the normal limits is 
still associated with an increased risk of renal and CV disease [201]. A collaborative 
meta-analysis, involving 105,872 participants from the general population indicated 
that an albumin creatinine ratio (ACR) of 1.1 mg/mmol (which is below the threshold 
of microalbuminuria) was associated with a 20% amplified risk of all-cause mortality 
[202]. These findings highlight that MAB can be used in other disease groups 
associated with increased CV risk; one of which is COPD.   
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1.9.4.2 Microalbuminuria and COPD 
The limited number of studies which investigated the prevalence of MAB in patients 
with COPD have shown that MAB is frequent in patients at times of exacerbations 
[203, 204] and at clinical stability; although the prevalence varies across studies [205-
207]. John et al. demonstrated that patients with COPD (n=52) at clinical stability had 
glomerular damage evidenced by increased UACR, and associated with aortic stiffness 
in patients with COPD, compared to smokers without COPD (n=34) [208]. Findings 
from the Nord-Trøndelag Health Study involving 3,129 participants also reported that 
patients with COPD and confirmed MAB (n=136) were at 54% increased risk of all-
cause mortality, compared to patients with COPD without MAB (n=495)[209]. Of 
importance though, these results remained the same even after excluding CV disease 
at baseline. Microalbuminuria may be a potential marker to detect patients with COPD 




1.10  Summary and aims of the studies in this thesis 
COPD presents a significant public health issue, with increased prevalence, morbidity, 
and mortality globally. COPD is associated with a number of comorbidities, including 
CV disease, cognitive impairment, dementia, and depression. These comorbidities 
have a considerable impact on disease management and are associated with increased 
morbidity and mortality. Increase the understanding of these comorbidities has 
important management implications for the multidisciplinary team who manage 
COPD across primary and secondary care. 
Although a significant proportion of patients with COPD suffer and die from CV 
disease, assessment of CV status is neither performed at diagnosis nor during follow-
up. Simple, clinically relevant biomarkers may help identify patients at increased CV 
risk and assist in assessing and diagnosing patients in clinical settings. Two possible 
biomarkers are investigated in this thesis, which might have a role in COPD related to 
prognostication/presence of CV comorbidities: 1) soluble Receptor for Advanced 
Glycation End-products (sRAGE) and 2) Microalbuminuria (MAB).   
Cognitive impairment and dementia are common in COPD, yet there are considerable 
disparities in the report of their prevalence and incidence within the general COPD 
population. Further, the awareness of the increased burden of cognitive impairment 
and dementia in patients with COPD emphasises the need for more research. Also, 
depression is amongst the understudied key comorbidities in COPD, with serious 
impacts on health and prognosis.  
This introduction underlines important gaps in our understanding of COPD 
comorbidities and circulating biomarkers. Reviewing the existing literature has 
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enabled me to address these gaps by applying different methodologies from clinical 
and epidemiological perspectives. Thus, the specific aims of this thesis are: 
1- To explore the potential role of sRAGE as a cardiovascular (CV) biomarker, 
in patients with COPD from the ERICA multicentre cohort of stable patients 
Chapter 2).  
2- To determine the prevalence of microalbuminuria (MAB) and explore the role 
of MAB as a CV biomarker in patients with COPD at clinical stability, using 
data from the ERICA cohort (Chapter 3).  
3- To report the prevalence of cognitive impairment and dementia at the time of 
COPD diagnosis, compared to subjects without COPD, using primary care data 
within The Health Improvement Network (THIN) (Chapter 4).  
4- To determine the incidence of cognitive impairment and dementia in patients 
with COPD, compared to subjects without COPD, using the THIN database 
(Chapter 4)   
5- To determine the incidence of newly diagnosed depression or antidepressant 
prescription following a diagnosis of COPD and compare this to subjects 
without COPD using the THIN database (Chapter 5).  
6- To evaluate the association between antidepressant prescription and 
respiratory-related morbidity (pneumonia and COPD exacerbations) in patients 




Chapter 2  Soluble Receptor for Advanced Glycation End 
Products (sRAGE) and Cardiorespiratory Physiology in 




2.1  INTRODUCTION 
It is well-established that patients with COPD are at increased risk of cardiovascular 
(CV) disease independent of age, gender, smoking and other common risk factors [87, 
97]. Whilst CV disease is a known cause of morbidity [87] and mortality [73] in 
COPD, there is no systematic assessment of CV status in routine practice. Thus, a shift 
in patient care is needed to actively assess and screen CV risk in patients with COPD. 
Given the impact of CV disease on COPD, early detection is important. Although CV 
risk scores (which use algorithms to predict CV risk) have been developed to identify 
those at increased CV risk and to guide treatment [210, 211], they do not include 
COPD, which gives a cause for concern that CV risk estimation may not be optimal in 
COPD [212]. Other methods for assessing the CV risk have been suggested. Aortic 
stiffness, determined by aortic pulse wave velocity (PWV), is a non-invasive measure 
of vascular function and an independent marker for increased CV risk in both the 
general population and in patients with COPD [213-215]; however, it is not part of 
routine clinical practice. Carotid intima-media thickness (CIMT), a surrogate for 
subclinical atherosclerosis, is another subclinical marker that has been associated with 
increased CV risk and mortality in COPD patients [216, 217]. However, the use of 
CIMT in clinical settings is limited, owing to its high cost and technical nature. The 
identification of CV biomarkers using a fresh approach to aid the assessment of 
patients with increased CV risk is therefore of interest.  
Advanced Glycation End-products (AGEs), its receptor (RAGE) and soluble receptor 
(sRAGE) have been implicated in CV disease [218]. AGEs are markers of 
inflammatory and oxidative stress which can damage tissues (e.g. collagen and elastin) 
by modifying protein function and structure through cross-linking between molecules 
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or by binding with it receptor - RAGE [219]. sRAGE, which can be detected in blood 
samples, has predictive value for CV risk in other disease groups [170, 188, 189] and 
may, therefore, be applicable as a CV biomarker in COPD. 
The role of AGEs, RAGE (in the airways), and sRAGE (in the circulating) in COPD 
has been considered [177, 179, 220]. Current evidence shows associations of COPD 
with sRAGE [179, 181]. RAGE appears to have a pathogenic role in COPD whilst 
sRAGE appears to be protective. In a case-control study, Ferhani et al. demonstrated 
that patients with COPD (n = 30) have increased levels of RAGE, especially in their 
proximal and distal airways (bronchial tissues), compared to never smokers (n = 20) 
and smokers without COPD (n = 20) [220]. On the other hand, sRAGE is found at 
lower levels in patients with COPD compared to those without COPD [178-180]. 
Smith et al. reported that the reduction in sRAGE levels in patients with COPD was 
independently associated with the degree of airflow obstruction, as defined by FEV1 
[179]. John et al. also reported direct associations between sRAGE and spirometric 
measures but not with aortic stiffness [221]; however, the role of sRAGE as a CV 
biomarker in COPD has not been fully explored. 
Given the existing literature, it is hypothesised that sRAGE is independently related to 
measures of CV risk and lung function. The aim of this chapter is to evaluate whether 
sRAGE is associated with measures of both CV and lung functional status in patients 
with COPD in the ‘Evaluating the Role of Inflammation in Chronic Airway disease’ 





The ERICA study is an observational, longitudinal study that was conducted at five 
centres across the UK (Nottingham, Cambridge, London, Liverpool and Cardiff) and 
supported by Innovate UK (formerly the Technology Strategy Board). This chapter 
provides an analysis of the baseline, cross-sectional data of one aspect of the ERICA 
study. The patient recruitment and data collection were conducted by research 
personnel at the five universities prior to the commencement of my PhD.  
2.2.2 Subjects 
The ERICA study has been described in detail in the literature [222]. Briefly, the study 
included 729 patients with confirmed COPD (GOLD II–IV). All subjects provided 
written informed consent. The study was approved by the Cambridge South East 
Research Ethics Committee (REC: 11/EE/0357), and the research and development 
departments at each participating site [222]. The ERICA study was registered with the 
UK Clinical Research Network Study Portfolio. 
The original ERICA study was powered based on tertiary analysis of two key 
variables: aortic pulse wave velocity and quadriceps maximal volitional contraction, 
with an estimated sample of 800 patients. Additional information can be found in the 
original protocol [222]. 
2.2.3 Inclusion and exclusion criteria 
Patients were included if they were clinically diagnosed with COPD, had a post-
bronchodilator forced expiratory volume in the first second (FEV1) of ≤80% of 
predicted values, had a baseline FEV1/forced vital capacity (FVC) ratio of <0.7, were 
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40 years of age or older, had a smoking history of ≥ 10 pack years, and were clinically 
stable (no hospitalisation or exacerbation) for at least four weeks prior to the study 
commencement. Participants were excluded if they were unable to provide written 
consent, were deficient in alpha-1 antitrypsin, had neurological or muscular disorders, 
were pregnant or were participating in a trial of an experimental drug. Patients with 
other self-reported comorbidities, such as diabetes, cerebrovascular disease or 
ischaemic heart disease (IHD) were deliberately not excluded to be representative of 
clinical practice. 
2.2.4 Measurements 
All study measurements were conducted at baseline over two visits. Details of the 
standardised procedures and outcome measures that were used in all participating 
centres are described elsewhere [222]. Measurements of interest that are relevant to 
this study are described in this chapter.  
Cardiovascular measurements 
• Blood Pressure 
Blood pressure (BP) was measured in the non-dominant arm in the supine position 
after 10 minutes of rest, and an average of the final two out of three measurements 
(separated by a 1-minute interval) was recorded. A further recording was considered 
if the difference between the second and third readings was greater than 5mm Hg. 
Mean arterial pressure (MAP) and pulse pressure (PP) were calculated. Heart rate (HR) 
was also measured.  The calculations of MAP and PP were conducted as follows: 
• MAP = ((2 x diastolic blood pressure) + systolic blood pressure) ÷ 3 
• PP= systolic blood pressure – diastolic blood pressure 
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• Aortic pulse wave velocity 
Aortic (carotid-femoral) pulse wave velocity (PWV) was calculated via the 
SphygmoCor® system (AtCor,West Ryde, Australia), using a piezoelectric tonometer 
placed over the artery and Electrocardiogram (ECG) gating as described previously 
[222]. Patients fasted for at least 4 hours and refrained from bronchodilators for at least 
6 hours before the aortic PWV measurement. 
• Carotid intima-media thickness 
High-resolution B-mode ultrasound imaging using a 7–12 MHz linear probe [222] was 
applied to determine the carotid intimal medial thickness (CIMT) of the right and left 
common carotid arteries, measured at 1 cm from the carotid bulb. Measurements were 
obtained following 10 minutes of supine rest. Each artery had three 10-second loops 
recordings. The highest values for the right and left CIMT were recorded, and the mean 
was used in the analysis. Image analysis was conducted using Vascular Tools 5 
software (Medical Imaging Application LLC, Coralville, USA).  
Anthropometry and lung function 
Height and weight were measured, and body mass index (BMI) was calculated. Fat-
free mass (FFM) was determined using bioelectric impedance (Tanita Corporation, 
Tokyo, Japan). A height squared fat-free mass index (FFMI) was calculated. 
Post-bronchodilator spirometry was performed within 1 hour of administration of the 
patient’s bronchodilator to determine the post-bronchodilator FEV1, FVC and 
FEV1/FVC ratio. 
Blood parameters, biochemistry and other measurements 
Venous blood samples were drawn from a peripheral vein by venepuncture after four 
hours of fasting and six hours of refraining from medications [222]. Plasma sRAGE 
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levels in the venous blood samples were determined using an enzyme-linked 
immunosorbent assay (ELISA) method in batched samples following storage at -80 
degrees celsius. Cholesterol profiles were also obtained. The estimated glomerular 
filtration rate (eGFR) was calculated [223]. 
Detailed histories, including comorbidities, medication and smoking, were recorded. 
Participants completed the COPD assessment tool (CAT) questionnaire [224]. 
2.2.5 Statistics 
Data were analysed using Stata (version 15) statistical software. The results are 
presented as number (%) or arithmetic mean (SD) for categorical and continuous 
variables, respectively. The normality of the data was graphically assessed. Within 
group differences (e.g. smokers vs ex-smokers) in the mean (SD) sRAGE levels were 
analysed using parametric tests (independent sample t-test and one-way analysis of 
variance (ANOVA)).  
The primary analyses tested the associations between sRAGE and CV measures (aortic 
PWV and CIMT), and lung function measures. Correlation of sRAGE with aortic 
PWV, CIMT, lung function measures and other factors was determined using 
Pearson’s correlation coefficient. Multiple linear regression was performed to assess 
whether sRAGE was independently associated with aortic PWV, CIMT, and lung 
function measures, with adjustment for potential confounders. Confounders were 
considered as such if they changed the regression coefficient by 10%. Known CV risk 
factors (e.g. smoking) have also been considered for their confounding effects. All 
potential covariates were assessed in separate regression models. A P value of <0.05 
was considered significant. For assessing the association with aortic PWV and CIMT, 
adjustments were made for BMI, FEV1% predicted, smoking status, smoking history, 
pulse pressure and self-reported comorbidities (diabetes, cerebrovascular disease or 
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IHD). For assessing the association of sRAGE with FEV1% predicted, adjustments 
were made for BMI, smoking status, smoking history and the presence of self-reported 
comorbidities. A priori confounders such as age and gender were considered regardless 
of their confounding effects. These associations were assessed in all patients with 
COPD and then in those without self-reported comorbidities (diabetes, 
cerebrovascular disease or IHD).  
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2.3  RESULTS 
Out of a total of 746 patients screened, 729 met the inclusion criteria. Of those, 677 
subjects were included in this analysis, representing those with a sRAGE result (Figure 
2-1). The mean (SD) age of the study population was 67 (8) years, and there were more 
males (62%) than females. A third of the cohort were current smokers and the mean 
(SD) FEV1% predicted was 52.4% (16%). The population had mean (SD) levels of 
sRAGE of 1056 (543.2) pg/ml, aortic PWV of 10.2 (3) m/sec and CIMT of 0.78 (0.2) 
mm. The baseline characteristics for the patients included in the ERICA study, and 






Subjects screened for inclusion in the 
ERICA study 
(n = 746) 
Eligibility: 
• Clinically diagnosed with COPD 
• post-bronchodilator FEV1 ≤ 80%  
• FEV1/FVC < 0.7 
• ≥40 years of age 
• Smoking pack-year history ≥10 
years 
• Clinically stable for the 4 weeks 
prior to the study 
Subjects included in the 
ERICA study 
(n = 729) 
Subjects with a sRAGE 
result included in this cross-
sectional analysis 
(n = 677) 
Subjects excluded from this 
analysis because they did not 
have a sRAGE result 
(n = 52) 




Table 2-1. Characteristics of patients included in the ERICA study 
Variable/ (No. missing observations*) Subjects in ERICA 
study (n = 729) 
Subjects with 
sRAGE result  
(n = 677) 
Age (years) 67 (8) 67 (8) 
Gender (male %) 441 (61%) 417 (62%) 
Clinical parameters   
BMI (kg/m2)/(n = 11) 27.3 (5.8) 27.3 (5.7) 
Fat-free mass index (FFM kg/m2)/(n = 37) 18.2 (2.7) 18.2 (2.6) 
CAT score/(n=16) 19.7 (8.4) 19.6 (8.4) 
Smoking history (pack-years)/(n = 10) 47.6 (27.7) 47.6 (27.2) 









Lung function parameters   
FEV1 (L)/(n = 3) 1.34 (0.53) 1.34 (0.52) 
FVC (L)/ (n=3) 2.8 (0.87) 2.8 (0.86) 
FEV1% predicted /(n = 3) 52.2 (16.1) 52.4 (16.1) 
FEV1/FVC ratio/(n = 3) 0.48 (0.13) 0.48 (0.12) 
Haemodynamic parameters   
Aortic PWV (m/s)/(n = 67) 10.3 (2.6) 10.2 (2.6) 
Mean CIMT (mm)/(n = 71) 0.78 (0.16) 0.78 (0.16) 
Supine systolic BP (mm Hg)/(n = 16) 138 (17) 138 (17) 
Supine diastolic BP (mm Hg)/(n = 16) 77(10) 77 (10) 
Supine MAP (mm Hg)/(n = 16) 97 (11) 97 (11) 
Supine PP (mm Hg)/(n = 16) 61 (13.7) 61 (15.2) 
HR (bpm)/(n = 58) 70 (12) 70 (12) 
Blood biochemistry   
sRAGE (pg/ml)/(n = 52) ─ 1056 (543.2) 
eGFR (ml/min)/(n = 41) 88 (18.3) 88. (18.4) 
Total cholesterol (mmol/L)/(n = 15) 5.1 (1.2) 5.1 (1.1) 
LDL cholesterol (mmol/L)/(n = 38) 2.9 (0.9) 2.9 (0.9) 
HDL cholesterol (mmol/L)/(n = 14) 1.5 (0.5) 1.5 (0.5) 
Self-reported comorbidities   
Diabetes (%)/(n = 8) 82 (11%) 79 (12%) 
IHD (%)/(n = 10) 57 (8%) 54 (8%) 
Cerebrovascular disease (%)/(n = 10) 57 (%) 54 (8%) 
Medications   
High blood pressure a (%)/(n = 418) 248 (34%) 228 (33.8%) 
Values are presented as mean (SD) unless otherwise stated. 
Abbreviations: BMI: body mass index; BP: blood pressure; CAT: COPD assessment test; CIMT: carotid intima-
media thickness; eGFR: estimated glomerular filtration; FEV1: forced expiratory volume in 1 second; FVC: 
forced vital capacity; distance; FM: fat-free mass; HR: heart rate; IHD: ischaemic heart disease; MAP: mean 
arterial pressure; PP: pulse pressure; PWV: pulse wave velocity; sRAGE: soluble receptor for advanced 
glycation end products. 
* Number of missing observations per variable from subjects in ERICA study (n = 729). 
a list of high blood pressure medications is provided in the appendices (Appendix 9-1). 
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Associations of sRAGE levels with vascular measures 
The results of the associations of sRAGE (as the dependent variable) with aortic PWV 
and CIMT are presented in Table 2-2. sRAGE was not found to be associated with 
either aortic PWV (p = 0.312; n = 619) or CIMT (p = 0.413; n = 615) overall or in the 
subgroup without self-reported comorbidities.  
In all patients, there was a positive weak correlation between sRAGE and pulse 
pressure (r = 0.13; p < 0.001), and inverse correlations with heart rate (r = -0.11; p = 
0.002) and diastolic blood pressure (r = -0.09; p = 0.022). Similar correlations were 




Table 2-2. Analysis of the associations of sRAGE with aortic PWV, and CIMT in 1) all 
subjects with COPD and 2) subjects without comorbidities 
Dependent variable: sRAGE (pg/mL) 
All patients with COPD 
 β (95% CI) Adjusted β (95% CI) P-value 
Aortic PWV – per 
1 m/sec change 
-14.1 (-31.2 to 3.1) 
(n = 619) 
-9.4 (-23.7 to 11.7)1 
(n = 606) 
0.503 
CIMT – per 1 mm 
change 
-59.6 (-327.1 to 207.8) 
(n = 615) 
-111.9 (-383.2 to 159.3)1 
(n = 602) 
0.413 
Patients without comorbidities 
 β (95% CI) Adjusted β (95% CI) P-value 
Aortic PWV – per 
1 m/sec change 
-6.7 (-27.3 to 13.8) 
(n = 473) 
-2.10 (-23.7 to 19.5)2 
(n = 464) 
0.848 
CIMT – per 1 mm 
change  
-22.7 (-313.6 to 268.3) 
(n = 461) 
-88.9 (-396.7 to 218.8)2 
(n = 451) 
0.146 
1 Adjusted for age, sex, BMI, smoking status, smoking history, PP, self-reported comorbidities and study site. 
2 Adjusted for age, sex, BMI, smoking status, smoking history, PP and study site. 
Abbreviations: BMI: body mass index; CI: confidence interval; CIMT: carotid intima-media thickness; FEV1: 
forced expiratory volume in 1 second; PP: pulse pressure; PWV: pulse wave velocity. 





Table 2-3. Correlations between sRAGE and vascular measures in 1) all patients with 
COPD and 2) patients without self-reported comorbidities 
Variable All patients with COPD  Patients without comorbidities 
 sRAGE sRAGE 





















Abbreviations: DBP: diastolic blood pressure; HR: heart rate; PP: pulse pressure. 
Patients without comorbidities: excluding patients with diabetes, ischaemic heart disease, and cerebrovascular 
disease 
 
sRAGE levels in relation to self-reported comorbidities and smoking status  
Analysis of sRAGE levels in the subgroup of patients with self-reported IHD (n = 54) 
compared to those without (n = 616) showed no statistical difference (1123 [555.5] vs. 
1051 [544.5] pg/mL; p = 0.353). Similarly, there was no statistical significant 
difference in sRAGE levels in those with diabetes (n = 79) and those without (n = 593; 
1006 [475.7] vs. 1064 [553.2] pg/mL; p = 0.375). 
sRAGE levels were also compared in current (n = 208) and former smokers (n = 466). 
There was no statistical difference in the mean (SD) sRAGE levels in current 1081 
(574.6) pg/mL and ex-smokers 1045 (529.9) pg/mL (p = 0.428) and the history of 




Association of sRAGE with lung function measures 
The mean sRAGE levels for each of the GOLD stages of COPD (II, III, IV) are 
presented in Table 2-4.  As seen, there was a progressive decrease in the sRAGE level 
as the GOLD severity increased (p = 0.001). Even after adjusting for confounders, a 
more advanced COPD stage was associated with reduced sRAGE compared to less 
severe COPD, Table 2-5.  
Table 2-4. sRAGE according to stages of COPD based on GOLD classification 
GOLD stage n sRAGE (pg/ml) 
GOLD II 335 (49%) 1146.9 (626.6) 
GOLD III 279 (41%) 978.6 (430.2) 
GOLD IV 61 (9%) 920.9 (427.9) 
Results are presented as mean (SD) 
Abbreviation: GOLD: Global Initiative for Chronic Obstructive Lung Disease 
 
Pearson correlation analysis showed that there was a positive weak correlation 
between sRAGE and FEV1% predicted (r = 0.12; p = 0.001; n = 675) and FEV1/FVC 
(r = 0.15, p < 0.001, n = 675) in all patients with COPD. This was also seen in patients 
without self-reported comorbidities for FEV1% predicted (r = 0.11; p = 0.14; n = 512) 
and FEV1/FVC (r = 0.14; p = 0.001; n = 512).  
A multiple linear regression model showed that FEV1% predicted was associated with 
sRAGE levels following adjustment for age, sex, BMI, smoking status, smoking 
history self-reported comorbidities, and study site (adjusted β: 3.5 pg/mL; 95% CI: 
1.16–6.52; p = 0.001; n = 664; Table 2-5). In the subset of patients without either 
diabetes, cerebrovascular disease or ischaemic heart disease (n = 514), sRAGE 
remained independently associated with FEV1% predicted (adjusted β: 3.4 pg/mL; 
95% CI: 0.40–6.5; p = 0.026; n = 503; Table 2-5).  
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Table 2-5. Analysis of the associations of sRAGE with lung function measures 
Dependent variable: sRAGE (pg/mL) 
All patients with COPD  
 β (95% CI) Adjusted β (95% CI) P-value 
FEV1 – per 1% 
predicted change 
4.2 (1.6 to 6.8) 
(n = 675) 
3.5 (1.2 to 6.5)1 
(n = 664) 
0.005 
GOLD stage    
GOLD II Reference Reference  
GOLD III -168.5 (-253.9 to -83.1) -183.8 (-269.6 to -98.1)1 <0.001 
GOLD IV -225.9 (-372.6 to -79.2) -202.7 (-351.2 to -54.3)1 0.008 
Patients without comorbidities 
 β (95% CI) Adjusted β (95% CI) P-value 
FEV1 – per 1% 
predicted change 
3.6 (0.7 to 6.5) 
(n=512) 




GOLD II Reference Reference  
GOLD III -153.3 (-253.9 to -52.7) -209.7 (-313.5 to -105.9)2 0.001 
GOLD IV -182.9 (-347.6 to -18.2) -233.1 (-406.6 to -59.5) 2 0.009 
1 Adjusted for age, sex, BMI, smoking status, smoking history, self-reported comorbidities and study site. 
2 Adjusted for age, sex, BMI, smoking status, smoking history and study site. 
Abbreviations: BMI: body mass index; CI: confidence interval; FEV1: Forced expiratory volume in 1 
second. 





In this well-defined group of patients with COPD, a direct, independent association 
was found between sRAGE, and FEV1 % predicted, albeit weak. However, neither 
aortic stiffness nor carotid intima-media thickness were associated with sRAGE, 
despite separate reports in the literature supporting the role of sRAGE in both COPD 
and CVD [172, 179]. Therefore, this study does not support the application of sRAGE 
as a clinical CV biomarker in patients with COPD.  
sRAGE and CV risk in COPD 
sRAGE has been studied in several other chronic inflammatory conditions, including 
CV disease, a common COPD comorbidity. However, the literature on the associations 
of sRAGE with CV events is inconsistent with studies showing both direct and inverse 
associations [186, 225]. These discrepancies are attributed to study designs (e.g., cross-
sectional and longitudinal), study populations, and ethnic groups. However, increased 
sRAGE levels have been associated with CV events in some disease groups [188-190, 
226]. Nin et al. demonstrated that elevated sRAGE at baseline in subjects with type 1 
diabetes (n = 339) free of CV disease, followed for 12 years, was associated with an 
increased risk of CV disease and mortality [170]. Recently, a 3-year longitudinal study 
of patients with proven CV disease (n = 933) demonstrated that elevated sRAGE was 
associated with new CV events [189], highlighting the possibility that sRAGE may 
have different relationships in different disease states.  
It is well-established that patients with COPD are at increased CV risk. Current 
evidence shows that patients with COPD have increased aortic stiffness and CIMT 
relative to subjects without COPD. Contrary to expectations, the present study found 
no associations between sRAGE and subclinical vascular measures (aortic PWV or 
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CIMT), or with CV disease or diabetes. This suggests that sRAGE is unlikely to be a 
useful clinical marker to address the CV status in COPD, adding further evidence to 
the existing literature [221]. Although a study by John and colleagues [221] 
demonstrated a weak association between aortic stiffness (PWV) and skin AGEs 
(which are increased in COPD), they failed to find an association with sRAGE. 
Whereas some literature shows reduced sRAGE levels in patients with COPD [178, 
179, 181], the opposite appears to be true in CV disease [189], which may explain the 
lack of association here. Furthermore, the finding that there was no difference in 
sRAGE levels in patients with and without IHD suggests that the reduced sRAGE 
consistently reported in COPD is unlikely to be attributed to the presence of CV 
disease, in line with the existing literature [179]. However, it is still important to 
consider the likelihood of the presence of subclinical CV disease in patients with 
COPD, which emphasises the need for a new approach for CV disease prognostication.  
sRAGE in patients with COPD and lung function 
There has been recent interest in the possible role of sRAGE in predicting disease 
progression and assisting in phenotyping in subjects with COPD [227]. Current 
research shows that sRAGE levels are lower in patients with stable COPD compared 
to subjects without COPD [179, 181]. Smith et al. reported that patients with COPD 
(GOLD II or worse) have reduced sRAGE levels compared to healthy controls [179]. 
The mechanisms behind the reduced sRAGE levels that are consistently found in 
patients with COPD are currently unknown. Although this study did not have a 
comparator group (e.g., control), the mean (SD) sRAGE levels presented in this study 
are comparable to those reported from previous studies in patients with stable COPD 
[184, 221]. Gopal et al. reported a mean (SD) sRAGE of 1042.41 (928.81) pg/mL in 
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patients with stable COPD (GOLD I-IV; n = 146) compared to 1477.66 (668.68) 
pg/mL in healthy controls (n=81) [184].  
The finding that lower sRAGE is independently associated with lung function (FEV1) 
is concordant with the current literature [179, 181]. This study also found an inverse 
association between sRAGE and COPD severity, extending the findings from a 
previous study [181]. Gopal et al. demonstrated that reduced sRAGE level in patients 
with COPD is related to lung function, and patients with COPD receiving long-term 
oxygen therapy have lower levels of sRAGE than patients not receiving oxygen [184].  
The longitudinal association of sRAGE and lung function has also been studied. 
Iwamoto et al. reported that reduced sRAGE was correlated with a greater lung 
function decline (FEV1/FVC), particularly in smokers with COPD (n = 51) [178]. 
However, the correlations were mainly weak, with a marked variation in the sRAGE 
levels of patients with COPD and significant overlap between patients with COPD and 
non-COPD subjects. In contrast, recent data from the SUMMIT trial, including 1,673 
subjects, showed no association between sRAGE at baseline and lung function decline 
over 3 months [228], thus raising questions over the clinical utility of sRAGE in 
predicting the decline in lung function in patients with COPD. Although statistically 
significant associations are important for research, they do not necessarily mean that 
they are of clinical importance. For a single biomarker (e.g. sRAGE) to be used in 
clinical practice, it must provide important information beyond that obtained using 
everyday practice procedures. Therefore, a realistic interpretation of the role of 
sRAGE as a biomarker in COPD should be considered.  
This study found no difference in the sRAGE levels in current and ex-smokers; 
although the impact of smoking on sRAGE levels is not fully understood. However, it 
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is important to note that this study does not have a control group to determine whether 
smoking is the exact cause of reduced sRAGE commonly seen in patients with COPD. 
Nevertheless, in a study conducted by Smith and colleagues, sRAGE levels were 
similar in healthy subjects who ever smoked and in those who never smoked, and 
significantly greater than those in patients with COPD [179]. In the latter study, 
multiple linear regression analysis did not show that a previous smoking history was 
associated with sRAGE, suggesting other mechanisms to the reduced sRAGE in 
patients with COPD. Even in the studies that have shown reduced sRAGE among 
smokers (young control subjects, old control subjects, and patients with COPD), it is 
likely that the reduction is a consequence of recent smoking (within 2 hours of a blood 
sample) instead of chronic exposure, as suggested by Pouwels and colleges [229]. The 
latter study also showed that there was no difference in sRAGE levels between active 
and never smokers [229]. While some literature shows no difference in sRAGE levels 
between smokers and non-smokers [179, 230], others showed lower sRAGE among 
smokers [178, 231], which could, again, be attributed to recent smoking effect within 
the smoking groups. Thus, whether the reduced sRAGE commonly seen in patients 
with COPD is caused by smoking – per se, is to be determined. 
2.4.1 Strengths and limitations of the study 
This study is one of a few to have examined the relationship between sRAGE and CV 
measures in COPD. The strengths of this study are its well-defined inclusion criteria 
and analyses with adjustments for relevant physiological confounders and CV risk 
factors. In addition, this study included patients with co-existing comorbidities, 
making it representative of typical patients with COPD. However, the main limitation 
of this analysis is its cross-sectional nature with regards to the physiological markers; 
thus, it does not allow the determination of causality, despite follow-up being ongoing. 
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Another limitation is that some data for key measures were missing for some of the 
patients. However, these patients had similar characteristics to the rest of the patients 
who were included in the analyses, and the number of patients included in each 
analysis was also reported. It is worth mentioning that participants in the ERICA were 
allowed to perform some of the study measurements over either a single or two visits 
(within three months), meaning that some markers (including sRAGE) may have been 
measured on a separate day to aortic PWV and CIMT. 
2.5 CONCLUSION 
In conclusion, this study has shown that sRAGE is associated with simple spirometric 
lung function but not with physiological CV measures, CV disease or diabetes in the 
ERICA cohort. This study does not support sRAGE being a clinical CV biomarker in 




Chapter 3 Microalbuminuria in Patients with COPD: A 






Although the current COPD guidelines recommend recognising CV disease in patients 
with COPD [1], there is no detailed information on when and how to screen/assess for 
CV risk in patients with COPD. This considerable gap has been highlighted in the 
literature [157, 158], reinforcing that CV risk should be assessed in COPD. The 
identification of easy-to-use CV markers in COPD is the subject of increased research 
interest. Such markers could, therefore, help identify patients at increased CV risk, 
understand CV disease pathophysiology, offer targets for intervention and personalise 
therapy for that particular phenotype [232].  
Microalbuminuria (MAB), which is assessed via the urinary albumin creatinine ratio 
(UACR), is regarded as an early index for microvascular impairment, reflecting 
vascular abnormalities of the glomeruli [233]. In other words, the kidneys act as a 
window to the vasculature. The presence of MAB is not only considered the hallmark 
of renal damage in patients with diabetes [234] but has also been associated with CV 
events and mortality in subjects from the general population [195, 235]. Therefore, it 
is proposed as a potential biomarker, which could identify patients with COPD at 
increased CV risk and may also be a target for CV risk reduction. 
Only a few studies in the literature have evaluated the prevalence of MAB in patients 
with COPD at clinical stability [205-209, 236]. These studies reported that MAB is 
common in patients with COPD, but the prevalence varies, depending on the study 
design, sample size [207] and study population age, which may affect UACR [206], 
and whether the co-existence of COPD associated comorbidities (which are likely to 
affect the prevalence) was considered [209]. The presence of MAB has been associated 
with all-cause mortality in patients with COPD, compared to patients without MAB, 
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even after excluding patients with CV comorbidities [209]; highlighting the significant 
impact of MAB on patients with COPD. 
The associations of MAB with indices of macrovascular complications, such as aortic 
pulse wave velocity (PWV) and CIMT, have been reported in several conditions (e.g., 
diabetes and hypertension) and in the general population [198-200]. However, very 
few investigations have evaluated these relationships in patients with COPD. In a small 
cross-sectional study, John et al. showed that, compared with non-COPD subjects (n 
= 34), patients with COPD (n = 52) had increased UACR, being related to increased 
arterial stiffness, suggesting potential subclinical renal damage [208]. Nevertheless, 
the full extent of the relationship requires further investigation.  
Based on the existing literature, it is hypothesised that MAB, as measured by increased 
UACR, is prevalent in patients with COPD and is related to macrovascular indices 
(aortic PWV and CIMT), indicating subclinical glomerular damage and potential CV 
events.   
The objectives of this chapter are: 
1- To determine and compare the prevalence of MAB in patients with COPD 
with and without co-existing COPD comorbidities (diabetes, 
cerebrovascular disease and ischaemic heart disease). 
2- To assess the relationship of aortic stiffness and carotid intima-media 
thickness with urinary albumin creatinine ratio (UACR) as an indicator for 
the presence of subclinical glomerular injury and CV events in all patients 




3.2.1 Study design and participants 
This study used data obtained from the previously described ERICA cohort [222] 
(Chapter 2). The cross-sectional baseline data from four of the five participating 
centres were analysed. Data from patients with confirmed COPD recruited from the 
Nottingham, Cambridge, London and Liverpool study sites were included. Data from 
the Cardiff site was not available. All data collection was performed by research 
personnel at the participating universities prior to my commencing this PhD.  
3.2.2 Inclusion and exclusion criteria 
The inclusion and exclusion criteria are described in Chapter 2 (subsection 2.2.3.). 
Briefly, patients with COPD (GOLD II–IV) confirmed by post-bronchodilator 
spirometry were included. Patients had to be clinically stable, which means that they 
experienced no exacerbation in the four weeks prior to recruitment. Patients with co-
existing comorbidities were not excluded. 
3.2.3  Measurements 
Details of all procedures and measurements are described elsewhere [222]. Variables 
related to this analysis are described below. 
Anthropometry measures and lung function  
The anthropometry and lung function measures are described in detail in Chapter 2. In 
brief, BMI was calculated from height and weight. FFMI was calculated from a height 
squared. Post-bronchodilator spirometry was performed to determine FEV1, FVC, and 





Spot urine samples were collected after 4 hours of fasting and stored for later 
determination of urinary albumin, protein and creatinine. All samples were analysed 
by Nottingham University Hospitals Trust clinical laboratories. From this, the urinary 
albumin creatinine ratio (UACR) and protein to creatinine ratio (UPCR) were 
obtained. Clinical microalbuminuria (MAB) thresholds of 2.5 mg/mmol for males and 
3.5 mg/mmol for females were used. Macroalbuminuria was defined as UACR >30 
mg/mmol.  
Venous blood samples were drawn after four hours of fasting and six hours of 
refraining from medications and analysed for urea, electrolytes, creatinine, total 
cholesterol, HDL cholesterol and triglycerides. The estimated glomerular filtration rate 
(eGFR) was calculated [223]. 
Cardiovascular measurements 
Cardiovascular measurements were described in Chapter 2. 
• Blood pressure was measured in the supine position after 10 minutes of rest. 
From this, MAP and PP were calculated. 
• Aortic pulse wave velocity 
Aortic stiffness was assessed based on the aortic (carotid-femoral) pulse wave velocity 
(aortic PWV) as described previously [237].  
• Carotid intima medic thickness 
CIMT was measured using B-mode ultrasound with a 7–12 MHz linear probe [222]. 
The largest values for the right and left bilateral CIMT were obtained, and the mean 





Self-reported history of comorbidities, such as ischaemic heart disease, diabetes and 
cerebrovascular disease, was recorded. 
Other measurements 
Medication and smoking history were recorded. 
3.2.4  Statistics 
The data are summarised as relative frequencies for categorical data and arithmetic 
mean (SD) for normally distributed continuous variables where appropriate. The 
normality of the data was assessed graphically. Non-normally distributed (e.g. 
positively skewed) continuous data (UACR, urine albumin, urine creatinine, urine 
protein and UPCR) were log10 transformed in order to perform parametric analysis. 
The results of these variables were back-transformed to obtain the geometric mean 
(SD). 
In this study, the COPD patients were divided into two groups: those with and without 
comorbidities. Independent sample t-tests were performed to compare the mean 
differences between groups for continuous variables, and the chi-squared test was used 
for categorical variables.  
The prevalence of MAB in patients with and without comorbidities was calculated. 
Multivariable logistic regression analysis was performed to estimate the odds ratio 
(OR) for MAB in patients with COPD with and without comorbidities, with 
adjustments for confounders. Confounders were considered as such if they changed 
the OR by 10%. The model was adjusted for age, sex, BMI, smoking and MAP. A P 
value of <0.05 was considered significant.  
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Multiple linear regression models were then applied to estimate the dependence of 
log10 UACR on aortic PWV and CIMT, with adjustments for potential confounders. 
All known and expected confounders were assessed in separate regression models and 
then included in the final models if they altered the regression coefficient by ≥10%. 
Known risk factors for increased CV risk have also been considered as potential 
confounders. For determining the association with aortic PWV, adjustments were 
made for age, sex, BMI, oxygen saturation, eGFR, MAP, smoking status and 
comorbidities. For the association with CIMT, adjustments were made for age, sex, 
BMI, MAP, smoking status, and comorbidities. These analyses were done in 1) all 
subjects (excluding those with macroalbuminuria), and then 2) in patients without any 
co-existing comorbidities (in order to minimise the residual confounding of underlying 
disease). A priori confounders such as age and gender were considered regardless of 
their confounding effects. only complete cases were considered, and the number of 
observations included in each analysis was reported. Data management and analyses 
were done using Stata (version 15) statistical software. 
3.2.4.1 Sensitivity analyses 
In the sensitivity analyses, clinical characteristics and haemodynamic and vascular 
measures (aortic PWV and CIMT) were compared in patients with clinical 
macroalbuminuria versus patients without macroalbuminuria. The sensitivity analyses 
were conducted as the clinical threshold of MAB is defined as UACR of 2.5 mg/mmol 
for males and 3.5 mg/mmol for females, although a small increase in UACR within 




Of the 729 patients in the ERICA cohort, 335 patients were included in the current 
study, representing those with urine samples and hence UACR data (Figure 3-1).  For 
information, patients studied at Cardiff did not have available urine. Three further 
patients were excluded because they had macroalbuminuria. Of the 332 remaining, 68 
patients had at least one comorbidity (diabetes, cerebrovascular disease or IHD). There 
were a total of 56 (17%) patients with a clinical threshold of MAB. Baseline 
characteristics for the whole study population are presented in Table 3-1.  
The baseline characteristics for the sample included in this analysis (n = 332) are 
similar to those for the subjects included in the ERICA cohort (n = 729) in terms of 







Subjects included in the ERICA study 
(n = 729) 
Subjects with urine data 
(n = 335) 
Subjects included in the cross-
sectional analysis 
(n = 332) 
Subjects excluded because they 
did not have urine data 
(n = 394) 
Subjects excluded because they 
had UACR > 30 mg/mmol 
(n = 3) 
Patients with 
comorbidities 
(n = 68)  
Patients without 
comorbidities 
(n = 264) 
Figure 3-1. Flow chart of the included study population 
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Table 3-1. Baseline characteristics for subjects included in the study (n = 332) 
Variable/ No. missing observations Mean (SD unless stated otherwise) 
Age  67.9 (8) 
Male, n (%) 225 (67%) 
Clinical parameters  
BMI (kg/m2)/(n = 6) 26.4 (5.9) 
FFMI (FFM kg/m2)/(n = 27) 18.1 (2.8) 
Smoking history (pack-years)/(n = 7) 47.8 (28.8) 
Smoking status, n (%)  






Urine biochemistry  
UACR (mg/mmol)a 0.83 (3.2) 
Urine albumin (mg/l)a 7.3 (4.1) 
Urine creatinine (mmol/l)a 8.7 (1.9) 
Urine protein (mg/l)a 83.9 (2.1) 
UPCR (mg/mmol)a 9.7 (1.7) 
Clinical MAB, n (%) 56 (17%) 
Haemodynamic status  
Aortic PWV (m/s)/(n = 50) 10.2 (2.8) 
Mean CIMT (mm)/(n = 117) 0.78 (0.15) 
Supine MAP (mm Hg)/(n = 8) 102 (12.6) 
Supine PP (mm Hg)/(n = 5) 59 (13.8) 
Supine heart rate (beats/min)/(n = 45) 75 (0.78) 
Lung function parameters  
FEV1 (L)/(n = 2) 1.34 (0.52) 
FEV1% predicted (%)/(n = 2) 50.4 (16.4) 
FVC (L)/(n = 2) 3 (0.8) 
Oxygen saturations (%)/ (n= 13) 95 (2) 
Blood biochemistry  
eGFR (ml/min)/(n = 19) 85 (18.6) 
Total cholesterol (mmol/L)/(n = 3) 5.1 (1.1) 
LDL cholesterol (mmol/L)/(n = 3) 2.9 (0.8) 
HDL cholesterol (mmol/L)/(n = 3) 1.6 (0.5) 
Triglycerides (mg/dL)/(n = 6) 1.29 (0.6) 
Medical therapy  
High blood pressure medication b/(n = 198) 106 (32%) 
a Geometric mean. 
b A list of high blood pressure medications is described in the appendices. 
Abbreviations: BMI: body mass index; CIMT: carotid intima-media thickness; eGFR: estimated glomerular 
filtration rate; FFMI: fat-free mass index; FEV1: forced expiratory volume in 1 second; FVC: forced volume 
capacity; MAB: microalbuminuria; MAP: mean arterial pressure; PP: pulse pressure; PWV: pulse wave 




Clinical characteristics, renal, haemodynamic and vascular markers in patients with 
and without self-reported comorbidities  
Patients with COPD and comorbidities were older and had a higher BMI, but the 
gender proportion was not different (Table 3-2). Of all patients, there were 30 patients 
with eGFR < 60 ml/min. Of those, there were 12 patients with comorbidities and 18 
patients without comorbidities.  
The geometric mean (SD) for UACR was significantly greater for patients with COPD 
and comorbidities (1.17 [3.5] mg/mmol) compared to those without comorbidities 
(0.76 [3.1] mg/mmol; p = 0.008). The difference remained significant following 
adjustment for age, sex, BMI, smoking and MAP (adjusted β [95% CI] of 1.49 [1.09 
– 2.06]; n = 320; p = 0.013; Table 3-3). The proportion of patients with clinical MAB 
was greater for those with COPD and comorbidities (n = 15/68; 22%) than for those 
without comorbidities (n = 41/264; 15.5%) but the difference did not reach statistical 
significance (p = 0.200). Furthermore, the odds of having clinical MAB were not 
significantly different between patients with and without comorbidities (adjusted odds 
ratio (aOR) 1.89; 95% CI 0.91–3.89; n = 320; p = 0.083; Table 3-3).  
Haemodynamic measures were mostly similar between patients with and without 
comorbidities. The mean (SD) aortic PWV was greater in patients with comorbidities 
(10.94 [2.9] m/s) than in those without comorbidities (10.05 [2.8] ms/s; p = 0.037). 
However, adjustments for confounders diminished the difference (adjusted β: 0.63 
ms/s; 95% CI -0.14 to 1.40; n = 279; p = 0.109; Table 3-3). Further, CIMT was not 




Table 3-2. Baseline characteristics for patients with comorbidities (n = 68) vs. patients 
without comorbidities (n = 264) 
Variable Without 
comorbidities 





(n = 68) 
P-value 
 
Age  67.3 (7.7) 70.6 (7.9) 0.002 
Male, n (%) 175 (66.3%) 50 (73.5%) 0.255 
Clinical parameters     
BMI (kg/m2) 25.9 (5.8) 28.3 (5.9) 0.003 
FFMI (FFM kg/m2) 17.9 (2.8) 19.10 (2.6) 0.004 
Smoking history (pack-years) 47.5 (28.7) 48.8 (29.3) 0.730 
Smoking status, n (%)    








Urine biochemistry    
UACR (mg/mmol)b  0.76 (3.1) 1.17 (3.5) 0.008 
Urine albumin (mg/l)b 6.8 (3.9) 9.1 (4.3) 0.131 
Urine creatinine (mmol/l)b 8.9 (2.1) 7.7 (1.9) 0.126 
Urine Protein (mg/l)b 82.2 (2.1) 90.9 (2.3) 0.340 
UPCR (mg/mmol)b 9.2 (1.6) 11.7 (1.8) 0.001 
Clinical MAB, n (%) 41 (15.5%) 15 (22%) 0.200 
Haemodynamic status    
Aortic PWV (m/s) 10.1 (2.8) 10.9 (2.9) 0.037 
Mean CIMT (mm) 0.75 (0.15) 0.79 (0.14) 0.153 
Supine MAP (mm Hg) 103 (13) 101 (12) 0.252 
Supine PP (mm Hg) 57 (14) 64 (15) 0.001 
Heart rate (beat/min) 76.49 (12.5) 73 (48) 0.095 
Lung function parameters    
FEV1 (L) 1.3 (0.5) 1.4 (0.5) 0.417 
FEV1% predicted (%) 49.7 (17) 53 (15) 0.141 
FVC (L) 3 (0.8) 3 (0.8) 0.681 
Oxygen saturations (%) 95 (2) 95 (2) 0.174 
Blood biochemistry    
eGFR (ml/min) 86.3 (18.1) 78.1 (19.4) 0.002 
Total cholesterol (mmol/L) 5.2 (1) 4.6 (1.2) 0.001 
LDL cholesterol (mmol/L)  3.01 (0.8) 2.43 (0.9) 0.001 
HDL cholesterol (mmol/L) 1.61 (0.5) 1.52 (0.5) 0.182 
Triglycerides (mg/dL) 1.26 (0.6) 1.39 (0.6) 0.940 
Medical therapy    
High blood pressure medication c 70 (27%) 36 (53%) 0.100 
a COPD with comorbidities: diabetes, cerebrovascular disease or ischaemic heart disease. 
b Geometric mean. 
c A list of high blood pressure medications is described in the appendices. 
Abbreviations: BMI: body mass index; CIMT: carotid intima-media thickness; eGFR: estimated glomerular 
filtration rate; FFMI: fat-free mass index; FEV1: forced expiratory volume in 1 second; FVC: forced volume 
capacity; MAB: microalbuminuria; MAP: mean arterial pressure; PP: pulse pressure; PWV: pulse wave velocity; 
UACR: urinary albumin creatinine ratio; UPCR: urinary protein creatinine ratio. 
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Table 3-3. Comparison of renal markers and vascular measures in patients with and 
without comorbidities 






UACR (mg/mmol), β (95% CI) 
Unadjusted (95% CI)  Reference 1.53 (1.12 to 2.1)  0.008 
Adjusted (95% CI) Reference 1.49 (1.09 to 2.06)1 0.013 
Clinical MAB, OR (95% CI)  
Unadjusted (95% CI) Reference 1.54 (0.79-2.98) 0.202 
Adjusted (95% CI) Reference 1.89 (0.91-3.89)1 0.083 
Vascular markers 
PWV (m/s), β (95% CI) 
Unadjusted (95% CI)  Reference 0.88 (0.05 to 1.71) 0.037 
Adjusted (95% CI) Reference 0.63 (-0.14 to 1.40)2 0.109 
CIMT (mm), β (95% CI) 
Unadjusted (95% CI) Reference 0.04 (-0.013 to 0.086) 0.153 
Adjusted (95% CI) Reference 0.006 (-0.043 to 0.055)2 0.833 
1 Adjusted for age, sex, BMI, smoking and MAP. 
2 Adjusted for age, sex, BMI, smoking, FEV1% predicted and MAP. 
Abbreviations: BMI: body mass index; CI: confidence interval; CIMT: carotid intimal medial thickness; FEV1: 
forced expiratory volume in 1 second; MAB: microalbuminuria; MAP: Mean arterial pressure; OR: odds ratio; 




Association of log10 UACR with vascular markers and other variables 
The results from multivariable linear regression models with log10 UACR as the 
dependent variable and its associations with aortic PWV and CIMT adjusted for 
confounders are presented in Table 3-4. Log10 UACR was associated with both aortic 
PWV and CIMT following adjusting for age and sex in all subjects or in patients 
without comorbidities. However, in the fully adjusted models, neither aortic PWV nor 
CIMT were associated with log10 UACR in all subjects or in patients without 
comorbidities (Table 3-4).  
Table 3-4. Associations of log10 UACR with aortic PWV and CIMT in 1) all subjects with 
COPD and 2) subjects without comorbidities 
Dependent variable: log10 UACR 
All subjects with COPD 
 β (95% CI) Adjusted β (95% CI) P-value 
Aortic PWV – per 
1 m/sec change 
0.033  
(0.013 to 0.054) 
(n = 282) 
0.012  
(-0.010 to 0.036)1 
(n = 269) 
0.278 
CIMT – per 1 mm 
change 
0.51 
(0.047 to 0.92) 
(n = 215) 
0.37  
(-0.12 to 0.87)2 
(n = 209) 
0.140 
Subjects without comorbidities 
 β (95% CI) Adjusted β (95% CI) P-value 
Aortic PWV – per 
1 m/sec change 
0.025  
(0.002 to 0.049) 
(n = 227) 
0.011  
(-0.014 to 0.037)3 
(n=217) 
0.386 
CIMT – per 1 mm 
change 
0.60  
(0.077 to 1.12) 
(n = 166) 
0.44  
(-0.12 to 1.01)4 
(n = 161) 
0.122 
1 Adjusted for age, sex, BMI, oxygen saturation, eGFR, MAP, smoking status, comorbidities and study site. 
2 Adjusted for age, sex, BMI, MAP, smoking status, comorbidities and study site 
3 Adjusted for age, sex, BMI, oxygen saturation, eGFR, MAP, comorbidities and study site 
4 Adjusted for age, sex, BMI, MAP, smoking status, comorbidities and study site 
Abbreviations: BMI: body mass index; CI: confidence interval; CIMT: carotid intimal medial thickness; eGFR: 
estimated glomerular filtration rate; MAP: mean arterial pressure; PWV: pulse wave velocity; UACR: urine 
albumin creatinine ratio. 




In the whole study population, log10 UACR was also positively correlated with age (r 
= 0.15; p < 0.005; n = 332), MAP (r = 0.17; p = 0.002; n = 324) and PP (r = 0.12; p = 
0.020; n = 327) and inversely correlated with eGFR (r = -0.11; p = 0.047; n = 313) and 
resting oxygen saturation (r = -0.11; p = 0.035; n = 320), but no associations were 
observed with FEV1% predicted or BMI. In the subgroup without comorbidities, these 
associations remained largely similar, except for supine PP and eGFR (Table 3-4).  
Table 3-5. Correlations between log10 UACR and vascular measures (aortic PWV and 
CIMT) and other factors in all patients with COPD and 2) patients without comorbidities 
Variable All patients with COPD  Patients without comorbidities  
 Log10 UACR Log10 UACR 






































Abbreviations: BMI: body mass index; eGFR: estimated glomerular filtration rate; FEV1: forced expiratory 
volume in 1 second; MAP: mean arterial pressure; PP: pulse pressure; PWV: pulse wave velocity; UACR: urine 
albumin creatinine ratio. 




Sensitivity analysis: Clinical characteristics and vascular measures in patients with 
and without microalbuminuria  
The patients included in this study (n = 332) were divided into two groups based on 
the presence or absence of microalbuminuria. The demographics and clinical 
characteristics were largely similar between the two groups (Table 3-6). 
The mean aortic PWV was significantly greater for patients with MAB (11.51 [2.8] 
m/s) compared to patients without MAB (10.03 [2.8] m/s; p = 0.019). Even following 
adjustment for confounders, the aortic PWV was 1.03 m/s higher in patients with MAB 
than patients without MAB (adjusted β: 1.03 m/s; 95% CI: 0.12 to 1.96; n = 263; p = 
0.038; Table 3-7). However, there was no difference in CIMT in patients with and 




Table 3-6. Baseline characteristics of COPD patients with and without clinical 
microalbuminuria 
Variable COPD without 
MAB (n = 276) 
COPD with 
MAB (n = 56) 
P-value 
Age  67.7 (7.8) 69.4 (7.9) 0.131 
Male, n (%) 191 (66%) 34 (61%) 0.215 
Clinical parameters     
BMI (kg/m2) 26.5 (5.9) 25.9 (5.9) 0.522 
FFMI (FFM kg/m2) 18.1 (2.8) 18 (3.1) 0.932 
Smoking history (pack-years) 48 (28.9) 46.6 (28.1) 0.759 








Haemodynamic status    
Aortic PWV (m/s) 10.03 (2.8) 11.51 (2.8) 0.002 
Mean CIMT (mm) 0.76 (0.15) 0.78 (0.14) 0.445 
Supine MAP (mm Hg) 101 (12.1) 106 (14.3) 0.017 
Supine PP (mm Hg) 58.02 (13.4) 63.44 (16.7) 0.014 
Lung function parameters    
FEV1 (L) 1.36 (0.52) 1.23 (0.48) 0.088 
FEV1% predicted (%) 51 (16.6) 47 (14.9) 0.118 
FVC (L) 3.1 (0.8) 2.8 (0.7) 0.068 
Oxygen saturations (%) 95 (2) 95 (2) 0.175 
Blood biochemistry    
eGFR (ml/min) 85.84 (17.8) 78.19 (21.5) 0.008 
Total cholesterol (mmol/L) 5.08 (1.1) 5.02 (1.1) 0.746 
LDL cholesterol (mmol/L)  2.92 (0.9) 2.72 (0.9) 0.145 
HDL cholesterol (mmol/L) 1.57 (0.5) 1.69 (0.6) 0.155 
Abbreviations: BMI: body mass index; CIMT: carotid intima-media thickness; eGFR: estimated glomerular 
filtration rate; FEV1: forced expiratory volume in 1 second; FFMI: fat-free mass index; FVC: forced volume 





Table 3-7. Vascular measures (aortic PWV and CIMT) in patients with and without 
microalbuminuria 
 Patients without MAB Patients with MAB P-value 
PWV (m/sec), β (95% CI) 
Unadjusted (95% CI)  Reference 1.48 (0.52 to 2.44) 
(n = 282) 
0.002 
Adjusted (95% CI) Reference 1.03 (0.12 to 1.96)1 
(n = 263) 
0.038 
CIMT (mm), β (95% CI) 
Unadjusted (95% CI) Reference 0.02 (0.03 to 0.08) 
(n = 215) 
0.446 
Adjusted (95% CI) Reference 0.01 (0.05 to 0.07)1 
(n = 202) 
0.729 
1 Adjusted for age, sex, BMI, smoking status, eGFR, MAP, and comorbidities.  
Abbreviations: BMI: body mass index; CI: confidence interval; CIMT: carotid intimal medial thickness; eGFR: 
estimated glomerular filtration rate; FEV1: forced expiratory volume in 1 second; MAB: microalbuminuria; 
MAP: mean arterial pressure; PWV: pulse wave velocity; UACR: urine albumin creatinine ratio. 




3.4  DISCUSSION 
In this group of stable patients with COPD, patients with co-existing comorbidities 
exhibited significantly greater UACR than patients without  comorbidities. The 
prevalence of microalbuminuria was also greater in patients with comorbidities, 
although this did not reach statistical significance. However, the associations of log10 
UACR with aortic PWV and CIMT were nullified, becoming non-statistically 
significant, after adjustments for known confounders.  
Only a few studies in the literature have reported the prevalence of MAB in COPD at 
clinical stability [205-207, 209, 236]. Current estimates of the prevalence of MAB in 
patients with COPD vary across studies, depending on sample size, population age, 
COPD severity and whether co-existing comorbidities were considered. For instance, 
Casanova et al. showed that the prevalence of MAB in patients with COPD was 24% 
compared with 6% in smokers without COPD [206]. However, age was markedly 
different between groups, which is likely to affect UACR and, consequently, the 
prevalence of MAB. The overall prevalence of MAB reported in this study at 17% 
(22% in patients with comorbidities) is slightly higher than the prevalence reported by 
Johan and colleagues at 13%, using similar inclusion criteria [208]. However, Johan’s 
study included patients with GOLD I (unlike this study where patients with GOLD II 
and worse were included). This suggests that MAB is common in patients with COPD 
regardless of the co-existing comorbidities and level of severity.  
It was a little unexpected not to find an independent association for log10 UACR with 
aortic PWV and CIMT, following adjustments for confounders. Both aortic PWV and 
CIMT are well-recognised markers for increased CV risk in people with COPD [214-
217] and have also been associated with MAB in a number of conditions as well as in 
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the general population [198-200]. However, there is a lack of studies investigating the 
association between UACR and aortic PWV or CIMT in patients with COPD. In a 
previous study, John et al. reported an association between aortic PWV and UACR in 
patients with COPD, independent of common risk factors [208]. In their study, 29% 
(15/52) of patients with COPD had an eGFR < 60 ml/min (mean eGFR = 67 ml/min; 
mean age = 68 years), demonstrating that a large proportion of patients have renal 
dysfunction, and highlighting the increased risk of CV events [238]. In contrast, only 
9% (30/332) of patients included in this study had an eGFR < 60 ml/min (mean = 84.7 
ml/min; mean age = 68 years). In fact, there is no apparent reason that the eGFR noted 
by John et al. should be different from the eGFR reported in this study, as the age and 
clinical characteristics were largely similar, except that patients in the ERICA cohort 
were recruited across five centres (four included in this analysis), and that the cross-
sectional measurements were performed over either one or two visits.  
Another point to consider for the lack of associations between UACR and aortic PWV 
is that the aortic PWV reported in this study was generally lower than in previous 
literature [208]. John and colleagues reported a higher aortic PWV in patients with 
confirmed microalbuminuria (mean = 12.3 m/sec) compared to the aortic PWV of 11.5 
m/sec found in this study [208]. Indeed, current evidence demonstrates that an increase 
of 1 m/sec in aortic PWV is associated with a 14% increase in total CV events and a 
15% increase in CV mortality [239]. The differences in the patient characteristics 
across studies are likely to produce different results. It is also possible that the lack of 
associations reported here is because patients had a low UACR, and their 
haemodynamic measures were generally within the normal range (including aortic 
PWV and CIMT). In addition, given that a third of the study population were on blood 
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pressure medications, which are known to reduce aortic stiffness and 
microalbuminuria [240], may also explain the lack of associations.   
Despite the lack of associations between UACR and aortic PWV or CIMT, it is 
important to emphasise that the existence of MAB, by itself, is an indicator of 
increased CV risk and a predictor for mortality in the general population [194-197]. 
This study showed that MAB was prevalent even in patients with COPD without 
known comorbidities. Romundstad et al. demonstrated that patients with COPD and 
MAB were at 54% increased risk of all-cause mortality (but not CV mortality) 
compared to patients without MAB [209]. Interestingly, the risk also remains (49% 
increased risk) even after excluding patients with self-reported CV disease [209]. 
Therefore, periodic MAB monitoring for potential renal impairment, CV events and 
mortality should be considered for patients with COPD. 
Current evidence suggests that albuminuria is a continuum and that kidney injury and 
CV disease can still occur even below the clinical threshold for microalbuminuria 
[241-243]. A collaborative meta-analysis showed that a urine albumin creatinine ratio 
of 1.1 mg/mmol (which is below the clinical threshold of MAB) was associated with 
a 20% increased risk of all-cause mortality in the general population, compared with a 
urine albumin creatinine ratio of 0.6 mg/mmol [202]. It has also been suggested that 
an increase in UACR of 3.5 mg/g (≈ 0.4 mg/mmol) is associated with a 6% increase 
in CV risk [197]. In this context, it is important to consider the minimal increase in 
UACR in patients with COPD. Indeed, this study showed that patients with self-
reported comorbidities have a significantly higher UACR compared to those without 
(although both were within the normal range), highlighting the potential increased risk 
of subsequent CV events and mortality. 
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In addition to the macrovascular abnormalities associated with increased arterial 
stiffness, it has also been linked to microvascular damage (e.g. renal dysfunction) [244, 
245]. Studies have shown that elevated arterial stiffness is an independent risk factor 
for a renal function decline in patients with kidney disease [246, 247]. The present 
study demonstrated that patients with COPD and MAB (which is a marker of renal 
impairment) had significantly higher aortic PWV compared to patients without MAB. 
Indeed, increased aortic stiffness contributes to greater pressure and oscillation 
exposure in the renal system [248] and, since the kidneys are very sensitive, they are 
more likely to be affected by the excessive blood pressure [249], potentially leading to 
injured glomerular capillaries. Further investigation is needed to determine whether 
the increase in aortic stiffness mechanistically leads to the development of MAB. 
Nevertheless, the clinical prognostic implications of the microvascular state should be 
considered in COPD management. 
The prevalence of patients with COPD having renal impairment has been highlighted 
in the literature [250-254]. Incalzi et al. showed that patients with COPD have 
increased prevalence of chronic renal failure (both overt and concealed), defined as 
(GFR < 60 mL/min/1.73 m2) compared to age-matched subjects without COPD [250]. 
However, identifying renal impairment based on eGFR alone is likely to underestimate 
the true prevalence as its role in the elderly is still under debate [255]. This does not 
imply that eGFR should not be taken into consideration when assessing renal function, 
but rather it should be interpreted with caution. Microalbuminuria usually occurs 
before any loss of GFR. In addition, it is considered the most important indicator for 
renal impairment and has also been associated with worse clinical outcomes, 




3.4.1 Clinical implications 
Increasing evidence suggests that COPD and CV disease often co-exist [97]. Current 
COPD guidelines recognise CV disease as one of the most common comorbidities in 
patients with COPD  and suggest that it should be routinely assessed and managed [1]. 
Although no specific recommendations have been made on how to do so, healthcare 
professionals are encouraged to manage comorbidities (CV disease in this instance) as 
if the patients do not have COPD. This, however, implies recognising, diagnosing and 
assessing the co-existing comorbidity in the first place. For instance, if kidney function 
is influenced by changes in the haemodynamic status or vice versa, it is therefore 
important to assess the interplay between micro- and macro-vascular states in patients 
with COPD. 
The utilisation of biological markers not only helps identify patients at increased CV 
risk but also provides a route for targeted therapy for that particular phenotype. Indeed, 
MAB is considered as a therapeutic target in the clinical management of patients with 
diabetes and hypertension [257, 258]. Thus, MAB could provide an opportunity for 
early and appropriate interventions before the development of a major CV disease in 
patients with COPD. 
3.4.2 Strengths and limitations 
The main strengths of this study are its well-defined inclusion criteria and adjustments 
for known physiological confounders. Additionally, this study included patients with 
confirmed COPD with co-existing comorbidities, such as diabetes, cerebrovascular 
disease and ischaemic heart disease, a different approach that has not been widely used 
in previous studies. It is thus representative of typical patients with COPD seen in 
clinical settings. However, the current study has some limitations. First, the cross-
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sectional nature of the study did not allow assessment for any causality. Second, the 
patients with COPD and comorbidities were significantly older than the patients 
without comorbidities, which could explain the higher UACR observed in patients 
with comorbidities. However, age and gender were adjusted for in the multivariable 
analysis and UACR was still higher. Another limitation is that some key measures 
were missing for some of the patients, which may lead to potential bias, loss of power 
and therefore an underestimation to the examined associations. It is acknowledged that 
missing data is a common issue in epidemiological research and should therefore be 
dealt with appropriately. It is nevertheless important to mention that the complete case 
analysis approach used in this chapter was appropriate, as the complete cases (patients 
included in these analyses) have similar characteristics to those who were missing 
(patients included in the ERICA cohort). In addition, only data (urine samples) from 4 
of the 5 recruiting centres for ERICA were available for this analysis and thus included 
in this chapter. This study has also reported the number of observations included in 
each analysis and carried a number of sensitivity analyses to test the robustness of the 
main findings.   
3.5  CONCLUSION 
Although there is evidence of increased UACR in patients with co-existing 
comorbidities, UACR was not found to be strongly associated with aortic stiffness or 
carotid intima-media thickness in the ERICA cohort. However, microalbuminuria was 
still prevalent in all patients with COPD, highlighting a potential risk of sub-
glomerular damage and subsequent CV events. Therefore, screening for MAB and 
early intervention to optimise the CV status should be considered. 
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Chapter 4  Dementia and Cognitive Impairment in Patients 





4.1 INTRODUCTION  
Cognitive impairment contributes to greater functional disability [259, 260], increased 
need for care services [119], lower adherence to complex medication regimens [261], 
difficulties in managing chronic diseases [262], worse clinical outcomes [263] and 
predicts mortality in certain COPD populations [264]. Potential causes contributing to 
impaired cognitive state in patients with COPD are likely multiple and include ageing, 
co-existent cardiovascular (CV) disease, smoking, hypoxemia and hypercapnia [106].   
Despite an association between cognitive impairment and COPD [129, 265, 266], the 
prevalence of cognitive impairment in COPD remains uncertain. Cognitive 
impairment is estimated to affect between 4% to 61% of patients with COPD [262, 
267], depending on the study populations and assessment methods [129, 268]. 
However, it remains less clear how this compares to age- and sex-matched subjects 
without COPD. Current literature also suggests that the prevalence increase in line 
with severity of COPD, although severity measures have not been consistent across 
studies [129, 268]. The existing studies investigating the prevalence of cognitive 
impairment in COPD are limited by methodological differences, such as study design, 
population age, inadequate matching group, and short follow-up [269-272]. Thus, the 
estimated prevalence is caveated.  
Cognitive impairment represents a spectrum leading to dementia in a proportion of 
patients [122]; however, not all patients with confirmed cognitive impairment will 
eventually progress to dementia. Current literature on the association between COPD 
and dementia are generally scarce. However, it is suggested that COPD increases the 
risk of cognitive impairment and subsequent dementia [136, 138]. Although these prior 
studies provide some information on the relationship between COPD and dementia, 
they utilised a self-reported history of COPD or had a short follow-up time. Current 
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evidence suggests that patients with COPD and cognitive impairment are at increased 
risk of developing dementia [271]. Identifying the proportion of patients with COPD 
at increased risk of cognitive impairment and dementia is important in understanding 
the broader clinical spectrum of COPD and in providing services that are structured to 
meet patient needs.   
The association between COPD and either cognitive impairment or dementia remains 
less clear. The hypothesises of this chapter are 1) patients with COPD would have a 
greater proportion of coded cognitive impairment and dementia at the time of COPD 
diagnosis/index date compared to subjects without COPD, and 2) they are at increased 
risk of incident cognitive impairment and dementia following COPD diagnosis/index 
date.   
The aims of this chapter are twofold: 
1- To report the prevalence of cognitive impairment and dementia at the time of 
COPD diagnosis in patients with COPD and matched subjects without COPD.  
2-  To determine the incidence of cognitive impairment and dementia following a 
diagnosis of COPD in patients with COPD and matched subjects without 





4.2.1 Study design 
Aim 1:  A case-control study was used to describe and report the prevalence of 
cognitive impairment at the time of COPD diagnosis. A similar study design was also 
conducted to report the prevalence of dementia. 
Aim 2: A matched cohort study was conducted to determine the incidence of cognitive 
impairment following COPD diagnosis/index date in patients with COPD and subjects 
without COPD. The incidence of dementia was also determined using the same study 
design.  
4.2.2 Data source 
The cohort information was obtained using The Health Improvement Network 
(THIN). See subsection 4.2.2.1.  
4.2.2.1 Description of The Health Improvement Network (THIN) 
The THIN is a large, representative UK database, which contains longitudinal fully 
anonymised patients’ electronic health records (>12 million people) from over 550 
general practices (GPs) and covering more than 6% of the UK population, using Vision 
computer software [273]. The data collection in THIN started in January 2003. This 
was after the partnership between the Epidemiology and Pharmacology Information 
Core (EPIC) (which provides the primary care data) and In Practice Systems (which 
developed the software used in GP practices). A significant proportion of people 
whose records are recorded within THIN are still actively contributing data. Historical 
data may also be present for those who have died or left the GP practice.    
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All information obtained from primary care visits to a GP, or any other healthcare 
professionals at practices participating in THIN is recorded in the database. Data are 
stored in several files (patient, medical, therapy, additional health details, and postcode 
variable indicator), created by individual practice, and linked to each other by a unique 
identifier (patient, consultation, or staff). Patients’ data within THIN include 
demographics, medications, past medical history, diagnostic results, and lifestyle 
characteristics [274]. Clinical Information within THIN is recorded using hierarchical 
READ codes, and medication information is recorded using drug codes.     
The recruitment of practices in THIN is done through the partnership between the two 
companies (EPIC and In practice Systems). Participating practices in THIN are paid 
for the utilisation of their data. It is important to note that practices must meet 
minimum quality standards for data recording, suggested by EPIC, in order to join 
THIN. Such standards are subject to routine adjustments to meet the changes in NHS 
requirement for data collection and storage. Failure to meet the required quality of 
recordings can result in a suspension of that practice until problems are resolved. If 
problems persist, that practice may be excluded from THIN.     
The version of the THIN data used in this thesis was provided by the University of 
Nottingham, Division Respiratory medicine and Division of epidemiology and public 
health. The initial data preparation - pulling the raw data from THIN -  which contains 
records of all patients with COPD and subjects without COPD, was organised by Dr. 
Gibson prior to commencing this PhD. The candidate performed subsequent data 
extractions and performed all data analyses.  
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4.2.3  Ethical approval 
Ethical approval for this study was provided by an independent Scientific Review 
Committee (SRC), reference number - 17THIN095.  
4.2.4 Study population  
The index population comprised individuals aged ≥40 years with a first-time COPD 
diagnosis (defined based READ codes; appendix 9-2) from 1st April 2006 to 31st 
December 2015, with ≥ 1 year of record prior to the diagnosis of COPD. Up to four 
comparison subjects without a diagnosis of COPD were matched for each patient with 
COPD by age, gender and GP practice. The beginning of the study period (01-04-
2006) was chosen based on the initial introduction of dementia coding to the quality 
and outcomes framework (QOF) [275].        
4.2.5 Outcome definitions  
1- Cognitive impairment was defined based on READ codes. In this study, the 
term cognitive impairment does not include a diagnosis of dementia (READ 
coded), as cognitive impairment does not necessarily lead to a diagnosis of 
dementia.    
2- A diagnosis of dementia was defined based on READ codes. An expert 
geriatrician (Prof. Adam Gordon) was consulted to help identify all available 
Read codes related to dementia. An inclusive approach was taken where any 
potentially relevant diagnosis was considered. (Read codes are available in 
appendices 9-3 & 9-4).    
3- Either cognitive impairment or dementia was also considered as a separate 
outcome (see subsection 4.2.7.1). In the absence of the systematic assessment 
in GP practice, these terms may have been used synonymously. It is also 
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important to note that anyone with a diagnosis of dementia is, by definition, 
cognitively impaired. Therefore, it was important to consider such an outcome.   
4.2.6 Outcome measures and follow-up 
Prevalence 
The prevalence of cognitive impairment was defined as the first of any READ code 
recorded prior to, at, or 6 months after the index date. This was determined in patients 
with COPD and subjects without COPD. The prevalence of coded dementia was 
similarly determined.   
Incidence 
1- Cognitive impairment: subjects with a code of cognitive impairment and 
dementia recorded prior to, at, or 6 months after the index date were excluded. 
Subjects were then followed-up from 6 months after the index date until either 
they received a cognitive impairment Read code (first READ code), left the 
GP practice, died or reached the end of the follow-up (31/12/2015), whichever 
came first.  
2- Dementia:  subjects with a former diagnosis of dementia recorded prior to, at, 
or 6 months after the index were excluded from analyses related to dementia 
incidence. Incident dementia was defined as the first READ coded recorded 




Explanatory variables and potential confounders 
A number of explanatory variables were identified at baseline.  
Definition of variables   
• Age at diagnosis was determined and categorised as follows: < 60, 60-69, 70-
79, and 80 years and older.    
• Body mass index (BMI) was determined within 2 years (before and after) of 
index date. BMI consisted of documented and computed values. Where there 
was no documented BMI, where possible, BMI was calculated from the height 
and weight records. The BMI was then categorised as follows: (underweight - 
<18.5 kg/m2, normal – 18.5-<25 kg/m2, overweight – 25-<30 kg/m2, obese - 
>30 kg/m2). Subjects with no available BMI data were categorised under “no 
records”.  
• The closest record of MRC dyspnoea score [37], 1 year either side of the index 
date, was obtained. The MRC score was categorized as follows: 1, 2, 3 or 4-5. 
A further category of “no records” was then added for any subject without 
available data.  
• For smoking, the most recent record to COPD diagnosis, whether prior or after 
the index date, was used. The smoking status was categorized into 3 main 
categories: never smoked, ex-smoker, and current smoker. A 4th category 
“unknown” was then added for subjects without available smoking data. 
Individuals who were initially recorded as “current smoker” then “never 
smoked” were recorded as “ex-smoker.” 
• A modified Charlson Comorbidity Index (CCI) [276, 277], excluding dementia 
and cardiovascular (CV) disease (congestive heart failure, ischemic heart 
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disease, and peripheral vascular disease), was determined before or at the index 
date. A modified CCI was categorised as follows: 0-1, 2, 3, and ≥ 4. CCI is an 
approach to classify comorbid conditions, where each comorbidity is assigned 
to score (from 1 to 6). (Appendix 9-7).  
• For alcohol, the most recent record to COPD diagnosis was determined, 
whether prior to or at the index date. Alcohol status was categorised into three 
main groups as follows: lifelong teetotaller, ex-drinker, and current drinker. 
Subjects with no available data were categorised under “no records”. 
• Townsend score (a measurement of social class) [278] was determined before 
or at the index date. It was classified as follows: 1 (least deprived), 2, 3, 4, and 
5 (most deprived). The Townsend score combines information from different 
categories, such as unemployment, car ownership, homeownership, and 
overcrowding.   
• Having been prescribed at least one prescription of corticosteroids within one 
year (prior and after) of the index date was considered as a risk factor.  
• Individual comorbidities such as diabetes, cardiovascular disease, and 
cerebrovascular disease were determined prior to, at, or 6 months after the 




4.2.7 Statistical analysis 
Aim 1: The prevalence of cognitive impairment was obtained by calculating the 
proportion of individuals who had coded cognitive impairment within the COPD and 
without COPD population before, at, or 6 months within the index date. McNemar test 
was used to compare categorical data, including the prevalence of cognitive 
impairment between groups. A p<0.05 was considered significant.  
Multivariable conditional logistic regression analysis was performed to estimate the 
odds ratio (OR) for the prevalence of cognitive impairment for both groups (patients 
with COPD and subjects without COPD). The OR of the prevalence of cognitive 
impairment was assessed in a multiple conditional logistic regression to adjust for 
accepted confounders. Confounders were considered in the final model if they 
independently changed the OR for cognitive impairment by ≥ 5%. All covariates were 
assessed in separate regression models.   
Aim 2: Those with a coded cognitive impairment and/or coded dementia at baseline 
(prior, at, or within 6 months after the index date) were excluded from analysis related 
to cognitive impairment incidence. The incidence of cognitive impairment was defined 
as the time from 6 months after the index date to the diagnosis of cognitive impairment, 
leaving the GP clinic, death, or end of the follow up (31/12/2015), whichever comes 
first.  
Cox proportional hazards regression analysis was used to estimate the hazard ratio 
(HR) for cognitive impairment in patients with COPD and matched subjects. Survival 
analysis and Kaplan-Meier plots were performed to compare the incidence of cognitive 
impairment between patients with COPD and subjects without COPD. Potential 
confounders as above were considered in the final model (for each outcome) if they 
changed the HR by 5% or more. Each confounder was assessed in a sperate model 
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(one at a time), with removing the existing potential confounder before adding the next 
one. Potential confounders include BMI, MRC dyspnoea score, smoking status, 
modified CCI, Townsend score, corticosteroid prescription, and CV disease. The 
assumption of cox regression model was checked using Schoenfeld residuals.  
The same analyses were then conducted for dementia in place of cognitive impairment 
in subjects without a former code of dementia. Data management and statistical 
analyses were conducted using STATA version 15.0 software.   
4.2.7.1 Sensitivity analyses 
Several sensitivity analyses were carried. 
1- The prevalence and incidence of cognitive impairment were compared within 
patients with COPD based on MRC dyspnoea score (1-3 vs 4-5). Similarly, 
analysis for dementia was conducted in place of cognitive impairment. 
2- The prevalence and incidence of coded vascular dementia were determined in 
patients with COPD and subjects without COPD. 
3- A sensitivity analysis was conducted to examine the difference in the 
prevalence and incidence of dementia in patients with COPD and their matched 
subjects without COPD at two different incident COPD diagnosis timeframes: 
1) 01-01-2004 (the National Institute for Health and Care Excellence (NICE) 
[279] COPD guideline published in 2004) to 31-12-2015 and 2) 01-04-2012 
(the enhancement of dementia coding in QOF [280]) to 31-12-2015 in 
individuals who are 65 years and older.   
4- The cumulative prevalence of either cognitive impairment/dementia or both 
were determined in patients with COPD and subjects without COPD from 01-
04-2006 onwards to 31-12-2015. 
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5- The incidence of either cognitive impairment or dementia was also determined 
in patients with COPD and subjects without COPD, excluding subjects with a 




A total of 65,068 patients with COPD and 249,166 subjects without COPD were 
included in the analyses (Figure 4-1). The baseline characteristics of the study 
population are presented in Table 4-1. There were more males than females (53% vs 
47%). The mean (SD) at diagnosis was 65 (10.9) years. The median follow-up period 
was 4.3 years across both groups. Co-morbidities were greater in patients with COPD 
compared to subjects without COPD.  
Figure 4.1. Flow chart to the study   
  
Study participants from The Health 
Improvement Network (THIN) database 
N=314,234  
Eligibility: 
≥40 years old 
Index date- 1/4/2006 to 31/12/2015 





Evaluating prevalence of cognitive 
impairment and dementia  
















N= 61,569  
Excluding subjects with prevalent 
dementia  
Evaluating the incidence of dementia  
Excluding subjects with prevalent 
cognitive impairment  
-    
90 
 
Table 4-1. Baseline characteristics for patients with COPD and up to four subjects 
without COPD matched by age, gender and GP 
Characteristics Patients with COPD  Subjects without 
COPD 
 
   
 n = 65,068 % n = 249,166 % P-value 
Age at diagnosis (years) 
<60 17,957 27.60 71,181 28.57  
 
 
60–69 21,269 32.69 83,070 33.34 
70–79 17,716 27.23 66,504 26.69 
≥80  8,126 12.49 28,411 11.40 
Gender      
Male 34,404 52.87 130,292 52.29  
Female 30,664 47.13 118,874 47.71  
Townsend score      
1 least deprived 10,563 16.23 60,373 24.23  
 
<0.001 
2 11,518 17.70 55,552 22.30 
3 13,171 20.24 49,063 19.69 
4 14,837 22.80 43,390 17.41 
5 most deprived 12,490 19.20 30,452 12.22 
No records 2,489 3.83 10,336 4.15  
BMI (kg/m
2
)       
Underweight (<18) 3,898 5.99 4,421 1.77  
 
<0.001 
Normal (18-24.9) 21,923 33.69 72,544 29.11 
Overweight (25-29.9) 20,296 31.19 87,720 35.21 
Obese (≥30) 17,645 27.12 61,860 24.83 
No records 1,306 2.01 22,621 9.08  
MRC dyspnoea score  
1 9,197 14.13 1,151 0.46  
 
<0.001 
2 18,928 29.1 1,066 0.43 
3 10,126 15.56 433 0.17 
4–5 5,032 7.73 173 0.07 
No records 21,785 33.47 246,343 98.87  
Smoking status  
Never smoked 5,466 8.40 117,190 47.03  
<0.001 Ex-smoker 35,400 54.40 89,839 36.06 
Current smoker 24,127 37.08 34,307 13.77 
Unknown 75 0.12 7,830 3.14  
Modified CCI      
0–1 33,851 52.02 178,172 71.51  
 
<0.001 
2 10,119 15.55 35,175 14.12 
3 10,389 15.97 19,609 7.87 
≥ 4 10,709 16.46 16,210 6.51 
Medications       




 Table 4-1. (continued) 
Characteristics Patients with COPD Subjects without 
COPD 
 
   
 n = 65,068 % n = 249,166 % P-value 
Comorbidities  
Diabetes mellitus 9,047 13.90 32,271 12.95 <0.001 
CV disease  
(CHF, IHD, PVD) 
17,400 26.74 41,848 16.80 0.001 
Cerebrovascular disease 5,489 8.44 14,721 5.91 <0.001 
Alcohol status      
Lifelong teetotaler 13,114 20.15 44,753 17.96  
<0.001 Ex-drinker 4,606 7.08 9,206 3.69 
Current drinker 44,046 67.69 171,476 68.82 
No records 3,302 5.07 23,731 9.52  
Abbreviations: BMI: body mass index; CCI, Charlson comorbidity index; CHF: chronic heart failure; CV: 





Prevalence around index date  
Prevalence of cognitive impairment 
A total of 10,517 subjects (patients with COPD and subjects without COPD) had a 
doctor recode of cognitive impairment at index date. The proportion of cognitive 
impairment without a diagnosis of dementia was significantly greater for patients with 
COPD (n=2,629; 4.1%) than for subjects without COPD (n=7,883; 3.2%), p<0.001. 
Cognitive impairment remained more prevalent in patients with COPD after 
adjustment for age, gender, and GP practice (OR: 1.32 (95% CI: 1.26 to 1.39, 
p<0.001); Table 4-2). This association was then diminished by the effect of smoking, 
CV disease, and modified CCI in the fully adjusted model (adjusted OR [aOR]: 0.97 








Table 4-2. Univariate and multivariate conditional logistic regression models of the 
prevalence of cognitive impairment for patients with COPD (n= 65,068) and subjects 
without COPD (n= 249,166), matched by age, gender, and GP practice 
Descriptor OR (95% CI) Fully adjusted OR (95% CI) 
Subjects   
Subjects without COPD 1 1 
Patients with COPD 1.32 (1.26 to 1.39) 0.97 (0.87 to 1.09) 
Modified CCI   
Score 0-1 1 1 
Score 2 1.57 (1.53 to 1.30) 1.62 (1.53 to 1.70) 
Score 3 2.97 (2.87 to 3.05) 2.48 (1.35 to 2.64) 
Score 4 and more 3.84 (3.73 to 3.95) 2.93 (2.75 to 3.13) 
Smoking Status   
Never 1 1 
Former 9.79 (9.47 to 10.1) 7.24 (6.68 to 7.65) 
Current 18.79 (18.14 to 19.47) 14.81 (13.96 to 15.79) 
Unknown 0.20 (0.16 to 0.26) 0.49 (0.35 to 0.70) 
Townsend score   
1 least deprived 1 1 
2 1.25 (1.21 to 1.29) 1.16 (1.09 to 1.24) 
3 1.71 (1.66 to 1.76) 1.35 (1.27 to 1.45) 
4 2.32 (2.25 to 2.39) 1.66 (1.55 to 1.78) 
5 most deprived 3.01 (2.91 to 3.11) 1.80 (1.17 to 1.53) 
No records 1.60 (1.51 to 1.70) 1.36 (1.20 to 1.53) 
CV disease   
No 1 1 
Yes 1.87 (1.83 to 1.91) 1.08 (1.02 to 1.12) 
Corticosteroids   
No 1 1 
Yes 11.08 (10.8 to 11.37) 7.37 (7.37 to 8.10) 
The fully adjusted Odds Ratio (aOR) was 0.97, 95% CI 0.87 to 1.09, p=0.629 – the multivariable conditional 
logistic regression model derived aOR was adjusted for age, gender, GP practice, modified Charlson comorbidity 
index, smoking status, socioeconomic class, Cardiovascular disease, and  oral corticosteroid use.  
Abbreviations: CCI, Charlson comorbidity index; CI: confidence interval; CV: cardiovascular; GP: general 





Prevalence of Dementia 
At index date, there were less patients with COPD with coded dementia (705; 1.1%) 
than subjects without COPD (4,209; 1.7%), p<0.001. The prevalence of dementia was 
less frequently recorded in patients with COPD, compared to subjects without COPD, 
after adjusting for confounders (aOR: 0.86; 95% CI: 0.74 to 0.98; p=0.049; Table 4-3).  
A sensitivity analysis was performed to estimate the prevalence of vascular dementia 
at index date in patients with COPD and subjects without COPD. There were less 
patients with COPD with vascular dementia compared to subjects without COPD 
(n=1,132 (0.45%) vs n=214 (0.33%); p<0.001). After adjusting for confounders, the 
prevalence of vascular dementia was not different between patients with COPD and 
subjects without COPD (aOR: 0.90; 95% CI, 0.67-1.20; p=0.663; Table 4-4).  
The difference in the prevalence of dementia was assessed at two incident COPD 
diagnosis timeframes: 1) 01-01-2004 to 31-12-2015, and 2) 01-04-2012 to 31-12-
2015. In the first timeframe (2004-2015), the prevalence of coded dementia was lower 
in patients with COPD (n=80,874) compared to subjects without COPD (n=308,999) 
(aOR, 0.69; 95% CI, 0.59 to 0.80; P<0.001). In older subjects (≥ 65 years old) included 
from 2012 onwards to 2015, the prevalence of coded dementia was not statistically 
different between patients with COPD patients (n=12,932) and subjects without COPD 




Table 4-3. Univariate and multivariate conditional logistic regression models of the 
prevalence of dementia for patients with COPD (n= 65,068) and subjects without COPD 
(n= 249,166), matched by age, gender, and GP practice 
Descriptor OR (95% CI) Fully adjusted OR (95% CI) 
Subjects   
Subjects without COPD 1 1 
Patients with COPD 0.57 (0.52 to 0.62) 0.86 (0.74 to 0.98) 
Modified CCI   
Score 0-1 1 1 
Score 2 1.57 (1.53 to 1.61) 1.49 (1.41 to 1.57) 
Score 3 2.96 (2.88 to 3.05) 2.47 (2.36 to 2.63) 
Score 4 and more 3.38 (3.72 to 3.94) 2.89 (2.75 to 3.09) 
Smoking Status   
Never 1 1 
Former 9.78 (9.46 to 10.1) 7.20 (6.78 to 7.64) 
Current 18.78 (18.12 to 19.45) 14.84 (13.95 to 15.78) 
Unknown 0.20 (0.16 to 0.26) 0.50 (0.35 to 0.71) 
Townsend score   
1 least deprived 1 1 
2 1.25 (1.21 to 1.29) 1.23 (1.16 to 1.31) 
3 1.71 (1.66 to 1.76) 1.61 (1.52 to 1.72) 
4 2.32 (2.25 to 2.39) 2.09 (1.52 to 1.72) 
5 most deprived 3.01 (2.91 to 3.11) 1.62 (1.44 to 1.82) 
No records 1.60 (1.51 to 1.70) 1.36 (1.21 to 1.54) 
CV disease   
No 1 1 
Yes 1.88 (1.84 to 1.92) 1.07 (1.02 to 1.12) 
Corticosteroids   
No 1 1 
Yes 11.07 (10.80 to 11.35) 7.71 (7.34 to 8.09) 
The fully adjusted Odds Ratio (aOR) was 0.86, 95% CI 0.74 to 0.98, p=0.049 – the multivariable conditional 
logistic regression model derived aOR was adjusted for age, gender, GP practice, modified Charlson 
comorbidity index, smoking status, socioeconomic class, CV disease, and oral corticosteroid use.  





Table 4-4. Univariate and multivariate conditional logistic regression models of the 
prevalence of vascular dementia for patients with COPD (n= 65,068) and subjects 
without COPD (n= 249,166), matched by age, gender, and GP practice 
Descriptor OR (95% CI) Fully adjusted OR (95% CI) 
Subjects   
Subjects without COPD 1 1 
Patients with COPD 0.66 (0.57 to 0.76) 0.90 (0.67 to 1.20) 
Modified CCI   
Score 0-1 1 1 
Score 2 1.57 (1.53 to 1.61) 1.62 (1.53 to 1.71) 
Score 3 2.97 (2.89 to 3.05) 2.51(1.37 to 2.66) 
Score 4 and more 3.38 (3.72 to 3.95) 2.97 (2.78 to 3.17) 
Smoking Status   
Never 1 1 
Former 9.77 (9.46 to 10.11) 7.22 (6.78 to 7.64) 
Current 18.80 (18.15 to 19.47) 17.56 (16.37 to 18.83) 
Unknown 0.20 (0.16 to 0.26) 0.57 (0.40 to 0.81) 
BMI (kg/m
2
)   
Underweight (<18) 2.95 (2.82 to 3.09) 2.68 (2.44 to 2.94) 
Normal (18-24.9) 1  
Overweight (25-29.9) 0.76 (0.74 to 0.77) 0.76 (0.72 to 0.79) 
Obese (≥30) 0.95 (0.93 to 0.97) 0.82 (0.78 to 0.86) 
No records 0.17 (0.16 to 0.19) 0.51 (0.46 to 0.56) 
Townsend score   
1 least deprived 1 1 
2 1.25 (1.21 to 1.29) 1.15 (1.07 to 1.23) 
3 1.71 (1.66 to 1.76) 1.33 (1.24 to 1.43) 
4 2.32 (2.25 to 2.39) 1.61 (1.50 to 1.73) 
5 most deprived 3.01 (2.91 to 3.11) 1.29 (1.12 to 1.48) 
No records 1.60 (1.51 to 1.70) 1.34 )1.19 to 1.52) 
CV disease   
No 1 1 
Yes 1.88 (1.84 to 1.92) 1.12 (1.05 to 1.17) 
Corticosteroids   
No 1 1 
Yes 11.08 (10.81 to 11.37) 7.72 (7.36 to 8.10) 
The fully adjusted Odds Ratio (aOR) was 0.90, 95% CI 0.76 to 1.20, p=0.503 – the multivariable conditional 
logistic regression model derived aOR was adjusted for age, gender, GP practice, modified Charlson 
comorbidity index, smoking status, BMI; socioeconomic class, CV disease, and oral corticosteroid use. 
Abbreviations: BMI: body mass index; CCI, Charlson comorbidity index; CI: confidence interval; CV: 




Prevalence of either cognitive impairment or dementia  
The prevalence of either coded cognitive impairment and/or dementia at index date 
was calculated for patients with COPD and subjects without COPD.  There were 3,334 
(5.1%) patients with COPD with either cognitive impairment or dementia, compared 
with 12,092 (4.9%) subjects without COPD, p<0.004. 
 There was no significant difference in the prevalence of either cognitive impairment 
and/or dementia between patients with COPD and subjects without COPD following 




Table 4-5. Univariate and multivariate conditional logistic regression models of the 
prevalence of either cognitive impairment or dementia for patients with COPD (n= 
65,068) and subjects without COPD (n= 249,166), matched by age, gender, and GP 
practice 
Descriptor OR (95%CI) Fully adjusted OR (95% CI) 
Subjects   
Subjects without COPD 1 1 
Patients with COPD 1.02 (0.98 to 1.07) 0.96 (0.86 to 1.06) 
Modified CCI   
Score 0-1 1 1 
Score 2 1.57 (1.53 to 1.62) 1.62 (1.53 to 1.70) 
Score 3 2.98 (2.90 to 3.06) 2.49 (1.35 to 2.64) 
Score 4 and more 3.86 (3.75 to 3.97) 2.93 (2.75 to 3.13) 
Smoking Status   
Never 1 1 
Former 9.79 (9.48 to 10.11) 7.25 (6.83 to 7.71) 
Current 18.80 (18.14 to 19.47) 14.84 (13.95 to 15.79) 
Unknown 0.21 (0.16 to 0.26) 0.56 (0.40 to 0.79) 
Townsend score   
1 least deprived 1 1 
2 1.25 (1.21 to 1.29) 1.15 (1.07 to 1.23) 
3 1.71 (1.66 to 1.76) 1.34 (1.25 to 1.43) 
4 2.32 (2.25 to 2.39) 1.62 (1.51 to 1.74) 
5 most deprived 3.01 (2.91 to 3.11) 1.77 (1.64 to 1.92) 
No records 1.60 (1.51 to 1.70) 1.36 (1.21 to 1.54) 
CV disease   
No 1 1 
Yes 1.87 (1.84 to 1.92) 1.07 (1.02 to 1.13) 
Corticosteroids   
No 1 1 
Yes 11.09 (10.81 to 11.37) 7.72 (7.37 to 8.10) 
The fully adjusted Odds Ratio (aOR) was 0.96, 95% CI 0.86 to 1.06, p=0.435– the multivariable conditional 
logistic regression model derived aOR was adjusted for age, gender, GP practice, modified Charlson 
comorbidity index, smoking status, socioeconomic class, CV disease, and oral corticosteroid use.  





Table 4-6. Summary of the prevalence of cognitive impairment, dementia, and either 
cognitive impairment or dementia for patients with COPD (n= 65,068) and subjects 
without COPD (n= 249,166), matched by age, gender, and GP practice 
 Subjects without 
COPD 
Patients with COPD 
 
P-value 
Cognitive impairment, n (%) 2,629 (4.1%) 7,883 (3.2%) <0.001 
OR (95% CI) 1 1.32 (1.26 to 1.39) <0.001 
Fully adjusted (95% CI) 1 0.97 (0.87 to 1.09) a 0.629 
Dementia, n (%) 705 (1.1%) 4,209 (1.7%) <0.001 
OR (95% CI) 1 0.57 (0.52 to 0.62) <0.001 
Fully adjusted (95% CI) 1 0.86 (0.74 to 0.98) a 0.049 
Either cognitive impairment 
or dementia, n (%) 
3,334 (5.1%) 12,092 (4.9%) 0.004 
OR (95% CI) 1 1.02 (0.98 to 1.07) 0.203 
Fully adjusted (95% CI) 1 0.96 (0.86 to 1.06) a 0.435 
a The multivariable conditional logistic regression model derived aOR was adjusted for age, gender, GP practice, 
modified CCI, smoking status, socioeconomic class, CV disease, and oral corticosteroid use. 
Abbreviations: CCI, Charlson comorbidity index; CI: confidence interval; CV: cardiovascular; GP: general 





Association of MRC dyspnoea score with prevalence of cognitive impairment, 
dementia, and either  
A sensitivity analysis was conducted to estimate the prevalence of cognitive 
impairment in patients with COPD based on MRC dyspnoea score (1-3 vs 4-5) at time 
of COPD diagnosis. A total of 43,283 patients with COPD were identified with coded 
MRC dyspnoea score. Of those, 38,251 patients had an MRC dyspnoea score 1-3, and 
5,032 patients with MRC score 4-5.  
Patients with COPD with MRC dyspnoea score 4-5 had a greater prevalence of 
cognitive impairment (n=317; 6.3%) than patients with MRC score 1-3 (n=1,643; 
4.3%), Table 4-7. The prevalence of cognitive impairment at COPD diagnosis in 
patients with MRC score 4-5 remained significantly greater, even after adjustment for 
confounders (aOR, 1.14; 95% CI, 1.01 to 1.28; p=0.034).  
 In the fully adjusted models, there was a significantly greater prevalence of dementia 
(aOR, 1.36; 95% CI, 1.05 to 1.75; p=0.018), and either cognitive impairment or 
dementia (aOR, 1.17; 95% CI, 1.04 to 1.31; p=0.008) in patients with an MRC score 




Table 4-7. Comparison of prevalence of cognitive impairment, dementia, or either 
cognitive impairment or dementia in patients with COPD according to MRC dyspnoea 
score (1–3 vs 4–5) 
 MRC dyspnea  
score 1-3 
(n = 38,251) 
MRC dyspnea  
score 4-5 
(n = 5,032) 
P-value 
Cognitive impairment, n (%) 1,643 (4.3%) 317 (6.3%) <0.001 
OR (95% CI) 1 1.29 (1.15 to 1.45) <0.001 
Fully adjusted (95% CI) 1 1.14 (1.01 to 1.28) a 0.034 
Dementia, n (%) 267 (0.7%) 89 (1.8%) <0.001 
OR (95% CI) 1 1.52 (1.18 to 1.95) <0.001 
Fully adjusted (95% CI) 1 1.36 (1.05 to 1.75) a 0.018 
Either cognitive impairment 
or dementia, n (%) 
1,910 (5%) 406 (8.1%) <0.001 
OR (95% CI) 1 1.32 (1.18 to 1.48) <0.001 
Fully adjusted (95% CI) 1 1.17 (1.04 to 1.31) a 0.008 
a Adjusted for age, gender, modified Charlson comorbidity index, smoking status, socioeconomic class, CV 
disease, and oral corticosteroid use. 
Abbreviations: CCI, Charlson comorbidity index; CI: confidence interval; CV: cardiovascular; MRC: Medical 






Incidence of Cognitive Impairment 
After excluding subjects with former coded cognitive impairment and/or dementia, 
there were 61,569 patients with COPD and 227,995 subjects without COPD; and 
demographics remained similar. Of patients with COPD, 5,059 (8.3%) had a recorded 
incidence of cognitive impairment (without a diagnosis of dementia) compared to 
14,514 (6.4%) subjects without COPD, p<0.001.   
The incidence rate of cognitive impairment in patients with COPD was 23.1 per 1,000 
person-years (95% CI: 22.4 to 23.4) compared to 16.3 per 1,000 person-years (95% 
CI: 16.1 to 16.4) in subjects without COPD. The time to first recorded incidence of 
cognitive impairment was significantly shorter in patients with COPD compared to 
non-COPD subjects, P<0.001, Figure 4-2. In the fully adjusted model, patients with 
COPD, compared with subjects without COPD, were significantly more likely to have 
an incident diagnosis of cognitive impairment (adjusted HR [aHR]: 1.17 (95% CI 1.12 






Figure 4-2. Kaplan-Meier analysis of the incidence of cognitive impairment for patients 
with COPD and subjects without COPD 
 
Kaplan-Meier plots comparing the incidence of cognitive impairment for patients with COPD and 
subjects without COPD. The Y-axis represents the probability of patients free of cognitive impairment. 
The X-axis represents the follow-up time in years (2006 to 2015). The solid line represents subjects 
























0 2 4 6 8 10
Follo-up time (Years)
Subjects without COPD Patients with COPD
104 
 
Table 4-8. Univariate and multivariate Cox regression models of the incidence of 
cognitive impairment for patients with COPD (n=61,569) and subjects without COPD 
(n=227,995) matched by age, gender, and GP practice 
Descriptor HR (95% CI) Adjusted HR (95% CI) 
Subjects   
Subjects without COPD 1 1 
Patients with COPD 1.48 (1.43 to 1.53) 1.17 (1.12 to 1.23) 
Modified CCI   
Score 0-1 1 1 
Score 2 1.52 (1.44 to 1.59) 1.23 (1.17 to 1.29) 
Score 3 2.28 (2.17 to 2.41) 1.87 (1.77 to 1.97) 
Score 4 and more 2.84 (2.68 to 3.01) 1.92 (1.81 to 2.04) 
Smoking Status   
Never 1 1 
Former 1.30 (1.25 to 1.36) 1.17 (1.13 to 1.22) 
Current 1.17 (1.10 to 1.24) 1.09 (1.30 to 1.16) 
Unknown 0.18 (0.01 to 0.04) 0.24 (0.01 to 0.05) 
Townsend score   
1 least deprived 1 1 
2 0.99 (0.95 to 1.04) 0.99 (0.94 to 1.04) 
3 1.04 (0.99 to 1.10) 0.95 (0.96 to 1.07) 
4 1.10 (1.04 to 1.17) 1.05 (0.99 to 1.12) 
5 most deprived 1.20 (1.12 to 1.18) 1.12 (1.04 to 1.20) 
No records 1.06 (0.93 to 1.20) 1.14 (0.87 to 1.08) 
CV disease   
No 1 1 
Yes 3.15 (3.03 to 3.28) 2.27 (2.17 to 2.37) 
Corticosteroids   
No 1 1 
Yes 1.18 (1.12 to 1.24) 1.09 (1.03 to 1.14) 
The fully adjusted Hazard Ratio (aHR) was 1.17, 95% CI 1.12 to 1.23, p<0.001 – the cox regression model was 
adjusted for age, gender, modified Charlson comorbidity index, smoking status, socioeconomic class, CV 
disease, and oral corticosteroid use. 








Incidence of Dementia 
After excluding subjects with former codes of dementia (but not those with cognitive 
impairment codes), there were 64,280 patients with COPD and 242,605 subjects 
without COPD, and demographics remained similar.  
Of patients with COPD, 1,041 (1.6%) were recorded with incident dementia compared 
to 4,158 (1.7%) subjects without COPD, p=0.099. The incidence rate was 4.4 per 1,000 
person-years for patients with COPD and subjects without COPD. The incidence of 
dementia was not statistically different between patients with COPD and subjects 
without COPD following adjustments for age, gender, and GP practice (HR: 1.01; 95% 
CI: 0.94 to 1.09; p=0.665). Following adjustments for confounders, the incidence of 
coded dementia in patients with COPD was less than in non-COPD subjects (aHR: 
0.87, 95% CI: 0.77 to 0.96; p=0.019; Table 4-9).   
Similar proportions of patients in both groups with cognitive impairment developed 
dementia (around 7.8%). In patients with COPD, those with diagnosed cognitive 
impairment were nearly nine times more likely to develop dementia than those without 
cognitive impairment (aHR: 8.85; 95% CI: 7.42–10.54). A similar finding was also 
observed in subjects without COPD.  
There were more patients with COPD with coded vascular dementia (n=386; 0.6%) 
compared to subjects without COPD (n=1,263; 0.5%), p=0.014. The incidence rate of 
vascular dementia in patients with COPD was 1.6 per 1,000 person-years (95% CI: 1.5 
to 1.8) compared to 1.3 per 1,000 person-years (95% CI: 1.2 to 1.4) in subjects without 
COPD. The incidence of vascular dementia was greater in patients with COPD than 
non-COPD subjects matched for age, gender and GP (HR: 1.29; 95% CI: 1.14–1.46). 
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In the fully adjusted model, this association was diminished (aHR: 1.09; 95% CI: 0.89–
1.33; p = 0.388; Table 4-10).  
A sensitivity analysis was conducted in subjects who were identified from 2004 until 
2015. The incidence of dementia was less frequently coded in patients with COPD 
compared to subjects without COPD (aHR 0.76; 95% CI: 0.72 to 0.81; p<0.001). In 
contrast, subjects who were older than 65 years with an incident diagnosis of COPD 
from 01-04-2012 to 31-12-2015 did not show any differences even after adjusting for 






Table 4-9. Univariate and multivariate Cox regression models of the incidence of 
dementia for patients with COPD (n=64,280) and subjects without COPD (n=242,605) 
matched by age, gender, and GP practice 
Descriptor  HR (95% CI) Adjusted HR (95% CI) 
Subjects   
Subjects without COPD 1 1 
Patients with COPD 1.01 (0.94 to 1.09) 0.87 (0.77 to 0.96) 
Modified CCI   
Score 0-1 1 1 
Score 2 1.11 (1.01 to 1.21) 1.05 (0.96 to 1.15) 
Score 3 1.14 (1.01 to 1.28) 1.06 (0.94 to 1.96) 
Score 4 and more 1.37 (1.20 to 1.55) 1.24 (1.09 to 1.42) 
Smoking Status   
Never 1 1 
Former 1.06 (0.89 to 1.04) 1.05 (0.97 to 1.14) 
Current 0.97 (0.86 to 1.10) 0.84 (0.74 to 0.95) 
Unknown 0.03 (0.01 to 0.07) 0.04 (0.02 to 0.09) 
BMI (kg/m
2
)   
Underweight (<18) 1.79 (1.55 to 2.07) 1.82 (1.57 to 2.11) 
Normal (18-24.9) 1  
Overweight (25-29.9) 0.69 (0.64 to 0.75) 0.67 (0.62 to 0.73) 
Obese (≥30) 0.65 (0.59 to 0.72) 0.62 (0.56 to 0.69) 
No records 0.44 (0.38 to 0.52) 0.70 (0.59 to 0.83) 
Townsend score   
1 least deprived 1 1 
2 1.08 (0.97 to 1.19) 1.09 (0.98 to 1.21) 
3 1.07 (0.96 to 1.19) 1.09 (0.98 to 1.22) 
4 1.15 (1.03 to 1.28) 1.16 (1.04 to 1.31) 
5 most deprived 1.23 (1.08 to 1.40) 1.27 (1.12 to 1.45) 
No records 1.09 (0.89 to 1.34) 1.16 (0.94 to 1.44) 
CV disease   
No 1 1 
Yes 1.33 (1.23 to 1.43) 1.24 (1.16 to 1.36) 
Corticosteroids   
No 1 1 
Yes 1.05 (0.94 to 1.16) 1.02 (0.92 to 1.13) 
The fully adjusted Hazard Ratio (aHR) was 0.87, 95% CI 0.77 to 0.96, p=0.019– the cox regression model was 
adjusted for age, gender, GP practice, modified Charlson comorbidity index, smoking status, BMI, 
socioeconomic class, cardiovascular disease, and oral corticosteroid use. 
Abbreviations: BMI: body mass index; CCI: Charlson comorbidity index; CI: confidence interval; CV: 




Table 4-10. Univariate and multivariate Cox regression models of the incidence of 
vascular dementia for patients with COPD (n=64,280) and subjects without COPD 
(n=242,605) matched by age, gender, and GP practice 
Descriptor HR (95% CI) Adjusted HR (95% CI) 
Subjects   
Subjects without COPD 1 1 
Patients with COPD 1.29 (1.42 to 1.46) 1.09 (0.89 to 1.33) 
Modified CCI   
Score 0-1 1 1 
Score 2 1.23 (1.12 to 1.44) 1.07 (0.91 to 1.27) 
Score 3 1.38 (1.14 to 1.69) 1.09 (0.88 to 1.33) 
Score 4 and more 1.87 (1.53 to 2.30) 1.39 (1.12 to 1.37) 
Smoking Status   
Never 1 1 
Former 1.22 (1.06 to 1.40) 1.14 (0.99 to 1.32) 
Current 1.27 (1.03 to 1.57) 1.06 (0.85 to 1.33) 
Unknown 0.09 (0.03 to 0.24) 0.13 (0.04 to 0.37) 
BMI (kg/m
2
)   
Underweight (<18) 2.03 (1.57 to 2.61) 1.99 (1.53 to 2.58) 
Normal (18-24.9) 1  
Overweight (25-29.9) 0.86 (0.74 to 0.98) 0.82 (0.71 to 0.94) 
Obese (≥30) 0.81 (0.68 to 0.69) 0.77 (0.64 to 0.92) 
No records 0.41 (0.30 to 0.56) 0.65 (0.46 to 0.92) 
Townsend score   
1 least deprived 1 1 
2 1.04 (0.86 to 1.25) 1.02 (0.84 to 1.24) 
3 1.07 (0.88 to 1.29) 1.05 (0.86 to 1.28) 
4 1.18 (0.97 to 1.45) 1.11 (0.90 to 1.37) 
5 most deprived 1.27 (1.01 to 1.59) 1.25 (0.99 to 1.59) 
No records 1.56 (1.11 to 2.19) 1.48 (1.03 to 2.12) 
CV disease   
No 1 1 
Yes 2.30 (1.03 to 2.60) 2.12 (1.86 to 2.42) 
Corticosteroids   
No 1 1 
Yes 1.12 (0.94 to 1.34) 1.02 (0.92 to 1.13) 
The fully adjusted Hazard Ratio (aHR) was 1.09, 95% CI 0.89 to 0.33, p=0.388– the cox regression model was 
adjusted for age, gender, GP practice, modified Charlson comorbidity index, smoking status, BMI, 
socioeconomic class, cardiovascular disease, and oral corticosteroid use. 
Abbreviations: BMI: body mass index; CCI: Charlson comorbidity index; CI: confidence interval; CV: 






Incidence of either Cognitive Impairment or Dementia 
In this analysis, all subjects (patients with COPD and subjects without COPD) with a 
former code of cognitive impairment and/or dementia were excluded. This has resulted 
in a total of 61,569 patients with COPD and 227,995 subjects without COPD. 
Demographics and clinical characteristics remained similar. 
There were more patients with COPD with either coded cognitive impairment or 
dementia (n=5,971; 9.7%) compared to subjects without COPD (n=17,961; 7.3%), 
p<0.001.  The incidence rate of either cognitive impairment or dementia in patients 
with COPD was 27.2 per 1,000 person-years (95% CI: 26.5−27.9) compared with 
20.04 per 1,000 person-years (95% CI: 20.1–20.7) in subjects without COPD. Patients 
with COPD were more likely to have a recorded incidence of either cognitive 
impairment or dementia compared to subjects without COPD (aHR: 1.11, 95% CI: 








Table 4-11. Univariate and multivariate Cox regression models of the incidence of either 
cognitive impairment or dementia for patients with COPD (n=61,569) compared with 
subjects without COPD (n=227,995) matched by age, gender, and GP practice 
Descriptor  HR (95% CI) Adjusted HR (95% CI) 
Subjects   
Subjects without COPD 1 1 
Patients with COPD 1.39 (1.35 to 1.44) 1.11 (1.06 to 1.15) 
Modified CCI   
Score 0-1 1 1 
Score 2 1.45 (1.39 to 1.51) 1.20 (1.14 to 1.25) 
Score 3 2.04 (1.95 to 1.41) 1.68 (1.60 to 1.77) 
Score 4 and more 2.54 (2.42 to 2.68) 1.79 (1.70 to 1.89) 
Smoking Status   
Never 1 1 
Former 1.26 (1.22 to 1.31) 1.15 (1.11 to 1.20) 
Current 1.13 (1.07 to 1.19) 1.06 (1.01 to 1.12) 
Unknown 0.02 (0.01 to 0.04) 0.29 (0.01 to 0.05) 
BMI (kg/m
2
)   
Underweight (<18) 1.32 (1.21 to 2.45) 1.40 (1.27 to 1.54) 
Normal (18-24.9) 1 1 
Overweight (25-29.9) 0.98 (0.94 to 1.02) 0.94 (0.90 to 0.98) 
Obese (≥30) 1.20 (1.15 to 1.25) 1.08 (1.03 to 1.13) 
No records 0.35 (0.32 to 0.40) 0.61 (0.54 to 0.67) 
Townsend score   
1 least deprived 1 1 
2 1.01 (0.97 to 1.06) 1.02 (0.97 to 1.07) 
3 1.05 (1.01 to 1.10) 1.02 (0.97 to 1.07) 
4 1.12 (1.06 to 1.17) 1.07 (1.08 to 1.23) 
5 most deprived 1.21 (1.14 to 1.29) 1.15 (1.02 to 1.28) 
No records 1.07 (0.96 to 1.19) 1.13 (1.01 to 1.27) 
CV disease   
No 1 1 
Yes 2.71 (2.62 to 2.81) 2.34 (2.25 to 2.43) 
Corticosteroids   
No 1 1 
Yes 1.15 (1.09 to 1.20) 1.07 (1.02 to 1.12) 
The fully adjusted Hazard Ratio (aHR) was 1.11, 95% CI 1.06 to 1.15, p<0.001– the cox regression model was 
adjusted for age, gender, GP practice, modified Charlson comorbidity index, smoking status, BMI, 
socioeconomic class, cardiovascular disease, and oral corticosteroid use. 
Abbreviations: BMI: body mass index; CCI: Charlson comorbidity index; CI: confidence interval; CV: 




Association of MRC dyspnoea score with the incidence of cognitive impairment, 
dementia, and either  
The association of MRC dyspnoea score (recorded at time of COPD diagnosis) with 
incident cognitive impairment amongst patients with COPD was evaluated. After 
excluding subjects with former coded cognitive impairment and/or dementia, there 
were 36,246 patients with MRC score 1-3 and 4,608 with MRC score 4-5.  
The incidence of cognitive impairment was greater in patients with MRC dyspnoea 
score 4-5 (n=444; 9.6%) compared to patients with MRC score 1-3 (n=3,146; 8.7%), 
p<0.031. Following COPD diagnosis, patients with MRC score 4-5 were 11% more 
likely to have a recorded incidence of cognitive impairment (aHR, 1.11; 95% CI, 1.02-
1.22; p=0.030) following adjustment for age, gender, and socioeconomic class. Further 
adjustments have diminished the relationship (Table 4-12).  
There were 37,942 patients with MRC score 1-3, and 4,932 patients with MRC score 
4-5 included in the dementia analysis. Patients with MRC score 4-5 were 27% more 
likely to have a recorded incidence of dementia compared to patients with MRC score 
1-3 (aHR: 1.27; 95% CI: 1.02 to 1.60; p=0.032), Table 4-12. 
The incidence of either cognitive impairment or dementia was greater in patients with 
MRC dyspnoea score 4-5 (n=524; 11.37%) compared to patients with MRC score 1-3 
(n=3,514; 9.69%), p<0.001. Following COPD diagnosis, patients with MRC score 4-
5 were 13% more likely to have a recorded incidence of either cognitive impairment 
or dementia (aHR, 1.13; 95% CI, 1.03-1.24; p=0.007) following adjustment for age, 
gender and socioeconomic class. Further adjustments have diminished the 




Table 4-12. Comparison of incidence of cognitive impairment, dementia, and either 
cognitive impairment or dementia in patients with COPD according to MRC dyspnoea 
score (1–3 vs 4–5) 
MRC dyspnoea score  No. events 
(%) 
HR 
 (95% CI) 














(1.02 to 1.22) 
0.98 













(1.02 to 1.60) 
1.27 
(1.02 to 1.60) 
0.032 











(1.03 to 1.24) 
0.99 
(0.90 to 1.09) 
0.905 
HR: adjusted for age, gender, and socioeconomic class. 
Fully adjusted HR: adjusted for age, gender, modified CCI, smoking socioeconomic class, CV disease. 
Abbreviations: CCI, Charlson comorbidity index; CI: confidence interval; CV: cardiovascular; MRC: Medical 





4.4  DISCUSSION 
The coded prevalence of cognitive impairment was significantly greater in patients 
with COPD compared with subjects without COPD matched for age, gender and GP 
surgery, although the association was attenuated with additional confounder 
adjustment, becoming non-significant. The incidence of cognitive impairment was 
significantly greater in patients with COPD. In contrast, the prevalence and incidence 
of coded dementia were significantly less in patients with COPD. To the best of our 
knowledge, this is the first study to investigate this in patients with COPD using UK 
electronic GP records.   
Prevalence and incidence of cognitive impairment in COPD 
Although a large body of literature has investigated the prevalence of cognitive 
impairment in COPD, there is no consensus on the overall prevalence. Cognitive 
impairment is present in 4% of older patients (≥65 years old) with mild COPD [262] 
and up to 61% in patients with COPD and severe hypoxemia [267]. This wide variation 
in the current estimates is attributed to the severity of COPD [268], whether cognitive 
impairment was systematically assessed or self-reported, and the use of different 
diagnostic criteria and tools for cognitive impairment [129]. In addition, studies had 
different threshold definitions for cognitive impairment, even when using the same 
cognitive assessment tool. A unique aspect of this study is that it reported the 
prevalence of cognitive impairment at the time of COPD diagnosis, and included all 
patients with COPD, which therefore, making it a representative sample to the general 
populations of COPD. However, the proportion of coded cognitive impairment at 
COPD diagnosis in the GP electronic health records presented in this study (4.1%) was 
far lower than the proportion in clinical studies at 50% when cognitive impairment 
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was systematically assessed [281, 282]. This gives a cause for concern of subclinical 
underdiagnosed cognitive impairment, which may lead to a delayed intervention and 
consequently, a missed opportunity to alleviate the negative effects of cognitive 
impairment on this vulnerable population.  
Current evidence suggests that patients with COPD are at amplified risk of cognitive 
impairment and even dementia. The finding that patients with COPD had a higher 
incidence of cognitive impairment is consistent with prior literature [136, 137, 283]. 
A previous study from Finland showed that a diagnosis of COPD in midlife was 
associated with 85% increased risk of mild cognitive impairment/dementia in later life 
[136]. However, the latter study incorporated self-reported COPD as opposed to a 
COPD diagnosis that is objectively confirmed. The present study also found that 
patients with COPD and cognitive impairment were at a greater risk of dementia 
compared with patients with COPD without cognitive impairment. In this context, 
establishing accurate estimates of the proportion of patients with COPD and cognitive 
impairment could help to further understand the clinical relevance of cognitive decline 
in patients with COPD and identify a high-risk group. This is also important to allow 
for appropriate therapeutic interventions and changes in lifestyle, which could prevent 
or delay the cognitive deterioration to clinical dementia.  
The prevalence of cognitive impairment has been associated with COPD severity. 
Grant et al. showed that the prevalence of cognitive impairment was 27% in patients 
with mild hypoxemia compared to 62% in patients with severe hypoxemia [267]. A 
recent systematic review showed that the relationship between cognitive impairment 
and COPD severity (as measured by GOLD and blood gases) is mainly seen in patients 
with severe and very severe COPD [268]. In a longitudinal study, Hung et al. reported 
that patients with severe COPD (defined by oxygen use and limited physical activity) 
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were associated with a rapid cognitive decline [271], highlighting the potential 
increased risk of subsequent dementia. Using MRC dyspnoea score as a severity 
measure [37], this study is consistent that those with more breathlessness were at 
greater risk of cognitive impairment and dementia compared to those with a better 
MRC score. This finding has important clinical implications, as cognitive impairment 
and dementia interfere with patient’s ability to adhere to their medications and manage 
their own disease [261, 284], which may consequently lead to worse health outcomes 
[264]. 
A major pitfall in studying the association of COPD severity with cognitive 
impairment and dementia is the possibility of misdiagnosis of COPD. To explain, 
patients with cognitive impairment/dementia may not be able to follow instructions to 
perform spirometry, which may lead to erroneous estimation to lung function [269]; 
and consequently a misdiagnosis of COPD and its severity. This highlights the 
challenge in accurately assessing the relationship between cognitive impairment and 
COPD severity, and partly accounts for the observed discrepancies in the prevalences 
of cognitive impairment in COPD across study populations (e.g. severe and very 
severe airflow obstruction). 
Prevalence and Incidence of Dementia in COPD 
There is growing evidence linking cognitive impairment with COPD. Nevertheless, 
the literature on dementia in COPD is lacking, and prior studies are also limited by 
study population [138], self-reported assessment of COPD [136], short or even 
undefined follow-up time [134, 138], and inadequate matching group [135]. The most 
surprising finding in this study is that the prevalence and incidence of dementia were 
significantly lower in patients with COPD. Although at first glance, these findings 
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suggest that patients with COPD may be at lower risk of dementia, there is a likelihood 
that a dementia diagnosis in patients with COPD has been unintentionally missed. It is 
likely that COPD symptoms may predominate and be the central focus during GP 
visits. In addition, doctors may find limited explanatory value in attaching a label of 
dementia to cognitive impairment in the context of multi-system functional decline as 
COPD progresses. It is, however, possible that treatment opportunities and, in many 
jurisdictions, the opportunity to access dementia-specific services are being missed, 
ultimately to the detriment of the patient. Therefore, the formalisation of dementia 
might not be addressed accordingly. These findings reinforce the need for a systematic 
assessment of the cognitive state of patients with COPD during routine clinical follow 
up. 
In this study, the cumulative prevalence and incidence of either cognitive impairment 
or dementia have been investigated as a separate outcome. This is because the term 
“cognitive impairment” varies across studies. For instance, Rusanen et al. define 
“cognitive impairment” as the presence of either mild cognitive impairment or 
dementia [136]. In contrast, a recent systematic review has investigated the prevalence 
of cognitive impairment, by excluding any study that reported a diagnosis of dementia 
[129]. Since the analyses of this chapter are based on primary care data (GP records), 
where comprehensive cognitive assessment may not be performed, recording of these 
conditions (cognitive impairment and dementia) in the medical records may vary 
across practices. This means that dementia diagnosis may have been coded as 
cognitive impairment and vice versa. Thus, it was important to investigate whether this 
– coding limitations – might have influenced the findings. This study found that 
patients with COPD were at increased incident risk of either cognitive states. However, 
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a clear distinction between these cognitive states can only be confirmed by performing 
a systematic assessment. 
Analysis from the Cardiovascular Risk Factors, Aging and Dementia (CAIDE) study 
(n=2,000) showed that a self-reported diagnosis of COPD in later life (≥ 65 years) was 
inversely related, although not significant, to mild cognitive impairment/dementia 
[136]. The findings of the latter study were attributed to survival bias as opposed to 
the effect of COPD. As COPD and cognitive impairment are both associated with an 
increased risk of death in their own, it is reasonable to assume that the risk of death 
will be even greater if both conditions coexist. Indeed, cognitive impairment increases 
the risk of mortality in certain COPD populations [264]. Furthermore, dementia is a 
progressive condition and may take decades to develop. In the co-existence of COPD 
with cognitive impairment, there is a possibility that patients may die before they even 
receive a diagnosis of dementia. 
Patients with COPD usually present with a smoking history and have a wide range of 
comorbidities, one of which is CV disease. As expected, in this study, the proportions 
of current smoking and CV disease were greater in patients with COPD, and these 
confounders attenuated the association with vascular dementia. Because COPD and 
CV comorbidities share similar risk factors and patients with COPD are more likely to 
be predisposed to cardiovascular events [97], it is, therefore, difficult to determine 
whether COPD is associated with increased risk of vascular dementia. Although it is 
unlikely for CV comorbidities or smoking per se to account for vascular dementia in 
COPD, it is important to encourage healthcare professionals to identify and manage 
any modifiable risk factors.       
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4.4.1  Clinical Implications  
Both COPD and dementia are public health threats with severe impacts on health and 
prognosis. Therefore, prevention and treatment for both conditions are of clinical 
importance. The findings of the current study showed that COPD is associated with 
increased risk of incident cognitive impairment or dementia. This association was 
independent of age, gender, and other risk factors, suggesting that COPD may causally 
be associated with increased risk of cognitive impairment, and even dementia. Recent 
data from the ARIC study demonstrated that reduced lung function (COPD pattern) 
was associated with greater risk of either mild cognitive impairment or dementia [137]; 
in agreement with findings of the current study. It is important to mention that 
cognitive impairment and dementia in patients with COPD are not only caused – per 
se- by COPD alone, but rather, it is due to multiple factors. To explain, CV risk and 
smoking, which are highly prevalent in patients with COPD and contribute to the 
increased risk of dementia, could play an important role in the increased risk of 
dementia in COPD. Thus, it is crucial to reinforce the importance of smoking 
cessation, as it improves lung function and reduces the risk of cognitive impairment 
and dementia.  In addition, the presence of multiple comorbidities, which is also 
common in patients with COPD, could also magnify the risk of cognitive impairment 
and dementia in those with COPD. Proper management of these comorbidities with 
appropriate interventions could reduce the risk. 
The increased understanding of the relationships between COPD with cognitive 
impairment and dementia has important clinical implications. First, cognitive 
impairment and dementia have a considerable impact on the clinical management of 
COPD. Cognitively impaired patients have poor adherence to their medications 
regimens, incorrect use of inhaler techniques [261], which could result in an increased 
119 
 
risk of exacerbation and worse health outcomes [285]. Cognitive impairment and 
dementia also affect the self-management skills in patients with COPD. Indeed, 
patients with COPD need to adopt healthy lifestyles (e.g. stop smoking, healthy diet, 
and be physically active). However, these behavioural changes require healthy 
cognitive function, which may be limited or even completely impaired in patients with 
dementia. The co-existence of cognitive impairment in patients with COPD also 
interfere with participation and adherence to pulmonary rehabilitation programs [125]. 
In contrast, patients with dementia may not even be referred to a PR program in the 
first place.  
4.4.2 Strengths and limitations 
A strength of this study is that using electronic primary care health records provides a 
representative sample for the general UK COPD population [273]. The data source 
includes longitudinal data on various potential risk factors, such as demographic 
factors and medical conditions. Further, the analyses adjusted for a wide range of 
potential confounders. Patients with COPD from 2006 onwards were included, after 
QOF had been already established, meaning that COPD diagnoses were based on 
spirometry [286]. However, there is still a possibility of COPD misdiagnosis [287]. In 
addition, retrospective analyses based on medical records that were mainly collected 
for administrative purposes rather than research are subject to some limitations. There 
is a possibility that free text (which is largely inaccessible for research due to issues 
around patient confidentiality) instead of READ codes may be used to record this 
information. Although QOF was introduced to improve the quality of recording, some 
variables used in this study may have changed from the last recorded coded entry, such 
as self-reported smoking. This study has investigated the impact of COPD severity on 
cognitive impairment and dementia using MRC dyspnoea score as opposed to lung 
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function measures; the latter is poorly recorded in the THIN database. It is however 
important to mention that dyspnoea is not specific for COPD and may also exist in 
other conditions, heart failure, for instance. The possibility of residual confounding of 
important risk factors, such as hypoxia, hypercapnia, oxidative stress, and 
inflammation, cannot be excluded. Information on oxygen saturations, oxygen 
therapy, and inflammatory markers are not well recorded in the utilised database 
(THIN); thus, these factors could not be adjusted for in the analyses.  
4.5 CONCLUSION 
Cognitive impairment was more prevalent in patients with COPD than in subjects 
without COPD. Moreover, the incidence of cognitive impairment was also greater. In 
contrast, the prevalence and incidence of coded dementia were lower in patients with 
COPD, highlighting the potential likelihood of under-diagnosis of dementia with a 
missed opportunity for proper intervention, and underlining the need to accurately 
estimate the proportion of patients with COPD and dementia with a systematic 
assessment.   
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It is increasingly recognised that the presence of comorbidities play a major role in 
COPD prognosis and greatly contribute to the severity of the disease [1]. Depression 
is amongst the most common comorbidities in COPD, resulting in impaired quality of 
life [288], poor adherence to medication regimens and pulmonary rehabilitation  [139, 
140], increased risk of COPD exacerbation [289], and mortality [141]. Given this, the 
UK National Institute for Health and Care Excellence (NICE) COPD guidelines 
encourage identifying and managing depression [40].  
The reported prevalence of depression in COPD ranges from 15% to 36%, depending 
on the study population and methodological designs [143]. However, there is no recent 
work on the incidence rate of a new onset of depression following a diagnosis of 
COPD.  Previous studies are also limited to small sample size [146], short follow-up 
period [148], and inconsistency of definitions for depression [290]. An earlier UK 
population-based study reported that the incidence rate of depression in patients with 
COPD was 16.2 per 1,000 person-years on data from 1995 to 2005 [147]. However, 
this predominantly predated the publication of the first UK COPD and depression 
NICE guidelines in December 2004 [291, 292] and the introduction of GP Quality and 
Outcomes Framework (QOF); both of which have impacted on the clinical 
management and recording of COPD and depression [293].  
Mechanisms underlying the association between depression in COPD are not fully 
understood. Risk factors associated with increased prevalence of depression in COPD 
are likely multiple and include age, female gender, and smoking [142, 143, 294]. The 
COPD severity has also been associated with an increased prevalence of depression; 
however, studies have not been consistent on severity definition [290]. Breathlessness 
123 
 
(dyspnoea) is a core symptom in COPD and has been associated with worse depression 
symptoms [294]. Lower socioeconomic class is another risk factor that could also 
contribute to the increased risk of depression in patients with COPD. In fact, separate 
literature has previously shown that lower socioeconomic class is associated with 
COPD as well as with depression [28, 295]. Whether the incidence of depression 
among patients with COPD may be explained, at least in part, through socioeconomic 
class is worth exploring.  
This study hypothesised that the incidence of depression or antidepressant prescription 
in patients with COPD would be greater than in subjects without COPD. This chapter 
aims to 1) determine the incidence of newly diagnosed depression or antidepressant 
prescription following a diagnosis of COPD and compare this to subjects without 
COPD using a large primary care database; and 2) to assess the incidence of 
antidepressant prescription in patients with COPD and incident depression compared 





5.2.1  Study design 
A matched cohort study was conducted to assess the incidence of depression, 
antidepressant prescription, or either in patients with COPD compared to subjects 
without COPD.  
5.2.2  Data source  
The data source for this study has been fully described in the previous chapter. (See 
subsection 4.2.2).  
5.2.3  Study populations 
The study population comprised individuals aged ≥40 years with a COPD diagnosis 
from 1st January 2004 to 31st December 2015, with ≥ 1 year of record prior to the 
COPD diagnosis. In addition, a comparison group free of COPD was identified at 
random from THIN. To create a matched cohort, each patient with COPD was matched 
by age, gender and GP surgery to up to four subjects free of COPD, and each subject 
without COPD was assigned the same index date as the matched patients with COPD. 
Subjects with a missing diagnosis date were excluded from this study. Further, those 
who were censored or left the GP surgery before index date were also excluded.  
5.2.4  Ethical approval 
Ethical approval for this study was obtained by an independent Scientific Review 





5.2.5 Follow-up and outcome definitions 
Patients with COPD and subjects without COPD with a code of depression prior to 
index date were excluded. Also, subjects with antidepressant prescription codes of 
more than 2 years prior to COPD diagnosis/index date were excluded.  
Subjects were followed up form COPD diagnosis/index date until either they 
experienced the outcome of interest (first recorded depression, antidepressant 
prescription or either), left the GP practice, died or reached the end of the follow-up 
(31/12/2015), whichever came first. Diagnosis for depression was solely defined based 
on READ codes (Appendix 9-11). Antidepressants were defined based on drug codes 
(Appendix 9-12).  
The incident of either depression or antidepressant was also investigated as a sperate 
outcome, as antidepressant prescription might have been coded with a depression 
episode, and also to account for the under-diagnosed (under-recorded) depression in 
patients with COPD [296].    
5.2.6 Covariate and confounders 
A series of explanatory variables were determined at baseline, including age, gender 
and Townsend social deprivation score [278]. In addition, clinical variables such as 
smoking status and the Medical Research Council (MRC) dyspnoea scale [37] were 
recorded closest to the index date (whether prior to, or after index date). A modified 
Charlson Comorbidity Index (CCI) was determined before or at index date. Body mass 
index (BMI) was determined within 2 years (before and after) of index date.   
5.2.7  Statistical analyses 
Demographics and clinical characteristics of patients with COPD and subjects without 
COPD were described at baseline in terms of frequency or mean and standard 
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deviation as appropriate. Categorical data were compared using McNemar test. P 
<0.05 was considered significant. 
Incidence rates were estimated for both patients with COPD and subjects without 
COPD. Cox proportional hazard regression model was used to evaluate the risk of 
incident depression, antidepressant, or either following COPD diagnosis. The 
assumption of cox regression model was checked using Schoenfeld residuals. Only the 
first event following the index date was considered. Person-time commenced at the 
index date and ended when either the outcome of interest (depression, antidepressant 
prescription, or either) occurred, subjects left the GP clinic, subjects died, or end of 
the study period (31/12/2015), whichever came first. Confounders were included in 
the final model if they independently changed the HR for depression, antidepressant 
prescription, or either by ≥ 5%. All covariates were assessed in separate regression 
models.   
5.2.7.1  Sensitivity analyses 
The incidence of the first antidepressant prescription within 1-month following 
incident depression was calculated and compared between 1) patients with COPD and 
incident depression and 2) subjects without COPD and incident depression.  
To assess the impact of severity, incidence of depression, antidepressant prescription, 
or either was calculated amongst patients with COPD using the MRC dyspnoea score 
(1-3 vs 4-5) at time of diagnosis.  
Since socioeconomic class has been associated with both COPD and depression, this 
study assessed the incidence of depression, antidepressant, or either based on 
socioeconomic class (high (1-2) vs low (3-5)) amongst patients with COPD. STATA 
15.0 software was used for data management and statistical analyses.  
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5.3  RESULTS 
There were 80,874 patients with COPD and 308,999 subjects without COPD identified 
in THIN from 1st January 2004 to 31st December 2015 (Figure 5-1). After excluding 
those with either former coded depression or antidepressant prescription, there were 
44,362 patients with COPD and 124,140 subjects without COPD. The mean (SD) age 
at index date was 67.6 (10.5) years, and 65% were males. The median follow-up period 
was 5.95 years across the groups. The characteristics of the subjects included in the 
analyses are presented in Table 5-1. 
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Excluded subjects (patients with 
COPD and subjects without COPD) 
with a history of depression, or with 
antidepressant codes of more than 2 
years prior to index date.  
Figure 5-1. Study population flo  diagra  
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Table 5-1. Baseline characteristics for patients with COPD and up to four subjects 
without COPD with no prior diagnosis of depression or prescription of any 
antidepressant matched by age, gender and GP practice 
Characteristics Patients with COPD Subjects without  
COPD 
 
   
 n = 44,362 % n = 124,140 % p-value 
Mean age at index date 
(years, SD) 
67.8 (10.6)  67.5 (10.5)   
Gender      
Male 27,737 62.5 82,270 66.3  
Female 16,625 37.5 41,870 33.7  
Townsend score (prior or at index date) 
1 least deprived 8,071 18.2 31,593 25.4  
 
<0.001 
2 8,596 19.4 29,176 23.5 
3 9,239 20.8 24,669 19.9 
4 9,469 21.3 20,352 16.4 
5 most deprived 7,331 16.5 13,064 10.5 
No records 1,656 3.7 5,286 4.3  
MRC dyspnoea score (most recent record whether prior or after index date) 
1 5,571 12.5 413 0.3  
 
<0.001 
2 10,234 23.1 313 0.3 
3 5,048 11.4 124 0.1 
4–5 2,339 5.3 38 0.03 
No records 21,170 47.7 123,252 99.31  
BMI (kg/m
2
) (2 years either side of index date)  
Underweight (<18) 1,832 4.1 910 0.7  
 
<0.001 
Normal (18-24.9) 13,827 31.2 21,407 17.2 
Overweight (25-29.9) 13,196 29.7 31,631 25.5 
Obese (≥30) 9,624 21.7 21,248 17.1 
No records 5,883 13.3 48,944 39.4  
Smoking status 
Never smoked 4,788 10.8 38,506 31.1  
<0.001 Ex-smoker 22,970 51.9 30,361 24.5 
Current smoker 15,785 35.6 16,471 13.3 
Unknown 819 1.9 38,802 31.3  
Modified CCI (prior to or at index date) 
0–1 32,713 73.7 97,019 78.2  
<0.001 2 6,039 13.6 14,835 11.9 
3 3,079 6.9 7,247 5.8 
≥ 4 2,531 5.7 5,039 4.1 
Abbreviations: BMI: body mass index; CCI, Charlson comorbidity index; MRC: Medical Research Council. 
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 Incidence of depression and antidepressant prescription following index date 
Of patients with COPD, 2,155 (4.9%) had an incident diagnosis of depression 
following the index date compared to 3,400 (2.7%) subjects without COPD, P<0.001. 
The time to first recorded depression was significantly shorter in patients with COPD 
than in subjects without COPD, P<0.001. Patients with COPD were 98% more likely 
to have an incident diagnosis of depression, compared to subjects without COPD (HR: 
1.98; 95% CI: 1.87–2.10, Figure 5-2). This association remained significant even after 
adjusting for BMI, smoking, modified CCI, and socioeconomic class (aHR: 1.42; 95% 
CI: 1.32 – 1.53; p<0.001; Table 5-2). The incidence rate of depression in patients with 
COPD was 11.4 per 1,000 person-years (95% CI: 10.9–11.8) compared with 5.7 per 













Figure 5-2. Kaplan-Meier analysis of the incidence of depression in patients with COPD 
and subjects without COPD 
 
Kaplan-Meier plots comparing the incidence of depression for patients with COPD and subjects without 
COPD. The Y-axis represents the probability of subjects free of depression. The X-axis represents the 
follow-up time in years (2004 to 2015).  The solid line represents subjects without COPD. The dashed 
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Table 5-2. Univariate and multivariate Cox regression models of the incidence of 
depression for patients with COPD (n= 44,362) and subjects without COPD (n= 124,140), 
matched by age, gender, and GP practice 
Descriptor HR (95% CI) Adjusted HR (95% CI) 
Subjects   
Subjects without COPD 1 1 
Patients with COPD 1.98 (1.87 to 2.10) 1.42 (1.32 to 1.53) 
Modified CCI   
Score 0-1 1 1 
Score 2 1.28 (1.15 to 1.42) 1.18 (1.06 to 1.31) 
Score 3 1.56 (1.34 to 1.81) 1.32 (1.13 to 1.53) 
Score 4 and more 1.43 (1.18 to 1.75) 1.24 (1.02 to 1.51) 
BMI (kg/m
2
)   
Underweight (<18) 0.96 (0.74 to 1.24) 0.95 (0.73 to 1.23) 
Normal (18-24.9) 1 1 
Overweight (25-29.9) 0.97 (0.89 to 1.07) 0.97 (0.89 to 1.07) 
Obese (≥30) 0.99 (0.89 to 1.09) 0.96 (0.86 to 1.06) 
No records 0.48 (0.44 to 0.54) 0.56 (0.50 to 0.62) 
Smoking Status   
Never 1 1 
Former  1.08 (0.98 to 1.20) 1.07 (0.99 to 1.19) 
Current 1.08 (1.06 to 1.32) 1.24 (1.12 to 1.37) 
Unknown 0.51 (0.46 to 0.57) 0.66 (0.58 to 0.74) 
Townsend score   
1 least deprived 1 1 
2 1.14 (1.03 to 1.27) 1.14 (1.02 to 1.27) 
3 1.27 (1.14 to 1.41) 1.23 (1.10 to 1.38) 
4 1.31 (1.17 to 1.47) 1.27 (1.13 to 1.43) 
No records  1.58 (1.28 to 1.96) 1.65 (1.33 to 2.06) 
The fully adjusted Hazard Ratio (aHR) was 1.42, 95% CI 1.32 to 1.53, p<0.001 – the cox regression model was 
adjusted for age, gender, GP practice, modified Charlson comorbidity index, BMI smoking status, and 
socioeconomic class.  






Following COPD diagnosis, 7,918 (17.9%) patients had a coded antidepressant 
prescription compared with 14,561 (11.7%) subjects without COPD, p<0.001. The 
incidence rate of antidepressant prescription in patients with COPD was 45.7 per 1,000 
person-years (95% CI: 44.7–46.6) compared with 25.7 per 1,000 person-years (95% 
CI: 25.3–26.1) in subjects without COPD. Patients with COPD were 78% more likely 
to have a recorded incidence of antidepressant prescription than the subjects without 
COPD (HR, 1.78; 95% CI, 1.73 – 1.84, Table 5-3). In the fully adjusted model, this 
association remained significant (aHR: 1.40; 95% CI: 1.35–1.45; p<0.001, Table 5-3). 
In addition, the incidence of either depression or antidepressant was greater in patients 
with COPD compared with subjects without COPD following adjustment for 













Table 5-3. Univariate and multivariate Cox regression models of the incidence of 
antidepressant prescription for patients with COPD (n= 44,362) and subjects without 
COPD (n=124,140), matched by age, gender, and GP practice 
Descriptor  HR (95% CI) Adjusted HR (95% CI) 
Subjects   
Subjects without COPD 1 1 
Patients with COPD 1.78 (1.73 to 1.84) 1.40 (1.35 to 1.45) 
Modified CCI   
Score 0-1 1 1 
Score 2 1.33 (1.27 to 1.41) 1.22 (1.16 to 1.29) 
Score 3 1.54 (1.42 to 1.66) 1.29 (1.20 to 1.39) 
Score 4 and more 1.84 (1.68 to 2.01) 1.55 (1.26 to 1.69) 
BMI (kg/m
2
)   
Underweight (<18) 0.99 (0.86 to 1.14) 0.97 (0.85 to 1.11) 
Normal (18-24.9) 1 1 
Overweight (25-29.9) 0.99 (0.86 to 1.08) 0.94 (0.89 to 0.98) 
Obese (≥30) 1.01 (0.98 to 1.09) 1.01 (0.95 to 1.05) 
No records 0.59 (0.57 to 0.62) 0.68 (0.65 to 0.72) 
Smoking Status   
Never 1 1 
Former  1.09 (1.04 to 1.14) 1.07 (1.03 to 1.12) 
Current 1.15 (1.09 to 1.22) 1.20 (1.13 to 1.26) 
Unknown 0.58 (0.54 to 0.61) 0.69 (0.65 to 0.73) 
Townsend score   
1 least deprived 1 1 
2 1.07 (1.01 to 1.13) 1.05 (1.01 to 1.12) 
3 1.09 (1.03 to 1.16) 1.07 (1.02 to 1.13) 
4 1.14 (1.08 to 1.21) 1.10 (1.03 to 1.16) 
5 most deprived 1.22 (1.14 to 1.31) 1.17 (1.09 to 1.25) 
No records 1.14 (1.01 to 1.27) 1.18 (1.05 to 1.32) 
The fully adjusted Hazard Ratio (aHR) was 1.40, 95% CI 1.35 to 1.45, p<0.001 – the cox regression model 
was adjusted for age, gender, GP practice, modified Charlson comorbidity index, BMI smoking status, and 
socioeconomic class.  




Table 5-4. Univariate and multivariate Cox regression models of the incidence of either 
depression or antidepressant prescriptions for patients with COPD (n= 44,362) and 
subjects without COPD (n=124,140), matched by age, gender, and GP practice 
Descriptor HR (95% CI) Adjusted HR (95% CI) 
Subjects   
Subjects without COPD 1 `1 
Patients with COPD 1.81 (1.76 to 1.86) 1.41 (1.36 to 1.46) 
Modified CCI    
Score 0-1 1 1 
Score 2 1.29 (1.23 to 1.36) 1.22 (1.16 to 1.28) 
Score 3 1.51 (1.41 to 1.62) 1.32 (1.23 to 1.42) 
Score 4 and more 1.83 (1.76 to 1.92) 1.54 (1.42 to 1.68) 
BMI (kg/m
2
)   
Underweight (<18) 0.98 (0.86 to 1.11) 0.97 (0.86 to 1.10) 
Normal (18-24.9) 1 1 
Overweight (25-29.9) 0.96 (0.92 to 1.01) 0.95 (0.91 to 0.99) 
Obese (≥30) 1.04 (0.99 to 1.02) 1.01 (0.96 to 1.06) 
No records 0.59 (0.55 to 0.61) 0.67 (0.64 to 0.71) 
Smoking Status   
Never 1 1 
Former  1.09 (1.04 to 1.14) 1.08 (1.04 to 1.13) 
Current 1.15 (1.10 to 1.21) 1.20 (1.14 to 1.26) 
Unknown  0.57 (0.54 to 0.60) 0.69 (0.65 to 0.72) 
Townsend score   
1 least deprived 1 1 
2 1.07 (1.02 to 1.24) 1.06 (1.01 to 1.12) 
3 1.10 (1.05 to 1.16) 1.08 (1.02 to 1.13) 
4 1.14 (1.08 to 1.20) 1.10 (1.04 to 1.16) 
5 most deprived 1.23 (1.15 to 1.31) 1.18 (1.11 to 1.26) 
No records 1.17 (1.04 to 1.30) 1.21 (1.08 to 1.35) 
The fully adjusted Hazard Ratio (aHR) was 1.41, 95% CI 1.36 to 1.46, p<0.001 – the cox regression model 
was adjusted for age, gender, GP practice, modified Charlson comorbidity index, BMI smoking status, and 
socioeconomic class.  




Table 5-5. Summary of the univariate and multivariate Cox regression models of the 
incidence of depression antidepressant prescription, or either for patients with COPD 
compared with subjects without COPD matched by age, gender, and GP practice 







Depression    
Rate/1000 person-years (95% CI) 5.7 
(5.4 to 5.8) 
11.4 
(10.9 to 11.8) 
 
HR (95% CI) 1 1.98 (1.87 to 2.10) <0.001 
Fully adjusted (95% CI) 1 1.42 (1.32 to 1.53) a <0.001 
Antidepressant prescription    
Rate/1000 person-years (95% CI) 25.7 
(25.3 to 26.1) 
45.7 
(44.6 to 46.7) 
 
HR (95% CI) 1 1.78 (1.73 to 1.84) <0.001 
Fully adjusted (95% CI) 1 1.40 (1.35 to 1.45) a <0.001 
Either depression or antidepressant prescription   
Rate/1000 person-years (95% CI) 27.4 
(26.9 to 27.8) 
49.6 
(48.5 to 50.6) 
 
HR (95% CI) 1 1.81 (1.76 to 1.86) <0.001 
Fully adjusted (95% CI) 1 1.41 (1.36 to 1.46) a <0.001 
HR – adjusted for age, gender, and GP practice 
a Fully adjusted for age, gender, GP, BMI, modified CCI, smoking status, and socioeconomic class. 
Abbreviations: BMI: body mass index; CCI, Charlson comorbidity index; CI: confidence interval; GP: general 




Of all subjects with incident depression, 51% were prescribed antidepressant within 1-
month of a depression diagnosis. The incidence of antidepressant prescription 
following a diagnosis of depression was significantly higher for patients with COPD 
compared with subjects without COPD following adjustment for age, gender, BMI, 
modified CCI, and socioeconomic class (aHR: 1.09; 95% CI: 1.01–1.18; p=0.022). 
Further adjustments for smoking have attenuated the relationship.    
The association of MRC dyspnoea score amongst patients with COPD at the time of 
diagnosis was evaluated. There were 20,853 patients with MRC score 1-3 and 2,339 
with MRC score 4-5. There was a significantly greater incidence of new depression 
diagnosis (aHR: 1.28; 95% CI: 1.01–1.63; p=0.044), antidepressant prescription (aHR: 
1.29; 95% CI: 1.16–1.44, p>0.001), or either (aHR: 1.32; 95% CI: 1.19–1.46; p>0.001) 
in patients with an MRC score of 4–5 compared with those with an MRC score 1–3 
(Table 5-6).  
A total of 42,706 patients with COPD with Townsend index score were identified. 
Patients with lower socioeconomic status (n=26,039) had a greater risk of depression 
(aHR: 1.12; 95% CI: 1.02–1.23 ;p=0.016), antidepressant prescription (aHR:1.11; 
95%CI: 1.05–1.17), or either (aHR:1.08; 95% CI: 1.04–1.13), compared to patients 





Table 5-6. Comparison of incidence of either depression or antidepressant prescription 
in patients with COPD according to MRC dyspnoea score (1–3 vs 4–5) 
 MRC dyspnea  
score 1-3 
(n = 20,853) 
MRC dyspnea  
score 4-5 
(n = 2,339) 
P-value 
Depression 
HR (95% CI) 1 1.38 (1.12-1.71) 0.002 
Fully adjusted (95% CI) 1 1.28 (1.01–1.63) a 0.044 
Antidepressant prescription 
HR (95% CI) 1 1.35 (1.22–1.51) <0.001 
Fully adjusted (95% CI) 1 1.29 (1.16–1.44) a <0.001 
Either depression or antidepressant prescription 
HR (95% CI) 1 1.38 (1.24–1.53) <0.001 
Fully adjusted (95% CI) 1 1.32 (1.19–1.46) a <0.001 
a  Adjusted for age, gender, BMI, modified CCI, smoking status, and socioeconomic class. 
Abbreviations: BMI: body mass index; CCI: Charlson comorbidity index; CI: confidence interval; HR: hazard 




Table 5-7. Comparison of incidence of depression, antidepressant prescription, or either 
in patients with COPD according to Townsend index score (1–2 vs 3–5) 
 High social class (1–2) 
(n = 16,667) 
Low social class (3–5) 
(n = 26,039) 
P-value 
Depression 
HR (95% CI) 1 1.17 (1.06-1.28) 0.001 
Fully adjusted (95% CI) 1 1.12 (1.02–1.23) a 0.016 
Antidepressant prescription 
HR (95% CI) 1 11.13 (1.08–1.19) <0.001 
Fully adjusted (95% CI) 1 1.11 (1.05–1.17) a <0.001 
Either depression or antidepressant prescription 
HR (95% CI) 1 1.11 (1.06–1.17) <0.001 
Fully adjusted (95% CI) 1 1.08 (1.04–1.13) a <0.001 
a  Adjusted for age, gender, BMI, modified CCI, MRC dyspnea score, and smoking status. 
Abbreviations: BMI: body mass index; CCI: Charlson comorbidity index; CI: confidence interval; HR: hazard 






The coded incidence rates of depression or antidepressant prescription were 
significantly greater in patients with COPD compared to subjects without COPD, even 
after adjustments of age, gender, GP surgery, and other confounders. In addition, the 
risk of depression is further increased in patients with worse breathlessness and in 
those with a lower socioeconomic class. This study provides contemporaneous 
information with the current practice of managing patients with COPD.  
Studies on the incidence of depression following COPD is currently old. The findings 
that the incidence rate of depression was greater for patients with COPD compared to 
subjects without COPD is consistent with existing literature. However, the incidence 
of depression in the GP medical records reported in this study at 4.9% is slightly lower 
than the incidence reported in other population-based and clinical studies at 6% to 
14%, respectively [146, 297]. The difference is attributed to methodological 
differences such as sample size, follow-up period, definitions depression, and study 
designs. This large population-based study was conducted after the publication of 
NICE COPD guidelines and introduction of QOF recommendations for COPD; thus, 
reporting the incidence rate of depression according to the current primary care 
practice. 
Several risk factors are contributing to increased risk of depression in patients with 
COPD; one of which is COPD severity [290]. Using MRC dyspnoea score as a severity 
measure, the findings that patients with COPD and more breathlessness dyspnoea 
score were at a greater risk of incident depression are concordant with current 
literature. Yohannes et al. found that the odds of a new onset of depression was greater 
in patients with ≥ 2 modified MRC score compared to patients with less breathlessness 
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in a 3-year follow up study [297]. However, this does not imply that less breathless 
patients with COPD are not at risk of depression. Indeed, dyspnoea has been suggested 
as an important risk factor for depression in patients with COPD [36].  Breathlessness 
is the most burdensome symptom in COPD and is highly prevalent, even in patients 
with mild airflow limitation [34]. Therefore, it is vital to consider the psychological 
impact of COPD severity, particularly dyspnoea, and use targeted interventions. 
As expected, this study found that patients with COPD from lower socioeconomic 
status were at increased risk of depression compared to those in the higher class; 
consistent with previous reports linking low socioeconomic status to increased 
prevalence of COPD [28], depression [295, 298], and adverse health outcomes [299]. 
Patients living at more deprived areas are likely to be exposed to several stressors, 
including financial strain, poor housing, lower level of health literacy, and social 
isolation. In addition, there are also healthcare inequalities, with patients from more 
deprived areas having poor health care access, ultimately to the detriment of the patient 
[300]. Indeed, Steiner et al. found that patients with COPD from more deprived areas 
were less likely to adhere to pulmonary rehabilitation [301]. The latter study suggested 
that poor adherence may be due to lack of transport but may also be because these 
patients are less likely to be referred in the first place. Taken together, the findings of 
this study suggest that healthcare systems should understand the impact of social 
disadvantage and be determined to provide equity when addressing issues in patients 
with COPD.  
With regard to depression, this study found that 51% of patients with incident 
depression were prescribed antidepressant, a proportion that is far lower than 
previously reported (88%) [147]. The difference in these figures can be attributed to 
methodological differences (e.g. sample size) but can also be due to a change in clinical 
141 
 
practice after the initiative of the NICE guideline [302]. Antidepressant is not the sole 
treatment for depression [302], and the current depression NICE guideline 
recommends a stepwise approach when managing depression starting with the least 
intrusive and most effective approach first. Therefore, non-pharmacological 
interventions may be the first-line therapy for treating depression in patients with 
COPD.   
Establishing that patients with COPD are a high-risk group of depression highlights 
that healthcare professionals involving in the management of COPD need to be aware 
of this association at the annual review, thereby permitting appropriate treatment 
strategies and improving the quality of life in this population. Pulmonary 
rehabilitation, the cornerstone of care in patients with COPD, should be considered in 
all patients with COPD, particularly for those with MRC dyspnoea score of 3-5 [58] 
and is effective in reducing dyspnoea, and has also been shown to improve depression 
in COPD [58, 303].  
5.4.1 Strength and limitations    
The current large-scale population-based study has several strengths. Firstly, the 
primary care database is large and provides a representative sample of patients with 
COPD within the UK [273]; thus, offering high external validity and generalisability. 
Secondly, patients with COPD from 2004 onwards were included after the initiatives 
of NICE guidelines and QOF. Thirdly, this study adjusted for a wide range of relevant 
confounders, in addition to matching patients with COPD to subjects without COPD 
by age, gender, and GP practice; thus, reducing sources of bias.  
Regarding limitations, the actual incidence rate of depression might be 
underestimated, as it may be recorded as a free-text instead of READ-codes; therefore, 
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unlikely to appear in the search. In addition, some variables reported in QOF are 
subject to reporting bias. For instance, smoking, which is a self-reported, may have 
changed from the last recorded coded entry. This study only considered the first 
incident of depression or antidepressant prescription and did not consider repeated 
events. Another limitation is that the THIN database has some missing data, 
particularly on MRC dyspnoea score, which it may have led to inaccurate estimation. 
However, only those with MRC dyspnoea score were included in the MRC analysis.  
5.5 CONCLUSION   
This large population-based study demonstrated an increased risk of incident 
depression and antidepressant prescription in patients with confirmed COPD. This 







Chapter 6 Association between Antidepressants and 
Respiratory Related Morbidity in Patients with COPD: A 






























Poor mental health in patients with COPD has a significant impact on health and 
prognosis. In some cases, antidepressants may be needed for these patients, and the 
current guidelines recommend using selective serotonin reuptake inhibitors (SSRIs) or 
serotonin–noradrenaline reuptake inhibitors (SNRIs) [302]. 
There is growing evidence that antidepressants may be associated with respiratory 
harm in patients with COPD, even with SSRI/SNRI, which have better overall safety 
and acceptability records compared to tricyclic antidepressants (TCAs) [151, 304]. In 
fact, each antidepressant class has its own side-effects. The anticholinergic component 
of TCAs is associated with dry mouth [305], which may potentially lead to increased 
risk of pneumonia amongst elderly [306]. Current statistics show that up to 30% of 
antidepressant (SSRs/SNRIs) users experience side-effects of vomiting and nausea 
[307, 308], which are risk factors for aspiration pneumonia, and may also contribute 
to COPD exacerbation. In addition, SSRs/SNRIs may also have immunosuppressant 
effects, which can lower the threshold of infection [309, 310], making antidepressant 
recipients (from patients with COPD) more likely to experience a COPD exacerbation.        
A recent population-based study examined the association between antidepressant use 
and adverse respiratory events in the 90 days following antidepressant (SSRI/SNRI) 
prescription [151]. The findings showed that new users of SSRIs and/or SNRIs with 
COPD had increased risks of hospitalisation, emergency visits, pneumonia and 
mortality compared to non-users [151], highlighting a potential concern of 
antidepressant use in patients with COPD. However, these findings are subject to some 
limitations such as residual confounding and unmeasured factors. A major issue of 
studying such an association using traditional observational approach (e.g. cohort 
study) is the problem of uncontrolled confounding effects. Thus, utilising more 
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sophisticated analyses to eliminate “between-person” confounding and to further 
investigate these associations are worthwhile. 
The aim of this chapter is to investigate whether antidepressants are associated with 
an increased risk of pneumonia and COPD exacerbation using primary care electronic 





6.2.1 Study Design 
A self-controlled case series (SCCS) study design was used to examine the association 
between incident pneumonia and COPD exacerbation and antidepressant prescription 
in patients with a diagnosis of COPD.  
6.2.1.1  An overview of the SCCS design 
The SCCS method is a type of cohort study developed to investigate potential 
associations between transient exposures and acute outcomes. It estimates the relative 
incidence of an outcome in the exposure risk periods (exposed periods), with incidence 
during other baseline times (unexposed) within a person [311]. The main question, 
therefore, becomes “when” as opposed to “who”. A clear definition (e.g. precise 
timing) of the risk periods (exposed periods) is required for the SCCS, as it is best 
suited to investigate the temporal association between a time-varying exposure and an 
outcome event [311, 312]. The analysis is based only on data from cases (e.g. patients 
with COPD with a record of antidepressant prescription and who have the outcome of 
interest). The baseline (unexposed) period may include time both before and after the 
risk periods.  
The SCCS estimates the incidence rate ratio (IRR) ─ that is, the rate of an event in a 
given ‘exposed time’ compared to the rate of an event in ‘unexposed times’. The 
relative incidence is therefore estimated using a conditional Poisson model of the total 
number of events and exposures which each ‘case’ has experienced over a pre-
determined observation period. The SCCS was initially developed to study vaccine 
safety in a variety of settings where control groups are not readily available [313]. 
Since then, it has been extensively applied in different situations in pharmaco-
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epidemiology studies, including studies that used UK primary care data (e.g. THIN) 
[314-317]. Recently, the SCCS method has been used in studying the incident risk of 
cardiovascular events associated with infection and inflammation [318, 319]. 
A major advantage of SCCS is, as the name suggests,  that it is self-controlled ─ each 
participant acts as his/her own control ─ meaning that it accounts for all constant 
(fixed) confounders (e.g. sex, socioeconomic status, genetics) over the period of 
observation. In other words, the influence of confounding between subjects is 
eliminated [311, 320]. In addition, the SCCS allows for the assessment of risk 
alteration with exposure’ duration and provides a statistical power comparable to that 
of a cohort study [313]. 
6.2.1.2  Selection of the SCCS method in this study 
The decision to select the SCCS method to assess the association between 
antidepressant prescription and respiratory-related morbidity (pneumonia and COPD 
exacerbation) was made for two main reasons. First, there are several possible 
confounding sources when studying the association between the use of antidepressants 
and pneumonia and COPD exacerbation, including sex, socioeconomic status, and co-
existing comorbidities. This is in addition to other unknown/unmeasured confounders 
which may affect the association and are challenging to determine from electronic 
health records. However, the SCCS implicitly accounts for these factors as it is based 
on within-person comparisons. Secondly, the SCCS method permits the study of the 
duration of hypothesised increased risk in relation to the transient exposure 
(antidepressant prescription).   
Although this study could have been conducted using a cohort approach, confounding 
effects would have been introduced. There is also another within-person study design 
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(e.g. case cross-over (CCO) design) which could have been used to eliminate between-
person confounding effects associated with cohort study [321], and therefore to 
conduct this study. In brief, the CCO is analogous to a case-control study, in which all 
persons who have the outcome of interest (e.g. pneumonia and COPD exacerbation) 
are identified, and the exposure (antidepressant prescription) during risk period(s) 
immediately prior to the event is compared with the individual’s exposure at an earlier 
time (control periods) [321, 322]. However, the CCO design requires a strong 
stationary assumption ─ that is the exposure must have a stable (exchangeable) 
prevalence over successive time periods intervals (risk periods and baseline periods) 
[322], which is unlikely to be the case in this study.  
Some key features of the SCCS highlighted by Whitaker et al. [312, 320, 323] are as 
follows: 
• It is based on cases only, and the estimates of incidence related to different 
periods (exposed vs non-exposed).  
• It controls for non-varying confounders. 
• It can be applied to rare acute events and recurrent events.  
6.2.2  Data source and study population 
The cohort information was obtained using the THIN dataset, which contains 
anonymised patients records from over 550 GP practices within the UK [273]. See 
subsection 4.2.2.  
The study included all individuals aged ≥40 years with a new READ-coded COPD 
diagnosis between 1/01/2004 and 31/12/2015, who have at least one year of data prior 
to their COPD diagnosis [286] and have at least one record of anti-depressant 
prescription/dispensing. From those with antidepressant prescription(s), we included 
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all individuals (cases) with the outcomes of interest (pneumonia and COPD 
exacerbation) in the SCCS analyses.  Outcomes (pneumonia and COPD exacerbations) 
were identified using a list of READ codes. See subsection 6.2.6.  
6.2.3  Ethical approval 
Ethical approval for this study was provided by an independent Scientific Review 
Committee (SRC), reference number - 18THIN098.  
6.2.4 Exposure definition 
The exposure of interest was the prescription of any antidepressant. Antidepressant 
prescriptions were further divided into four classes: SSRIs, SNRIs, TCAs, Monoamine 
oxidase inhibitors (MAOIs), and collectively all together (Appendix 9-12). Data on 
antidepressant prescriptions were extracted for all cases in the study population.  
Detailed recordings of the length of prescriptions are not always found in THIN. In 
practice, patients are unlikely to collect the subsequent medication prescribed on 
exactly the day after the last day of the previous dispensing. Rather, they may collect 
it earlier (overlap between two prescriptions) or later (time gap between two 
prescriptions). To account for these irregularities, it is advised to allow for a certain 
number of days between prescriptions [324]. Therefore, to constitute a new episode of 
antidepressants, a 90-day interval between prescriptions was used, as it has 
consistently been used in primary care studies [316], and also according to the standard 
practice in the UK [325]. Thus, this study made a conservative assumption, in which 




6.2.5  Exposed and unexposed periods definitions 
The follow-up was defined as finishing when patients left the GP practice, date of 
death, or end of the study period. The core of the SCCS is to estimate the relative 
incidence risk amongst different risk periods to that in the baseline periods. The 
outcomes for each case were estimated during 7 different periods (Figure 6-1). 
Following a previous study [151], the decision was made to include a 90-day 
“hypothesised risk window” following the day of the first prescription. The selection 
of the 90-day risk period was made because this study intended to assess the acute 
effects of antidepressant related adverse events, and since it is acknowledged that 
antidepressant may take several weeks before it reaches its full effects. To assess the 
temporal changes associated with antidepressant prescription, this period (90-day) was 
then divided into 3 segments of 30 days each, where the risk of each period was 
assessed individually. A period of a variable-length was also included to cover the 
remainder period of that episode, followed by a 90-day washout period after the end 
of the antidepressant episode/course. In a situation where a new episode of 
antidepressant was started within these last two periods, the exposure statuses 
associated with that episode had taken over.  

















1- The time when cases are not exposed to antidepressants (baseline). 
2- A 30-day pre-exposure period including the first prescription date. Since 
antidepressants may be prescribed for anxiety or depression caused by the 
outcomes (pneumonia or COPD exacerbation), this period was added to correct 
for event-dependent exposure - that is to remove any pneumonia or 
exacerbation that might have led to prescribing an antidepressant. One 
approach to account for  “a temporary increase in exposure after an event” is 
to consider a pre-exposure risk period [311]. (See subsection: 6.2.7.1 
Assumptions and sensitivity analyses).   
3- A 30-day period following the 1st prescription date (from day 1 to day 30 on 
treatment).  
4- A 30-day period (from day 31 to day 60 on treatment).  
5- A 30-day period (from day 61 to day 90 on treatment).  
6- The remainder of that course to cover the entire exposure period (from day 91 
until the end of that course). 
7- A 90-day washout period following the end of that course.  




Date of first 
prescription 
End of last 
prescription within 
the same episode 
End of observation 
period 




6.2.6 Outcome definitions 
Two outcomes were assessed. Firstly, we assessed the association between 
antidepressants with READ-coded pneumonia (Appendix 9-13). All events of 
pneumonia were considered, and a new event was considered as such if at least 90 
days had elapsed from the previous incidence of pneumonia. This was determined after 
considering the number of days between pneumonia episodes and in line with current 
literature [326, 327]. Analyses for multiple events assume that an event is independent 
within an individual, meaning that an occurrence of an event must not change the 
probability of the following event (see subsection: 6.2.10. Assumption and sensitivity 
analyses). 
Secondly, we assessed the association between antidepressants and COPD 
exacerbation. Incidents of COPD exacerbation were defined based on algorithms 
constructed from multiple READ and drug codes as follows:  “1) a medical diagnosis 
of lower respiratory tract infection (LRTI) or acute exacerbation of COPD 
(AECOPD), or 2) a prescription of COPD-specific antibiotic combined with oral 
corticosteroids (OCS) for 5–14 days, or 3) a record of two or more respiratory 
symptoms of AECOPD along with a prescription of COPD-specific antibiotics and/or 
OCS on the same day” [328]. A new COPD exacerbation episode was considered as 
such if at least 8 weeks (56 days) had elapsed from the previous coded exacerbation 
[67]. READ and drug codes for constructing COPD exacerbations are available in the 




6.2.7 Statistical analysis 
Baseline characteristics and demographics were summarised as relative frequencies 
for categorical data and mean (SD) for normally distributed continuous variables as 
appropriate. The incidence rate ratio (IRR) for the outcomes (pneumonia and COPD 
exacerbation) were calculated using fixed-effects Poisson regression by comparing the 
incidence ratio during each exposure period with the incidence when the same 
individual was unexposed (baseline), with an adjustment for age (3-year bands) [320]. 
The age-adjusted IRR for each antidepressant class was calculated individually, as well 
as when all antidepressants were collectively combined for each outcome. STATA 
15.0 software was used for data management and statistical analyses.   
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6.2.7.1 Assumptions and sensitivity analyses 
For the SCCS model to be valid, the following key assumptions must be fulfilled: 
1- The occurrence of an outcome must not alter the probability of subsequent 
exposure so that there is no short term-dependency between the outcome and 
the subsequent exposure. As both pneumonia and COPD exacerbations are 
associated with depression and anxiety [329, 330], which therefore might 
increase the probability of antidepressants prescriptions, there is a potential 
short-term dependency that may lead to change in prescription. To account for 
this, Whitaker et al. proposed including a pre-exposure risk period to remove 
any outcome events that may have led to antidepressant prescription [312]. 
This approach has been widely used in previous studies [315-317, 326]. 
Therefore, a 30-day pre-exposure period was included, wherein there is a 
significant difference in the IRR at the 30-day pre-exposure period would 
indicate that the event has influenced the probability of subsequent exposure.  
2- The second assumption is that an event should not alter the probability of a 
subsequent event (occurrence of outcomes is independent), especially for 
modelling multiple events. Since COPD exacerbation is known to increase the 
risk of a future exacerbation [66], and pneumonia may also increase the 
probability of a future event, the assumption might be violated. To overcome 
this assumption, however, Whitaker et al. proposed another strategy ─ that is 
to limit the analysis to the first event [312, 323]. Therefore, a sensitivity 
analysis was conducted restricting the analysis to the first outcome event (e.g. 
pneumonia and COPD exacerbation). This approach is only valid for rare 
outcomes, such that the probability of an independent recurrence is trivial 
relative to that of an outcome-dependent (clustered) recurrence. It is unlikely 
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that COPD exacerbations meet this assumption, so the true independent IRR 
with antidepressant use is likely to lie between the two estimates. 
3- The outcome should not increase the probability of observation censoring; in 
other words, it does not lead to increased risk of death ─ which will inevitably 
alter the probability of subsequent exposures. Indeed, both outcomes 
(pneumonia and COPD exacerbation) are associated with increased risk of 
death; thus, the assumption might be violated. A number of approaches have 
been proposed to circumvent this assumption. Where the exposure of interest 
is a single fixed event and the exposure statuses that would have applied post-
censorship are known, censored observations may simply be extended to 
encompass the additional exposed time [331]; however, this approach is not 
viable in this case as the exposure period is of variable duration. An alternative 
case-series model applicable to event-dependent censoring is available [332]. 
However, this model relies on the assumption that events are rare and non-
recurrent, which is inapplicable to the present study data. Therefore, this study 
opted to carry out a secondary analysis using a simpler approach wherein 
patients who died following an event were excluded, similar to previous studies 
[317, 318, 326, 333, 334]. Thus, the primary analyses were repeated in patients 
whose follow-up was not censored because of death for 1) 6 months, and 2) 12 
months following the outcome event, to observe whether this resulted in a 




6.3  RESULTS 
Of the 31,253 patients with COPD with at least one record of antidepressant 
prescription during the study period, 1,969 individuals who had a coded pneumonia, 
and 18,483 individuals with COPD exacerbation were included in the SCCS analyses 
(Figure 6-2). The mean age (SD) was 65 (11) years, and more than 50% were females. 


















Patients with COPD identified in 
THIN from 1/01/2004 to 
31/12/2015 (n=80,874) 
Patients with COPD with at least 
one record of antidepressant 
(n=31,253) 
Excluded - no 
antidepressant within 
the study period 
(n=49,621) 
Patients with at least one record of 
antidepressant and one record of 
COPD exacerbation (n=18,483) 
Excluded - patients 
without pneumonia 
(n=29,284) 
Patients with at least one record of 
antidepressant and one record of 
pneumonia (n=1,969) 








Table 6-1. Baseline characteristics for patients with COPD with a record of 
antidepressant prescription (n=31,253) with pneumonia (n=1,969) or COPD 








Mean Age (years, SD) 65.1 (11.2) 71.8 (10.8) 67.7 (10.9) 
Gender     
Male  13,283 (44%) 950 (48%) 7,407 (41%) 
Female 17,970 (56%) 1,019 (52%) 11,076 (59%) 
Follow-up (years, median, IQR) 5.9 (3.3-8.7) 7.7 (5.5-9.8) 6.7 (4.2-9.1) 
Townsend score, n (%)    
1 least deprived  4,300 (14%) 252 (13%) 2,458 (14%) 
2 4,927 (16.2%) 300 (15%) 2,884 (16%) 
3 6,240 (20%) 386 (20%) 3,694 (20%) 
4 7,541 (24%) 513 (26%) 4,494 (24%) 
5 most deprived  6,902 (21.3%) 443 (22%) 4,217 (21.6%) 
No records 1,343 (4.5%) 75 (4%) 736 (4.4%) 
BMI (kg/m
2
), n (%)    
underweight (<18) 13,790 (44%) 863 (43%) 13,854 (44%) 
normal (18-24.99) 9,758 (31%) 623 (32%) 10,098 (32%) 
Overweight (25-29.99) 4,942 (16%) 289 (15%) 4,971 (16%) 
Obese (>30) 2,567 (6%) 314 (6%) 1,736 (5%) 
No records 952 (3%) 75 (4%) 543 (3%) 
MRC dyspnoea score, n (%)    
1 2,821 (10.3%) 94 (5%) 1,364 (7%) 
2 6,856 (23.6%) 285 (14%) 3,744 (20%) 
3 4,372 (14%) 231 (12%) 2,634 (14%) 
4-5 2,419 (7.4%) 174 (9%) 1,463 (8%) 
No records 14,785 (44.7%) 1,185 (60%) 9,278 (45.5%) 
Smoking status, (%)     
Never smoked  2,754 (9%) 164 (8.3%) 1,551 (8%) 
EX-smoker  13,608 (44%) 959 (48.7%) 8,092 (44%) 
Current smoker  14,480 (45%) 823 (42%) 8,667 (47%) 
Unknown  411 (2%) 23 (1%) 173 (1%)   
Modified CCI     
0-1 15,141 (48%) 790 (40%) 9,197 (50%) 
2 5,230 (16.5%) 358 (18%) 3,004 (16%) 
3 5,397 (17.5%) 368 (19%) 3,270 (18%) 
≥ 4 5,485 (18%) 453 (23%) 3,012 (16%) 




Association with pneumonia 
A total of 1,969 patients with COPD and antidepressant prescription had at least one 
event of pneumonia during the observation period (Table 6-2). The median number of 
pneumonia events is 1 (IQR: 1-2) per patent. The risk of pneumonia was compared 
across several risk periods. Compared to an unexposed period, collective 
antidepressant, SSRI/SNRI, and TCA prescriptions showed marked associations with 
pneumonia throughout all risk periods. However, the associations were then 
diminished after withdrawal from the treatment.  
The 90-day period following any antidepressant prescription was associated with a 
79% increased risk of pneumonia (age-adjusted IRR 1.79, 95% CI: 1.54 to 2.07). The 
risk also persisted throughout the remainder period (age-adjusted IRR 1.88, 95% CI: 
1.68 to 2.11). The initiation of SSRI/SNRI and TCAs, separately, were also associated 
with increased risk of pneumonia that extended to the remainder period (Table 6-2). 
In the sensitivity analysis, when restricting the analysis to the first event of pneumonia 
following antidepressant prescription, the risk remained across all risk periods and 
persisted to the remainder period for collective antidepressants, SSRI/SNRI and TCAs. 
However, no associations were observed after withdrawal of the treatment. Following 
pneumonia, there were 295 and 388 patients censored within 6 and 12 months, 
respectively.  In those who were not censored within 6 months after incident 
pneumonia, there was a 48% (1.26 to 1.75) increased risk of pneumonia in the 90 days 
following the prescription of any antidepressant. In this analyses, the results and trends 
were mostly similar to the primary analyses but slightly lower in magnitude (Table 6-4 




Table 6-2. Age-adjusted incidence rate ratio of pneumonia (multiple events) in exposure periods after antidepressant prescription relative to 
unexposed periods in patients with COPD, calculated by case series analytical technique, UK, 2004-2015 
Antidepressants No. of exposed 
cases with 
Pneumonia 
Day 1-30  
IRR (95%CI) 
Day 31-60  
IRR (95% CI) 
Day 61-90  
IRR (95% CI) 
Day 1-90 
IRR (95% CI) 
Remainder 
period 
IRR (95% CI) 
90 days 
washout 




(1.33 to 2.13) 
1.83  
(1.48 to 2.27) 
1.89 
(1.43 to 2.49) 
1.79 
(1.54 to 2.07) 
1.88 
(1.68 to 2.11) 
1.03 
(0.76 to 1.40) 
SSRI or SNRI 
 
1,218 1.75 
(1.29 to 2.38) 
1.62  
(1.22 to 2.15) 
2.56  
(1.88 to 3.50) 
1.76 
(1.46 to 2.12) 
1.83  
(1.58 to 2.12) 
1.02  




(1.62 to 2.39) 
1.53  
(1.13 to 2.07) 
2.65  
(1.94 to 3.62) 
1.86 
(1.54 to 2.4) 
1.79  
(1.54 to 2.09) 
0.95  




(0.73 to 3.91) 
1.23 
(0.53 to 2.86) 
1.61 
(0.59 to 4.36) 
1.48 
(0.86 to 2.55) 
1.91 
(1.31 to 2.79) 
1.29 




(1.10 to 2.03) 
1.92 
(1.46 to 2.52) 
1.40 
(0.95 to 2.07) 
1.64 
(1.35 to 1.98) 
1.78 
(1.54 to 2.07) 
1.29 




(0.07 to 7.43) 
0.93 
(0.10 to 8.14) 
─ 0.62 
(0.13 to 2.90) 
2.44 
(0.95 to 5.7) 
1.38  
(0.33 to 5.77) 
The “Collective Antidepressants” does not equate to the total of all individual class as some subjects received more than one antidepressant in each class 
Exposure time periods:  
1- Day 1-30: A 30-day risk period starting from the day after the date of prescription. 
2- Day 31-60: A 30-day risk period starting from day 31 after the date of prescription. 
3- Day 61-90: A 30-day risk period starting from day 61 after the date of prescription. 
4- Day 1-90: A 90-day risk period accounts for the entire risk window (day 1 to 90). 
5- Remainder period: A period starts 90 days after the date of the prescription until the end of the course (from day 91 after date of prescription until the end of the course). 
6- 90 days washout: A 90-day period starting the day after the end of the course and continuing for 90 days (day 1 after the end of the course until day 90 after the end of the 
course). Abbreviations: SSRI: Selective Serotonin Reuptake Inhibitor; SNRI:  serotonin-norepinephrine reuptake Inhibitor; TCA: Tricyclic antidepressants; MAOI: 




Table 6-3. Age-adjusted incidence rate ratio of pneumonia (first event) in exposure periods after antidepressant prescription relative to 
unexposed periods in patients with COPD, calculated by case series analytical technique, UK, 2004-2015 
Antidepressants No. of exposed 
cases with 
Pneumonia 
Day 1-30  
IRR (95%CI) 
Day 31-60  
IRR (95% CI) 
Day 61-90  
IRR (95% CI) 
Day 1-90 
IRR (95% CI) 
Remainder 
period 
IRR (95% CI) 
90 days 
washout 




(1.13 to 2.10) 
1.57 
(1.18 to 2.08) 
1.59 
(1.08 to 2.34) 
1.51 
(1.45 to 2.17) 
2.15 
(1.86 to 2.48) 
0.92 
(0.62 to 1.38) 
SSRI or NRI 
 
1,218 1.69 
(1.21 to 2.35) 
1.55  
(1.15 to 2.10) 
2.51  
(1.80 to 3.15) 
1.79 
(1.46 to 2.18) 
1.91  
(1.64 to 2.23) 
1.02  
(0.68 to 1.54) 
SSRI 
 
1,143 1.71  
(1.21 to 2.41) 
1.45  
(1.05 to 2.01) 
2.60  
(1.85 to 3.66) 
1.70 
(1.38 to 2.08) 
1.89 
(1.61 to 2.22) 
0.95  




(0.85 to 4.69) 
1.42 
(0.60 to 2.38) 
1.47 
(0.46 to 4.66) 
1.59 
(0.90 to 2.80) 
2.20 
(1.35 to 3.02) 
2.23 




(1.17 to 2.21) 
1.75 
(1.29 to 2.38) 
1.28  
(0.83 to 1.98) 
1.55 
(1.26 to 1.90) 
1.77 
(1.51 to 2.08) 
1.28 




(0.09 to 11.2) 
1.22 
(0.10 to 12.3) 
─ 0.95 
(0.18 to 4.81) 
2.03 
(0.66 to 6.21) 
1.06  
(0.14 to 8.18) 
The “Collective Antidepressants” does not equate to the total of all individual class as some subjects received more than one  antidepressant in each class 
Exposure time periods:  
1- Day 1-30: A 30-day risk period starting from the day after the date of prescription. 
2- Day 31-60: A 30-day risk period starting from day 31 after the date of prescription. 
3- Day 61-90: A 30-day risk period starting from day 61 after the date of prescription. 
4- Day 1-90: A 90-day risk period accounts for the entire risk window (day 1 to 90). 
5- Remainder period: A period starts 90 days after the date of the prescription until the end of the course (from day 91 after date of prescription until the end of the course). 
6- 90 days washout: A 90-day period starting the day after the end of the course and continuing for 90 days (day 1 after the end of the course until day 90 after the end of the 
course). Abbreviations: SSRI: Selective Serotonin Reuptake Inhibitor; SNRI:  serotonin-norepinephrine reuptake Inhibitor; TCA: Tricyclic antidepressants; MAOI: 




Table 6-4. Age-adjusted incidence rate ratio of pneumonia (excluding cases who died within 6 months following the date of pneumonia 
diagnosis) in exposure periods after antidepressant prescription relative to unexposed periods in patients with COPD, calculated by case series 
analytical technique, UK, 2004-2015 
Antidepressants No. of exposed 
cases with 
Pneumonia 
Day 1-30  
IRR (95%CI) 
Day 31-60  
IRR (95% CI) 
Day 61-90  
IRR (95% CI) 
Day 1-90 
IRR (95% CI) 
Remainder 
period 
IRR (95% CI) 
90 days 
washout 




(1.12 to 1.66) 
1.64  
(1.30 to 2.07) 
1.44 
(1.04 to 2.02) 
1.48 
(1.26 to 1.75) 
1.56 
(1.37 to 1.77) 
0.85 
(0.59 to 1.23) 
SSRI or SNRI 
 
1,048 1.32 
(0.92 to 1.89) 
1.44  
(1.05 to 1.97) 
2.03  
(1.41 to 2.91) 
1.50 
(1.22 to 1.84) 
1.51  
(1.28 to 1.78) 
0.86  




(0.86 to 1.85) 
1.41  
(1.02 to 1.95) 
2.15  
(1.49 to 3.1) 
1.55 
(1.26 to 1.91) 
1.48  
(1.26 to 1.75) 
0.83  




(0.30 to 2.70) 
1.15 
(0.46 to 2.84) 
1.72 
(0.63 to 4.67) 
1.17 
(0.64 to 2.15) 
1.81 
(1.22 to 2.70) 
2.03 




(0.88 to 1.74) 
1.71 
(1.27 to 2.30) 
1.21 
(0.77 to 1.88) 
1.42 
(1.15 to 1.74) 
1.56 
(1.32 to 1.83) 
1.04 




(0.08 to 7.86) 
0.91 
(0.10 to 8.46) 
─ 0.62 
(0.13 to 3.02) 
1.70 
(0.58 to 4.94) 
1.47  
(0.36 to 6.14) 
The “Collective Antidepressants” does not equate to the total of all individual class as some subjects received more than one  antidepressant in each class 
Exposure time periods:  
1- Day 1-30: A 30-day risk period starting from the day after the date of prescription. 
2- Day 31-60: A 30-day risk period starting from day 31 after the date of prescription. 
3- Day 61-90: A 30-day risk period starting from day 61 after the date of prescription. 
4- Day 1-90: A 90-day risk period accounts for the entire risk window (day 1 to 90). 
5- Remainder period: A period starts 90 days after the date of the prescription until the end of the course (from day 91 after date of prescription until the end of the course) 
6- 90 days washout: A 90-day period starting the day after the end of the course and continuing for 90 days (day 1 after the end of the course until day 90 after the end of the 
course). Abbreviations: SSRI: Selective Serotonin Reuptake Inhibitor; SNRI:  serotonin-norepinephrine reuptake Inhibitor; TCA: Tricyclic antidepressants; MAOI: 
Monoamine oxidase inhibitors.  
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Table 6-5. Age-adjusted incidence rate ratio of pneumonia (excluding cases who died within 12 months following the date of pneumonia 
diagnosis) in exposure periods after antidepressant prescription relative to unexposed periods in patients with COPD, calculated by case series 
analytical technique, UK, 2004-2015 
Antidepressants No. of exposed 
cases with 
Pneumonia 
Day 1-30  
IRR (95%CI) 
Day 31-60  
IRR (95% CI) 
Day 61-90  
IRR (95% CI) 
Day 1-90 
IRR (95% CI) 
Remainder 
period 
IRR (95% CI) 
90 days 
washout 




(1.02 to 1.75) 
1.51 
(1.18 to 1.92) 
1.46 
(1.04 to 2.05) 
1.43 
(1.21 to 1.70) 
1.48 
(1.30 to 1.68) 
0.79 
(0.53 to 1.17) 
SSRI or SNRI 989 1.33 
(0,92 to 1.91) 
1.38  
(1.01 to 1.89) 
1.97  
(1.36 to 2.87) 
1.48 
(1.19 to 1.83) 
1.42  
(1.20 to 1.68) 
0.87  
(0.57 to 1.39) 
SSRI 922 1.24 
(0.85 to 1.84) 
1.23  
(0.87 to 1.74) 
2.02  
(1.38 to 2.69) 
1.51 
(1.22 to 1.86) 
1.34  
(1.12 to 1.60) 
0.86  
(0.54 to 1.38) 
SNRI 153 0.91 
(0.30 to 2.76) 
1.16 
(0.47 to 2.90) 
1.77 
(0.65 to 4.82) 
1.19 
(0.65 to 2.19) 
1.75 
(1.61 to 2.63) 
2.09 
(0.97 to 4.54) 
TCA 1,065 1.25 
(0.88 to 1.76) 
1.58 
(1.16 to 2.15) 
1.19 
(0.75 to 1.88) 
1.40 
(1.13 to 1.72) 
1.50 
(1.27 to 1.78) 
0.95 
(0.62 to 1.44) 
MAOI 44 0.85 
(0.09 to 8.05) 
0.93 
(0.10 to 8.64) 
─ 0.64 
(0.13 to 3.10) 
1.76 
(0.60 to 5.16) 
1.50  
(0.36 to 6.32) 
The “Collective Antidepressants” does not equate to the total of all individual class as some subjects received more than one antidepressant in each class 
Exposure time periods:  
1- Day 1-30: A 30-day risk period starting from the day after the date of prescription. 
2- Day 31-60: A 30-day risk period starting from day 31 after the date of prescription. 
3- Day 61-90: A 30-day risk period starting from day 61 after the date of prescription. 
4- Day 1-90: A 90-day risk period accounts for the entire risk window (day 1 to 90). 
5- Remainder period: A period starts 90 days after the date of the prescription until the end of the course (from day 91 after date of prescription until the end of the course) 
6- 90 days washout: A 90-day period starting the day after the end of the course and continuing for 90 days (day 1 after the end of the course until day 90 after the end of the 
course). Abbreviations: SSRI: Selective Serotonin Reuptake Inhibitor; SNRI:  serotonin-norepinephrine reuptake Inhibitor; TCA: Tricyclic antidepressants; MAOI: 
Monoamine oxidase inhibitors. 
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Association with COPD exacerbation 
The results of the association of antidepressant use and COPD exacerbation are shown 
in Table 6-6. There were 18,483 patients with COPD identified who had been 
prescribed antidepressants and had ≥ 1 COPD exacerbation event. The median number 
of COPD exacerbations was 3 (IQR; 2-6) events per patient, using validated definitions 
suggested by Rothnie and colleagues [328]. 
Compared to a period when patients were not exposed to antidepressant, there was a 
16% increased risk of COPD exacerbation (age-adjusted IRR= 1.16, 95% CI: 1.13 to 
1.20) in the first 90 days following any antidepressant prescription that slightly 
increased in the remainder period (age-adjusted IRR= 1.38, 95% CI: 1.34 to 1.41), but 
the association was diminished after 90 days from stopping the treatment. Similar 
trends were observed in SSRI/SNRI and TCAs (Table 6-6).  
The 90 days following antidepressant prescription were associated with increased risk 
of the first event of COPD exacerbation (age-adjusted IRR= 1.41, 95% CI: 1.34 to 
1.49; Table 6-7) The risk has also extended throughout the remainder period, but then 
diminished in the washout period.  
To assess the impact of COPD exacerbation on increasing the probability of censoring, 
the analyses were repeated in those who were not censored within 6 and 12 months 
after COPD exacerbation. The results showed that there were 1331 and 2,078 patients 
censored within 6 and 12 months, respectively, following a COPD exacerbation. There 
was 12% increased risk of COPD exacerbation in the 90 days following any 
antidepressants in those whose observations were not censored within 6 and 12 months 
after COPD exacerbation, compared to unexposed periods (Table 6-8 & Table 6-9). 
The risk persisted through the remainder period.
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Table 6-6. Age-adjusted incidence rate ratio of COPD exacerbation (multiple events) in exposure periods after antidepressant prescription 
relative to unexposed periods in patients with COPD, calculated by case series analytical technique, UK, 2004-2015 
Antidepressants No. of exposed cases 
with exacerbation 
Day 1-30  
IRR (95%CI) 
Day 31-60  
IRR (95%CI) 






IRR (95% CI) 
90 days 
washout 




(1.06 to 1.17) 
1.18  
(1.12 to 1.23) 
1.23 
(1.15 to 1.31) 
1.16 
(1.13 to 1.20) 
1.38 
(1.34 to 1.41) 
0.98 
(0.92 to 1.05) 
SSRI or SNRI 11,770 1.10 
(1.03 to 1.17) 
1.16  
(1.09 to 1.23) 
1.22 
(1.13 to 1.33) 
1.15 
(1.11 to 1.20) 
1.39  
(1.35 to 1.43) 
0.99  
(0.93 to 1.10) 
SSRI 10,919 1.07 
(1.01 to 1.45) 
1.13 
(1.06 to 1.21) 
1.29 
(1.10 to 1.30) 
1.12 
(1.08 to 1.17) 
1.36  
(1.32 to 1.41) 
1.02  
(0.94 to 1.11) 
SNRI 1,753 1.14 
(0.94 to 1.40) 
1.29 
(1.10 to 1.52) 
1.34 
(1.09 to 1.65) 
1.23 
(1.10 to 1.38) 
1.36 
(1.26 to 1.47) 
1.06 
(0.87 to 1.33) 
TCA 11,936 1.09 
(1.02 to 1.16) 
1.16 
(1.10 to 1.23) 
1.26  
(1.17 to 1.37) 
1.16 
(1.11 to 1.21) 
1.27 
(1.23 to 1.32) 
1.02 
(0.93 to 1.09) 
MAOI 416 1.14 
(0.77 to 1.68) 
1.57 
(1.11 to 2.23) 
1.17 
(0.71 to 1.92) 
1.33 
(1.07 to 1.66) 
1.15 
(0.89 to 1.50) 
0.76  
(0.49 to 1.18) 
The “Collective Antidepressants” does not equate to the total of all individual class as some subjects received more than one  antidepressant in each class 
Exposure time periods:  
1- Day 1-30: A 30-day risk period starting from the day after the date of prescription. 
2- Day 31-60: A 30-day risk period starting from day 31 after the date of prescription. 
3- Day 61-90: A 30-day risk period starting from day 61 after the date of prescription. 
4- Day 1-90: A 90-day risk period accounts for the entire risk window (day 1 to 90). 
5- Remainder period: A period starts 90 days after the date of the prescription until the end of the course (from day 91 after date of prescription until the end of the course) 
6- 90 days washout: A 90-day period starting the day after the end of the course and continuing for 90 days (day 1 after the end of the course until day 90 after the end of the 
course). Abbreviations: SSRI: Selective Serotonin Reuptake Inhibitor; SNRI:  serotonin-norepinephrine reuptake Inhibitor; TCA: Tricyclic antidepressants; MAOI: 




Table 6-7. Age-adjusted incidence rate ratio of COPD exacerbation (first event) in exposure periods after antidepressant prescription relative 
to unexposed periods in patients with COPD, calculated by case series analytical technique, UK, 2004-2015 
Antidepressant No. of exposed 
cases with 
exacerbation 
Day 1-30  
IRR (95% CI) 
Day 31-60  
IRR (95% CI) 
Day 61-90  
IRR (95% CI) 
Day 1-90 
IRR (95% CI) 
Remainder 
period 
IRR (95% CI) 
90 days 
washout 




(1.30 to 1.52) 
1.21  
(1.12 to 1.31) 
1.73 
(1.59 to 1.89) 
1.41 
(1.34 to 1.49) 
1.34 
(1.28 to 1.39) 
0.97 
(0.85 to 1.10) 
SSRI or SNRI 11,770 1.48 
(1.34 to 1.64) 
1.19  
(1.08 to 1.32) 
1.73  
(1.54 to 1.93) 
1.43 
(1.34 to 1.53) 
1.39  
(1.32 to 1.45) 
1.12  
(0.98 to 1.27) 
SSRI 20,885 1.45  
(1.30 to 1.61) 
1.18 
(1.06 to 1.31) 
1.62 
(1.44 to 1.83) 
1.39 
(1.30 to 1.49) 
1.37  
(1.30 to 1.44) 
0.97  
(0.85 to 1.10) 
SNRI 4,128 1.29 
(0.97 to 1.72) 
1.56 
(1.17 to 2.07) 
2.24 
(1.71 to 2.92) 
1.64 
(1.38 to 1.95) 
1.32 
(1.16 to 1.50) 
1.26 
(0.88 to 1.78) 
TCA 23,786 1.36 
(1.22 to 1.51) 
1.22  
(1.10 to 1.35) 
1.70  
(1.52 to 1.91) 
1.23 
(1.16 to 1.30) 
1.23 
(1.17 to 1.31) 
0.98 
(0.86 to 1.07) 
MAOI 416 0.98 
(0.48 to 2.00) 
1.18 
(0.67 to 2.09) 
1.62 
(0.83 to 13.1) 
1.23 
(0.83 to 1.81) 
1.15 
(0.78 to 1.70) 
1.07  
(0.54 to 2.10) 
The “Collective Antidepressants” does not equate to the total of all individual class as some subjects received more than one  antidepressant in each class 
Exposure time periods:  
1- Day 1-30: A 30-day risk period starting from the day after the date of prescription. 
2- Day 31-60: A 30-day risk period starting from day 31 after the date of prescription. 
3- Day 61-90: A 30-day risk period starting from day 61 after the date of prescription. 
4- Day 1-90: A 90-day risk period accounts for the entire risk window (day 1 to 90) 
5- Remainder period: A period starts 90 days after the date of the prescription until the end of the course (from day 91 after date of prescription until the end of the course) 
6- 90 days washout: A 90-day period starting the day after the end of the course and continuing for 90 days (day 1 after the end of the course until day 90 after the end of the 
course). Abbreviations: SSRI: Selective Serotonin Reuptake Inhibitor; SNRI:  serotonin-norepinephrine reuptake Inhibitor; TCA: Tricyclic antidepressants; MAOI: 




Table 6-8. Age-adjusted incidence rate ratio of COPD exacerbation (excluding cases who died within 6 months following the date of COPD 
exacerbation) in exposure periods after antidepressant prescription relative to unexposed periods in patients with COPD, calculated by case 
series analytical technique, UK, 2004-2015 
Antidepressant No. of exposed 
cases with 
exacerbation 
Day 1-30  
IRR (95% CI) 
Day 31-60  
IRR (95% CI) 
Day 61-90  
IRR (95% CI) 
Day 1-90 
IRR (95% CI) 
Remainder 
period 
IRR (95% CI) 
90 days 
washout 




(1.02 to 1.13) 
1.12  
(1.07 to 1.18) 
1.18 
(1.11 to 1.26) 
1.12 
(1.08 to 1.15) 
1.30 
(1.27 to 1.33) 
0.99 
(0.93 to 1.07) 
SSRI or SNRI 10,938 1.07 
(1.01 to 1.15) 
1.13  
(1.06 to 1.20) 
1.18  
(1.08 to 1.28) 
1.12 
(1.07 to 1.17) 
1.32  
(1.28 to 1.36) 
1.01  
(0.92 to 1.08) 
SSRI 10,133 1.05 
(0.97 to 1.12) 
1.10 
(1.03 to 1.18) 
1.16 
(1.06 to 1.27) 
1.09 
(1.05 to 1.14) 
1.30  
(1.25 to 1.34) 
1.02  
(0.94 to 1.11) 
SNRI 1,666 1.11 
(0.90 to 1.36) 
1.24 
(1.05 to 1.47) 
1.27 
(1.02 to 1.58) 
1.19 
(1.06 to 1.33) 
1.32 
(1.23 to 1.43) 
1.08 
(0.87 to 1.34) 
TCA 11,114 1.05 
(0.98 to 1.12) 
1.12  
(1.05 to 1.19) 
1.22  
(1.12 to 1.32) 
1.11 
(1.07 to 1.16) 
1.21 
(1.17 to 1.25) 
1.02 
(0.95 to 1.11) 
MAOI 394 1.10 
(0.74 to 1.65) 
1.61 
(1.16 to 2.23) 
1.22 
(0.74 to 1.95) 
1.37 
(1.10 to 1.71) 
1.19 
(0.93 to 1.52) 
0.95  
(0.62 to 1.45) 
The “Collective Antidepressants” does not equate to the total of all individual class as some subjects received more than one antidepressant in each class 
Exposure time periods:  
1- Day 1-30: A 30-day risk period starting from the day after the date of prescription. 
2- Day 31-60: A 30-day risk period starting from day 31 after the date of prescription. 
3- Day 61-90: A 30-day risk period starting from day 61 after the date of prescription. 
4- Day 1-90: A 90-day risk period accounts for the entire risk window (day 1 to 90). 
5- Remainder period: A period starts 90 days after the date of the prescription until the end of the course (from day 91 after date of prescription until the end of the course) 
6- 90 days washout: A 90-day period starting the day after the end of the course and continuing for 90 days (day 1 after the end of the course until day 90 after the end of the 
course). Abbreviations: SSRI: Selective Serotonin Reuptake Inhibitor; SNRI:  serotonin-norepinephrine reuptake Inhibitor; TCA: Tricyclic antidepressants; MAOI: 
Monoamine oxidase inhibitors. 
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Table 6-9. Age-adjusted incidence rate ratio of COPD exacerbation (excluding cases who died within 12 months following the date of COPD 
exacerbation) in exposure periods after antidepressant prescription relative to unexposed periods in patients with COPD, calculated by case 
series analytical technique, UK, 2004-2015 
Antidepressant No. of exposed 
cases with 
exacerbation 
Day 1-30  
IRR (95% CI) 
Day 31-60  
IRR (95% CI) 
Day 61-90  
IRR (95% CI) 
Day 1-90 
IRR (95% CI) 
Remainder 
period 
IRR (95% CI) 
90 days 
washout 




(1.02 to 1.13) 
1.11 
(1.05 to 1.16) 
1.17 
(1.10 to 1.26) 
1.12 
(1.07 to 1.15) 
1.27 
(1.24 to 1.30) 
0.99 
(0.93 to 1.07) 
SSRI or SNRI 10,472 1.06 
(0.99 to 1.14) 
1.11  
(1.04 to 1.18) 
1.19  
(1.09 to 1.30) 
1.11 
(1.06 to 1.16) 
1.29  
(1.25 to 1.33) 
1.01  
(0.92 to 1.09) 
SSRI 9,696 1.04  
(0.96 to 1.11) 
1.09 
(1.02 to 1.16) 
1.17 
(1.07 to 1.28) 
1.09 
(1.04 to 1.14) 
1.26  
(1.22 to 1.31) 
1.06  
(0.94 to 1.12) 
SNRI 1,609 1.10 
(0.89 to 1.36) 
1.22 
(1.03 to 1.44) 
1.24 
(0.99 to 1.55) 
1.17 
(1.04 to 1.31) 
1.29 
(1.20 to 1.40) 
1.08 
(0.87 to 1.35) 
TCA 10,638 1.05 
(0.97 to 1.12) 
1.10  
(1.03 to 1.17) 
1.21  
(1.11 to 1.31) 
1.10 
(1.06 to 1.15) 
1.18 
(1.13 to 1.22) 
1.02 
(0.96 to 1.11) 
MAOI 381 1.11 
(0.75 to 1.63) 
1.61 
(1.16 to 2.24) 
1.27 
(0.79 to 1.02) 
1.39 
(1.11 to 1.74) 
1.24 
(0.97 to 1.59) 
0.96  
(0.62 to 1.49) 
The “Collective Antidepressants” does not equate to the total of all individual class as some subjects received more than one  antidepressant in each class 
Exposure time periods:  
1- Day 1-30: A 30-day risk period starting from the day after the date of prescription. 
2- Day 31-60: A 30-day risk period starting from day 31 after the date of prescription. 
3- Day 61-90: A 30-day risk period starting from day 61 after the date of prescription. 
4- Day 1-90: A 90-day risk period accounts for the entire risk window (day 1 to 90). 
5- Remainder period: A period starts 90 days after the date of the prescription until the end of the course (from day 91 after date of prescription until the end of the course) 
6- 90 days washout: A 90-day period starting the day after the end of the course and continuing for 90 days (day 1 after the end of the course until day 90 after the end of the 
course). Abbreviations: SSRI: Selective Serotonin Reuptake Inhibitor; SNRI:  serotonin-norepinephrine reuptake Inhibitor; TCA: Tricyclic antidepressants; MAOI: 





In this self-controlled case series study utilising primary care data, there were 
increased risks of both pneumonia and COPD exacerbations in the 90 days following 
the use of antidepressants, including SSRIs or SNRIs, and TCAs among patients with 
COPD. The increased risk remained even when the analyses were restricted to the first 
event. However, the risk of pneumonia and COPD exacerbation both diminished once 
antidepressants are discontinued. This study provides important information on the 
potential adverse reactions of antidepressants in patients with COPD and adds to the 
body of literature.  
There has been growing evidence that antidepressants may lead to respiratory-related 
adverse events in patients with COPD. The current study found that there is an 
increased risk of pneumonia in the 90-day following antidepressant prescription and 
was also extended as long as patients with COPD were receiving antidepressants. 
Although this study further supports findings from a previous study that SSRI or SNRI 
users with COPD have increased risk of pneumonia compared to non-users [151], the 
risk of pneumonia reported in this study was of a greater magnitude and longer period. 
In addition, this study also explored these associations in other antidepressant classes 
and identifying precise timing and duration of amplified risk; something has not been 
investigated before.   
The causal link between antidepressants and the development of pneumonia has not 
been established. However, there is evidence suggesting that depression/anxiety 
(which are highly prevalent in COPD [143, 296], and may be accompanied with 
antidepressants) is independently associated with increased risk of respiratory 




pneumonia in the 90-day period after hospitalisation for depression [336], highlighting 
the possibility that antidepressants contribute to the increased risk. Furthermore, 
Hennessy et al. found an association between antidepressants and increased risk of 
pneumonia, despite the nullified association upon further adjustments [337]. There is 
also a possibility that the side effects associated with antidepressants, such as dry 
mouth, vomiting, and nausea, may contribute to increased risk of pneumonia (e.g. 
aspiration pneumonia) [307, 308, 338]. It is possible, however, that the increased 
pneumonia risk observed here may be additive to the risk associated with COPD, as 
COPD itself is associated with increased risk of pneumonia [339]. 
COPD exacerbation is an important event in the natural history of COPD. On average, 
patients with COPD may experience two exacerbation episodes every year [340]. This 
study found an increased risk of COPD exacerbation in the 90-day period following 
antidepressant prescriptions, which has also extended during the time when patients 
were on continues antidepressant. In contrast, a previous study has shown that new 
users (patients with COPD) of antidepressant (SSRI/SNRI) were at lower risk of 
COPD exacerbation compared to non-users in the 90-day following antidepressant, 
owning this to increased and competing risk of other respiratory events and death 
[151]. Crucially, the current study compared the incidence relative risk of COPD 
exacerbation during antidepressant exposure periods with the patients’ own stable 
period, not the risk of COPD exacerbation between individuals. Although having a 
history of COPD exacerbation is the greatest risk factor of future exacerbations [66], 
this study found a similar relationship ─ there is an increased risk of COPD 
exacerbation following antidepressant prescriptions ─ when the analysis was restricted 





6.4.1  Strengths and validity of the SCCS method 
The use of case-only study designs, such as SCCS, has been widely employed in 
pharmaco-epidemiological studies. It circumvents the problem of selecting an 
appropriate comparator group and minimises the effect of unmeasured and unknown 
confounding that may be seen in the traditional observational designs (e.g. case-control 
and cohort studies). This is an important point to consider, as there may be systematic 
differences between subjects. However, the SCCS accounts for the time-independent 
confounder, making the estimation more robust than traditional observational designs. 
Indeed, the statistical power of the SCCS is comparable to that of a cohort study [341]. 
Furthermore, the SCCS method also provides an opportunity to assess the temporal 
changes in outcome (e.g. pneumonia and COPD exacerbation) risk associated with 
antidepressants prescriptions, something which has not been fully explored before.  
Although the initial research question of this study may seem to violate some 
assumptions of the SCCS, this study used recommended approaches to overcome these 
issues, such as 1) including a pre-exposure period, 2) studying the first event, and 3) 
excluding those whose observations were censored because of death.  The 30-day pre-
exposure period was designed to exclude any outcomes (e.g. pneumonia and COPD 
exacerbation) that might have led to prescriptions of antidepressants. It is unsurprising 
that the IRRs of both pneumonia and COPD exacerbation were significantly increased 
in this period. This is because both outcomes (pneumonia and COPD exacerbation) 
have been associated with depression [329, 330], which therefore might increase the 
probability of antidepressant prescriptions. Because the day of the antidepressant 
prescription was included in the 30-day pre-exposure period, it is also possible that the 




that started in secondary care) as opposed to the antidepressants causing the pneumonia 
or COPD exacerbation events. Therefore, it was essential to consider such an 
adjustment.  
The validity of the SCCS analytical approach relies on whether recurrent events occur 
independently. In an ideal world, the model allows outcomes (pneumonia and COPD 
exacerbation) to be recurrent, but they must be independent. However, independence 
is not always present in practice. In fact, the greatest risk factor of COPD exacerbation 
is a history of previous exacerbation [66]. In this instance, bias might be introduced. It 
is simpler, however, to consider a non-recurrent event as the first event, even when 
recurrence is unlikely to happen [323]. Therefore, a sensitivity analysis was conducted 
by studying the first event, and the results were consistent with the primary analyses; 
thus, satisfying this assumption.       
Another critical assumption for the SCCS method is that both the distribution of 
exposure and the observation period must be independent of the time of the event. In 
other words, the occurrence of an event must not censor or disrupt the exposure 
process, which is inevitable in the case of death [342]. If an event is associated with 
increased risk of mortality, such as pneumonia or COPD exacerbation, there is a 
chance that the observation period might be altered, and exposures (e.g. 
antidepressant) will not be observed. This could possibly produce a biased estimate 
(e.g. inflation of the IRRs) of pneumonia or COPD exacerbation [331], although a 
violation of the assumption does not always result in severe bias. It is therefore 
important to have an applicable method to account for this. It is also worth noting that 
the alternative approach (which assumes non-recurrence) is equally problematic, as 




was circumvented by excluding patients whose observations were censored within 6 
and 12 months of their outcome event. This approach has been widely used in the 
literature [318, 326, 333, 334], as it ensures that only cases who were followed until 
the end of the observation period were included, and therefore meeting the requirement 
of the assumption. The results for the 90-day “risk window” were consistent with the 
primary analyses, although lower in magnitude due to loss of power.   
6.4.2 Strengths and limitations of the study 
This study has several strengths. First, the primary care database is large and provides 
a representative sample of patients with COPD within the UK [273].  Second, the use 
of within-individual comparison has control for time-independent confounders such as 
sex, socioeconomic status, and genetics; thus, providing a robust estimate. Third, this 
study used validated definitions for COPD exacerbation in electronic health records 
[328]. However, this study has some limitations. Although the SCCS does not account 
for time-varying confounders, this study accounted for these by adjusting for age-
bands. Another limitation is that some lifestyle exposures are not regularly updated, 
making it difficult to exclude confounding factors that are known to accompany the 
issue of antidepressant prescription. For instance, smoking consumption may become 
more frequent during depression or anxiety episodes (and hence antidepressant 
prescription), which could consequently confound the observed relationship. In 
addition, it was difficult to determine whether patients collected and/or adhered to their 
antidepressants as prescribed. In fact, THIN does not provide information on whether 
the antidepressants were dispensed. Moreover, the current analysis only studied 
pneumonia and COPD exacerbation events reported in general practice but could not 




6.4.3 Clinical implications 
The findings of this study should be interpreted with caution. Instead of completely 
avoiding prescribing antidepressants to patients with COPD, the findings should raise 
awareness of the potential respiratory adverse effects associated with antidepressants. 
Clinicians should adopt a meticulous approach when managing patients with COPD 
and poor mental health. This includes explaining both the condition and the side effects 
of the treatment. It is also important for clinicians to stay vigilant and accept the 
challenges of antidepressants by monitoring each patient closely following the 
prescription of the treatment. On the other hand, these findings also highlight the 
importance of considering non-pharmacological therapies that have been shown to 
improve mental health disorders such as psychological support [343].     
6.5 CONCLUSION 
Compared to the stable period, antidepressants were associated with increased risk of 
pneumonia and COPD exacerbation in the 90 days following a prescription of 
antidepressants. If cause and effect relationships are confirmed, clinicians should be 






Chapter 7  Summary of conclusions, implications, and 
























7.1  Summary of findings 
Research in this thesis contributes to the body of knowledge on COPD comorbidities 
and clinical biomarkers. The findings of each study have led to the following 
conclusions: 
7.1.1 Clinical circulating biomarkers 
• In a cross-sectional analysis, soluble Receptor for Advanced Glycation End-
products (sRAGE) was not associated with aortic stiffness, carotid intimal 
media thickness, or coexistent cardiovascular disease in patients with COPD, 
but there was a weak association between sRAGE and FEV1% predicted.  
• Patients with COPD and either diabetes, ischaemic heart disease, or 
cerebrovascular disease have increased urinary albumin creatinine ratio 
compared to patients without these conditions. The prevalence of clinical 
microalbuminuria in patients with COPD and either diabetes, ischaemic heart 
disease, or cerebrovascular disease was 22%, and it was 15% in patients 
without these comorbidities.  
• The associations of urinary albumin creatinine ratio with aortic stiffness and 
carotid intimal media thickness in all patients with COPD were nullified when 
adjusted for known confounders.  
• Aortic stiffness was significantly greater in patients with clinical 





7.1.2 COPD comorbidities 
• A UK-population-based study demonstrates that the prevalence of cognitive 
impairment at the time of COPD diagnosis was greater than in subjects without 
COPD, matched by age, gender, and GP practice.  
• Patients with COPD were more likely to have an incident diagnosis of 
cognitive impairment (incident rate: 23.1 per 1,000 person-years), compared to 
subjects without COPD (incident rate: 16.3 per 1,000 person-years).   
• The prevalence and incidence of dementia were less frequently recorded in 
patients with COPD compared to matched subjects without COPD. 
• Patients with COPD and worse breathlessness were associated with a greater 
prevalence and incidence of cognitive impairment and dementia compared to 
patients with less breathlessness.  
• In a large cohort study, the risk of incident depression following a COPD 
diagnosis was greater (incidence rate: 11.4 per 1,000 person-years) than in 
subjects without COPD (incidence rate: 5.7 per 1,000 person-years) matched 
by age, gender, and GP practice. 
• Patients with COPD with lower socioeconomic status had a greater risk of 
depression compared to patients with COPD with higher socioeconomic class.  
• Patients with COPD and worse breathlessness were associated with increased 
risk of incident depression compared to patients with less breathlessness.  
• Antidepressant use was associated with increased risks of pneumonia and 
COPD exacerbations in patients with COPD, relative to a period of unexposed 




• The risks of pneumonia and COPD exacerbations both diminished once 
antidepressants were discontinued.   
 
The co-existence of comorbidities presents a significant challenge in the clinical 
management of COPD, impacting on patients’ health status and affecting the rate of 
hospitalisations, exacerbations, and mortality [69-74]. Increased knowledge of the 
burden of COPD comorbidities helps in developing appropriate interventions, 
improving clinical practice, and reframing guidelines. The findings of this thesis 
highlight important aspects of recognising, understanding, and managing 
comorbidities in patients with COPD. The following sections will discuss the 
implications of the thesis findings and provide recommendations for future research. 
7.2  Implications of findings 
7.2.1 Cardiovascular risk prognostication in COPD 
Cardiovascular (CV) disease is recognised as a significant cause of morbidity and 
mortality in patients with COPD  [73, 87], yet the CV state is not routinely assessed. 
The burden of CV events in patients with COPD can be significantly ameliorated by 
preventative strategies (primary and secondary preventions). However, this implies 
recognising CV disease and CV risk factors (e.g. smoking, cholesterol, and 
hypertension), and taking necessary actions as early as possible.  
Cardiovascular disease often remains underdiagnosed and undertreated in patients 
with COPD [344]. This may be attributed to the lack of clinical guidelines for 
managing CV disease in patients with COPD. Although the current COPD guidelines 
recommend recognising CV disease in patients with COPD [1], there has been no 




risk. This issue has been highlighted in the literature which emphasises on routine 
assessment to the CV state in patients with COPD [157-159]. We, therefore, should be 
continuously seeking opportunities for CV risk identification and prevention in 
primary care as well as in secondary care clinics. 
Current recommendations suggest that management of CV disease in patients with 
COPD should be performed using its own individual guidelines (as if the patient does 
not have COPD), which have been developed by those specialists. This, however, 
contrasts other guidelines for other disease groups (e.g. kidney disease, diabetes, and 
arthritis) where specific recommendations are made available for assessing and 
managing CV disease [345-347]. As an example, individuals with diabetes (without 
CV disease) are routinely assessed for the presence of microalbuminuria to identify 
patients at increased risk of renal impairment and/or future CV events [346]. Patients 
with COPD are at 2 to 5 times increased risk of CV diseases [97], which is comparable 
or even greater than these conditions (e.g. subjects with diabetes are at two times 
increased risk of CV disease) [348].  Therefore, there needs to be more information 
available on how to perform a CV risk assessment in patients with COPD; and more 
importantly, how to integrate it into clinical practice.  
In current practice, there are considerable gaps in the CV risk 
detection/prognostication in patients with COPD. Active detection for CV risk should 
be considered for all patients with COPD. Identifying new and simple biomarkers that 
can be used to aid the detection of patients with increased CV risk is also of clinical 
importance. Indeed, if patients at increased CV risk are identified, we can apply 
preventive strategies before the development of any major CV events. This, in turn, 




mortality, and the economic burden. However, it is important to note that preventative 
strategies (primary and secondary) for CV risk reduction would not be successful if 
patients do not adhere to medical advice. Indeed, current guidelines state that the most 
important and effective way to prevent CV risk is by promoting a healthy lifestyle, 
which includes smoking cessation, physical activity and appropriate diet. These 
lifestyle modifications should be considered before any pharmacological therapies. 
Two biological circulating markers have been investigated in this thesis: blood 
(soluble RAGE) and urine (microalbuminuria). First, soluble RAGE was not 
associated with physiological measures of increased CV risk in the ERICA cohort. 
These findings, although contrary to expectations, do not support that soluble RAGE 
being a biomarker to address the CV status in patients with COPD. However, these 
findings add to the existing literature [221].  
Second, microalbuminuria is frequent in patients with COPD, highlighting the 
potential risk of sub-clinical renal damage and future CV events [192, 196, 197]. 
Screening for microalbuminuria is simple, non-invasive, and inexpensive; and can, 
therefore, be performed routinely to aid the detection of micro- and macro-vascular 
abnormalities in patients with COPD. In addition, patients with COPD and confirmed 
microalbuminuria have increased aortic stiffness compared to those without 
microalbuminuria (as shown in this thesis), which also reinforces the need to intervene. 
Optimising the CV state in patients with COPD using aggressive interventions to target 
microalbuminuria is a potential area of future research.       
7.2.2  Cognitive impairment and dementia in COPD  
Cognitive impairment and subsequent dementia have negative impacts on COPD 




early intervention within the frame of respiratory assessment. Indeed, early 
identification of cognitively impaired patients is of clinical importance, as it allows for 
appropriate therapeutic interventions and change in lifestyle (e.g. physical activity, 
healthy nutrition, and social interaction), which could prevent or at least minimise the 
cognitive deterioration to clinical dementia.  
Dementia is a devastating, irreversible condition, impacting on all aspects of life for 
both patients and caregivers. Individuals with COPD are at increased risk of neuronal 
damage leading to cognitive impairment and even subsequent dementia. Establishing 
an early diagnosis of dementia permits patients to access service that meets their needs. 
Therefore, healthcare providers involved in the management of COPD should be aware 
of the increased burden of cognitive impairment and dementia.   
The increased prevalence and incidence of cognitive impairment in patients with 
COPD should extend the clinical focus to identify and manage modifiable risk factors 
contributing to the development of cognitive impairment and subsequent dementia. 
For instance, smoking, CV disease, and hypoxemia are common risk factors linked to 
cognitive impairment in COPD [265], and should, therefore, be evaluated and 
managed during routine follow-up. Given that cognitive impairment, by itself, is a 
major risk factor leading to dementia, it is very likely that in the settings of COPD, 
where the prevalence of smoking and CV disease is high, the risk of dementia will be 
magnified. This is of clinical importance, particularly as there are no curative therapies 
for dementia. Early interventions (e.g. smoking cessation, oxygen therapy, and change 
in lifestyle) to manage these modifiable risk factors should, therefore, be prioritized.  
Early intervention also permits dealing with functional impairments, which can pose a 




significantly affect adherence to medication regimens [261]. For instance, if planning 
and sequencing (e.g. praxic skills) are impaired, it is unlikely for the patient to be able 
to self-administer their inhalation therapies. Moreover, patients with COPD and 
cognitive impairment are less likely to gain benefits from pulmonary rehabilitation 
programs due to increased functional dependence and poor adherence to instructions 
[125], whereas patients with confirmed dementia will not be referred at the first place. 
Cognitive impairment also leads to problems with educational achievements and 
smoking-abstinence; all of which are vital elements of pulmonary rehabilitation. In 
these contexts, pulmonary rehabilitation programs may be tailored to meet patients’ 
needs in order to bring greater benefits.   
Furthermore, cognitive impairment and dementia also have a considerable impact on 
dependency and self-management in COPD [126]. Having adequate cognitive 
functioning is necessary for patients with COPD to maintain independence, uptake 
information properly, follow instructions, and adhere to medication regimens, which 
underpin effective care. However, failure to maintain these functions leads to reduce 
the effectiveness of treatment, which may result in worse outcomes.  
Given the considerable impacts of cognitive impairment and dementia on patients with 
COPD, it is of importance to consider active cognitive screening/assessment. 
Otherwise, cognitive impairment and dementia will remain under- or even un-
diagnosed, with a missed opportunity for timely intervention. Cognitive screening can 
be performed using a brief cognitive assessment, which will indicate the presence and 
severity of cognitive impairment, and help determine the type and amount of required 
support and assistance. Further consideration should also be given to patients 




It is important to mention here that the evidence of screening and systematic 
assessment for cognitive impairment and dementia in patients with COPD is currently 
scarce. In addition, there are also other factors which may interfere with performing a 
systematic assessment, such as high workload, staff shortage, and time constraints for 
patient visit.  This opens new doors for researchers to explore the role of cognitive 
screening/assessment in improving diagnosis for cognitive impairment and dementia, 
and whether it needs to be implemented/standardised as an element of the respiratory 
assessment in patients with COPD. 
7.2.3 Depression in COPD  
Depression is amongst the most common comorbidities in patients with COPD. 
However, it often remains underdiagnosed and undertreated, which can significantly 
affect clinical outcomes. Therefore, clinicians caring for patients with COPD should 
be alert to the existence of depression and aware of its symptoms and consequences.  
The very first step to improve outcomes and reduce the impact of depression is to 
identify depression as early as possible. Although the current guidelines recommend 
recognising depression in patients with COPD [40], there is no evidence that 
depression is currently part of the standard assessment. Early identification of 
depression plays a vital role in the clinical management of COPD. It allows healthcare 
professionals to develop appropriate treatment strategies, guide the choice of 
pharmacological and non-pharmacological therapies, and minimise the risk of missing 
critical patients’ symptoms; all of which aim to improve clinical outcomes.  
Patients with COPD are offered routine check-ups, mainly at primary care practices. 
In other words, health care professionals in direct contact with those patients play an 




the increased risk of depression, patients with COPD need to be actively screened. To 
be efficiently performed, screening should be quick and straightforward. There are 
several validated screening tools for depression which can be simply incorporated 
within the respiratory assessment. The NICE guideline for depression suggests asking 
two screening questions: ‘‘during the last month, have you often been bothered by 
feeling down, depressed or hopeless?’’ and ‘‘during the last month, have you often 
been bothered by having little interest or pleasure in doing things?’’ [291]. These two 
questions can be quickly done during COPD assessment, and the answers to these 
questions will then determine whether further assessment for depression is indicated. 
7.2.4 Antidepressants and adverse events in COPD 
Antidepressants are associated with multiple side effects, and there is a growing 
concern that they may contribute to increased risk of respiratory-related morbidities 
such as pneumonia and COPD exacerbations in patients with COPD [151]. 
Nevertheless, it is important not to deny the relevant outcomes of antidepressants 
completely. Therefore, a meticulous approach should be considered when prescribing 
antidepressants to those patients. 
Clinicians are required to stay alert and accept the challenges associated with the 
therapy. It is also worthwhile that clinicians closely monitor the side effects of 
antidepressants after prescription. When antidepressants are needed, it is essential to 
adopt the concept “start low and go slow” to allow patients to tolerate the drug. As 
patients with COPD often co-exist with multiple comorbidities, prescribers should 
keep in mind the possible side effects and drug interactions. Prescribers should also 
educate patients about antidepressants and possible adverse effects and how to manage 




the first and early stages of the treatment. Thereafter, periodic follow-ups (e.g. phone 
call) may suffice.  
When managing mental health in patients with COPD, pharmacological interventions 
(e.g. antidepressants) should not be the sole treatment. Patients with COPD and poor 
mental health may benefit from other forms of non-pharmacological interventions 
such as cognitive psychological therapies and pulmonary rehabilitation. The current 
clinical guidelines promote a stepwise approach for poor mental health ─ that is 
starting with the least intrusive and most effective approach [291].  
7.3 Recommendation for future research 
This thesis has investigated important but inadequately researched aspects of COPD 
comorbidities and circulating biomarkers. The following sections will suggest 
directions for future research to build-up on the presented work.  
7.3.1 Microalbuminuria in COPD 
Since microalbuminuria is common in patients with COPD, studies should be 
conducted to understand the risk factors of the development of microalbuminuria in 
patients with COPD and confirmed microalbuminuria. Furthermore, determining 
whether microalbuminuria is a potential target in the management of patients with 
COPD at clinical stability and at times of exacerbation is also a potential area for future 
research. Indeed, aggressive interventions for CV risk factors (e.g. lowering blood 
pressure, promoting smoking cessation, reducing high cholesterol level, and maintain 
a healthy lifestyle) are recommended in patients with diabetes and hypertension with 
confirmed microalbuminuria [257, 258]. Since MAB was prevalent (even in patients 




aggressive interventions will improve microalbuminuria (and thus the increased CV 
risk) and clinical outcomes in patients with COPD.  It is, however, important to 
mention that some pharmacological therapies that are used to treat CV disease may 
alter the natural history of COPD; therefore, careful consideration for this issue should 
be applied. 
7.3.2 Cognitive impairment and dementia in COPD 
Understanding the cognitive decline in patients with COPD should be considered for 
future research. Although a previous study suggested that a self-reported diagnosis of 
severe COPD was associated with a cognitive decline (assessed by a questionnaire) 
over time [271], this association is yet to be confirmed. A future longitudinal study 
should be carried to confirm this association using objective measures to determine 
COPD severity and assess the impact of which on cognitive function. Understanding 
such an association will promote more research to develop interventions to slow this 
rate of decline.   
A need also exists for mechanistic studies looking to understand the factors associated 
with increased risk of cognitive impairment and dementia in COPD. Further work 
should consider the contribution of comorbidities (e.g. CV disease), hypoxemia, and 
smoking in relation to cognitive impairment, and which factors affect the cognitive 
function in COPD the most.  
An important area to explore is the role of screening of cognitive impairment in 
patients with COPD at primary care settings. Whether screening/assessment for 
cognitive impairment and dementia will improve diagnosis at an early stage, and 
whether this will promote better care (e.g. opportunity to intervene) and consequently 




impairment will offer a tailored smoking cession program to those patients, and 
whether this will slow the rate of decline to dementia. It is also worth knowing whether 
screening for cognitive impairment and dementia will identify a group of patients with 
COPD, who are struggling with poor adherence to medication or improper techniques 
for inhaled medications. This can be done by taking a group of patients with COPD, 
who are failing to use their medications and perform a cognitive assessment to 
determine the commonality of cognitive impairment in that group. Furthermore, 
understanding the acceptability (e.g. social, economic, and health benefits and 
challenges) of cognitive screening in patients with COPD and/or a certain group of 
COPD is also worth consideration.  
7.3.3 Depression in COPD 
Given the increased risk of depression in patients with COPD, future research into 
effective treatment should be considered. Thus, there is a need to understand whether 
pharmacological or psychological treatments, alone or in combination, are more 
effective than exercise alone.  The evidence of pulmonary rehabilitation in improving 
depressive symptoms is well-established. However, what remains unknown is how to 
maximise benefits during a pulmonary rehabilitation program. There is also a need to 
understand barriers and facilitators for pulmonary rehabilitation adherence, the 
possibility of uptake and completion in patients with COPD and depression. In other 
words, whether these outcomes are associated with depression in patients with COPD. 
Another area worth considering is to understand which other add-on interventions (e.g. 
psychological therapy) in conjunction with PR in comparison to PR alone are more 
beneficial to those patients. A future randomised controlled trial should be conducted 




7.3.4 Antidepressants in COPD 
Given that antidepressant use is associated with increased risks of both pneumonia and 
COPD exacerbations, there is a need to understand the mechanisms of these 
associations further. This can be done by a lab-based approach to understand the 
pathological pathways. In addition, it remains unknown whether patients with COPD 
are aware of the side effects associated with antidepressants and whether they are also 
aware of other forms of non-pharmacological treatments for their mental illness. A 
cross-sectional, self-administered questionnaire can be used to evaluate patients’ 
awareness.   
A further understanding of the observed relationships is required. An observational 
approach using other appropriate databases (from primary and secondary care) to 
explore the risk of hospitalisation and mortality in patients with COPD after use of 
antidepressants is of interest.   
7.4 Concluding remarks 
COPD is associated with multiple comorbidities, which have a substantial effect on 
health and prognosis. This PhD has utilised different methodologies and datasets to 
address several areas related to COPD comorbidities, which have not been adequately 
researched. Increase the understanding of comorbid conditions in patients with COPD 
has important implications. The findings outlined in this thesis advance our knowledge 
of different aspects of COPD comorbidities and biomarkers, and provide new evidence 
into the clinical management of COPD. There is still a need to understand the 
mechanisms linking these comorbidities to COPD and, how these comorbidities 
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Appendix 9-2. COPD codes 
Code Description 
H3...00 CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
H3...11 CHRONIC OBSTRUCTIVE AIRWAYS DISEASE 
H31..00 CHRONIC BRONCHITIS 
H310.00 SIMPLE CHRONIC BRONCHITIS 
H310000 CHRONIC CATARRHAL BRONCHITIS 
H310z00 SIMPLE CHRONIC BRONCHITIS 
H311.00 MUCOPURULENT CHRONIC BRONCHITIS 
H311000 PURULENT CHRONIC BRONCHITIS 
H311100 FETID CHRONIC BRONCHITIS 
H311z00 MUCOPURULENT CHRONIC BRONCHITIS NOS 
H312.00 OBSTRUCTIVE CHRONIC BRONCHITIS 
H312000 CHRONIC ASTHMATIC BRONCHITIS 
H312011 CHRONIC WHEEZY BRONCHITIS 
H312100 EMPHYSEMATOUS BRONCHITIS 
H312300 BRONCHIOLITIS OBLITERANS 
H312z00 OBSTRUCTIVE CHRONIC BRONCHITIS  
H313.00 MIXED SIMPLE AND MUCOPURULENT CHRONIC 
BRONCHITIS 
H31y.00 OTHER CHRONIC BRONCHITIS 
H31y100 CHRONIC TRACHEOBRONCHITIS 
H31yz00 OTHER CHRONIC BRONCHITIS  
H31z.00 CHRONIC BRONCHITIS  
H32..00 EMPHYSEMA 
H320.00 CHRONIC BULLOUS EMPHYSEMA 
H320000 SEGMENTAL BULLOUS EMPHYSEMA 
H320100 ZONAL BULLOUS EMPHYSEMA 
H320200 GIANT BULLOUS EMPHYSEMA 
H320300 BULLOUS EMPHYSEMA WITH COLLAPSE 
H320311 TENSION PNEUMATOCELE 




H321.00 PAN-LOBULAR EMPHYSEMA 
H322.00 CENTRILOBULAR EMPHYSEMA 
H32y.00 OTHER EMPHYSEMA 
H32y000 ACUTE VESICULAR EMPHYSEMA 
H32y100 ATROPHIC (SENILE) EMPHYSEMA 
H32y111 ACUTE INTERSTITIAL EMPHYSEMA 
H32y200 MACLEOD'S UNILATERAL EMPHYSEMA 
H32yz00 OTHER EMPHYSEMA NOS 
H32z.00 EMPHYSEMA 
H36..00 MILD CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
H37..00 MODERATE CHRONIC OBSTRUCTIVE PULMONARY 
DISEASE 
H38..00 SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
H39..00 VERY SEVERE CHRONIC OBSTRUCTIVE PULMONARY 
DISEASE 
H3A..00 END-STAGE CHRONIC OBSTRUCTIVE AIRWAYS DISEASE 
H3y..00 OTHER SPECIFIED CHRONIC OBSTRUCTIVE AIRWAYS 
DISEASE 
H3y..11 OTHER SPECIFIED CHRONIC OBSTRUCTIVE 
PULMONARY DISEASE 
H3z..00 CHRONIC OBSTRUCTIVE AIRWAYS DISEASE 






Appendix 9-3. Cognitive impairment codes 
Code Description 
14Od.00 AT RISK OF DEMENTIA 
1B1A.00 MEMORY LOSS - AMNESIA 
1B1A.12 MEMORY LOSS SYMPTOM 
1B1A.13 MEMORY DISTURBANCE 
28E..00 COGNITIVE DECLINE 
28E0.00 MILD COGNITIVE IMPAIRMENT 
28E1.00 MODERATE COGNITIVE IMPAIRMENT 
28E2.00 SEVERE COGNITIVE IMPAIRMENT 
28E3.00 COGNITIVE IMPAIRMENT 
38Dv.00 GPCOG - GENERAL PRACTITIONER ASSESSMENT OF 
COGNITION 
3A...11 MEMORY ASSESSMENT 
3A10.00 MEMORY: OWN AGE NOT KNOWN 
3A20.00 MEMORY: PRESENT TIME NOT KNOWN 
3A30.00 MEMORY: PRESENT PLACE NOT KNOWN 
3A40.00 MEMORY: PRESENT YEAR NOT KNOWN 
3A50.00 MEMORY: OWN DOB NOT KNOWN 
3A60.00 MEMORY: PRESENT MONTH NOT KNOWN 
3A70.00 MEMORY: IMPORTANT EVENT NOT KNOWN 
3A80.00 MEMORY: IMPORTANT PERSON NOT KNOWN 
3A91.00 MEMORY: COUNT DOWN UNSUCCESSFUL 
3AA1.00 MEMORY: ADDRESS RECALL UNSUCCESSFUL 
3AE1.00 GDS LEVEL 2 - VERY MILD COGNITIVE DECLINE 
3AE2.00 GDS LEVEL 3 - MILD COGNITIVE DECLINE 
3AE3.00 GDS LEVEL 4 - MODERATE COGNITIVE DECLINE 
3AE4.00 GDS LEVEL 5 - MODERATELY SEVERE COGNITIVE 
DECLINE 
3AE5.00 GDS LEVEL 6 - SEVERE COGNITIVE DECLINE 
3AE6.00 GDS LEVEL 7 - VERY SEVERE COGNITIVE DECLINE 




9Nk1.00 SEEN IN MEMORY CLINIC 
E2A1000 MILD MEMORY DISTURBANCE 
E2A1100 ORGANIC MEMORY IMPAIRMENT 
Eu05700 MILD COGNITIVE DISORDER 
R00z011 MEMORY DEFICIT 
Z7C1.00 IMPAIRED COGNITION 
Z7CE414 MEMORY DISTURBANCE 
Z7CE415 LOSS OF MEMORY 
Z7CE611 MEMORY LOSS 
Z7CE615 LOSS OF MEMORY 
Z7CEH00 MEMORY IMPAIRMENT 
Z7CEH11 MEMORY DYSFUNCTION 
Z7CEH12 MEMORY DEFICIT 
Z7CEH14 MEMORY PROBLEM 
Z7CEH15 POOR MEMORY 
Z7CEL00 MILD MEMORY DISTURBANCE 






Appendix 9-4. Dementia codes 
Code Description 
E00..11 SENILE DEMENTIA 
E00..12 SENILE/PRESENILE DEMENTIA 
E000.00 UNCOMPLICATED SENILE DEMENTIA 
E001.00 PRESENILE DEMENTIA 
E001000 UNCOMPLICATED PRESENILE DEMENTIA 
E001200 PRESENILE DEMENTIA WITH PARANOIA 
E001300 PRESENILE DEMENTIA WITH DEPRESSION 
E001z00 PRESENILE DEMENTIA 
E002.00 SENILE DEMENTIA WITH DEPRESSIVE OR PARANOID 
FEATURES 
E002000 SENILE DEMENTIA WITH PARANOIA 
E002100 SENILE DEMENTIA WITH DEPRESSION 
E002z00 SENILE DEMENTIA WITH DEPRESSIVE OR PARANOID 
FEATURES 
E041.00 DEMENTIA IN CONDITIONS  
Eu00.00 DEMENTIA IN ALZHEIMER’S DISEASE 
Eu00000 DEMENTIA IN ALZHEIMER’S DISEASE WITH EARLY 
ONSET 
Eu00011 PRESENILE DEMENTIA, ALZHEIMER’S TYPE 
Eu00012 PRIMARY DEMENTIA, ALZHEIMER’S TYPE, PRESENILE 
ONSET 
Eu00013 ALZHEIMER’S DISEASE TYPE 2 
Eu00100 DEMENTIA IN ALZHEIMER’S DISEASE WITH LATE 
ONSET 
Eu00111 ALZHEIMER’S DISEASE TYPE 1 
Eu00112 SENILE DEMENTIA, ALZHEIMER’S TYPE 
Eu00113 PRIMARY DEGEN DEMENTIA OF ALZHEIMER’S TYPE, 
SENILE ONSET 





Eu00z00 DEMENTIA IN ALZHEIMER’S DISEASE, UNSPECIFIED 
Eu00z11 ALZHEIMER’S DEMENTIA UNSPECIFIC 
Eu02.00 DEMENTIA IN OTHER DISEASES CLASSIFIED 
ELSEWHERE 
Eu02000 DEMENTIA IN PICK'S DISEASE 
Eu02300 DEMENTIA IN PARKINSON’S DISEASE 
Eu02y00 DEMENTIA IN OTHER SPECIFIED DISEASES  
Eu02z00 UNSPECIFIED DEMENTIA 
Eu02z11 PRESENILE DEMENTIA  
Eu02z13 PRIMARY DEGENERATIVE DEMENTIA  
Eu02z14 SENILE DEMENTIA  
Eu02z16 SENILE DEMENTIA, DEPRESSED OR PARANOID TYPE 
F110.00 ALZHEIMER'S DISEASE 
F110000 ALZHEIMER'S DISEASE WITH EARLY ONSET 
F110100 ALZHEIMER'S DISEASE WITH LATE ONSET 
Fyu3000 OTHER ALZHEIMER'S DISEASE 
ZS7C500 LANGUAGE DISORDER OF DEMENTIA 
Vascular dementia  
E004.00 ARTERIOSCLEROTIC DEMENTIA 
E004.11 MULTI INFARCT DEMENTIA 
E004000 UNCOMPLICATED ARTERIOSCLEROTIC DEMENTIA 
E004100 ARTERIOSCLEROTIC DEMENTIA WITH DELIRIUM 
E004200 ARTERIOSCLEROTIC DEMENTIA WITH PARANOIA 
E004300 ARTERIOSCLEROTIC DEMENTIA WITH DEPRESSION 
E004z00 ARTERIOSCLEROTIC DEMENTIA  
Eu01.00 VASCULAR DEMENTIA 
Eu01.11 ARTERIOSCLEROTIC DEMENTIA 
Eu01000 VASCULAR DEMENTIA OF ACUTE ONSET 
Eu01100 MULTI-INFARCT DEMENTIA 
Eu01200 SUBCORTICAL VASCULAR DEMENTIA 





Eu01y00 OTHER VASCULAR DEMENTIA 






Appendix 9-5. MRC score codes 
173H.00 MRC BREATHLESSNESS SCALE: GRADE 1 
173I.00 MRC BREATHLESSNESS SCALE: GRADE 2 
173J.00 MRC BREATHLESSNESS SCALE: GRADE 3 
173K.00 MRC BREATHLESSNESS SCALE: GRADE 4 






Appendix 9-6. Smoking codes 
1371.11 NON-SMOKER AMBIGUOUS 
137L.00 CURRENT NON-SMOKER AMBIGUOUS 
137X.00 CIGARETTE CONSUMPTION AMBIGUOUS 
137Y.00 CIGAR CONSUMPTION AMBIGUOUS 
137Z.00 TOBACCO CONSUMPTION NOS AMBIGUOUS 
137a.00 PIPE TOBACCO CONSUMPTION AMBIGUOUS 
6893.00 TOBACCO USAGE SCREEN AMBIGUOUS 
68T..00 TOBACCO USAGE SCREEN AMBIGUOUS 
ZV4K000 TOBACCO USE AMBIGUOUS 
137..11 SMOKER - AMOUNT SMOKED CURRENT 
1372.00 TRIVIAL SMOKER - < 1 CIG/DAY CURRENT 
1372.11 OCCASIONAL SMOKER CURRENT 
1373.00 LIGHT SMOKER - 1-9 CIGS/DAY CURRENT 
1374.00 MODERATE SMOKER - 10-19 CIGS/D CURRENT 
1375.00 HEAVY SMOKER - 20-39 CIGS/DAY CURRENT 
1376.00 VERY HEAVY SMOKER - 40+CIGS/D CURRENT 
137C.00 KEEPS TRYING TO STOP SMOKING CURRENT 
137G.00 TRYING TO GIVE UP SMOKING CURRENT 
137H.00 PIPE SMOKER CURRENT 
137J.00 CIGAR SMOKER CURRENT 
137M.00 ROLLS OWN CIGARETTES CURRENT 
137P.00 CIGARETTE SMOKER CURRENT 
137P.11 SMOKER CURRENT 
137Q.00 SMOKING STARTED CURRENT 
137Q.11 SMOKING RESTARTED CURRENT 
137R.00 CURRENT SMOKER CURRENT 
137V.00 SMOKING REDUCED CURRENT 
137b.00 READY TO STOP SMOKING CURRENT 






137d.00 NOT INTERESTED IN STOPPING 
SMOKING 
CURRENT 
137e.00 SMOKING RESTARTED CURRENT 
137f.00 REASON FOR RESTARTING SMOKING CURRENT 
137h.00 MINUTES FROM WAKING TO FIRST 
TOBACCO CONSUMPTION 
CURRENT 
137m.00 FAILED ATTEMPT TO STOP SMOKING CURRENT 
13p0.00 NEGOTIATED DATE FOR CESSATION 
OF SMOKING 
CURRENT 
13p5.00 SMOKING CESSATION PROGRAMME 
START DATE 
CURRENT 
13p5000 PRACTICE BASED SMOKING 
CESSATION PROGRAMME START 
DATE 
CURRENT 
6791.00 HEALTH ED. - SMOKING CURRENT 
67A3.00 PREGNANCY SMOKING ADVICE CURRENT 
67H1.00 LIFESTYLE ADVICE REGARDING 
SMOKING 
CURRENT 
745H000 NICOTINE REPLACEMENT THERAPY 
USING NICOTINE PATCHES 
CURRENT 
745H100 NICOTINE REPLACEMENT THERAPY 
USING NICOTINE GUM 
CURRENT 
745H200 NICOTINE REPLACEMENT THERAPY 
USING NICOTINE INHALATOR 
CURRENT 
745H300 NICOTINE REPLACEMENT THERAPY 
USING NICOTINE LOZENGES 
CURRENT 
745H400 SMOKING CESSATION DRUG 
THERAPY 
CURRENT 
745Hy00 OTHER SPECIFIED SMOKING 
CESSATION THERAPY 
CURRENT 






8B3f.00 NICOTINE REPLACEMENT THERAPY 
PROVIDED FREE 
CURRENT 
8BP3.00 NICOTINE REPLACEMENT THERAPY 
PROVIDED BY COMMUNITY 
PHARMACIES 
CURRENT 
8CAL.00 SMOKING CESSATION ADVICE CURRENT 
8CAg.00 SMOKING CESSATION ADVICE 
PROVIDED BY COMMUNITY 
PHARMACIST 
CURRENT 
8H7i.00 REFERRAL TO SMOKING CESSATION 
ADVISOR 
CURRENT 
8HTK.00 REFERRAL TO STOP-SMOKING CLINIC CURRENT 
8HkQ.00 REFERRAL TO NHS STOP SMOKING 
SERVICE 
CURRENT 
8I2I.00 NICOTINE REPLACEMENT THERAPY 
CONTRAINDICATED 
CURRENT 
8I39.00 NICOTINE REPLACEMENT THERAPY 
REFUSED 
CURRENT 
9OO7.00 STOP SMOKING MONITOR VERBING. CURRENT 
9OO8.00 STOP SMOKING MONITOR PHONE INV CURRENT 
9ko..00 CURRENT SMOKER ANNUAL REVIEW 
- ENHANCED SERVICES ADMIN 
CURRENT 
9ko..11 CURRENT SMOKER ANNUAL REVIEW CURRENT 
E251.00 TOBACCO DEPENDENCE CURRENT 
E251000 TOBACCO DEPENDENCE, 
UNSPECIFIED 
CURRENT 
E251100 TOBACCO DEPENDENCE, 
CONTINUOUS 
CURRENT 
E251200 TOBACCO DEPENDENCE, EPISODIC CURRENT 
E251z00 TOBACCO DEPENDENCE NOS CURRENT 




ZRBm200 FAGERSTROM TEST FOR NICOTINE 
DEPENDENCE 
CURRENT 
ZRBm211 FTND - FAGERSTROM TEST FOR 
NICOTINE DEPENDENCE 
CURRENT 
ZRaM.00 MOTIVES FOR SMOKING SCALE CURRENT 
ZRaM.11 MFS - MOTIVES FOR SMOKING SCALE CURRENT 
ZRao.00 OCCASIONS FOR SMOKING SCALE CURRENT 
ZRao.11 OFS - OCCASIONS FOR SMOKING 
SCALE 
CURRENT 
ZRh4.00 REASONS FOR SMOKING SCALE CURRENT 
ZRh4.11 RFS - REASONS FOR SMOKING SCALE CURRENT 
ZV6D800 [V]TOBACCO ABUSE COUNSELLING CURRENT 
1377.00 EX-TRIVIAL SMOKER (<1/DAY) EX-SMOKER  
1378.00 EX-LIGHT SMOKER (1-9/DAY) EX-SMOKER 
1379.00 EX-MODERATE SMOKER (10-19/DAY) EX-SMOKER 
137A.00 EX-HEAVY SMOKER (20-39/DAY) EX-SMOKER 
137B.00 EX-VERY HEAVY SMOKER (40+/DAY) EX-SMOKER 
137F.00 EX-SMOKER - AMOUNT UNKNOWN EX-SMOKER 
137K.00 STOPPED SMOKING EX-SMOKER 
137N.00 EX PIPE SMOKER EX-SMOKER 
137O.00 EX CIGAR SMOKER EX-SMOKER 
137S.00 EX-SMOKER EX-SMOKER 
137T.00 DATE CEASED SMOKING EX-SMOKER 
137l.00 EX ROLL-UP CIGARETTE SMOKER EX-SMOKER 
8HBM.00 STOP SMOKING FACE TO FACE 
FOLLOW-UP 
EX-SMOKER 
E251300 TOBACCO DEPENDENCE IN 
REMISSION 
EX-SMOKER 
137k.00 REFUSAL TO GIVE SMOKING STATUS EXCEPTION 






9hG0.00 EXCEPTED FROM SMOKING QUALITY 
INDICATORS: PATIENT UNSUITABLE 
EXCEPTION 
9hG1.00 EXCEPTED FROM SMOKING QUALITY 
INDICATORS: INFORMED DISSENT 
EXCEPTION 
1371.00 NEVER SMOKED TOBACCO NEVER 




9kn..11 NON-SMOKER ANNUAL REVIEW NEVER 
137..00 TOBACCO CONSUMPTION UNKNOWN 
137D.00 ADMITTED TOBACCO CONS UNTRUE  UNKNOWN 
137E.00 TOBACCO CONSUMPTION UNKNOWN UNKNOWN 
137g.00 CIGARETTE PACK-YEARS UNKNOWN 
13p..00 SMOKING CESSATION MILESTONES UNKNOWN 
13p1.00 SMOKING STATUS AT 4 WEEKS UNKNOWN 
13p2.00 SMOKING STATUS BETWEEN 4 AND 
52 WEEKS 
UNKNOWN 
13p3.00 SMOKING STATUS AT 52 WEEKS UNKNOWN 
13p4.00 SMOKING FREE WEEKS UNKNOWN 
38DH.00 FAGERSTR TEST FOR NICOTINE DEP UNKNOWN 
67H6.00 BRIEF INTERVENTION FOR SMOKING 
CESSATION 
UNKNOWN 
745H.00 SMOKING CESSATION THERAPY UNKNOWN 
745Hz00 SMOKING CESSATION THERAPY NOS UNKNOWN 
8I6H.00 SMOKING REVIEW NOT INDICATED UNKNOWN 
8IAj.00 SMOKING CESSATION ADVICE 
DECLINED 
UNKNOWN 
9N2k.00 SEEN BY SMOKING CESSATION 
ADVISOR 
UNKNOWN 






9NdV.00 CONSENT GIVEN FOLLOW-UP AFTER 
SMOKING CESSATION INTERVENTION 
UNKNOWN 
9NdW.00 CONSENT GIVEN FOR SMOKING 
CESSATION DATA SHARING 
UNKNOWN 
9NdY.00 DECLINE CONS FOLLOW-UP 
EVALUATION AFTER SMOKING CESS 
INTERVEN 
UNKNOWN 
9NdZ.00 DECLINED CONSENT FOR SMOKING 
CESSATION DATA SHARING 
UNKNOWN 
9Ndf.00 CONSENT GIVEN FOR FOLLOW-UP BY 
SMOKING CESSATION TEAM 
UNKNOWN 
9Ndg.00 DECLINED CONSENT FOR FOLLOW-
UP BY SMOKING CESSATION TEAM 
UNKNOWN 
9OO..00 ANTI-SMOKING MONITORING ADMIN. UNKNOWN 
9OO..11 STOP SMOKING CLINIC ADMIN. UNKNOWN 
9OO..12 STOP SMOKING MONITORING ADMIN. UNKNOWN 
9OO1.00 ATTENDS STOP SMOKING MONITOR. UNKNOWN 
9OO2.00 REFUSES STOP SMOKING MONITOR UNKNOWN 
9OO3.00 STOP SMOKING MONITOR DEFAULT UNKNOWN 
9OO4.00 STOP SMOKING MONITOR 1ST 
LETTER 
UNKNOWN 
9OO5.00 STOP SMOKING MONITOR 2ND 
LETTER 
UNKNOWN 
9OO6.00 STOP SMOKING MONITOR 3RD 
LETTER 
UNKNOWN 
9OO9.00 STOP SMOKING MONITORING 
DELETE 
UNKNOWN 
9OOA.00 STOP SMOKING MONITOR CHECK 
DONE 
UNKNOWN 






9kf1.11 REFERRED FOR COPD STRUCTURED 
SMOKING ASSESSMENT 
UNKNOWN 
9kf2.00 COPD STRUCTURED SMOKING 
ASSESSMENT DECLINED - ENHANCED 
SERVICES ADMIN 
UNKNOWN 
9kf2.11 COPD STRUCTURED SMOKING 
ASSESSMENT DECLINED 
UNKNOWN 
E023.00 NICOTINE WITHDRAWAL UNKNOWN 









Appendix 9-7. Charlson index score codes 
Code Description Score  
Myocardial infarction 
G301.00 OTHER SPECIFIED ANTERIOR MYOCARDIAL 
INFARCTION 
1 
G30z.00 ACUTE MYOCARDIAL INFARCTION NOS 1 
G30..14 HEART ATTACK 1 
G30..15 MI - ACUTE MYOCARDIAL INFARCTION 1 
G305.00 LATERAL MYOCARDIAL INFARCTION NOS 1 
G307.00 ACUTE SUBENDOCARDIAL INFARCTION 1 
14AH.00 H/O: MYOCARDIAL INFARCTION IN LAST YEAR 1 
G30y.00 OTHER ACUTE MYOCARDIAL INFARCTION 1 
G303.00 ACUTE INFERO-POSTERIOR INFARCTION 1 
G30..00 ACUTE MYOCARDIAL INFARCTION 1 
G300.00 ACUTE ANTEROLATERAL INFARCTION 1 
G32..12 PERSONAL HISTORY OF MYOCARDIAL 
INFARCTION 
1 
G30X000 ACUTE ST SEGMENT ELEVATION MYOCARDIAL 
INFARCTION 
1 
G30..13 CARDIAC RUPTURE FOLLOWING MYOCARDIAL 
INFARCTION (MI) 
1 
G307100 ACUTE NON-ST SEGMENT ELEVATION 
MYOCARDIAL INFARCTION 
1 
G307000 ACUTE NON-Q WAVE INFARCTION 1 
G301100 ACUTE ANTEROSEPTAL INFARCTION 1 
G32..00 OLD MYOCARDIAL INFARCTION 1 
G30..17 SILENT MYOCARDIAL INFARCTION 1 
G32..11 HEALED MYOCARDIAL INFARCTION 1 
G30..12 CORONARY THROMBOSIS 1 
G30yz00 OTHER ACUTE MYOCARDIAL INFARCTION NOS 1 
G302.00 ACUTE INFEROLATERAL INFARCTION 1 




G582.00 ACUTE HEART FAILURE 1 
G580.00 CONGESTIVE HEART FAILURE 1 
14A6.00 H/O: HEART FAILURE 1 
G58z.11 WEAK HEART 1 
G58..11 CARDIAC FAILURE 1 
1O1..00 HEART FAILURE CONFIRMED 1 
G580000 ACUTE CONGESTIVE HEART FAILURE 1 
8H2S.00 ADMIT HEART FAILURE EMERGENCY 1 
G58z.00 HEART FAILURE NOS 1 
G58..00 HEART FAILURE 1 
Peripheral vascular disease 
G714000 JUXTARENAL AORTIC ANEURYSM 1 
G711.00 THORACIC AORTIC ANEURYSM WHICH HAS 
RUPTURED 
1 
G73z.00 PERIPHERAL VASCULAR DISEASE 1 
G73zz00 PERIPHERAL VASCULAR DISEASE  1 
G71z.00 AORTIC ANEURYSM 1 
G713.00 ABDOMINAL AORTIC ANEURYSM WHICH HAS 
RUPTURED 
1 
7A14.11 AORTIC ANEURYSM REPAIR 1 
14NB.00 H/O: PERIPHERAL VASCULAR DISEASE 
PROCEDURE 
1 
G71..00 AORTIC ANEURYSM 1 
G713.11 RUPTURED ABDOMINAL AORTIC ANEURYSM 1 
Gyu7200 AORTIC ANEURYSM OF UNSPECIFIED SITE, 
NON-RUPTURED 
1 
G732300 GANGRENE OF THUMB 1 
R054000 GANGRENE, SPREADING CUTANEOUS 1 
G714.11 AAA - ABDOMINAL AORTIC ANEURYSM 
WITHOUT MENTION OF RUPTURE 
1 
G714.00 ABDOMINAL AORTIC ANEURYSM WITHOUT 





Gyu7400 OTHER SPECIFIED PERIPHERAL VASCULAR 
DISEASES 
1 
G718.00 LEAKING ABDOMINAL AORTIC ANEURYSM 1 
7A14411 TUBE GRAFT OF ABDOMINAL AORTIC 
ANEURYSM 
1 
G711.11 RUPTURED THORACIC AORTIC ANEURYSM 1 
Cerebrovascular disease 
G61..12 STROKE DUE TO INTRACEREBRAL 
HAEMORRHAGE 
1 
G600.00 RUPTURED BERRY ANEURYSM 1 
G601.00 SUBARACHNOID HAEMORRHAGE FROM 
CAROTID SIPHON AND BIFURCATION 
1 
G61..00 INTRACEREBRAL HAEMORRHAGE 1 
G605.00 SUBARACHNOID HAEMORRHAGE FROM 
BASILAR ARTERY 
1 
G68..00 LATE EFFECTS OF CEREBROVASCULAR 
DISEASE 
1 
Gyu6100 OTHER SUBARACHNOID HAEMORRHAGE 1 
S620.00 CLOSED TRAUMATIC SUBARACHNOID 
HAEMORRHAGE 
1 
Gyu6000 [X]SUBARACHNOID HAEMORRHAGE FROM 
OTHER INTRACRANIAL ARTERIES 
1 
G66..11 CVA UNSPECIFIED 1 
G660.00 MIDDLE CEREBRAL ARTERY SYNDROME 1 
662M.00 STROKE MONITORING 1 
G669.00 CEREBRAL PALSY, NOT CONGENITAL OR 
INFANTILE, ACUTE 
1 
G661.00 ANTERIOR CEREBRAL ARTERY SYNDROME 1 
G66..00 STROKE AND CEREBROVASCULAR ACCIDENT 
UNSPECIFIED 
1 




G66..13 CVA - CEREBROVASCULAR ACCIDENT 
UNSPECIFIED 
1 
G666.00 PURE SENSORY LACUNAR SYNDROME 1 
G663.00 BRAIN STEM STROKE SYNDROME 1 
G664.00 CEREBELLAR STROKE SYNDROME 1 
G665.00 PURE MOTOR LACUNAR SYNDROME 1 
G668.00 RIGHT SIDED CVA 1 
G66..12 STROKE UNSPECIFIED 1 
14A7.00 H/O: CVA/STROKE 1 
G662.00 POSTERIOR CEREBRAL ARTERY SYNDROME 1 
14A7.12 H/O: STROKE 1 




E001z00 PRESENILE DEMENTIA NOS 1 
E004200 ARTERIOSCLEROTIC DEMENTIA WITH 
PARANOIA 
1 
Eu00z11 [X]ALZHEIMER'S DEMENTIA UNSPECIFIC 1 
E001000 UNCOMPLICATED PRESENILE DEMENTIA 1 
Eu01z00 [X]VASCULAR DEMENTIA, UNSPECIFIED 1 
Eu02500 [X]LEWY BODY DEMENTIA 1 
Eu00112 [X]SENILE DEMENTIA, ALZHEIMER'S TYPE 1 
E004.11 MULTI INFARCT DEMENTIA 1 
Eu02z14 [X] SENILE DEMENTIA NOS 1 
E041.00 DEMENTIA IN CONDITIONS EC 1 
Eu01111 [X]PREDOMINANTLY CORTICAL DEMENTIA 1 
Eu02z16 [X] SENILE DEMENTIA, DEPRESSED OR 
PARANOID TYPE 
1 
Eu00.00 [X]DEMENTIA IN ALZHEIMER'S DISEASE 1 
Eu02z00 [X] UNSPECIFIED DEMENTIA 1 
Eu00011 [X]PRESENILE DEMENTIA, ALZHEIMER'S TYPE 1 




Eu02.00 [X]DEMENTIA IN OTHER DISEASES CLASSIFIED 
ELSEWHERE 
1 
Eu01000 [X]VASCULAR DEMENTIA OF ACUTE ONSET 1 
Eu01100 [X]MULTI-INFARCT DEMENTIA 1 
E000.00 UNCOMPLICATED SENILE DEMENTIA 1 
E004z00 ARTERIOSCLEROTIC DEMENTIA NOS 1 
Eu02y00 [X]DEMENTIA IN OTHER SPECIFIED DISEASES 
CLASSIFIED ELSEWHERE 
1 
E001.00 PRESENILE DEMENTIA 1 
Eu00z00 [X]DEMENTIA IN ALZHEIMER'S DISEASE, 
UNSPECIFIED 
1 
Eu01y00 [X]OTHER VASCULAR DEMENTIA 1 
Eu01.11 [X]ARTERIOSCLEROTIC DEMENTIA 1 
Eu00113 [X]PRIMARY DEGEN DEMENTIA OF 
ALZHEIMER'S TYPE, SENILE ONSET 
1 
E004000 UNCOMPLICATED ARTERIOSCLEROTIC 
DEMENTIA 
1 
E00..12 SENILE/PRESENILE DEMENTIA 1 
Eu00200 [X]DEMENTIA IN ALZHEIMER'S DIS, ATYPICAL 
OR MIXED TYPE 
1 
E00..11 SENILE DEMENTIA 1 
E004300 ARTERIOSCLEROTIC DEMENTIA WITH 
DEPRESSION 
1 
E004100 ARTERIOSCLEROTIC DEMENTIA WITH 
DELIRIUM 
1 
Eu00100 [X]DEMENTIA IN ALZHEIMER'S DISEASE WITH 
LATE ONSET 
1 
Eu01.00 [X]VASCULAR DEMENTIA 1 
Eu02z13 [X] PRIMARY DEGENERATIVE DEMENTIA NOS 1 
1461.00 H/O: DEMENTIA 1 
Eu01200 [X]SUBCORTICAL VASCULAR DEMENTIA 1 




Eu00012 [X]PRIMARY DEGEN DEMENTIA, ALZHEIMER'S 
TYPE, PRESENILE ONSET 
1 
Eu00000 [X]DEMENTIA IN ALZHEIMER'S DISEASE WITH 
EARLY ONSET 
1 
Eu01300 [X]MIXED CORTICAL AND SUBCORTICAL 
VASCULAR DEMENTIA 
1 
Chronic pulmonary disease 
H41..00 ASBESTOSIS 1 
9OJ1.00 ATTENDS ASTHMA MONITORING 1 
H352100 PIGEON-FANCIERS' LUNG 1 
H331.00 INTRINSIC ASTHMA 1 
H331.11 LATE ONSET ASTHMA 1 
H31..00 CHRONIC BRONCHITIS 1 
H350.00 FARMERS' LUNG 1 
H334.00 BRITTLE ASTHMA 1 
H582.00 COMPENSATORY EMPHYSEMA 1 
H57yz00 LUNG DISEASE WITH DISEASES EC NOS 1 
H311.00 MUCOPURULENT CHRONIC BRONCHITIS 1 
H31y100 CHRONIC TRACHEOBRONCHITIS 1 
H320200 GIANT BULLOUS EMPHYSEMA 1 
663N.00 ASTHMA DISTURBING SLEEP 1 
H310100 SMOKERS' COUGH 1 
H4y1000 CHRONIC PULMONARY FIBROSIS FOLLOWING 
RADIATION 
1 
1O2..00 ASTHMA CONFIRMED 1 
H464000 CHRONIC EMPHYSEMA DUE TO CHEMICAL 
FUMES 
1 
H331000 INTRINSIC ASTHMA WITHOUT STATUS 
ASTHMATICUS 
1 
H33z200 LATE-ONSET ASTHMA 1 




H410.00 PLEURAL PLAQUE DISEASE DUE TO 
ASBESTOSIS 
1 
H333.00 ACUTE EXACERBATION OF ASTHMA 1 
8H2P.00 EMERGENCY ADMISSION, ASTHMA 1 
H40..00 COAL WORKERS' PNEUMOCONIOSIS 1 
14B4.00 H/O: ASTHMA 1 
H320z00 CHRONIC BULLOUS EMPHYSEMA  1 
H310000 CHRONIC CATARRHAL BRONCHITIS 1 
H313.00 MIXED SIMPLE AND MUCOPURULENT CHRONIC 
BRONCHITIS 
1 
H31z.00 CHRONIC BRONCHITIS  1 
H331z00 INTRINSIC ASTHMA  1 
H434.00 SIDEROSIS 1 
H34..00 BRONCHIECTASIS 1 
H312100 EMPHYSEMATOUS BRONCHITIS 1 
H352z00 BIRD-FANCIER'S LUNG  1 
H331100 INTRINSIC ASTHMA WITH STATUS 
ASTHMATICUS 
1 
H35yz00 OTHER ALLERGIC ALVEOLITIS NOS 1 
H435.00 STANNOSIS 1 
H33z111 ASTHMA ATTACK NOS 1 
H35y300 FURRIERS' LUNG 1 
466 BC BRONCHITIS SUBACUTE 1 
h33z100 ASTHMA ATTACK 1 
663r.00 ASTHMA CAUSES NIGHT SYMPTOMS 1 TO 2 
TIMES PER MONTH 
1 
H32z.00 EMPHYSEMA NOS 1 
H330z00 EXTRINSIC ASTHMA NOS 1 
H33..11 BRONCHIAL ASTHMA 1 
H32y000 ACUTE VESICULAR EMPHYSEMA 1 




H464100 OBLITERATIVE BRONCHIOLITIS DUE TO 
CHEMICAL FUMES 
1 
Hyu4000 [X]PNEUMOCONIOSIS DUE TO OTHER DUST 
CONTAINING SILICA 
1 
H330011 HAY FEVER WITH ASTHMA 1 
H43..00 PNEUMOCONIOSIS DUE TO OTHER INORGANIC 
DUST 
1 
H423.00 MASSIVE SILICOTIC FIBROSIS 1 
H460z00 BRONCHITIS AND PNEUMONITIS DUE TO 
CHEMICAL FUMES NOS 
1 
H330000 EXTRINSIC ASTHMA WITHOUT STATUS 
ASTHMATICUS 
1 
H35z100 HYPERSENSITIVITY PNEUMONITIS NOS 1 
663u.00 ASTHMA CAUSES DAYTIME SYMPTOMS 1 TO 2 
TIMES PER WEEK 
1 
493 AD ASTHMA OCCASIONAL 1 
663P.00 ASTHMA LIMITING ACTIVITIES 1 
H57y.00 LUNG DISEASE WITH DISEASES EC 1 
5192CM OBSTRUCTIVE LUNG DISEASE COMPENSATORY 1 
H311000 PURULENT CHRONIC BRONCHITIS 1 
H581.00 INTERSTITIAL EMPHYSEMA 1 
5199CL OBSTRUCTIVE LUNG DISEASE 1 
H45..00 PNEUMOCONIOSIS NOS 1 
H311z00 MUCOPURULENT CHRONIC BRONCHITIS NOS 1 
SK07.00 SUBCUTANEOUS EMPHYSEMA 1 
7832AB WHEEZING BRONCHIAL 1 
Hyu4100 [X]PNEUMOCONIOSIS DUE TO OTHER SPECIFIED 
INORGANIC DUSTS 
1 
H300.00 TRACHEOBRONCHITIS NOS 1 
663w.00 ASTHMA LIMITS WALKING UP HILLS OR STAIRS 1 
H440.00 BYSSINOSIS 1 




H30z.00 BRONCHITIS NOS 1 
663p.00 ASTHMA TREATMENT COMPLIANCE 
UNSATISFACTORY 
1 
66YC.00 ABSENT FROM WORK OR SCHOOL DUE TO 
ASTHMA 
1 
H432.00 BERYLLIOSIS 1 
H32..00 EMPHYSEMA 1 
H312000 CHRONIC ASTHMATIC BRONCHITIS 1 
663W.00 ASTHMA PROPHYLACTIC MEDICATION USED 1 
H320000 SEGMENTAL BULLOUS EMPHYSEMA 1 
H312011 CHRONIC WHEEZY BRONCHITIS 1 
H441.00 CANNABINOSIS 1 
H311100 FETID CHRONIC BRONCHITIS 1 
H33zz12 ALLERGIC ASTHMA NEC 1 
L4930LO LATE ONSET ASTHMA 1 
H430.00 ALUMINOSIS OF LUNG 1 
H331111 INTRINSIC ASTHMA WITH ASTHMA ATTACK 1 
H431.00 BAUXITE FIBROSIS OF LUNG 1 
Hyu3000 [X]OTHER EMPHYSEMA 1 
H47y000 DETERGENT ASTHMA 1 
H35y.00 OTHER ALLERGIC ALVEOLITIS 1 
H330.00 EXTRINSIC (ATOPIC) ASTHMA 1 
173A.00 EXERCISE INDUCED ASTHMA 1 
Rheumatological disease 
7341AA LUPUS ERYTHEMATOSUS SYSTEMIC 1 
N041.00 FELTY'S SYNDROME 1 
Nyu1000 [X]RHEUMATOID ARTHRITIS ORGANS OR 
SYSTEMS 
1 
N001200 SYSTEMIC SCLEROSIS INDUCED BY DRUGS AND 
CHEMICALS 
1 
N04y011 CAPLAN'S SYNDROME 1 




N001.12 SYSTEMIC SCLEROSIS 1 
N040B00 RHEUMATOID ARTHRITIS OF HIP 1 
N000300 SYSTEMIC LUPUS ERYTHEMATOSUS WITH 
ORGAN OR SYS INVOLVE 
1 
N04y012 FIBROSING ALVEOLITIS ASSOCIATED WITH 
RHEUMATOID ARTHRITIS 
1 
N047.00 SEROPOSITIVE EROSIVE RHEUMATOID 
ARTHRITIS 
1 
N000.00 SYSTEMIC LUPUS ERYTHEMATOSUS 1 
N040J00 RHEUMATOID ARTHRITIS OF OTHER TARSAL 
JOINT 
1 
N04X.00 SEROPOSITIVE RHEUMATOID ARTHRITIS, 
UNSPECIFIED 
1 
Nyu1G00 SEROPOSITIVE RHEUMATOID ARTHRITIS, 
UNSPECIFIED 
1 
N040A00 RHEUMATOID ARTHRITIS OF DIP JOINT OF 
FINGER 
1 
N040300 RHEUMATOID ARTHRITIS OF 
STERNOCLAVICULAR JOINT 
1 
N240000 RHEUMATISM UNSPECIFIED 1 
N240200 MUSCULAR RHEUMATISM 1 
N200.00 GIANT CELL ARTERITIS WITH POLYMYALGIA 
RHEUMATICA 
1 
N20..00 POLYMYALGIA RHEUMATICA 1 
N040900 RHEUMATOID ARTHRITIS OF PIP JOINT OF 
FINGER 
1 
N000100 LIBMAN-SACKS DISEASE 1 
2A42.00 SYSTEMIC LUPUS ERYTHEMATOSUS WITH 
RENAL 
1 
N000400 SYSTEMIC LUPUS ERYTHEMATOSUS WITH 
PERICARDITIS 
1 




N040800 RHEUMATOID ARTHRITIS OF MCP JOINT 1 
N2y..00 OTHER SPECIFIED NONARTICULAR 
RHEUMATISM 
1 
H572.00 LUNG DISEASE WITH SYSTEMIC SCLEROSIS 1 
N04..00 RHEUMATOID ARTHRITIS AND OTHER 
INFLAMMATORY POLYARTHROPATHY 
1 
N040P00 SERONEGATIVE RHEUMATOID ARTHRITIS 1 
G5yA.00 RHEUMATOID CARDITIS 1 
H57y400 LUNG DISEASE WITH SYSTEMIC LUPUS 
ERYTHEMATOSUS 
1 
K01x411 LUPUS NEPHRITIS 1 
N001.11 ACROSCLEROSIS 1 
N000000 DISSEMINATED LUPUS ERYTHEMATOSUS 1 
N040T00 FLARE OF RHEUMATOID ARTHRITIS 1 
N040.00 RHEUMATOID ARTHRITIS 1 
N04y111 SERO-NEGATIVE POLYARTHRITIS 1 
Nyu4500 [X]OTHER FORMS OF SYSTEMIC SCLEROSIS 1 
N240z00 RHEUMATISM OR FIBROSITIS NOS 1 
N040L00 RHEUMATOID ARTHRITIS OF LESSER MTP JOINT 1 
N231400 POLYMYOSITIS OSSIFICANS 1 
Nyu1200 OTHER SPECIFIED RHEUMATOID ARTHRITIS 1 
F396600 MYOPATHY DUE TO SCLERODERMA 1 
F396400 MYOPATHY DUE TO RHEUMATOID ARTHRITIS 1 
N042100 RHEUMATOID LUNG DISEASE 1 
N040G00 RHEUMATOID ARTHRITIS OF SUBTALAR JOINT 1 
N040200 RHEUMATOID ARTHRITIS OF SHOULDER 1 
N040H00 RHEUMATOID ARTHRITIS OF TALONAVICULAR 
JOINT 
1 
N040D00 RHEUMATOID ARTHRITIS OF KNEE 1 
N040F00 RHEUMATOID ARTHRITIS OF ANKLE 1 




Nyu4300 OTHER FORMS OF SYSTEMIC LUPUS 
ERYTHEMATOSUS 
1 
Nyu1100 OTHER SEROPOSITIVE RHEUMATOID ARTHRITIS 1 
7179GB RHEUMATISM NONARTICULAR SHOULDER 1 
N004.00 POLYMYOSITIS 1 
H57y100 LUNG DISEASE WITH POLYMYOSITIS 1 
N040E00 RHEUMATOID ARTHRITIS OF TIBIO-FIBULAR 
JOINT 
1 
N040600 RHEUMATOID ARTHRITIS OF DISTAL RADIO-
ULNAR JOINT 
1 
N240.00 RHEUMATISM AND FIBROSITIS UNSPECIFIED 1 
N040C00 RHEUMATOID ARTHRITIS OF SACRO-ILIAC 
JOINT 
1 
N040K00 RHEUMATOID ARTHRITIS OF 1ST MTP JOINT 1 
N001.00 SCLERODERMA 1 
N2z..00 NON-ARTICULAR RHEUMATISM NOS 1 
N040500 RHEUMATOID ARTHRITIS OF ELBOW 1 
N000200 DRUG-INDUCED SYSTEMIC LUPUS 
ERYTHEMATOSUS 
1 
K01x400 NEPHROTIC SYNDROME IN SYSTEMIC LUPUS 
ERYTHEMATOSUS 
1 
H570.00 RHEUMATOID LUNG 1 
N000z00 SYSTEMIC LUPUS ERYTHEMATOSUS NOS 1 
N040700 RHEUMATOID ARTHRITIS OF WRIST 1 
N240700 HAND RHEUMATISM 1 
N040400 RHEUMATOID ARTHRITIS OF 
ACROMIOCLAVICULAR JOINT 
1 
N04y000 RHEUMATOID LUNG 1 
F371200 POLYNEUROPATHY IN RHEUMATOID 
ARTHRITIS 
1 
Peptic ulcer disease 




761D600 ENDOSCOPIC INJECTION HAEMOSTASIS OF 
GASTRIC ULCER 
1 
J14y400 UNSPECIFIED GASTROJEJUNAL ULCER WITH 
OBSTRUCTION 
1 
J13..00 PEPTIC ULCER - (PU) SITE UNSPECIFIED 1 
J102000 PEPTIC ULCER OF OESOPHAGUS 1 
J12yz00 UNSPECIFIED DUODENAL ULCER NOS 1 
J11..12 PYLORIC ULCER 1 
J141200 CHRONIC GASTROJEJUNAL ULCER WITH 
PERFORATION 
1 
J110.00 ACUTE GASTRIC ULCER 1 
J12y.00 UNSPECIFIED DUODENAL ULCER 1 
J121y00 CHRONIC DUODENAL ULCER UNSPECIFIED 1 
J110111 BLEEDING ACUTE GASTRIC ULCER 1 
J11yy00 UNSPECIFIC GASTRIC ULCER; UNSPECIFIED 
HAEMORRHAGE AND/OR PERFORATION 
1 
J111y00 CHRONIC GASTRIC ULCER UNSPECIFIED 1 
J111100 CHRONIC GASTRIC ULCER WITH 
HAEMORRHAGE 
1 
J14..15 STOMAL ULCER 1 
J131y00 CHRONIC PEPTIC ULCER UNSPECIFIED 1 
J110y00 ACUTE GASTRIC ULCER UNSPECIFIED 1 
J13z.00 PEPTIC ULCER NOS 1 
J11..11 PREPYLORIC ULCER 1 
J110300 ACUTE GASTRIC ULCER WITH HAEMORRHAGE 
AND PERFORATION 
1 
761Jz00 OPERATION ON GASTRIC ULCER NOS 1 
J14y100 UNSPECIFIED GASTROJEJUNAL ULCER WITH 
HAEMORRHAGE 
1 
J121400 CHRONIC DUODENAL ULCER WITH 
OBSTRUCTION 
1 




J12y400 UNSPECIFIED DUODENAL ULCER WITH 
OBSTRUCTION 
1 
J11y100 UNSPECIFIED GASTRIC ULCER WITH 
HAEMORRHAGE 
1 
J140400 ACUTE GASTROJEJUNAL ULCER WITH 
OBSTRUCTION 
1 
J12y000 UNSPECIFIED DUODENAL ULCER WITHOUT 
MENTION OF COMPLICATION 
1 
J122.00 DUODENAL ULCER DISEASE 1 
J121000 CHRONIC DUODENAL ULCER WITHOUT 
MENTION OF COMPLICATION 
1 
J14y200 UNSPECIFIED GASTROJEJUNAL ULCER WITH 
PERFORATION 
1 
J11..00 GASTRIC ULCER - (GU) 1 
J141y00 CHRONIC GASTROJEJUNAL ULCER 
UNSPECIFIED 
1 
J141300 CHRONIC GASTROJEJUNAL ULCER WITH 
HAEMORRHAGE AND PERFORATION 
1 
J11y400 UNSPECIFIED GASTRIC ULCER WITH 
OBSTRUCTION 
1 
J13y.00 UNSPECIFIED PEPTIC ULCER 1 
J131.00 CHRONIC PEPTIC ULCER 1 
J120z00 ACUTE DUODENAL ULCER NOS 1 
J140000 ACUTE GASTROJEJUNAL ULCER WITHOUT 
MENTION OF COMPLICATION 
1 
J110200 ACUTE GASTRIC ULCER WITH PERFORATION 1 
J111400 CHRONIC GASTRIC ULCER WITH OBSTRUCTION 1 
J121.00 CHRONIC DUODENAL ULCER 1 
J14yy00 UNSPECIFIC GASTROJEJUNAL ULCER; 
UNSPECIFIED HAEMORRHAGE/PERFORATION 
1 
J14..12 GASTROCOLIC ULCER 1 




J11y200 UNSPECIFIED GASTRIC ULCER WITH 
PERFORATION 
1 
J120300 ACUTE DUODENAL ULCER WITH 
HAEMORRHAGE AND PERFORATION 
1 
J120100 ACUTE DUODENAL ULCER WITH 
HAEMORRHAGE 
1 
J13y300 UNSPECIFIED PEPTIC ULCER WITH 
HAEMORRHAGE AND PERFORATION 
1 
J14y300 UNSPECIFIED GASTROJEJUNAL ULCER WITH 
HAEMORRHAGE AND PERFORATION 
1 
J131300 CHRONIC PEPTIC ULCER WITH HAEMORRHAGE 
AND PERFORATION 
1 
J111111 BLEEDING CHRONIC GASTRIC ULCER 1 
761J000 CLOSURE OF PERFORATED GASTRIC ULCER 1 
J120200 ACUTE DUODENAL ULCER WITH PERFORATION 1 
J130200 ACUTE PEPTIC ULCER WITH PERFORATION 1 
761J111 SUTURE OF ULCER OF STOMACH NEC 1 
J140100 ACUTE GASTROJEJUNAL ULCER WITH 
HAEMORRHAGE 
1 
J12y200 UNSPECIFIED DUODENAL ULCER WITH 
PERFORATION 
1 
J111z00 CHRONIC GASTRIC ULCER NOS 1 
J11yz00 UNSPECIFIED GASTRIC ULCER NOS 1 
J14z.00 GASTROJEJUNAL ULCER NOS 1 
J14y000 UNSPECIFIED GASTROJEJUNAL ULCER 
WITHOUT MENTION COMPLICATION 
1 
J11z.00 GASTRIC ULCER NOS 1 
J14y.00 UNSPECIFIED GASTROJEJUNAL ULCER 1 
J141z00 CHRONIC GASTROJEJUNAL ULCER NOS 1 
J13yy00 UNSPECIFIED PEPTIC ULCER; UNSPECIFIED 
HAEMORRHAGE AND/OR PERFORATION 
1 




J12yy00 UNSPECIFIED DUODENAL ULCER; UNSPECIFIED 
HAEMORRHAGE AND/OR PERFORATION 
1 
J111000 CHRONIC GASTRIC ULCER WITHOUT MENTION 
OF COMPLICATION 
1 
J110000 ACUTE GASTRIC ULCER WITHOUT MENTION OF 
COMPLICATION 
1 
J130000 ACUTE PEPTIC ULCER WITHOUT MENTION OF 
COMPLICATION 
1 
J111300 CHRONIC GASTRIC ULCER WITH 
HAEMORRHAGE AND PERFORATION 
1 
J140300 ACUTE GASTROJEJUNAL ULCER WITH 
HAEMORRHAGE AND PERFORATION 
1 
J13y000 UNSPECIFIED PEPTIC ULCER WITHOUT 
MENTION OF COMPLICATION 
1 
J14..00 GASTROJEJUNAL ULCER (GJU) 1 
J11y.00 UNSPECIFIED GASTRIC ULCER 1 
J120.00 ACUTE DUODENAL ULCER 1 
J130400 ACUTE PEPTIC ULCER WITH OBSTRUCTION 1 
J141400 CHRONIC GASTROJEJUNAL ULCER WITH 
OBSTRUCTION 
1 
J13y100 UNSPECIFIED PEPTIC ULCER WITH 
HAEMORRHAGE 
1 
J120000 ACUTE DUODENAL ULCER WITHOUT MENTION 
OF COMPLICATION 
1 
J121300 CHRONIC DUODENAL ULCER WITH 
HAEMORRHAGE AND PERFORATION 
1 
7627000 CLOSURE OF PERFORATED DUODENAL ULCER 1 
J131z00 CHRONIC PEPTIC ULCER NOS 1 
J13..11 STRESS ULCER NOS 1 
J130y00 ACUTE PEPTIC ULCER UNSPECIFIED 1 
J112.00 ANTI-PLATELET INDUCED GASTRIC ULCER 1 




J111.00 CHRONIC GASTRIC ULCER 1 
J110400 ACUTE GASTRIC ULCER WITH OBSTRUCTION 1 
J121z00 CHRONIC DUODENAL ULCER NOS 1 
J131000 CHRONIC PEPTIC ULCER WITHOUT MENTION OF 
COMPLICATION 
1 
J12..00 DUODENAL ULCER - (DU) 1 
J141.00 CHRONIC GASTROJEJUNAL ULCER 1 
J11y000 UNSPECIFIED GASTRIC ULCER WITHOUT 
MENTION OF COMPLICATION 
1 
J111200 CHRONIC GASTRIC ULCER WITH PERFORATION 1 
J123.00 DUODENAL EROSION 1 
J13y400 UNSPECIFIED PEPTIC ULCER WITH 
OBSTRUCTION 
1 
761J100 CLOSURE OF GASTRIC ULCER NEC 1 
J131400 CHRONIC PEPTIC ULCER WITH OBSTRUCTION 1 
J11z.12 MULTIPLE GASTRIC ULCERS 1 
J14yz00 UNSPECIFIED GASTROJEJUNAL ULCER NOS 1 
ZV12711 [V]PERSONAL HISTORY OF PEPTIC ULCER 1 
J130100 ACUTE PEPTIC ULCER WITH HAEMORRHAGE 1 
7612500 RESECTION OF GASTRIC ULCER BY CAUTERY 1 
J120400 ACUTE DUODENAL ULCER WITH OBSTRUCTION 1 
ZV12C00 [V] PERSONAL HISTORY OF GASTRIC ULCER 1 
J12y300 UNSPECIFIED DUODENAL ULCER WITH 
HAEMORRHAGE AND PERFORATION 
1 
J13yz00 UNSPECIFIED PEPTIC ULCER NOS 1 
761J.11 STOMACH ULCER OPERATIONS 1 
J111211 PERFORATED CHRONIC GASTRIC ULCER 1 
J12z.00 DUODENAL ULCER NOS 1 
J140200 ACUTE GASTROJEJUNAL ULCER WITH 
PERFORATION 
1 




J141000 CHRONIC GASTROJEJUNAL ULCER WITHOUT 
MENTION OF COMPLICATION 
1 
J131200 CHRONIC PEPTIC ULCER WITH PERFORATION 1 
J124.00 RECURRENT DUODENAL ULCER 1 
J130300 ACUTE PEPTIC ULCER WITH HAEMORRHAGE 
AND PERFORATION 
1 
J11y300 UNSPECIFIED GASTRIC ULCER WITH 
HAEMORRHAGE AND PERFORATION 
1 
J141100 CHRONIC GASTROJEJUNAL ULCER WITH 
HAEMORRHAGE 
1 
J121111 BLEEDING CHRONIC DUODENAL ULCER 1 
761Jy00 OTHER SPECIFIED OPERATION ON GASTRIC 
ULCER 
1 
J140z00 ACUTE GASTROJEJUNAL ULCER NOS 1 
J140y00 ACUTE GASTROJEJUNAL ULCER UNSPECIFIED 1 
J13y200 UNSPECIFIED PEPTIC ULCER WITH 
PERFORATION 
1 
J110100 ACUTE GASTRIC ULCER WITH HAEMORRHAGE 1 
761J.00 OPERATIONS ON GASTRIC ULCER 1 
J140.00 ACUTE GASTROJEJUNAL ULCER 1 
Mild liver disease 
J616100 SECONDARY BILIARY CIRRHOSIS 1 
J615400 FATTY PORTAL CIRRHOSIS 1 
J616z00 BILIARY CIRRHOSIS NOS 1 
J614.00 CHRONIC HEPATITIS 1 
J614y00 CHRONIC HEPATITIS UNSPECIFIED 1 
J615100 MULTI-LOBULAR PORTAL CIRRHOSIS 1 
J635600 TOXIC LIVER DISEASE WITH FIBROSIS AND 
CIRRHOSIS OF LIVER 
1 
C350012 PIGMENTARY CIRRHOSIS OF LIVER 1 
J615z14 LAENNEC'S CIRRHOSIS, NON-ALCOHOLIC 1 




J615z11 MACRONODULAR CIRRHOSIS OF LIVER 1 
J614100 CHRONIC ACTIVE HEPATITIS 1 
J615000 UNI-LOBULAR PORTAL CIRRHOSIS 1 
J615y00 PORTAL CIRRHOSIS UNSPECIFIED 1 
J615z00 NON-ALCOHOLIC CIRRHOSIS NOS 1 
J612.00 ALCOHOLIC CIRRHOSIS OF LIVER 1 
J615A00 PIPE-STEM PORTAL CIRRHOSIS 1 
J615.11 PORTAL CIRRHOSIS 1 
J615300 DIFFUSE NODULAR CIRRHOSIS 1 
J615C00 XANTHOMATOUS PORTAL CIRRHOSIS 1 
J615z13 CIRRHOSIS OF LIVER NOS 1 
J614300 RECURRENT HEPATITIS 1 
Jyu7100 [X]OTHER AND UNSPECIFIED CIRRHOSIS OF 
LIVER 
1 
J61..00 CIRRHOSIS AND CHRONIC LIVER DISEASE 1 
J615F00 SYPHILITIC PORTAL CIRRHOSIS 1 
C310400 GLYCOGENOSIS WITH HEPATIC CIRRHOSIS 1 
J615z12 CRYPTOGENIC CIRRHOSIS OF LIVER 1 
J616000 PRIMARY BILIARY CIRRHOSIS 1 
J616.00 BILIARY CIRRHOSIS 1 
J615.00 CIRRHOSIS - NON ALCOHOLIC 1 
J633.00 HEPATITIS UNSPECIFIED 1 
J615700 CARDIAC PORTAL CIRRHOSIS 1 
J614000 CHRONIC PERSISTENT HEPATITIS 1 
J600200 ACUTE YELLOW ATROPHY 1 
J615B00 TOXIC PORTAL CIRRHOSIS 1 
J61y300 PORTAL FIBROSIS WITHOUT CIRRHOSIS 1 
J614200 CHRONIC AGGRESSIVE HEPATITIS 1 
J601200 SUBACUTE YELLOW ATROPHY 1 
J615111 POSTNECROTIC CIRRHOSIS OF LIVER 1 
J612.11 FLORID CIRRHOSIS 1 





66AJ.11 UNSTABLE DIABETES 1 
C108600 INSULIN DEPENDENT DIABETES MELLITUS 
WITH GANGRENE 
1 
C101100 DIABETES MELLITUS, ADULT ONSET, WITH 
KETOACIDOSIS 
1 
C10M.00 LIPOATROPHIC DIABETES MELLITUS 1 
C103000 DIABETES MELLITUS, JUVENILE TYPE, WITH 
KETOACIDOTIC COMA 
1 
C109500 NON-INSULIN DEPENDENT DIABETES MELLITUS 
WITH GANGRENE 
1 
C109900 NON-INSULIN-DEPENDENT DIABETES MELLITUS 
WITHOUT COMPLICATION 
1 
C109412 TYPE 2 DIABETES MELLITUS WITH ULCER 1 
C10FG00 TYPE 2 DIABETES MELLITUS WITH 
ARTHROPATHY 
1 
C109.11 NIDDM - NON-INSULIN DEPENDENT DIABETES 
MELLITUS 
1 
C109G11 TYPE II DIABETES MELLITUS WITH 
ARTHROPATHY 
1 
C10z.00 DIABETES MELLITUS WITH UNSPECIFIED 
COMPLICATION 
1 
C10EM11 TYPE I DIABETES MELLITUS WITH 
KETOACIDOSIS 
1 
C107200 DIABETES MELLITUS, ADULT WITH GANGRENE 1 
C10FJ00 INSULIN TREATED TYPE 2 DIABETES MELLITUS 1 
C108911 TYPE I DIABETES MELLITUS MATURITY ONSET 1 
C102z00 DIABETES MELLITUS NOS WITH 
HYPEROSMOLAR COMA 
1 
G73y000 DIABETIC PERIPHERAL ANGIOPATHY 1 
66AJ.00 DIABETIC - POOR CONTROL 1 




C109F12 TYPE 2 DIABETES MELLITUS WITH PERIPHERAL 
ANGIOPATHY 
1 
C109300 NON-INSULIN-DEPENDENT DIABETES MELLITUS 
WITH MULTIPLE COMPS 
1 
C108400 UNSTABLE INSULIN DEPENDENT DIABETES 
MELLITUS 
1 
C10F900 TYPE 2 DIABETES MELLITUS WITHOUT 
COMPLICATION 
1 
C10y.00 DIABETES MELLITUS WITH OTHER SPECIFIED 
MANIFESTATION 
1 
C10F.11 TYPE II DIABETES MELLITUS 1 
C10FL00 TYPE 2 DIABETES MELLITUS WITH PERSISTENT 
PROTEINURIA 
1 
C109G00 NON-INSULIN DEPENDENT DIABETES MELLITUS 
WITH ARTHROPATHY 
1 
C109G12 TYPE 2 DIABETES MELLITUS WITH 
ARTHROPATHY 
1 
66A5.00 DIABETIC ON INSULIN 1 
C109511 TYPE II DIABETES MELLITUS WITH GANGRENE 1 
L180600 PRE-EXISTING DIABETES MELLITUS, NON-
INSULIN-DEPENDENT 
1 
C10FN00 TYPE 2 DIABETES MELLITUS WITH 
KETOACIDOSIS 
1 
C10E400 UNSTABLE TYPE 1 DIABETES MELLITUS 1 
C10zy00 OTHER SPECIFIED DIABETES MELLITUS WITH 
UNSPECIFIED COMPS 
1 
C10D.00 DIABETES MELLITUS AUTOSOMAL DOMINANT 
TYPE 2 
1 
C107z00 DIABETES MELLITUS NOS WITH PERIPHERAL 
CIRCULATORY DISORDER 
1 






C101000 DIABETES MELLITUS, JUVENILE TYPE, WITH 
KETOACIDOSIS 
1 
C100011 INSULIN DEPENDENT DIABETES MELLITUS 1 
C108411 UNSTABLE TYPE I DIABETES MELLITUS 1 
C103.00 DIABETES MELLITUS WITH KETOACIDOTIC 
COMA 
1 
C107.11 DIABETES MELLITUS WITH GANGRENE 1 
C10E500 TYPE 1 DIABETES MELLITUS WITH ULCER 1 
C109400 NON-INSULIN DEPENDENT DIABETES MELLITUS 
WITH ULCER 
1 
C10yy00 OTHER SPECIFIED DIABETES MELLITUS WITH 
OTHER SPEC COMPS 
1 
C109711 TYPE II DIABETES MELLITUS - POOR CONTROL 1 
C10A000 MALNUTRITION-RELATED DIABETES MELLITUS 
WITH COMA 
1 
C10F.00 TYPE 2 DIABETES MELLITUS 1 
C109J11 INSULIN TREATED NON-INSULIN DEPENDENT 
DIABETES MELLITUS 
1 
8A13.00 DIABETIC STABILISATION 1 
C108.00 INSULIN DEPENDENT DIABETES MELLITUS 1 
C10EG00 TYPE 1 DIABETES MELLITUS WITH PERIPHERAL 
ANGIOPATHY 
1 
C108E12 TYPE 1 DIABETES MELLITUS WITH 
HYPOGLYCAEMIC COMA 
1 
C108.13 TYPE I DIABETES MELLITUS 1 
C107100 DIABETES MELLITUS, ADULT,  PERIPHERAL 
CIRCULATORY DISORDER 
1 
C10A100 MALNUTRITION-RELATED DIABETES MELLITUS 
WITH KETOACIDOSIS 
1 
C102000 DIABETES MELLITUS, JUVENILE TYPE, WITH 
HYPEROSMOLAR COMA 
1 




C10F500 TYPE 2 DIABETES MELLITUS WITH GANGRENE 1 
C102100 DIABETES MELLITUS, ADULT ONSET, WITH 
HYPEROSMOLAR COMA 
1 
C108E11 TYPE I DIABETES MELLITUS WITH 
HYPOGLYCAEMIC COMA 
1 
C109K00 HYPEROSMOLAR NON-KETOTIC STATE IN TYPE 
2 DIABETES MELLITUS 
1 
66AJz00 DIABETIC - POOR CONTROL NOS 1 
C10FJ11 INSULIN TREATED TYPE II DIABETES MELLITUS 1 
C108500 INSULIN DEPENDENT DIABETES MELLITUS 
WITH ULCER 
1 
C109J00 INSULIN TREATED TYPE 2 DIABETES MELLITUS 1 
C10E800 TYPE 1 DIABETES MELLITUS - POOR CONTROL 1 
C108812 TYPE 1 DIABETES MELLITUS - POOR CONTROL 1 
C107400 NIDDM WITH PERIPHERAL CIRCULATORY 
DISORDER 
1 
C10G.00 SECONDARY PANCREATIC DIABETES MELLITUS 1 
C10EM00 TYPE 1 DIABETES MELLITUS WITH 
KETOACIDOSIS 
1 
66AV.00 DIABETIC ON INSULIN AND ORAL TREATMENT 1 
L180500 PRE-EXISTING DIABETES MELLITUS, INSULIN-
DEPENDENT 
1 
C10FP00 TYPE 2 DIABETES MELLITUS WITH 
KETOACIDOTIC COMA 
1 
C100.00 DIABETES MELLITUS WITH NO MENTION OF 
COMPLICATION 
1 
C10E600 TYPE 1 DIABETES MELLITUS WITH GANGRENE 1 
C109D12 TYPE 2 DIABETES MELLITUS WITH 
HYPOGLYCAEMIC COMA 
1 
C10FF00 TYPE 2 DIABETES MELLITUS WITH PERIPHERAL 
ANGIOPATHY 
1 




C109.00 NON-INSULIN-DEPENDENT DIABETES MELLITUS 1 
C109D00 NON-INSULIN DEPENDENT DIABETES MELLITUS 
WITH HYPOGLYCA COMA 
1 
C10zz00 DIABETES MELLITUS NOS WITH UNSPECIFIED 
COMPLICATION 
1 
C10EE00 TYPE 1 DIABETES MELLITUS WITH 
HYPOGLYCAEMIC COMA 
1 
66AS.00 DIABETIC ANNUAL REVIEW 1 
C107000 DIABETES MELLITUS, JUVENILE CIRCULATORY 
DISORDER 
1 
C10E412 UNSTABLE INSULIN DEPENDENT DIABETES 
MELLITUS 
1 
C10E900 TYPE 1 DIABETES MELLITUS MATURITY ONSET 1 
C101y00 OTHER SPECIFIED DIABETES MELLITUS WITH 
KETOACIDOSIS 
1 
C10FL11 TYPE II DIABETES MELLITUS WITH PERSISTENT 
PROTEINURIA 
1 
C109712 TYPE 2 DIABETES MELLITUS - POOR CONTROL 1 
Cyu2.00 DIABETES MELLITUS 1 
C10..00 DIABETES MELLITUS 1 
C10EA00 TYPE 1 DIABETES MELLITUS WITHOUT 
COMPLICATION 
1 
C100z00 DIABETES MELLITUS NOS WITH NO MENTION 
OF COMPLICATION 
1 
C103z00 DIABETES MELLITUS NOS WITH KETOACIDOTIC 
COMA 
1 
C108G00 INSULIN DEPENDENT DIAB MELL WITH 
PERIPHERAL ANGIOPATHY 
1 
C108E00 INSULIN DEPENDENT DIABETES MELLITUS 
WITH HYPOGLYCAEMIC COMA 
1 




C10E812 INSULIN DEPENDENT DIABETES MELLITUS - 
POOR CONTROL 
1 
C10F700 TYPE 2 DIABETES MELLITUS - POOR CONTROL 1 
66AK.00 DIABETIC - COOPERATIVE PATIENT 1 
C10B000 STEROID INDUCED DIABETES MELLITUS 
WITHOUT COMPLICATION 
1 
C100111 MATURITY ONSET DIABETES 1 
C10E.00 TYPE 1 DIABETES MELLITUS 1 
8H2J.00 ADMIT DIABETIC EMERGENCY 1 
C108811 TYPE I DIABETES MELLITUS - POOR CONTROL 1 
C10E.12 INSULIN DEPENDENT DIABETES MELLITUS 1 
C100100 DIABETES MELLITUS, ADULT ONSET, NO 
MENTION OF COMPLICATION 
1 
C10F400 TYPE 2 DIABETES MELLITUS WITH ULCER 1 
C10z100 DIABETES MELLITUS, ADULT ONSET,  
UNSPECIFIED COMPLICATION 
1 
L180X00 PRE-EXISTING DIABETES MELLITUS, 
UNSPECIFIED 
1 
8BL2.00 PATIENT ON MAXIMAL TOLERATED THERAPY 
FOR DIABETES 
1 
C10yz00 DIABETES MELLITUS NOS WITH OTHER 
SPECIFIED MANIFESTATION 
1 
C102.00 DIABETES MELLITUS WITH HYPEROSMOLAR 
COMA 
1 
C10A.00 MALNUTRITION-RELATED DIABETES MELLITUS 1 
C108.11 IDDM-INSULIN DEPENDENT DIABETES 
MELLITUS 
1 
C101z00 DIABETES MELLITUS NOS WITH KETOACIDOSIS 1 
C10FD00 TYPE 2 DIABETES MELLITUS WITH 
HYPOGLYCAEMIC COMA 
1 






C10EK00 TYPE 1 DIABETES MELLITUS WITH PERSISTENT 
PROTEINURIA 
1 
C10H.00 DIABETES MELLITUS INDUCED BY NON-
STEROID DRUGS 
1 
C107.00 DIABETES MELLITUS WITH PERIPHERAL 
CIRCULATORY DISORDER 
1 
C10D.11 MATURITY ONSET DIABETES IN YOUTH TYPE 2 1 
C107300 IDDM WITH PERIPHERAL CIRCULATORY 
DISORDER 
1 
C109F11 TYPE II DIABETES MELLITUS WITH PERIPHERAL 
ANGIOPATHY 
1 
C109D11 TYPE II DIABETES MELLITUS WITH 
HYPOGLYCAEMIC COMA 
1 
C10EL00 TYPE 1 DIABETES MELLITUS WITH PERSISTENT 
MICROALBUMINURIA 
1 
C100112 NON-INSULIN DEPENDENT DIABETES MELLITUS 1 
C10FM00 TYPE 2 DIABETES MELLITUS WITH PERSISTENT 
MICROALBUMINURIA 
1 
Cyu2000 [X]OTHER SPECIFIED DIABETES MELLITUS 1 
C109.12 TYPE 2 DIABETES MELLITUS 1 
C103y00 OTHER SPECIFIED DIABETES MELLITUS WITH 
COMA 
1 
C109.13 TYPE II DIABETES MELLITUS 1 
C108511 TYPE I DIABETES MELLITUS WITH ULCER 1 
C10EN11 TYPE I DIABETES MELLITUS WITH 
KETOACIDOTIC COMA 
1 
C109700 NON-INSULIN DEPENDENT DIABETES MELLITUS 
- POOR CONTROL 
1 
C10y100 DIABETES MELLITUS, ADULT, OTHER SPECIFIED 
MANIFESTATION 
1 
C10E.11 TYPE I DIABETES MELLITUS 1 




C10F711 TYPE II DIABETES MELLITUS - POOR CONTROL 1 
66AI.00 DIABETIC - GOOD CONTROL 1 
C100000 DIABETES MELLITUS, JUVENILE TYPE, NO 
MENTION OF COMPLICATION 
1 
Hemiplegia 
F241000 FLACCID PARAPLEGIA 2 
F222.00 LEFT HEMIPLEGIA 2 
F22z.00 HEMIPLEGIA NOS 2 
F230000 CONGENITAL PARAPLEGIA 2 
F221.00 SPASTIC HEMIPLEGIA 2 
F223.00 RIGHT HEMIPLEGIA 2 
F230.11 PARAPLEGIA - CONGENITAL 2 
F241100 SPASTIC PARAPLEGIA 2 
F241.00 PARAPLEGIA 2 
F141.00 HEREDITARY SPASTIC PARAPLEGIA 2 
F220.00 FLACCID HEMIPLEGIA 2 
F22..00 HEMIPLEGIA 2 
Renal disease 
K080000 PHOSPHATE-LOSING TUBULAR DISORDERS 2 
K032z00 NEPHRITIS UNSPECIFIC GLOMERULONEPHRITIS 
LESION NOS 
2 
K080100 RENAL DWARFISM 2 
K04z.00 ACUTE RENAL FAILURE NOS 2 
K101100 ACUTE PYELONEPHRITIS WITH MEDULLARY 
NECROSIS 
2 
K02z.00 CHRONIC GLOMERULONEPHRITIS NOS 2 
K060.11 IMPAIRED RENAL FUNCTION 2 
K021.00 CHRONIC MEMBRANOUS 
GLOMERULONEPHRITIS 
2 










1Z11.00 CHRONIC KIDNEY DISEASE STAGE 2 2 
K041.00 ACUTE RENAL CORTICAL NECROSIS 2 
K032y13 MESANGIO PROLIFERATIVE 
GLOMERULONEPHRITIS NEC 
2 
K0...00 NEPHRITIS, NEPHROSIS AND NEPHROTIC 
SYNDROME 
2 
K02..12 NEPHROPATHY - CHRONIC 2 
K08yz00 OTHER IMPAIRED RENAL FUNCTION DISORDER 
NOS 
2 
K081.00 NEPHROGENIC DIABETES INSIPIDUS 2 
K080.00 RENAL OSTEODYSTROPHY 2 




K06..00 RENAL FAILURE UNSPECIFIED 2 
K0A3200 CHRON NEPHRITIC SYNDROME DIFFUSE 
MEMBRANOUS GLOMERULONEPHRITIS 
2 
K034.00 RENAL CORTICAL NECROSIS UNSPECIFIED 2 
K02y200 CHRONIC FOCAL GLOMERULONEPHRITIS 2 
K03..00 NEPHRITIS AND NEPHROPATHY UNSPECIFIED 2 
K05..00 CHRONIC RENAL FAILURE 2 
K0A5500 [X]HEREDITARY NEPHROPATHY NEC DIFFUSE 
MESANGIOCAPILRY GALUMPH 
2 
K101000 ACUTE PYELONEPHRITIS WITHOUT 
MEDULLARY NECROSIS 
2 
K02..00 CHRONIC GLOMERULONEPHRITIS 2 
K080300 RENAL RICKETS 2 




K032.00 MEMBRANOPROLIFERATIVE NEPHRITIS 
UNSPECIFIED 
2 
K012.00 NEPHROTIC SYNDROME 
GLOMERULONEPHRITIS 
2 




1Z14.00 CHRONIC KIDNEY DISEASE STAGE 5 2 
Kyu2.00 [X]RENAL FAILURE 2 
K08z.00 IMPAIRED RENAL FUNCTION DISORDER NOS 2 
K050.00 END STAGE RENAL FAILURE 2 
K100000 CHRONIC PYELONEPHRITIS WITHOUT 
MEDULLARY NECROSIS 
2 
K04y.00 OTHER ACUTE RENAL FAILURE 2 
14D1.00 H/O: NEPHRITIS 2 
K02..11 NEPHRITIS - CHRONIC 2 
1Z10.00 CHRONIC KIDNEY DISEASE STAGE 1 2 
K032000 FOCAL MEMBRANOPROLIFERATIVE 
GLOMERULONEPHRITIS 
2 
K03..11 NEPHRITIS AND NEPHROPATHY UNSPECIFIED 2 
K042.00 ACUTE RENAL MEDULLARY NECROSIS 2 
K022.00 CHRONIC MEMBRANOPROLIFERATIVE 
GLOMERULONEPHRITIS 
2 
K032y14 MESANGIOCAPILLARY GLOMERULONEPHRITIS 
NEC 
2 
K080200 RENAL INFANTILISM 2 
K001.00 ACUTE NEPHRITIS WITH LESIONS OF 
NECROTISING GLOMERULITIS 
2 
1Z12.00 CHRONIC KIDNEY DISEASE STAGE 3 2 
K02yz00 OTHER CHRONIC GLOMERULONEPHRITIS NOS 2 
K02y300 CHRONIC DIFFUSE GLOMERULONEPHRITIS 2 




K019.00 NEPHROTIC SYNDROME DIFFUSE 
MESANGIOCAPILLARY GLOMERULONEPHRITIS 
2 
K035.00 RENAL MEDULLARY NECROSIS UNSPECIFIED 2 
K0A3700 CHRONIC NEPHRITIC SYNDROME DIFFUSE 
CRESCENTIC GLOMERULONEPHRITIS 
2 
K08y000 HYPOKALAEMIC NEPHROPATHY 2 
Kyu2100 [X]OTHER CHRONIC RENAL FAILURE 2 
K0A3500 CHRONIC NEPHRITIC SYNDROME DIFFUSE 
MESANGIOCAPILLARY GLOMERULONEPHRITIS 
2 
K02y000 CHRONIC GLOMERULONEPHRITIS DISEASES EC 2 
K100100 CHRONIC PYELONEPHRITIS WITH MEDULLARY 
NECROSIS 
2 
Kyu2000 [X]OTHER ACUTE RENAL FAILURE 2 
Diabetes with complications 
F464000 DIABETIC CATARACT 2 
C109212 TYPE 2 DIABETES MELLITUS WITH 
NEUROLOGICAL COMPLICATIONS 
2 
C104000 DIABETES MELLITUS, JUVENILE TYPE, WITH 
RENAL MANIFESTATION 
2 
C109111 TYPE II DIABETES MELLITUS WITH 
OPHTHALMIC COMPLICATIONS 
2 
2BBP.00 O/E - RIGHT EYE BACKGROUND DIABETIC 
RETINOPATHY 
2 
C108C11 TYPE I DIABETES MELLITUS WITH 
POLYNEUROPATHY 
2 
C108H00 INSULIN DEPENDENT DIABETES MELLITUS 
WITH ARTHROPATHY 
2 
C109C00 NON-INSULIN DEPENDENT DIABETES MELLITUS 
WITH NEPHROPATHY 
2 






C106100 DIABETES MELLITUS, ADULT ONSET, 
NEUROLOGICAL MANIFESTATION 
2 
C108000 INSULIN-DEPENDENT DIABETES MELLITUS 
WITH RENAL COMPLICATIONS 
2 
C109H00 NON-INSULIN DEPENDENT D M WITH 
NEUROPATHIC ARTHROPATHY 
2 
C108200 INSULIN-DEPENDENT DIABETES MELLITUS 
WITH NEUROLOGICAL COMPS 
2 
C10F100 TYPE 2 DIABETES MELLITUS WITH 
OPHTHALMIC COMPLICATIONS 
2 
2BBQ.00 O/E - LEFT EYE BACKGROUND DIABETIC 
RETINOPATHY 
2 
C109011 TYPE II DIABETES MELLITUS WITH RENAL 
COMPLICATIONS 
2 
F420200 PRE-PROLIFERATIVE DIABETIC RETINOPATHY 2 
C105000 DIABETES MELLITUS, JUVENILE TYPE, 
OPHTHALMIC MANIFESTATION 
2 
C10FR00 TYPE 2 DIABETES MELLITUS WITH 
GASTROPARESIS 
2 
C109100 NON-INSULIN-DEPENDENT DIABETES MELLITUS 
WITH OPHTHALMIC COMPS 
2 
C10FE00 TYPE 2 DIABETES MELLITUS WITH DIABETIC 
CATARACT 
2 
C108712 TYPE 1 DIABETES MELLITUS WITH 
RETINOPATHY 
2 
C106.13 DIABETES MELLITUS WITH POLYNEUROPATHY 2 
F420.00 DIABETIC RETINOPATHY 2 
C109612 TYPE 2 DIABETES MELLITUS WITH 
RETINOPATHY 
2 
C109B00 NON-INSULIN DEPENDENT DIABETES MELLITUS 
WITH POLYNEUROPATHY 
2 




C105y00 OTHER SPECIFIED DIABETES MELLITUS WITH 
OPHTHALMIC COMPLICATION 
2 
C109E11 TYPE II DIABETES MELLITUS WITH DIABETIC 
CATARACT 
2 
C10FB00 TYPE 2 DIABETES MELLITUS WITH 
POLYNEUROPATHY 
2 
C10FA00 TYPE 2 DIABETES MELLITUS WITH 
MONONEUROPATHY 
2 
C10F611 TYPE II DIABETES MELLITUS WITH 
RETINOPATHY 
2 
C10E200 TYPE 1 DIABETES MELLITUS WITH 
NEUROLOGICAL COMPLICATIONS 
2 
C108B11 TYPE I DIABETES MELLITUS WITH 
MONONEUROPATHY 
2 
C109600 NON-INSULIN-DEPENDENT DIABETES MELLITUS 
WITH RETINOPATHY 
2 
F381300 MYASTHENIC SYNDROME DUE TO DIABETIC 
AMYOTROPHY 
2 
C106z00 DIABETES MELLITUS NOS WITH 
NEUROLOGICAL MANIFESTATION 
2 
C104y00 OTHER SPECIFIED DIABETES MELLITUS WITH 
RENAL COMPLICATIONS 
2 
2BBV.00 O/E - LEFT EYE PROLIFERATIVE DIABETIC 
RETINOPATHY 
2 
C108711 TYPE I DIABETES MELLITUS WITH 
RETINOPATHY 
2 
F420400 DIABETIC MACULOPATHY 2 
C109C12 TYPE 2 DIABETES MELLITUS WITH 
NEPHROPATHY 
2 
C106.11 DIABETIC AMYOTROPHY 2 




C108D00 INSULIN DEPENDENT DIABETES MELLITUS 
WITH NEPHROPATHY 
2 
C108212 TYPE 1 DIABETES MELLITUS WITH 
NEUROLOGICAL COMPLICATIONS 
2 
C108100 INSULIN-DEPENDENT DIABETES MELLITUS 
WITH OPHTHALMIC COMPS 
2 
F3y0.00 DIABETIC MONONEUROPATHY 2 
F372.12 DIABETIC NEUROPATHY 2 
F420300 ADVANCED DIABETIC MACULOPATHY 2 
C10F011 TYPE II DIABETES MELLITUS WITH RENAL 
COMPLICATIONS 
2 
2BBl.00 O/E - LEFT EYE STABLE TREATED 
PROLIFERATIVE DIABETIC RETINOPATHY 
2 
C10FC00 TYPE 2 DIABETES MELLITUS WITH 
NEPHROPATHY 
2 
C10EF00 TYPE 1 DIABETES MELLITUS WITH DIABETIC 
CATARACT 
2 
C109E12 TYPE 2 DIABETES MELLITUS WITH DIABETIC 
CATARACT 
2 
C108D11 TYPE I DIABETES MELLITUS WITH 
NEPHROPATHY 
2 
C109B11 TYPE II DIABETES MELLITUS WITH 
POLYNEUROPATHY 
2 
C10F200 TYPE 2 DIABETES MELLITUS WITH 
NEUROLOGICAL COMPLICATIONS 
2 
C10EB00 TYPE 1 DIABETES MELLITUS WITH 
MONONEUROPATHY 
2 
C109H12 TYPE 2 DIABETES MELLITUS WITH 
NEUROPATHIC ARTHROPATHY 
2 






C108700 INSULIN DEPENDENT DIABETES MELLITUS 
WITH RETINOPATHY 
2 
C10EC00 TYPE 1 DIABETES MELLITUS WITH 
POLYNEUROPATHY 
2 
F374z00 POLYNEUROPATHY IN DISEASE NOS 2 
C109112 TYPE 2 DIABETES MELLITUS WITH 
OPHTHALMIC COMPLICATIONS 
2 
2BBL.00 O/E - DIABETIC MACULOPATHY PRESENT BOTH 
EYES 
2 
C109012 TYPE 2 DIABETES MELLITUS WITH RENAL 
COMPLICATIONS 
2 
C109000 NON-INSULIN-DEPENDENT DIABETES MELLITUS 
WITH RENAL COMPS 
2 
C109200 NON-INSULIN-DEPENDENT DIABETES MELLITUS 
WITH NEURO COMPS 
2 
F420700 HIGH RISK PROLIFERATIVE DIABETIC 
RETINOPATHY 
2 
C106.12 DIABETES MELLITUS WITH NEUROPATHY 2 
2BBS.00 O/E - LEFT EYE PRE-PROLIFERATIVE DIABETIC 
RETINOPATHY 
2 
C109E00 NON-INSULIN DEPENDS DIABETES MELLITUS 
WITH DIABETIC CATARACT 
2 
C10F600 TYPE 2 DIABETES MELLITUS WITH 
RETINOPATHY 
2 
C108C00 INSULIN DEPENDENT DIABETES MELLITUS 
WITH POLYNEUROPATHY 
2 
C108211 TYPE I DIABETES MELLITUS WITH 
NEUROLOGICAL COMPLICATIONS 
2 
C10E000 TYPE 1 DIABETES MELLITUS WITH RENAL 
COMPLICATIONS 
2 






C106.00 DIABETES MELLITUS WITH NEUROLOGICAL 
MANIFESTATION 
2 
C109611 TYPE II DIABETES MELLITUS WITH 
RETINOPATHY 
2 
F372.11 DIABETIC POLYNEUROPATHY 2 
2BBk.00 O/E - RIGHT EYE STABLE TREATED 
PROLIFERATIVE DIABETIC RETINOPATHY 
2 
F420z00 DIABETIC RETINOPATHY NOS 2 
C105z00 DIABETES MELLITUS NOS WITH OPHTHALMIC 
MANIFESTATION 
2 
C105100 DIABETES MELLITUS, ADULT ONSET, 
OPHTHALMIC MANIFESTATION 
2 
C10ED00 TYPE 1 DIABETES MELLITUS WITH 
NEPHROPATHY 
2 
C108F11 TYPE I DIABETES MELLITUS WITH DIABETIC 
CATARACT 
2 
C108011 TYPE I DIABETES MELLITUS WITH RENAL 
COMPLICATIONS 
2 
C10FC11 TYPE II DIABETES MELLITUS WITH 
NEPHROPATHY 
2 
C108012 TYPE 1 DIABETES MELLITUS WITH RENAL 
COMPLICATIONS 
2 
C109A11 TYPE II DIABETES MELLITUS WITH 
MONONEUROPATHY 
2 
F381311 DIABETIC AMYOTROPHY 2 
C109C11 TYPE II DIABETES MELLITUS WITH 
NEPHROPATHY 
2 
C10EQ00 TYPE 1 DIABETES MELLITUS WITH 
GASTROPARESIS 
2 






C108F00 INSULIN DEPENDENT DIABETES MELLITUS 
WITH DIABETIC CATARACT 
2 
C104.11 DIABETIC NEPHROPATHY 2 
2BBR.00 O/E - RIGHT EYE PRE-PROLIFERATIVE DIABETIC 
RETINOPATHY 
2 
C108J12 TYPE 1 DIABETES MELLITUS WITH 
NEUROPATHIC ARTHROPATHY 
2 
C10FB11 TYPE II DIABETES MELLITUS WITH 
POLYNEUROPATHY 
2 
C106y00 OTHER SPECIFIED DIABETES MELLITUS WITH 
NEUROLOGICAL COMPS 
2 
C10FH00 TYPE 2 DIABETES MELLITUS WITH 
NEUROPATHIC ARTHROPATHY 
2 
C10F000 TYPE 2 DIABETES MELLITUS WITH RENAL 
COMPLICATIONS 
2 
C105.00 DIABETES MELLITUS WITH OPHTHALMIC 
MANIFESTATION 
2 
F420100 PROLIFERATIVE DIABETIC RETINOPATHY 2 
C109211 TYPE II DIABETES MELLITUS WITH 
NEUROLOGICAL COMPLICATIONS 
2 
C104z00 DIABETES MELLITES WITH NEPHROPATHY NOS 2 
C10E100 TYPE 1 DIABETES MELLITUS WITH 
OPHTHALMIC COMPLICATIONS 
2 
Any tumour  
B072.00 MALIGNANT NEOPLASM OF LATERAL WALL OF 
NASOPHARYNX 
2 
B18y100 MALIGNANT NEOPLASM OF MESOCAECUM 2 
B173.00 MALIGNANT NEOPLASM OF PANCREATIC DUCT 2 
B337100 MALIGNANT NEOPLASM OF SKIN OF THIGH 2 






B614500 HODGKIN'S NODULAR SCLEROSIS OF INGUINAL 
REGION AND LEG 
2 
B63..00 MULTIPLE MYELOMA AND 
IMMUNOPROLIFERATIVE NEOPLASMS 
2 
B001.00 MALIGNANT NEOPLASM OF LOWER LIP, 
VERMILION BORDER 
2 
B04y.00 MALIGNANT NEOPLASM OF OTHER SITES OF 
FLOOR OF MOUTH 
2 
B072100 MALIGNANT NEOPLASM OF OPENING OF 
AUDITORY TUBE 
2 
B072000 MALIGNANT NEOPLASM OF PHARYNGEAL 
RECESS 
2 
B612600 HODGKIN'S SARCOMA OF INTRAPELVIC LYMPH 
NODES 
2 
B626400 MAST CELL MALIGNANCY OF LYMPH NODES OF 
AXILLA AND UPPER LIMB 
2 
B305700 MALIGNANT NEOPLASM OF CARPAL BONE - 
HAMATE 
2 
B49..00 MALIGNANT NEOPLASM OF URINARY BLADDER 2 
B430300 MALIGNANT NEOPLASM OF MYOMETRIUM OF 
CORPUS UTERI 
2 
B627C11 FOLLICULAR LYMPHOMA NOS 2 
Byu3300 [X]MALIGNANT NEOPLASM/BONE CARTILAGE, 
UNSPECIFIED 
2 
B03z.00 MALIGNANT NEOPLASM OF GUM NOS 2 
B340z00 MALIGNANT NEOPLASM OF NIPPLE OR AREOLA 
OF FEMALE BREAST NOS 
2 
B627D00 DIFFUSE NON-HODGKIN'S CENTROBLASTIC 
LYMPHOMA 
2 
B332000 MALIGNANT NEOPLASM OF SKIN OF AURICLE 
(EAR) 
2 




B062100 MALIGNANT NEOPLASM OF GLOSSOPALATINE 
FOLD 
2 
B600300 RETICULOSARCOMA OF INTRA-ABDOMINAL 
LYMPH NODES 
2 
B000.00 MALIGNANT NEOPLASM OF UPPER LIP, 
VERMILION BORDER 
2 
ZV10511 [V]PERSONAL HISTORY OF MALIGNANT 
NEOPLASM OF BLADDER 
2 
B41z.00 MALIGNANT NEOPLASM OF CERVIX UTERI NOS 2 
B4A1z00 MALIGNANT NEOPLASM OF RENAL PELVIS NOS 2 
B304400 MALIGNANT NEOPLASM OF ULNA 2 
B00y.00 MALIGNANT NEOPLASM OF OTHER SITES OF LIP 2 
B51y100 MALIGNANT NEOPLASM OF TAPETUM 2 
Byu1200 [X]MALIGNANT NEOPLASM OF INTESTINAL 
TRACT, PART UNSPECIFIED 
2 
B07z.00 MALIGNANT NEOPLASM OF NASOPHARYNX 
NOS 
2 
B242.00 MALIGNANT NEOPLASM OF ANTERIOR 
MEDIASTINUM 
2 
B333z00 MALIGNANT NEOPLASM SKIN OTHER AND 
UNSPECIFIC PART OF FACE NOS 
2 
B42..00 MALIGNANT NEOPLASM OF PLACENTA 2 
B471100 TERATOMA OF DESCENDED TESTIS 2 
B4A3.00 MALIGNANT NEOPLASM OF URETHRA 2 
B626500 MAST CELL MALIGNANCY OF LYMPH NODES 
INGUINAL REGION AND LEG 
2 
B616000 HODGKIN'S LYMPHOCYTIC DEPLETION OF 
UNSPECIFIED SITE 
2 
B02z.00 MALIGNANT NEOPLASM OF MAJOR SALIVARY 
GLAND NOS 
2 
B315300 MALIGNANT NEOPLASM OF CONNECTIVE AND 





B308.00 MALIGNANT NEOPLASM OF SHORT BONES OF 
LEG 
2 
B675.00 ACUTE MYELOFIBROSIS 2 
Byu4.00 [X]MELANOMA AND OTHER MALIGNANT 
NEOPLASMS OF SKIN 
2 
Byu9.00 [X]MALIGNANT NEOPLASM OF URINARY TRACT 2 
B62x000 T-ZONE LYMPHOMA 2 
B17y000 MALIGNANT NEOPLASM OF ECTOPIC 
PANCREATIC TISSUE 
2 
B141.12 RECTAL CARCINOMA 2 
B132.00 MALIGNANT NEOPLASM OF DESCENDING 
COLON 
2 
B330.00 MALIGNANT NEOPLASM OF SKIN OF LIP 2 
B627500 DIFFUSE NON-HODGKIN MIXED SML & LGE 
CELL (DIFFUSE) LYMPHOMA 
2 
B630.00 MULTIPLE MYELOMA 2 
B62x200 PERIPHERAL T-CELL LYMPHOMA 2 
B502.00 MALIGNANT NEOPLASM OF LACRIMAL GLAND 2 
B62x400 MALIGNANT RETICULOSIS 2 
ZV10y11 [V]PERSONAL HISTORY OF MALIGNANT 
NEOPLASM OF BONE 
2 
B305000 MALIGNANT NEOPLASM OF CARPAL BONE - 
SCAPHOID 
2 
B11..00 MALIGNANT NEOPLASM OF STOMACH 2 
B222100 MALIGNANT NEOPLASM OF UPPER LOBE OF 
LUNG 
2 
B106.00 MALIGNANT NEOPLASM, OVERLAPPING LESION 
OF OESOPHAGUS 
2 
ByuD.00 [X]MALIGNANT NEOPLASMS OF LYMPHOID, 
HAEMATOPOIETIC AND RELA 
2 




B066.00 MALIGNANT NEOPLASM OF LATERAL WALL OF 
OROPHARYNX 
2 
B62..00 OTHER MALIGNANT NEOPLASM OF LYMPHOID 
AND HISTIOCYTIC TISSUE 
2 
Byu5400 [X]MALIGNANT NEOPLASM/PERIPHERAL 
NERVES OF TRUNK, UNSPECIFIED 
2 
B101.00 MALIGNANT NEOPLASM OF THORACIC 
OESOPHAGUS 
2 
Byu1000 [X]OTHER SARCOMAS OF THE LIVER 2 
B66y000 ALEUKAEMIC MONOCYTIC LEUKAEMIA 2 
B68y.00 OTHER LEUKAEMIA OF UNSPECIFIED CELL 
TYPE 
2 
B326.00 MALIGNANT MELANOMA OF UPPER LIMB AND 
SHOULDER 
2 
B203.00 MALIGNANT NEOPLASM OF ETHMOID SINUS 2 
ZV10400 [V]PERSONAL HISTORY OF MALIGNANT 
NEOPLASM OF GENITAL ORGAN 
2 
B610600 HODGKIN'S PARAGRANULOMA OF 
INTRAPELVIC LYMPH NODES 
2 
B313.00 MALIGNANT NEOPLASM OF CONNECTIVE AND 
SOFT TISSUE OF THORAX 
2 
B31z000 KAPOSI'S SARCOMA OF SOFT TISSUE 2 
B041.00 MALIGNANT NEOPLASM OF LATERAL PORTION 
OF FLOOR OF MOUTH 
2 
B615100 HODGKIN'S MIXED CELLULARITY OF LYMPH 
NODES HEAD, FACE, NECK 
2 
B114.00 MALIGNANT NEOPLASM OF BODY OF STOMACH 2 
B620.11 RETICULOSARCOMA - FOLLICULAR OR 
NODULAR 
2 
Byu5A00 [X]MALIGNANT NEOPLASM OVERLAPPING 





B3...11 CARCINOMA OF BONE, CONNECTIVE TISSUE, 
SKIN AND BREAST 
2 
B613.00 HODGKIN'S DISEASE, LYMPHOCYTIC-
HISTIOCYTIC PREDOMINANCE 
2 
B610200 HODGKIN'S PARAGRANULOMA OF 
INTRATHORACIC LYMPH NODES 
2 
B490.00 MALIGNANT NEOPLASM OF TRIGONE OF 
URINARY BLADDER 
2 
ZV10112 [V]PERSONAL HISTORY OF MALIGNANT 
NEOPLASM OF LUNG 
2 
B523z00 MALIGNANT NEOPLASM OF SPINAL MENINGES 
NOS 
2 
B615000 HODGKIN'S DISEASE, MIXED CELLULARITY OF 
UNSPECIFIED SITE 
2 
B310200 MALIGNANT NEOPLASM OF SOFT TISSUE OF 
NECK 
2 
B220.00 MALIGNANT NEOPLASM OF TRACHEA 2 
B336z00 MALIGNANT NEOPLASM OF SKIN OF UPPER 
LIMB OR SHOULDER NOS 
2 
B213200 MALIGNANT NEOPLASM OF CUNEIFORM 
CARTILAGE 
2 
B339.00 DERMATOFIBROSARCOMA PROTUBERANS 2 
B180200 MALIGNANT NEOPLASM OF RETROCAECAL 
TISSUE 
2 
B651000 CHRONIC EOSINOPHILIC LEUKAEMIA 2 
B441.00 MALIGNANT NEOPLASM OF FALLOPIAN TUBE 2 
B231.00 MALIGNANT NEOPLASM OF VISCERAL PLEURA 2 
B004100 MALIGNANT NEOPLASM OF LIP UNSPECIFIED, 
FRENULUM 
2 






B337z00 MALIGNANT NEOPLASM OF SKIN OF LOWER 
LIMB OR HIP NOS 
2 
Byu5100 [X]MESOTHELIOMA, UNSPECIFIED 2 
B240.00 MALIGNANT NEOPLASM OF THYMUS 2 
B62y500 MALIGNANT LYMPHOMA NOS OF LYMPH NODE 
INGUINAL REGION AND LEG 
2 
B30z.00 MALIGNANT NEOPLASM OF BONE AND 
ARTICULAR CARTILAGE NOS 
2 
B161.00 MALIGNANT NEOPLASM OF EXTRAHEPATIC 
BILE DUCTS 
2 
B322z00 MALIGNANT MELANOMA OF EAR AND 
EXTERNAL AURICULAR CANAL NOS 
2 
B311100 MALIGNANT NEOPLASM OF CONNECTIVE AND 
SOFT TISSUE, UPPER ARM 
2 
B204.00 MALIGNANT NEOPLASM OF FRONTAL SINUS 2 
B325200 MALIGNANT MELANOMA OF BUTTOCK 2 
B24y.00 MALIGNANT NEOPLASM OF OTHER SITE OF 
HEART, THYMUS AND MEDIASTINUM 
2 
B308.11 MALIGNANT NEOPLASM OF METATARSAL 
BONES OF FOOT 
2 
B303.00 MALIGNANT NEOPLASM OF RIBS, STERNUM 
AND CLAVICLE 
2 
B225.00 MALIGNANT NEOPLASM OF OVERLAPPING 
LESION OF BRONCHUS & LUNG 
2 
B327100 MALIGNANT MELANOMA OF THIGH 2 
B1z1100 FIBROSARCOMA OF SPLEEN 2 
B620300 NODULAR LYMPHOMA OF INTRA-ABDOMINAL 
LYMPH NODES 
2 
B602.00 BURKITT'S LYMPHOMA 2 
B224z00 MALIGNANT NEOPLASM OF LOWER LOBE, 





B622100 SEZARY'S DISEASE OF LYMPH NODES OF HEAD, 
FACE AND NECK 
2 
B163.00 MALIGNANT NEOPLASM, OVERLAPPING LESION 
OF BILIARY TRACT 
2 
B161200 MALIGNANT NEOPLASM OF COMMON BILE 
DUCT 
2 
B515.00 MALIGNANT NEOPLASM OF CEREBRAL 
VENTRICLES 
2 
B102.00 MALIGNANT NEOPLASM OF ABDOMINAL 
OESOPHAGUS 
2 
B312200 MALIGNANT NEOPLASM CONNECTIVE AND 
SOFT TISSUE OF POPLITEAL SPACE 
2 
B454.00 MALIGNANT NEOPLASM OF VULVA 
UNSPECIFIED 
2 
B080.00 MALIGNANT NEOPLASM OF POST-CRICOID 
REGION 
2 
B03y.00 MALIGNANT NEOPLASM OF OTHER SITES OF 
GUM 
2 
B013000 MALIGNANT NEOPLASM OF ANTERIOR 2/3 OF 
TONGUE VENTRAL SURFACE 
2 
B327000 MALIGNANT MELANOMA OF HIP 2 
B064.00 MALIGNANT NEOPLASM OF ANTERIOR 
EPIGLOTTIS 
2 
B013.00 MALIGNANT NEOPLASM OF VENTRAL SURFACE 
OF TONGUE 
2 
ZV10018 [V]PERSONAL HISTORY OF MALIGNANT 
NEOPLASM OF STOMACH 
2 
B300000 MALIGNANT NEOPLASM OF ETHMOID BONE 2 
B6z..00 MALIGNANT NEOPLASM LYMPHATIC OR 
HAEMATOPOIETIC TISSUE NOS 
2 






B624z00 LEUKAEMIC RETICULO-ENDOTHELIOSIS NOS 2 
B412.00 MALIGNANT NEOPLASM, OVERLAPPING LESION 
OF CERVIX UTERI 
2 
B201000 MALIGNANT NEOPLASM OF AUDITORY 
(EUSTACHIAN) TUBE 
2 
B10z.00 MALIGNANT NEOPLASM OF OESOPHAGUS NOS 2 
ZV10y00 [V]PERSONAL HISTORY OF OTHER SPECIFIED 
MALIGNANT NEOPLASM 
2 
B011z00 MALIGNANT NEOPLASM OF DORSUM OF 
TONGUE NOS 
2 
B103.00 MALIGNANT NEOPLASM OF UPPER THIRD OF 
OESOPHAGUS 
2 
B310.00 MALIGNANT NEOPLASM OF CONNECTIVE AND 
SOFT TISSUE HEAD, FACE AND NECK 
2 
B334100 MALIGNANT NEOPLASM OF SKIN OF NECK 2 
B61z.00 HODGKIN'S DISEASE NOS 2 
B333100 MALIGNANT NEOPLASM OF SKIN OF CHIN 2 
B310000 MALIGNANT NEOPLASM OF SOFT TISSUE OF 
HEAD 
2 
B612800 HODGKIN'S SARCOMA OF LYMPH NODES OF 
MULTIPLE SITES 
2 
B523200 MALIGNANT NEOPLASM OF SPINAL PIA MATER 2 
B300700 MALIGNANT NEOPLASM OF SPHENOID BONE 2 
B33y.00 MALIGNANT NEOPLASM OF OTHER SPECIFIED 
SKIN SITES 
2 
B653z00 MYELOID SARCOMA NOS 2 
B325600 MALIGNANT MELANOMA OF UMBILICUS 2 
B601800 LYMPHOSARCOMA OF LYMPH NODES OF 
MULTIPLE SITES 
2 
B111.00 MALIGNANT NEOPLASM OF PYLORUS OF 
STOMACH 
2 




B18y400 MALIGNANT NEOPLASM OF PARIETAL 
PERITONEUM 
2 
B521200 MALIGNANT NEOPLASM OF CEREBRAL PIA 
MATER 
2 
B180000 MALIGNANT NEOPLASM OF PERIADRENAL 
TISSUE 
2 
B641.00 CHRONIC LYMPHOID LEUKAEMIA 2 
B072z00 MALIGNANT NEOPLASM OF LATERAL WALL OF 
NASOPHARYNX NOS 
2 
B....11 CANCERS 2 
B34y000 MALIGNANT NEOPLASM OF ECTOPIC SITE OF 
FEMALE BREAST 
2 
B224.00 MALIGNANT NEOPLASM OF LOWER LOBE, 
BRONCHUS OR LUNG 
2 
B304000 MALIGNANT NEOPLASM OF SCAPULA 2 
B315100 MALIGNANT NEOPLASM OF CONNECTIVE AND 
SOFT TISSUE OF INGUINAL REGION 
2 
B12..00 MALIGNANT NEOPLASM OF SMALL INTESTINE 
AND DUODENUM 
2 
B311200 MALIGNANT NEOPLASM OF CONNECTIVE AND 
SOFT TISSUE OF FORE-ARM 
2 
B622600 SEZARY'S DISEASE OF INTRAPELVIC LYMPH 
NODES 
2 
B626z00 MALIGNANT MAST CELL TUMOUR NOS 2 
B611200 HODGKIN'S GRANULOMA OF INTRATHORACIC 
LYMPH NODES 
2 
B550300 MALIGNANT NEOPLASM OF JAW NOS 2 
B6y0.11 MYELOPROLIFERATIVE DISEASE 2 
B306.00 MALIGNANT NEOPLASM OF PELVIC BONES, 
SACRUM AND COCCYX 
2 




B613100 HODGKIN'S, LYMPHOCYTIC-HISTIOCYTIC PRED 
OF HEAD, FACE, NECK 
2 
B616100 HODGKIN'S LYMPHOCYTIC DEPLETION OF 
HEAD, FACE AND NECK 
2 
B624.00 LEUKAEMIC RETICULOENDOTHELIOSIS 2 
B410z00 MALIGNANT NEOPLASM OF ENDOCERVIX NOS 2 
B524W00 MAL NEOPLASM/PERIPHERAL NERVES 
NERVOUS SYSTEM, UNSPECIFIC 
2 
B30W.00 MALIGNANT NEOPLASM/OVERLAP 
LESION/BONE CARTILAGE 
2 
B327300 MALIGNANT MELANOMA OF POPLITEAL FOSSA 
AREA 
2 
B620600 NODULAR LYMPHOMA OF INTRAPELVIC 
LYMPH NODES 
2 
B326100 MALIGNANT MELANOMA OF UPPER ARM 2 
B68..00 LEUKAEMIA OF UNSPECIFIED CELL TYPE 2 
B482.00 MALIGNANT NEOPLASM OF BODY OF PENIS 2 
B327900 MALIGNANT MELANOMA OF GREAT TOE 2 
B151000 MALIGNANT NEOPLASM OF INTERLOBULAR 
BILE DUCTS 
2 
B67y000 LYMPHOSARCOMA CELL LEUKAEMIA 2 
B500100 MALIGNANT NEOPLASM OF IRIS 2 
B327.00 MALIGNANT MELANOMA OF LOWER LIMB AND 
HIP 
2 
B60..00 LYMPHOSARCOMA AND RETICULOSARCOMA 2 
B24..00 MALIGNANT NEOPLASM OF THYMUS, HEART 
AND MEDIASTINUM 
2 
B627700 DIFFUSE NON-HODGKIN'S LYMPHOBLASTIC 
(DIFFUSE) LYMPHOMA 
2 
B45X.00 MALIGNANT NEOPLASM/OVERLAPPING 





B601600 LYMPHOSARCOMA OF INTRAPELVIC LYMPH 
NODES 
2 
B601500 LYMPHOSARCOMA OF LYMPH NODES OF 
INGUINAL REGION AND LEG 
2 
B510300 MALIGNANT NEOPLASM OF GLOBUS PALLIDUS 2 
B21..00 MALIGNANT NEOPLASM OF LARYNX 2 
B430211 MALIGNANT NEOPLASM OF ENDOMETRIUM 2 
B014.00 MALIGNANT NEOPLASM OF ANTERIOR 2/3 OF 
TONGUE UNSPECIFIED 
2 
B326400 MALIGNANT MELANOMA OF FINGER 2 
B62z700 UNSPECIFIC MALIGNANT NEOPLASM 
LYMPHOID/HISTIOCYTIC OF SPLEEN 
2 
B337400 MALIGNANT NEOPLASM OF SKIN OF LOWER 
LEG 
2 
ZV10414 [V]PERSONAL HISTORY OF MALIGNANT 
NEOPLASM OF OVARY 
2 
B200100 MALIGNANT NEOPLASM OF NASAL CONCHAE 2 
B201.00 MALIGNANT NEOPLASM AUDITORY TUBE, 
MIDDLE EAR AND MASTOID AIR CELLS 
2 
B205.00 MALIGNANT NEOPLASM OF SPHENOIDAL SINUS 2 
B21y.00 MALIGNANT NEOPLASM OF LARYNX, OTHER 
SPECIFIED SITE 
2 
B220100 MALIGNANT NEOPLASM OF MUCOSA OF 
TRACHEA 
2 
B612100 HODGKIN'S SARCOMA OF LYMPH NODES OF 
HEAD, FACE AND NECK 
2 
B335200 MALIGNANT NEOPLASM OF SKIN OF BREAST 2 
B325100 MALIGNANT MELANOMA OF BREAST 2 
B631.00 PLASMA CELL LEUKAEMIA 2 






B500200 MALIGNANT NEOPLASM OF CRYSTALLINE 
LENS 
2 
B67yz00 OTHER AND UNSPECIFIED LEUKAEMIA NOS 2 
ByuD200 [X]OTHER TYPES OF DIFFUSE NON-HODGKIN'S 
LYMPHOMA 
2 
B41..00 MALIGNANT NEOPLASM OF CERVIX UTERI 2 
B160.11 CARCINOMA GALLBLADDER 2 
B331000 MALIGNANT NEOPLASM OF CANTHUS 2 
B323000 MALIGNANT MELANOMA OF EXTERNAL 
SURFACE OF CHEEK 
2 
B4...00 MALIGNANT NEOPLASM OF GENITOURINARY 
ORGAN 
2 
B302100 MALIGNANT NEOPLASM OF THORACIC 
VERTEBRA 
2 
B30X.00 MALIGNANT NEOPLASM/BONES 
CARTILAGE/LIMB, UNSPECIFIC 
2 
B322000 MALIGNANT MELANOMA OF AURICLE (EAR) 2 
B61..00 HODGKIN'S DISEASE 2 
B471.00 MALIGNANT NEOPLASM OF DESCENDED TESTIS 2 
B500000 MALIGNANT NEOPLASM OF CILIARY BODY 2 
ByuDF00 [X]NON-HODGKIN'S LYMPHOMA, UNSPECIFIED 
TYPE 
2 
B62y.00 MALIGNANT LYMPHOMA NOS 2 
B523100 MALIGNANT NEOPLASM OF SPINAL 
ARACHNOID MATER 
2 
B626300 MAST CELL MALIGNANCY OF INTRA-
ABDOMINAL LYMPH NODES 
2 
B54X.00 MALIGNANT NEOPLASM-PLURIGLANDULAR 
INVOLVEMENT, UNSPECIFIC 
2 






B18..00 MALIGNANT NEOPLASM OF 
RETROPERITONEUM AND PERITONEUM 
2 
B30..11 CHONDROMA 2 
B150200 PRIMARY ANGIOSARCOMA OF LIVER 2 
B31..00 MALIGNANT NEOPLASM OF CONNECTIVE AND 
OTHER SOFT TISSUE 
2 
B650.00 ACUTE MYELOID LEUKAEMIA 2 
B661.00 CHRONIC MONOCYTIC LEUKAEMIA 2 
B306500 MALIGNANT SACRAL TERATOMA 2 
B200z00 MALIGNANT NEOPLASM OF NASAL CAVITIES 
NOS 
2 
B615200 HODGKIN'S MIXED CELLULARITY OF 
INTRATHORACIC LYMPH NODES 
2 
B18z.00 MALIGNANT NEOPLASM OF 
RETROPERITONEUM AND PERITONEUM NOS 
2 
B621300 MYCOSIS FUNGOIDES OF INTRA-ABDOMINAL 
LYMPH NODES 
2 
B52..00 MALIGNANT NEOPLASM OF OTHER AND 
UNSPECIFIED PARTS OF NERVOUS SYSTEM 
2 
B55y000 MALIGNANT NEOPLASM OF BACK NOS 2 
B304.00 MALIGNANT NEOPLASM OF SCAPULA AND 
LONG BONES OF UPPER ARM 
2 
B62z200 UNSPECIFIED MALIGNANT NEOPLASM 
LYMPHOID/HISTIOCYTIC OF INTRATHORACIC 
NODE 
2 
B55y100 MALIGNANT NEOPLASM OF TRUNK NOS 2 
B1z..00 MALIGNANT NEOPLASM OTHER/ILL-DEFINED 
SITES DIGESTIVE TRACT/PERITONEUM 
2 
B524300 MALIGNANT NEOPLASM OF PERIPHERAL 
NERVE OF THORAX 
2 
B1z1.00 MALIGNANT NEOPLASM OF SPLEEN NEC 2 




B55z.00 MALIGNANT NEOPLASM OF OTHER AND ILL-
DEFINED SITE NOS 
2 
Byu5011 [X]MESOTHELIOMA OF LUNG 2 
B303100 MALIGNANT NEOPLASM OF STERNUM 2 
B34..00 MALIGNANT NEOPLASM OF FEMALE BREAST 2 
B070.00 MALIGNANT NEOPLASM OF ROOF OF 
NASOPHARYNX 
2 
B680.00 ACUTE LEUKAEMIA NOS 2 
B51z.00 MALIGNANT NEOPLASM OF BRAIN NOS 2 
B232.00 MESOTHELIOMA OF PLEURA 2 
B302z00 MALIGNANT NEOPLASM OF VERTEBRAL 
COLUMN NOS 
2 
B11..11 GASTRIC NEOPLASM 2 
B510000 MALIGNANT NEOPLASM OF BASAL GANGLIA 2 
Byu7200 [X]MALIGNANT NEOPLASM/OVERLAPPING 
LESION/FEMALE GENITAL ORGANS 
2 
B308100 MALIGNANT NEOPLASM OF TALUS 2 
B20y.00 MALIGNANT NEOPLASM OTHER SITE NASAL 
CAVITY, MIDDLE EAR AND SINUSES 
2 
B662.00 SUBACUTE MONOCYTIC LEUKAEMIA 2 
B62y300 MALIGNANT LYMPHOMA NOS OF INTRA-
ABDOMINAL LYMPH NODES 
2 
B314100 MALIGNANT NEOPLASM OF CONNECTIVE AND 
SOFT TISSUES OF LUMB SPINE 
2 
Byu5800 [X]MAL NEOPLASM/CONNECTIVE? TISSUE OF 
TRUNK, UNSPECIFIED 
2 
B344.00 MALIGNANT NEOPLASM OF UPPER-OUTER 
QUADRANT OF FEMALE BREAST 
2 
B524600 MALIGNANT NEOPLASM, OVERLAP LESION 
PERIPHERAL NERVE & AUTON  
2 
B30..12 OSTEOMA 2 




B550200 MALIGNANT NEOPLASM OF NOSE NOS 2 
B337000 MALIGNANT NEOPLASM OF SKIN OF HIP 2 
B133.00 MALIGNANT NEOPLASM OF SIGMOID COLON 2 
ZV10214 [V]PERSONAL HISTORY OF MALIGNANT 
NEOPLASM OF NOSE 
2 
Byu2.00 [X]MALIGNANT NEOPLASM OF RESPIRATORY 
AND INTRATHORACIC ORGAN 
2 
B454.11 PRIMARY VULVAR CANCER 2 
B350z00 MALIGNANT NEOPLASM OF NIPPLE OR AREOLA 
OF MALE BREAST NOS 
2 
B2...11 CARCINOMA OF RESPIRATORY TRACT AND 
INTRATHORACIC ORGANS 
2 
B06z.00 MALIGNANT NEOPLASM OF OROPHARYNX NOS 2 
B52y.00 MALIGNANT NEOPLASM OF OTHER SPECIFIED 
PART OF NERVOUS SYSTEM 
2 
B41y000 MALIGNANT NEOPLASM OF CERVICAL STUMP 2 
B064100 MALIGNANT NEOPLASM OF GLOSSO-
EPIGLOTTIC FOLD 
2 
B222.00 MALIGNANT NEOPLASM OF UPPER LOBE, 
BRONCHUS OR LUNG 
2 
B610700 HODGKIN'S PARA-GRANULOMA OF SPLEEN 2 
B630200 PLASMACYTOMA NOS 2 
B52z.00 MALIGNANT NEOPLASM OF NERVOUS SYSTEM 
NOS 
2 
B001000 MALIGNANT NEOPLASM OF LOWER LIP, 
EXTERNAL 
2 
B150000 PRIMARY CARCINOMA OF LIVER 2 
B222z00 MALIGNANT NEOPLASM OF UPPER LOBE, 
BRONCHUS OR LUNG NOS 
2 
B512100 MALIGNANT NEOPLASM OF UNCUS 2 






B602600 BURKITT'S LYMPHOMA OF INTRAPELVIC 
LYMPH NODES 
2 
B....00 NEOPLASMS 2 
B000000 MALIGNANT NEOPLASM OF UPPER LIP, 
EXTERNAL 
2 
Byu4000 [X]MALIGNANT MELANOMA OF OTHER PARTS 
OF FACE 
2 
B524000 MALIGNANT NEOPLASM OF PERIPHERAL 
NERVES OF HEAD, FACE & NECK 
2 
B550.00 MALIGNANT NEOPLASM OF HEAD, NECK AND 
FACE 
2 
B34y.00 MALIGNANT NEOPLASM OF OTHER SITE OF 
FEMALE BREAST 
2 
B308C00 MALIGNANT NEOPLASM OF FIFTH 
METATARSAL BONE 
2 
B040.00 MALIGNANT NEOPLASM OF ANTERIOR 
PORTION OF FLOOR OF MOUTH 
2 
B303000 MALIGNANT NEOPLASM OF RIB 2 
B065.00 MALIGNANT NEOPLASM OF JUNCTIONAL 
REGION OF EPIGLOTTIS 
2 
B430z00 MALIGNANT NEOPLASM OF CORPUS UTERI NOS 2 
B003.00 MALIGNANT NEOPLASM OF LOWER LIP, INNER 
ASPECT 
2 
B137.00 MALIGNANT NEOPLASM OF SPLENIC FLEXURE 
OF COLON 
2 
ZV10y14 [V]PERSONAL HISTORY OF MALIGNANT 
NEOPLASM OF SKIN 
2 
B625700 LETTERER-SIWE DISEASE OF SPLEEN 2 
B300600 MALIGNANT NEOPLASM OF PARIETAL BONE 2 
B241.00 MALIGNANT NEOPLASM OF HEART 2 
B62y100 MALIGNANT LYMPHOMA NOS OF LYMPH 





B61z400 HODGKIN'S DISEASE NOS OF LYMPH NODES OF 
AXILLA AND ARM 
2 
B510100 MALIGNANT NEOPLASM OF CEREBRAL CORTEX 2 
B506.00 MALIGNANT NEOPLASM OF CHOROID 2 
ByuD700 [X]OTHER MONOCYTIC LEUKAEMIA 2 
B540z00 MALIGNANT NEOPLASM OF ADRENAL GLAND 
NOS 
2 
Byu2200 [X]MALIGNANT NEOPLASM/UPPER 
RESPIRATORY TRACT, PART UNSPECIFIED 
2 
B410000 MALIGNANT NEOPLASM OF ENDOCERVICAL 
CANAL 
2 
B691.00 CHRONIC MYELOMONOCYTIC LEUKAEMIA 2 
B326000 MALIGNANT MELANOMA OF SHOULDER 2 
B49y.00 MALIGNANT NEOPLASM OF OTHER SITE OF 
URINARY BLADDER 
2 
B630300 LAMBDA LIGHT CHAIN MYELOMA 2 
B612000 HODGKIN'S SARCOMA OF UNSPECIFIED SITE 2 
1841AN MALIGNANT NEOPLASM CANAL OF NUCK 2 
B313300 MALIGNANT NEOPLASM OF CONNECTIVE AND 
SOFT TISSUES OF THE SPINE 
2 
B308700 MALIGNANT NEOPLASM OF NAVICULAR 2 
B616.00 HODGKIN'S DISEASE, LYMPHOCYTIC 
DEPLETION 
2 
B41..11 CERVICAL CARCINOMA (UTERUS) 2 
B430.00 MALIGNANT NEOPLASM OF CORPUS UTERI, 
EXCLUDING ISTHMUS 
2 
B483.00 MALIGNANT NEOPLASM OF PENIS, PART 
UNSPECIFIED 
2 
B200000 MALIGNANT NEOPLASM OF CARTILAGE OF 
NOSE 
2 






B17yz00 MALIGNANT NEOPLASM OF SPECIFIED SITE OF 
PANCREAS NOS 
2 
B323100 MALIGNANT MELANOMA OF CHIN 2 
B05..00 MALIGNANT NEOPLASM OF OTHER AND 
UNSPECIFIED PARTS OF MOUTH 
2 
B513.00 MALIGNANT NEOPLASM OF PARIETAL LOBE 2 
By...00 NEOPLASMS OTHERWISE SPECIFIED 2 
B507.00 MALIGNANT NEOPLASM OF LACRIMAL DUCT 2 
B616z00 HODGKIN'S DISEASE, LYMPHOCYTIC 
DEPLETION NOS 
2 
B311300 MALIGNANT NEOPLASM OF CONNECTIVE AND 
SOFT TISSUE OF HAND 
2 
B305z00 MALIGNANT NEOPLASM OF HAND BONES NOS 2 
Byu3200 [X]MALIGNANT NEOPLASM/OVERLAP 
LESION/BONE??? CARTILAGE 
2 
B010.00 MALIGNANT NEOPLASM OF BASE OF TONGUE 2 
B602200 BURKITT'S LYMPHOMA OF INTRATHORACIC 
LYMPH NODES 
2 
B0z..00 MALIGNANT NEOPLASM OTHER/ILL-DEFINED 
SITES LIP, ORAL CAVITY, PHARYNX 
2 
B134.11 CARCINOMA OF CAECUM 2 
B030.00 MALIGNANT NEOPLASM OF UPPER GUM 2 
B621500 MYCOSIS FUNGOIDES OF LYMPH NODES OF 
INGUINAL REGION AND LEG 
2 
B071.00 MALIGNANT NEOPLASM OF POSTERIOR WALL 
OF NASOPHARYNX 
2 
B625200 LETTERER-SIWE DISEASE OF INTRATHORACIC 
LYMPH NODES 
2 
B625300 LETTERER-SIWE DISEASE OF INTRA-
ABDOMINAL LYMPH NODES 
2 




B113.00 MALIGNANT NEOPLASM OF FUNDUS OF 
STOMACH 
2 
B501.00 MALIGNANT NEOPLASM OF ORBIT 2 
B213000 MALIGNANT NEOPLASM OF ARYTENOID 
CARTILAGE 
2 
B62x100 LYMPHO-EPITHELIOID LYMPHOMA 2 
B322.00 MALIGNANT MELANOMA OF EAR AND 
EXTERNAL AURICULAR CANAL 
2 
Byu0.00 [X]MALIGNANT NEOPLASM OF LIP, ORAL 
CAVITY AND PHARYNX 
2 
B316.00 MALIGNANT NEOPLASM OF CONNECTIVE AND 
SOFT TISSUE TRUNK UNSPECIFIED 
2 
B06y.00 MALIGNANT NEOPLASM OF OROPHARYNX, 
OTHER SPECIFIED SITES 
2 
B3...00 MALIGNANT NEOPLASM OF BONE, 
CONNECTIVE TISSUE, SKIN AND BREAST 
2 
B510400 MALIGNANT NEOPLASM OF HYPOTHALAMUS 2 
ByuD900 [X]OTHER LEUKAEMIA OF UNSPECIFIED CELL 
TYPE 
2 
B141.00 MALIGNANT NEOPLASM OF RECTUM 2 
B63z.00 IMMUNOPROLIFERATIVE NEOPLASM OR 
MYELOMA NOS 
2 
B545z00 MALIGNANT NEOPLASM OF AORTIC BODY OR 
PARAGANGLIA NOS 
2 
B073000 MALIGNANT NEOPLASM OF FLOOR OF 
NASOPHARYNX 
2 
B306z00 MALIGNANT NEOPLASM OF PELVIS, SACRUM 
OR COCCYX NOS 
2 
B18y700 MALIGNANT NEOPLASM OF MESENTERY 2 






B6y1.00 MYELO-SCLEROSIS WITH MYELOID 
METAPLASIA 
2 
B611600 HODGKIN'S GRANULOMA OF INTRAPELVIC 
LYMPH NODES 
2 
B41y100 MALIGNANT NEOPLASM OF 
SQUAMOCOLUMNAR JUNCTION OF CERVIX 
2 
B62x.00 MALIGNANT LYMPHOMA OTHERWISE 
SPECIFIED 
2 
B4z..00 MALIGNANT NEOPLASM OF GENITOURINARY 
ORGAN NOS 
2 
B333500 MALIGNANT NEOPLASM OF SKIN OF TEMPLE 2 
ZV10411 [V]PERSONAL HISTORY OF MALIGNANT 
NEOPLASM OF CERVIX UTERI 
2 
B004300 MALIGNANT NEOPLASM OF LIP, ORAL ASPECT 2 
B600000 RETICULO-SARCOMA OF UNSPECIFIED SITE 2 
B651.11 CHRONIC GRANULOCYTIC LEUKAEMIA 2 
B150z00 PRIMARY MALIGNANT NEOPLASM OF LIVER 
NOS 
2 
B326300 MALIGNANT MELANOMA OF HAND 2 
ZV10713 [V]PERSONAL HISTORY OF OTHER 
HAEMATOPOIETIC NEOPLASM 
2 
B496.00 MALIGNANT NEOPLASM OF URETERIC ORIFICE 2 
1419AA LINGUAL/TONGUE CANCER 2 
B337.00 MALIGNANT NEOPLASM OF SKIN OF LOWER 
LIMB AND HIP 
2 
B43..00 MALIGNANT NEOPLASM OF BODY OF UTERUS 2 
B626200 MAST CELL MALIGNANCY OF INTRATHORACIC 
LYMPH NODES 
2 
B0zz.00 MALIGNANT NEOPLASM OF LIP, ORAL CAVITY 
AND PHARYNX NOS 
2 
B345.00 MALIGNANT NEOPLASM OF LOWER-OUTER 





ByuA100 [X]MALIGNANT NEOPLASM/CENTRAL NERVOUS 
SYSTEM, UNSPECIFIED 
2 
B2z..00 MALIGNANT NEOPLASM OTHER/ILL-DEFINED 
SITES RESP/INTRATHORACIC ORGANS 
2 
B337600 MALIGNANT NEOPLASM OF SKIN OF HEEL 2 
B313z00 MALIGNANT NEOPLASM OF CONNECTIVE AND 
SOFT TISSUE OF THORAX NOS 
2 
B44z.00 MALIGNANT NEOPLASM OF UTERINE ADNEXA 
NOS 
2 
Byu5200 [X]KAPOSI'S SARCOMA OF MULTIPLE ORGANS 2 
B64y100 PROLYMPHOCYTIC LEUKAEMIA 2 
ByuDE00 [X]UNSPECIFIED B-CELL NON-HODGKIN'S 
LYMPHOMA 
2 
B622.00 SEZARY'S DISEASE 2 
B180100 MALIGNANT NEOPLASM OF PERINEPHRIC 
TISSUE 
2 
B410.00 MALIGNANT NEOPLASM OF ENDOCERVIX 2 
B325700 MALIGNANT MELANOMA OF BACK 2 
B16y.00 MALIGNANT NEOPLASM OTHER 
GALLBLADDER/EXTRAHEPATIC BILE DUCT 
2 
B615500 HODGKIN'S MIXED CELLULARITY OF LYMPH 
NODES INGUINAL AND LEG 
2 
B241100 MALIGNANT NEOPLASM OF EPICARDIUM 2 
B004z00 MALIGNANT NEOPLASM OF LIP, INNER ASPECT 
NOS 
2 
B02y.00 MALIGNANT NEOPLASM OF OTHER MAJOR 
SALIVARY GLANDS 
2 
B201z00 MALIGNANT NEOPLASM AUDITORY TUBE, 
MIDDLE EAR, MASTOID AIR CELLS NOS 
2 
B616200 HODGKIN'S LYMPHOCYTIC DEPLETION OF 





B335100 MALIGNANT NEOPLASM OF SKIN OF CHEST, 
EXCLUDING BREAST 
2 
B005.00 MALIGNANT NEOPLASM OF COMMISSURE OF 
LIP 
2 
B517200 MALIGNANT NEOPLASM OF MIDBRAIN 2 
B0z1.00 MALIGNANT NEOPLASM OF WALDEYER'S RING 2 
B600100 RETICULO-SARCOMA OF LYMPH NODES OF 
HEAD, FACE AND NECK 
2 
B492.00 MALIGNANT NEOPLASM OF LATERAL WALL OF 
URINARY BLADDER 
2 
B161z00 MALIGNANT NEOPLASM OF EXTRAHEPATIC 
BILE DUCTS NOS 
2 
B5...00 MALIGNANT NEOPLASM OF OTHER AND 
UNSPECIFIED SITES 
2 
B61z000 HODGKIN'S DISEASE NOS, UNSPECIFIED SITE 2 
B2...00 MALIGNANT NEOPLASM OF RESPIRATORY 
TRACT AND INTRATHORACIC ORGANS 
2 
B622z00 SEZARY'S DISEASE NOS 2 
B335400 MALIGNANT NEOPLASM OF SKIN OF 
UMBILICUS 
2 
B4A1000 MALIGNANT NEOPLASM OF RENAL CALYCES 2 
Byu2400 [X]MALIGNANT NEOPLASM/ILL-DEFINED SITES 
WITHIN RESP SYSTEM 
2 
B411.00 MALIGNANT NEOPLASM OF EXOCERVIX 2 
ByuA.00 [X]MALIGNANT NEOPLASM OF EYE, BRAIN AND 
OTHER PARTS OF CENT 
2 
ByuDD00 [X]OTHER AND UNSPECIFIC PERIPHERAL & 
CUTANEOUS T-CELL LYMPHOMAS 
2 
B315000 MALIGNANT NEOPLASM OF CONNECTIVE AND 
SOFT TISSUE OF BUTTOCK 
2 




B340100 MALIGNANT NEOPLASM OF AREOLA OF 
FEMALE BREAST 
2 
B542000 MALIGNANT NEOPLASM OF PITUITARY GLAND 2 
B333000 MALIGNANT NEOPLASM OF SKIN OF CHEEK, 
EXTERNAL 
2 
B010z00 MALIGNANT NEOPLASM OF FIXED PART OF 
TONGUE NOS 
2 
B324100 MALIGNANT MELANOMA OF NECK 2 
B65y100 ACUTE PROMYELOCYTIC LEUKAEMIA 2 
B314z00 MALIGNANT NEOPLASM OF CONNECTIVE AND 
SOFT TISSUE OF ABDOMEN NOS 
2 
B500z00 MALIGNANT NEOPLASM OF EYEBALL NOS 2 
B312400 MALIGNANT NEOPLASM OF CONNECTIVE AND 
SOFT TISSUE OF FOOT 
2 
B311000 MALIGNANT NEOPLASM OF CONNECTIVE AND 
SOFT TISSUE OF SHOULDER 
2 
B340.00 MALIGNANT NEOPLASM OF NIPPLE AND 
AREOLA OF FEMALE BREAST 
2 
B00zz00 MALIGNANT NEOPLASM OF LIP, VERMILION 
BORDER NOS 
2 
B241000 MALIGNANT NEOPLASM OF ENDOCARDIUM 2 
B241300 MALIGNANT NEOPLASM OF PERICARDIUM 2 
ZV10416 [V]PERSONAL HISTORY OF MALIGNANT 
NEOPLASM OF TESTIS 
2 
B630.12 MYELOMATOSIS 2 
B350.00 MALIGNANT NEOPLASM OF NIPPLE AND 
AREOLA OF MALE BREAST 
2 
B690.00 ACUTE MYELOMONOCYTIC LEUKAEMIA 2 
B181.00 MESOTHELIOMA OF PERITONEUM 2 
B508.00 MALIGNANT NEOPLASM, OVERLAPPING LESION 
OF EYE AND ADNEXA 
2 




B62y600 MALIGNANT LYMPHOMA NOS OF INTRAPELVIC 
LYMPH NODES 
2 
B554.00 MALIGNANT NEOPLASM OF UPPER LIMB NOS 2 
B150.00 PRIMARY MALIGNANT NEOPLASM OF LIVER 2 
B524X00 MALIGNANT NEOPLASM/PERIPHERAL NERVES 
OF TRUNK, UNSPECIFIED 
2 
B443.00 MALIGNANT NEOPLASM OF PARAMETRIUM 2 
B342.00 MALIGNANT NEOPLASM OF UPPER-INNER 
QUADRANT OF FEMALE BREAST 
2 
B213100 MALIGNANT NEOPLASM OF CRICOID 
CARTILAGE 
2 
B620800 NODULAR LYMPHOMA OF LYMPH NODES OF 
MULTIPLE SITES 
2 
B337300 MALIGNANT NEOPLASM OF SKIN OF POPLITEAL 
FOSSA AREA 
2 
B551200 MALIGNANT NEOPLASM OF INTRATHORACIC 
SITE NOS 
2 
B311500 MALIGNANT NEOPLASM OF CONNECTIVE AND 
SOFT TISSUE OF THUMB 
2 
B613300 HODGKIN'S, LYMPHOCYTIC-HISTIOCYTIC PRED 
INTRA-ABDOMINAL NODE 
2 
Byu2300 [X] MALIGNANT NEOPLASM /OVERLAPPING 
LES/RESP ORGANS 
2 
ByuE.00 [X]MALIGNANT NEOPLASMS/INDEPENDENT 
(PRIMARY) MULTIPLE SITES 
2 
B410100 MALIGNANT NEOPLASM OF ENDOCERVICAL 
GLAND 
2 
Byu6.00 [X]MALIGNANT NEOPLASM OF BREAST 2 
B660.00 ACUTE MONOCYTIC LEUKAEMIA 2 
B311z00 MALIGNANT NEOPLASM CONNECTIVE SOFT 





B624300 LEUKAEMIC RETICULOEND OF INTRA-
ABDOMINAL LYMPH NODES 
2 
B305.11 MALIGNANT NEOPLASM OF CARPAL BONES 2 
B620000 NODULAR LYMPHOMA OF UNSPECIFIED SITE 2 
B621100 MYCOSIS FUNGOIDES OF THE LYMPH NODES OF 
HEAD, FACE AND NECK 
2 
B621400 MYCOSIS FUNGOIDES OF LYMPH NODES OF 
AXILLA AND UPPER LIMB 
2 
B00z100 MALIGNANT NEOPLASM OF LIP, UNSPECIFIED, 
LIPSTICK AREA 
2 
B622700 SEZARY'S DISEASE OF SPLEEN 2 
B230.00 MALIGNANT NEOPLASM OF PARIETAL PLEURA 2 
B10z.11 OESOPHAGEAL CANCER 2 
B62zz00 LYMPHOID AND HISTIOCYTIC MALIGNANCY 
NOS 
2 
B224100 MALIGNANT NEOPLASM OF LOWER LOBE OF 
LUNG 
2 
ZV10000 [V]PERSONAL HISTORY OF MALIGNANT 
NEOPLASM OF GASTROINTESTINAL TRACT 
2 
B504.00 MALIGNANT NEOPLASM OF CORNEA 2 
Byu5.00 [X]MALIGNANT NEOPLASM OF MESOTHELIAL 
AND SOFT TISSUE 
2 
B653000 CHLOROMA 2 
B334000 MALIGNANT NEOPLASM OF SCALP 2 
B66..00 MONOCYTIC LEUKAEMIA 2 
B622500 SEZARY'S DISEASE OF LYMPH NODES OF 
INGUINAL REGION AND LEG 
2 
B22y.00 MALIGNANT NEOPLASM OF OTHER SITES OF 
BRONCHUS OR LUNG 
2 
B540.11 PHEOCHROMOCYTOMA 2 




ZV10714 [V]PERSONAL HISTORY OF RETICULO-
SARCOMA 
2 
B307100 MALIGNANT NEOPLASM OF FIBULA 2 
B612.00 HODGKIN'S SARCOMA 2 
B613z00 HODGKIN'S, LYMPHOCYTIC-HISTIOCYTIC 
PREDOMINANCE NOS 
2 
B55y.00 MALIGNANT NEOPLASM OF OTHER SPECIFIED 
SITES 
2 
B420.00 CHORIOCARCINOMA 2 
B331200 MALIGNANT NEOPLASM OF LOWER EYELID 2 
B62z600 UNSPECIFIED MALIGNANT NEOPLASM 
LYMPHOID/HISTIOCYTIC OF INTRAPELVIC 
NODES 
2 
B300C00 MALIGNANT NEOPLASM OF VOMER 2 
B4A1.00 MALIGNANT NEOPLASM OF RENAL PELVIS 2 
ByuDC00 [X]DIFFUSE NON-HODGKIN'S LYMPHOMA, 
UNSPECIFIED 
2 
B625600 LETTERER-SIWE DISEASE OF INTRAPELVIC 
LYMPH NODES 
2 
B5...11 CARCINOMA OF OTHER AND UNSPECIFIED 
SITES 
2 
B110.00 MALIGNANT NEOPLASM OF CARDIA OF 
STOMACH 
2 
B553z00 MALIGNANT NEOPLASM OF PELVIS NOS 2 
B221100 MALIGNANT NEOPLASM OF HILUS OF LUNG 2 
B550z00 MALIGNANT NEOPLASM OF HEAD, NECK AND 
FACE NOS 
2 
B517z00 MALIGNANT NEOPLASM OF BRAIN STEM NOS 2 
B33z.00 MALIGNANT NEOPLASM OF SKIN NOS 2 
ByuDA00 [X]OTHER SPECIFIC MALIGNANT NEOPLASM 





B6...00 MALIGNANT NEOPLASM OF LYMPHATIC AND 
HAEMOPOIETIC TISSUE 
2 
B672.00 MEGAKARYOCYTIC LEUKAEMIA 2 
B67..00 OTHER SPECIFIED LEUKAEMIA 2 
B142000 MALIGNANT NEOPLASM OF CLOACOGENIC 
ZONE 
2 
B521000 MALIGNANT NEOPLASM OF CEREBRAL DURA 
MATER 
2 
Byu2500 [X]MALIGNANT NEOPLASM OF MEDIASTINUM, 
PART UNSPECIFIED 
2 
B337200 MALIGNANT NEOPLASM OF SKIN OF KNEE 2 
B612400 HODGKIN'S SARCOMA OF LYMPH NODES OF 
AXILLA AND UPPER LIMB 
2 
B211.00 MALIGNANT NEOPLASM OF SUPRA-GLOTTIS 2 
B337500 MALIGNANT NEOPLASM OF SKIN OF ANKLE 2 
B333300 MALIGNANT NEOPLASM OF SKIN OF FOREHEAD 2 
B17z.00 MALIGNANT NEOPLASM OF PANCREAS NOS 2 
B524400 MALIGNANT NEOPLASM OF PERIPHERAL 
NERVE OF ABDOMEN 
2 
B011000 MALIGNANT NEOPLASM OF ANTERIOR 2/3 OF 
TONGUE DORSAL SURFACE 
2 
B501100 MALIGNANT NEOPLASM OF EXTRAOCULAR 
MUSCLE OF ORBIT 
2 
B073z00 MALIGNANT NEOPLASM OF ANTERIOR WALL 
OF NASOPHARYNX NOS 
2 
B06yz00 MALIGNANT NEOPLASM OF OTHER SPECIFIED 
SITE OF OROPHARYNX NOS 
2 
B64y000 ALEUKAEMIC LYMPHOID LEUKAEMIA 2 
B062200 MALIGNANT NEOPLASM OF PALATOGLOSSAL 
ARCH 
2 
B553.00 MALIGNANT NEOPLASM OF PELVIS 2 




B622000 SEZARY'S DISEASE OF UNSPECIFIED SITE 2 
B32y000 OVERLAPPING MALIGNANT MELANOMA OF 
SKIN 
2 
B47z.00 MALIGNANT NEOPLASM OF TESTIS NOS 2 
B517100 MALIGNANT NEOPLASM OF MEDULLA 
OBLONGATA 
2 
B337700 MALIGNANT NEOPLASM OF SKIN OF FOOT 2 
B500300 MALIGNANT NEOPLASM OF SCLERA 2 
B32z.00 MALIGNANT MELANOMA OF SKIN NOS 2 
B4A..00 MALIGNANT NEOPLASM OF KIDNEY AND 
OTHER UNSPECIFIED URINARY ORGANS 
2 
B615600 HODGKIN'S MIXED CELLULARITY OF 
INTRAPELVIC LYMPH NODES 
2 
B623100 MALIGNANT HISTIOCYTOSIS OF LYMPH NODES 
HEAD, FACE AND NECK 
2 
B514.00 MALIGNANT NEOPLASM OF OCCIPITAL LOBE 2 
B515100 MALIGNANT NEOPLASM OF FLOOR OF 
CEREBRAL VENTRICLE 
2 
B315200 MALIGNANT NEOPLASM OF CONNECTIVE AND 
SOFT TISSUE OF PERINEUM 
2 
Byu5000 [X]MESOTHELIOMA OF OTHER SITES 2 
B325500 MALIGNANT MELANOMA OF PERINEUM 2 
B524.00 MALIGNANT NEOPLASM PERIPHERAL NERVES 
AND AUTONOMIC NERVOUS SYSTEM 
2 
B315z00 MALIGNANT NEOPLASM OF CONNECTIVE AND 
SOFT TISSUE OF PELVIS NOS 
2 
B517.00 MALIGNANT NEOPLASM OF BRAIN STEM 2 
B303400 MALIGNANT NEOPLASM OF COSTO-VERTEBRAL 
JOINT 
2 
B524100 MALIGNANT NEOPLASM OF PERIPHERAL 





B627400 DIFFUSE NON-HODGKIN'S SMALL CLEAVED 
CELL (DIFFUSE) LYMPHOMA 
2 
B323.00 MALIGNANT MELANOMA OF OTHER AND 
UNSPECIFIED PARTS OF FACE 
2 
B450000 MALIGNANT NEOPLASM OF GARTNER'S DUCT 2 
B444.00 MALIGNANT NEOPLASM OF ROUND LIGAMENT 2 
B3y..00 MALIGNANT NEOPLASM OF BONE, 
CONNECTIVE TISSUE, SKIN AND BREAST OS 
2 
B30..00 MALIGNANT NEOPLASM OF BONE AND 
ARTICULAR CARTILAGE 
2 
B45y000 MALIGNANT NEOPLASM OF OVERLAPPING 
LESION OF VULVA 
2 
B175.00 MALIGNANT NEOPLASM, OVERLAPPING LESION 
OF PANCREAS 
2 
B174.00 MALIGNANT NEOPLASM OF ISLETS OF 
LANGERHANS 
2 
B4Az.00 MALIGNANT NEOPLASM OF KIDNEY OR 
URINARY ORGANS NOS 
2 
B335000 MALIGNANT NEOPLASM OF SKIN OF AXILLARY 
FOLD 
2 
B056.00 MALIGNANT NEOPLASM OF RETROMOLAR 
AREA 
2 
B452.00 MALIGNANT NEOPLASM OF LABIA MINORA 2 
B03..00 MALIGNANT NEOPLASM OF GUM 2 
B18y600 MALIGNANT NEOPLASM OF THE POUCH OF 
DOUGLAS 
2 
B627600 DIFFUSE NON-HODGKIN'S IMMUNOBLASTIC 
(DIFFUSE) LYMPHOMA 
2 
ZV10700 [V]PERSONAL HISTORY OTHER 
LYMPHATIC/HAEMATOPOIETIC NEOPLASM 
2 






B336200 MALIGNANT NEOPLASM OF SKIN OF FORE-ARM 2 
B611z00 HODGKIN'S GRANULOMA NOS 2 
ZV10y16 [V]PERSONAL HISTORY OF MALIGNANT 
NEOPLASM OF TONGUE 
2 
B62z.00 MALIGNANT NEOPLASMS OF LYMPHOID AND 
HISTIOCYTIC TISSUE NOS 
2 
B140.00 MALIGNANT NEOPLASM OF RECTOSIGMOID 
JUNCTION 
2 
B681.00 CHRONIC LEUKAEMIA NOS 2 
ZV10011 [V]PERSONAL HISTORY OF MALIGNANT 
NEOPLASM OF ANUS 
2 
B341.00 MALIGNANT NEOPLASM OF CENTRAL PART OF 
FEMALE BREAST 
2 
B0zy.00 MALIGNANT NEOPLASM OF OTHER SITES LIP, 
ORAL CAVITY, PHARYNX 
2 
B300z00 MALIGNANT NEOPLASM OF BONES OF SKULL 
AND FACE NOS 
2 
B431z00 MALIGNANT NEOPLASM OF ISTHMUS OF 
UTERINE BODY NOS 
2 
B062z00 MALIGNANT NEOPLASM OF TONSILLAR FOSSA 
NOS 
2 
B004000 MALIGNANT NEOPLASM OF LIP UNSPECIFIED, 
BUCCAL ASPECT 
2 
B4A2.00 MALIGNANT NEOPLASM OF URETER 2 
B310z00 MALIGNANT NEOPLASM CONNECTIVE AND 
SOFT TISSUE HEAD, FACE, NECK NOS 
2 
B003100 MALIGNANT NEOPLASM OF LOWER LIP, 
FRENULUM 
2 
B223100 MALIGNANT NEOPLASM OF MIDDLE LOBE OF 
LUNG 
2 
B182.00 OVERLAPPING MALIGN LESION OF 





B305600 MALIGNANT NEOPLASM OF CARPAL BONE - 
CAPITATE 
2 
B651z00 CHRONIC MYELOID LEUKAEMIA NOS 2 
B003300 MALIGNANT NEOPLASM OF LOWER LIP, ORAL 
ASPECT 
2 
B002200 MALIGNANT NEOPLASM OF UPPER LIP, 
MUCOSA 
2 
B060000 MALIGNANT NEOPLASM OF FAUCIAL TONSIL 2 
B521.00 MALIGNANT NEOPLASM OF CEREBRAL 
MENINGES 
2 
B00z.00 MALIGNANT NEOPLASM OF VERMILION 
BORDER OF LIP UNSPECIFIED 
2 
B431.00 MALIGNANT NEOPLASM OF ISTHMUS OF 
UTERINE BODY 
2 
ZV10012 [V]PERSONAL HISTORY OF MALIGNANT 






B470000 MALIGNANT NEOPLASM OF ECTOPIC TESTIS 2 
B304300 MALIGNANT NEOPLASM OF RADIUS 2 
B11y000 MALIGNANT NEOPLASM OF ANTERIOR WALL 
OF STOMACH NEC 
2 
B600400 RETICULO-SARCOMA OF LYMPH NODES OF 
AXILLA AND UPPER LIMB 
2 
B117.00 MALIGNANT NEOPLASM, OVERLAPPING LESION 
OF STOMACH 
2 
B305800 MALIGNANT NEOPLASM OF FIRST 
METACARPAL BONE 
2 
B611000 HODGKIN'S GRANULOMA OF UNSPECIFIED SITE 2 




B100.00 MALIGNANT NEOPLASM OF CERVICAL 
OESOPHAGUS 
2 
B62y400 MALIGNANT LYMPHOMA NOS OF LYMPH 
NODES OF AXILLA AND ARM 
2 
B430000 MALIGNANT NEOPLASM OF CORNU OF CORPUS 
UTERI 
2 
B507100 MALIGNANT NEOPLASM OF NASOLACRIMAL 
DUCT 
2 
B612500 HODGKIN'S SARCOMA OF LYMPH NODES OF 
INGUINAL REGION AND LEG 
2 
B61zz00 HODGKIN'S DISEASE NOS 2 
B303200 MALIGNANT NEOPLASM OF CLAVICLE 2 
B601700 LYMPHOSARCOMA OF SPLEEN 2 
B66z.00 MONOCYTIC LEUKAEMIA NOS 2 
B180.00 MALIGNANT NEOPLASM OF 
RETROPERITONEUM 
2 
B60z.00 RETICULO-SARCOMA OR LYMPHOSARCOMA 
NOS 
2 
B50z.00 MALIGNANT NEOPLASM OF EYE NOS 2 
B620500 NODULAR LYMPHOMA OF LYMPH NODES OF 
INGUINAL REGION AND LEG 
2 
B600.00 RETICULO-SARCOMA 2 
B516.00 MALIGNANT NEOPLASM OF CEREBELLUM 2 
B523.00 MALIGNANT NEOPLASM OF SPINAL MENINGES 2 
B001z00 MALIGNANT NEOPLASM OF LOWER LIP, 
VERMILION BORDER NOS 
2 
Byu1100 [X]OTHER SPECIFIED CARCINOMAS OF LIVER 2 
B1...11 CARCINOMA OF DIGESTIVE ORGANS AND 
PERITONEUM 
2 
B52W.00 MALIGNANT NEOPLASM, OVERLAP LESION 





B616800 HODGKIN'S LYMPHOCYTIC DEPLETION LYMPH 
NODES MULTIPLE SITES 
2 
B49y000 MALIGNANT NEOPLASM, OVERLAPPING LESION 
OF BLADDER 
2 
B067.00 MALIGNANT NEOPLASM OF POSTERIOR WALL 
OF OROPHARYNX 
2 
B621z00 MYCOSIS FUNGOIDES NOS 2 
B624400 LEUKAEMIC RETICULOEND OF LYMPH NODES 
OF AXILLA AND ARM 
2 
B4y..00 MALIGNANT NEOPLASM OF GENITOURINARY 
ORGAN OS 
2 
B65z.00 MYELOID LEUKAEMIA NOS 2 
B110100 MALIGNANT NEOPLASM OF CARDIO-
OESOPHAGEAL JUNCTION OF STOMACH 
2 
B302.00 MALIGNANT NEOPLASM OF VERTEBRAL 
COLUMN 
2 
B011100 MALIGNANT NEOPLASM OF MIDLINE OF 
TONGUE 
2 
B334z00 MALIGNANT NEOPLASM OF SCALP OR SKIN OF 
NECK NOS 
2 
B011.00 MALIGNANT NEOPLASM OF DORSAL SURFACE 
OF TONGUE 
2 
B64y200 ADULT T-CELL LEUKAEMIA 2 
ByuD300 [X]OTHER SPECIFIED TYPES OF NON-HODGKIN'S 
LYMPHOMA 
2 
B337800 MALIGNANT NEOPLASM OF SKIN OF TOE 2 
B610800 HODGKIN'S PARAGRANULOMA OF LYMPH 
NODES OF MULTIPLE SITES 
2 
B23y.00 MALIGNANT NEOPLASM OF OTHER SPECIFIED 
PLEURA 
2 






B17..00 MALIGNANT NEOPLASM OF PANCREAS 2 
B1z2.00 MALIGNANT NEOPLASM, OVERLAPPING LESION 
OF DIGESTIVE SYSTEM 
2 
B063.00 MALIGNANT NEOPLASM OF VALLECULA 2 
B623300 MALIGNANT HISTIOCYTOSIS OF INTRA-
ABDOMINAL LYMPH NODES 
2 
B313100 MALIGNANT NEOPLASM OF DIAPHRAGM 2 
B303500 MALIGNANT NEOPLASM OF XIPHOID PROCESS 2 
B64..00 LYMPHOID LEUKAEMIA 2 
B150100 HEPATOBLASTOMA OF LIVER 2 
B49z.00 MALIGNANT NEOPLASM OF URINARY BLADDER 
NOS 
2 
B48..00 MALIGNANT NEOPLASM OF PENIS AND OTHER 
MALE GENITAL ORGANS 
2 
B682.00 SUBACUTE LEUKAEMIA NOS 2 
B450100 MALIGNANT NEOPLASM OF VAGINAL VAULT 2 
B602800 BURKITT'S LYMPHOMA OF LYMPH NODES OF 
MULTIPLE SITES 
2 
B620400 NODULAR LYMPHOMA OF LYMPH NODES OF 
AXILLA AND UPPER LIMB 
2 
B302200 MALIGNANT NEOPLASM OF LUMBAR 
VERTEBRA 
2 
B62y000 MALIGNANT LYMPHOMA NOS OF UNSPECIFIED 
SITE 
2 
B347.00 MALIGNANT NEOPLASM, OVERLAPPING LESION 
OF BREAST 
2 
B22z.00 MALIGNANT NEOPLASM OF BRONCHUS OR 
LUNG NOS 
2 
B625000 LETTERER-SIWE DISEASE OF UNSPECIFIED 
SITES 
2 
B323300 MALIGNANT MELANOMA OF FOREHEAD 2 




B223000 MALIGNANT NEOPLASM OF MIDDLE LOBE 
BRONCHUS 
2 
B471000 SEMINOMA OF DESCENDED TESTIS 2 
B615800 HODGKIN'S MIXED CELLULARITY OF LYMPH 
NODES OF MULTIPLE SITES 
2 
B17y.00 MALIGNANT NEOPLASM OF OTHER SPECIFIED 
SITES OF PANCREAS 
2 
B213.00 MALIGNANT NEOPLASM OF LARYNGEAL 
CARTILAGE 
2 
B062300 MALIGNANT NEOPLASM OF 
PALATOPHARYNGEAL ARCH 
2 
B68z.00 LEUKAEMIA NOS 2 
B610400 HODGKIN'S PARAGRANULOMA OF LYMPH 
NODES OF AXILLA AND ARM 
2 
B18y000 MALIGNANT NEOPLASM OF MESOCOLON 2 
B61z300 HODGKIN'S DISEASE NOS OF INTRA-
ABDOMINAL LYMPH NODES 
2 
ZV10712 [V]PERSONAL HISTORY OF LYMPHOSARCOMA 2 
B002300 MALIGNANT NEOPLASM OF UPPER LIP, ORAL 
ASPECT 
2 
B1zy.00 MALIGNANT NEOPLASM OTHER SPEC 
DIGESTIVE TRACT AND PERITONEUM 
2 
B442.00 MALIGNANT NEOPLASM OF BROAD LIGAMENT 2 
B042.00 MALIGNANT NEOPLASM, OVERLAPPING LESION 
OF FLOOR OF MOUTH 
2 
Byu1.00 [X]MALIGNANT NEOPLASM OF DIGESTIVE 
ORGANS 
2 
B12z.00 MALIGNANT NEOPLASM OF SMALL INTESTINE 
NOS 
2 
B21z.00 MALIGNANT NEOPLASM OF LARYNX NOS 2 






B08..00 MALIGNANT NEOPLASM OF HYPOPHARYNX 2 
B111100 MALIGNANT NEOPLASM OF PYLORIC CANAL OF 
STOMACH 
2 
B317.00 MALIGNANT NEOPLASM, OVERLAP LESION 
CONNECTIVE & SOFT TISSUE 
2 
B13z.00 MALIGNANT NEOPLASM OF COLON NOS 2 
B10..00 MALIGNANT NEOPLASM OF OESOPHAGUS 2 
B301.00 MALIGNANT NEOPLASM OF MANDIBLE 2 
B335500 MALIGNANT NEOPLASM OF SKIN OF GROIN 2 
B306100 MALIGNANT NEOPLASM OF ISCHIUM 2 
B335A00 MALIGNANT NEOPLASM OF SKIN OF SCAPULAR 
REGION 
2 
B325800 MALIGNANT MELANOMA OF CHEST WALL 2 
B327800 MALIGNANT MELANOMA OF TOE 2 
B623600 MALIGNANT HISTIOCYTOSIS OF INTRAPELVIC 
LYMPH NODES 
2 
Byu4300 [X]MALIGNANT NEOPLASM OF SKIN, 
UNSPECIFIED 
2 
ZV10y13 [V]PERSONAL HISTORY OF MALIGNANT 
NEOPLASM OF EYE 
2 
B304200 MALIGNANT NEOPLASM OF HUMERUS 2 
B04z.00 MALIGNANT NEOPLASM OF FLOOR OF MOUTH 
NOS 
2 
ZV10111 [V]PERSONAL HISTORY OF MALIGNANT 
NEOPLASM OF BRONCHUS 
2 
B550400 MALIGNANT NEOPLASM OF NECK NOS 2 
B551000 MALIGNANT NEOPLASM OF AXILLA NOS 2 
B670.11 DI GUGLIELMO'S DISEASE 2 
B620.00 NODULAR LYMPHOMA (BRILL - SYMMERS 
DISEASE) 
2 






B66..12 MONOBLASTIC LEUKAEMIA 2 
B652.00 SUBACUTE MYELOID LEUKAEMIA 2 
B63y.00 OTHER IMMUNOPROLIFERATIVE NEOPLASMS 2 
B630000 MALIGNANT PLASMA CELL NEOPLASM, 
EXTRAMEDULLARY PLASMACYTOMA 
2 
B11z.00 MALIGNANT NEOPLASM OF STOMACH NOS 2 
B48z.00 MALIGNANT NEOPLASM OF PENIS AND OTHER 
MALE GENITAL ORGAN NOS 
2 
B540.00 MALIGNANT NEOPLASM OF ADRENAL GLAND 2 
B312100 MALIGNANT NEOPLASM OF CONNECTIVE AND 
SOFT TISSUE THIGH AND UPPER LEG 
2 
B626100 MAST CELL MALIGNANCY OF LYMPH NODES OF 
HEAD, FACE AND NECK 
2 
B305D00 MALIGNANT NEOPLASM OF PHALANGES OF 
HAND 
2 
B223z00 MALIGNANT NEOPLASM OF MIDDLE LOBE, 
BRONCHUS OR LUNG NOS 
2 
B623700 MALIGNANT HISTIOCYTOSIS OF SPLEEN 2 
B0...11 CARCINOMA OF LIP, ORAL CAVITY AND 
PHARYNX 
2 
B222000 MALIGNANT NEOPLASM OF UPPER LOBE 
BRONCHUS 
2 
B327z00 MALIGNANT MELANOMA OF LOWER LIMB OR 
HIP NOS 
2 
B55yz00 MALIGNANT NEOPLASM OF SPECIFIED SITE NOS 2 
B013100 MALIGNANT NEOPLASM OF FRENULUM 
LINGUAE 
2 
Byu7300 [X]MALIGNANT NEOPLASM OF FEMALE 
GENITAL ORGAN, UNSPECIFIED 
2 
B023.00 MALIGNANT NEOPLASM, OVERLAPPING LESION 





B310500 MALIGNANT NEOPLASM SOFT TISSUES OF 
CERVICAL SPINE 
2 
Byu5600 [X]MAL NEOPLASM/PERIPH NERVES NERVOUS 
SYSTEM, UNSPECIFIC 
2 
ByuD000 [X]OTHER HODGKIN'S DISEASE 2 
B552.00 MALIGNANT NEOPLASM OF ABDOMEN 2 
B520z00 MALIGNANT NEOPLASM OF CRANIAL NERVES 
NOS 
2 
B082.00 MALIGNANT NEOPLASM ARYEPIGLOTTIC FOLD, 
HYPOPHARYNGEAL ASPECT 
2 
B625.11 HISTIOCYTOSIS X (ACUTE, PROGRESSIVE) 2 
B312000 MALIGNANT NEOPLASM OF CONNECTIVE AND 
SOFT TISSUE OF HIP 
2 
B501000 MALIGNANT NEOPLASM OF CONNECTIVE 
TISSUE OF ORBIT 
2 
B201200 MALIGNANT NEOPLASM OF TYMPANIC 
ANTRUM 
2 
B241400 MESOTHELIOMA OF PERICARDIUM 2 
ByuC000 [X]MALIGNANT NEOPLASM OF OTHER 
SPECIFIED SITES 
2 
B67z.00 OTHER SPECIFIED LEUKAEMIA NOS 2 
B18y.00 MALIGNANT NEOPLASM OF SPECIFIED PARTS 
OF PERITONEUM 
2 
B620z00 NODULAR LYMPHOMA NOS 2 
B327200 MALIGNANT MELANOMA OF KNEE 2 
B53..00 MALIGNANT NEOPLASM OF THYROID GLAND 2 
B545200 MALIGNANT NEOPLASM OF COCCYGEAL BODY 2 
B65yz00 OTHER MYELOID LEUKAEMIA NOS 2 
B431000 MALIGNANT NEOPLASM OF LOWER UTERINE 
SEGMENT 
2 




B337900 MALIGNANT NEOPLASM OF SKIN OF GREAT 
TOE 
2 
B308600 MALIGNANT NEOPLASM OF CUBOID 2 
Byu2100 [X]MALIGNANT NEOPLASM/OVERLAP 
LESION/HEART, MEDIASTINUM 
2 
B62x300 MALIGNANT RETICULO-ENDOTHELIOSIS 2 
ZV10100 [V]PERSONAL HISTORY OF MALIGNANT 
NEOPLASM OF TRACHEA/BRONCHUS/LUNG 
2 
B000100 MALIGNANT NEOPLASM OF UPPER LIP, 
LIPSTICK AREA 
2 
B611700 HODGKIN'S GRANULOMA OF SPLEEN 2 
B061.00 MALIGNANT NEOPLASM OF TONSILLAR FOSSA 2 
Byu8.00 [X]MALIGNANT NEOPLASM OF MALE GENITAL 
ORGANS 
2 
B335700 MALIGNANT NEOPLASM OF SKIN OF BACK 2 
Byu9000 [X]MALIGNANT NEOPLASM OF URINARY 
ORGAN, UNSPECIFIED 
2 
B65y000 ALEUKAEMIC MYELOID LEUKAEMIA 2 
B01z.00 MALIGNANT NEOPLASM OF TONGUE NOS 2 
B33z000 KAPOSI'S SARCOMA OF SKIN 2 
B41y.00 MALIGNANT NEOPLASM OF OTHER SITE OF 
CERVIX 
2 
B43z.00 MALIGNANT NEOPLASM OF BODY OF UTERUS 
NOS 
2 
B517300 MALIGNANT NEOPLASM OF PONS 2 
B201100 MALIGNANT NEOPLASM OF TYMPANIC CAVITY 2 
B20..00 MALIGNANT NEOPLASM NASAL CAVITIES, 
MIDDLE EAR AND ACCESSORY SINUSES 
2 
B143.00 MALIGNANT NEOPLASM OF ANUS UNSPECIFIED 2 
B623z00 MALIGNANT HISTIOCYTOSIS NOS 2 
B14..00 MALIGNANT NEOPLASM OF RECTUM, 





B520100 MALIGNANT NEOPLASM OF OPTIC NERVE 2 
B485.00 MALIGNANT NEOPLASM OF SPERMATIC CORD 2 
B510500 MALIGNANT NEOPLASM OF THALAMUS 2 
B540000 MALIGNANT NEOPLASM OF ADRENAL CORTEX 2 
B314000 MALIGNANT NEOPLASM OF CONNECTIVE AND 
SOFT TISSUE OF ABDOMINAL WALL 
2 
B308D00 MALIGNANT NEOPLASM OF PHALANGES OF 
FOOT 
2 
B48y200 MALIGNANT NEOPLASM, OVERLAPPING LESION 
MALE GENITAL ORGS 
2 
B050.11 MALIGNANT NEOPLASM OF BUCCAL MUCOSA 2 
B003z00 MALIGNANT NEOPLASM OF LOWER LIP, INNER 
ASPECT NOS 
2 
B612300 HODGKIN'S SARCOMA OF INTRA-ABDOMINAL 
LYMPH NODES 
2 
ZV10513 [V]PERSONAL HISTORY OF MALIGNANT 
NEOPLASM OF KIDNEY 
2 
B450z00 MALIGNANT NEOPLASM OF VAGINA NOS 2 
B62z000 UNSPECIFIED MALIGNANT NEOPLASM 
LYMPHOID/HISTIOCYTIC OF UNSPECIFIED SITE 
2 
B020.00 MALIGNANT NEOPLASM OF PAROTID GLAND 2 
B67y.00 OTHER AND UNSPECIFIED LEUKAEMIA 2 
B000z00 MALIGNANT NEOPLASM OF UPPER LIP, 
VERMILION BORDER NOS 
2 
B622800 SEZARY'S DISEASE OF LYMPH NODES OF 
MULTIPLE SITES 
2 
B01y.00 MALIGNANT NEOPLASM OF OTHER SITES OF 
TONGUE 
2 
B64y.00 OTHER LYMPHOID LEUKAEMIA 2 
B055000 MALIGNANT NEOPLASM OF JUNCTION OF HARD 





B051.00 MALIGNANT NEOPLASM OF VESTIBULE OF 
MOUTH 
2 
B614100 HODGKIN'S NODULAR SCLEROSIS OF HEAD, 
FACE AND NECK 
2 
B004200 MALIGNANT NEOPLASM OF LIP UNSPECIFIED, 
MUCOSA 
2 
B05z.00 MALIGNANT NEOPLASM OF MOUTH NOS 2 
B497.00 MALIGNANT NEOPLASM OF URACHUS 2 
B073.00 MALIGNANT NEOPLASM OF ANTERIOR WALL 
OF NASOPHARYNX 
2 
B670.00 ACUTE ERYTHRAEMIA AND ERYTHRON-
LEUKAEMIA 
2 
B24X.00 MALIGNANT NEOPLASM OF MEDIASTINUM, 
PART UNSPECIFIED 
2 
B45z.00 MALIGNANT NEOPLASM OF FEMALE GENITAL 
ORGAN NOS 
2 
B221000 MALIGNANT NEOPLASM OF CARINA OF 
BRONCHUS 
2 
B138.00 MALIGNANT NEOPLASM, OVERLAPPING LESION 
OF COLON 
2 
B451.00 MALIGNANT NEOPLASM OF LABIA MAJORA 2 
B512000 MALIGNANT NEOPLASM OF HIPPOCAMPUS 2 
B620100 NODULAR LYMPHOMA OF LYMPH NODES OF 
HEAD, FACE AND NECK 
2 
B310300 MALIGNANT NEOPLASM OF CARTILAGE OF EAR 2 
B002000 MALIGNANT NEOPLASM OF UPPER LIP, BUCCAL 
ASPECT 
2 
B430200 MALIGNANT NEOPLASM OF ENDOMETRIUM OF 
CORPUS UTERI 
2 
B002z00 MALIGNANT NEOPLASM OF UPPER LIP, INNER 
ASPECT NOS 
2 




B062.00 MALIGNANT NEOPLASM OF TONSILLAR PILLAR 2 
ZV10200 [V]PERSONAL HISTORY OF MALIGNANT 
NEOPLASM OTHER INTRATHORACIC ORGAN 
2 
B24z.00 MALIGNANT NEOPLASM OF HEART, THYMUS 
AND MEDIASTINUM NOS 
2 
B307000 MALIGNANT NEOPLASM OF FEMUR 2 
B308200 MALIGNANT NEOPLASM OF CALCANEUM 2 
B308A00 MALIGNANT NEOPLASM OF THIRD 
METATARSAL BONE 
2 
B022.00 MALIGNANT NEOPLASM OF SUBLINGUAL 
GLAND 
2 
B32..00 MALIGNANT MELANOMA OF SKIN 2 
B627200 FOLLICULAR NON-HODGKIN'S LARGE CELL 
LYMPHOMA 
2 
B600600 RETICULO-SARCOMA OF INTRAPELVIC LYMPH 
NODES 
2 
B630.11 KAHLER'S DISEASE 2 
B335z00 MALIGNANT NEOPLASM OF SKIN OF TRUNK, 
EXCLUDING SCROTUM, NOS 
2 
B111000 MALIGNANT NEOPLASM OF PREPYLORUS OF 
STOMACH 
2 
B35z000 MALIGNANT NEOPLASM OF ECTOPIC SITE OF 
MALE BREAST 
2 
B055z00 MALIGNANT NEOPLASM OF PALATE NOS 2 
B11y100 MALIGNANT NEOPLASM OF POSTERIOR WALL 
OF STOMACH NEC 
2 
B300200 MALIGNANT NEOPLASM OF MALAR BONE 2 
B50..00 MALIGNANT NEOPLASM OF EYE 2 
B123.00 MALIGNANT NEOPLASM OF MECKEL'S 
DIVERTICULUM 
2 
B50y.00 MALIGNANT NEOPLASM OF OTHER SPECIFIED 





B071z00 MALIGNANT NEOPLASM OF POSTERIOR WALL 
OF NASOPHARYNX NOS 
2 
B625500 LETTERER-SIWE DISEASE OF LYMPH NODES 
INGUINAL REGION AND LEG 
2 
B51y200 MALIGNANT NEOPLASM, OVERLAPPING LESION 
OF BRAIN 
2 
B054.00 MALIGNANT NEOPLASM OF UVULA 2 
B120.00 MALIGNANT NEOPLASM OF DUODENUM 2 
B553000 MALIGNANT NEOPLASM OF INGUINAL REGION 
NOS 
2 
ZV10.00 [V]PERSONAL HISTORY OF MALIGNANT 
NEOPLASM 
2 
B23z.00 MALIGNANT NEOPLASM OF PLEURA NOS 2 
ZV10016 [V]PERSONAL HISTORY OF MALIGNANT 
NEOPLASM OF OESOPHAGUS 
2 
B602300 BURKITT'S LYMPHOMA OF INTRA-ABDOMINAL 
LYMPH NODES 
2 
B54..00 MALIGNANT NEOPLASM OF OTHER ENDOCRINE 
GLANDS AND RELATED STRUCTURES 
2 
B22..00 MALIGNANT NEOPLASM OF TRACHEA, 
BRONCHUS AND LUNG 
2 
B61z500 HODGKIN'S DISEASE NOS OF LYMPH NODES 
INGUINAL REGION AND LEG 
2 
B51..00 MALIGNANT NEOPLASM OF BRAIN 2 
B600200 RETICULO-SARCOMA OF INTRATHORACIC 
LYMPH NODES 
2 
B35..00 MALIGNANT NEOPLASM OF MALE BREAST 2 
B602000 BURKITT'S LYMPHOMA OF UNSPECIFIED SITE 2 
Byu8100 [X]MALIGNANT NEOPLASM/OVERLAPPING 
LESION/MALE GENITAL ORGANS 
2 




Byu4100 [X]MALIGNANT MELANOMA OF SKIN, 
UNSPECIFIED 
2 
ZV10412 [V]PERSONAL HISTORY OF MALIGNANT 
NEOPLASM OF GENITAL ORGAN 
2 
B621.00 MYCOSIS FUNGOIDES 2 
B62z100 UNSPECIFIED MALIGNANT NEOPLASM 
LYMPHOID/HISTIOCYTIC LYMPH NODE 
HEAD/NECK 
2 
B25..00 MALIGNANT NEOPLASM, OVERLAPPING LESION 
OF HEART, MEDIASTINUM & PLEURA 
2 
ZV10017 [V]PERSONAL HISTORY OF MALIGNANT 
NEOPLASM OF RECTUM 
2 
B623000 MALIGNANT HISTIOCYTOSIS OF UNSPECIFIED 
SITE 
2 
B6y..00 MALIGNANT NEOPLASM LYMPHATIC OR 
HAEMATOPOIETIC TISSUE OS 
2 
B627300 DIFFUSE NON-HODGKIN'S SMALL CELL 
(DIFFUSE) LYMPHOMA 
2 
B308000 MALIGNANT NEOPLASM OF PATELLA 2 
B610100 HODGKIN'S PARAGRANULOMA OF LYMPH 
NODES OF HEAD, FACE, NECK 
2 
ZV10500 [V]PERSONAL HISTORY OF MALIGNANT 
NEOPLASM OF URINARY ORGAN 
2 
B51y000 MALIGNANT NEOPLASM OF CORPUS 
CALLOSUM 
2 
B523000 MALIGNANT NEOPLASM OF SPINAL DURA 
MATER 
2 
B310100 MALIGNANT NEOPLASM OF SOFT TISSUE OF 
FACE 
2 
B051100 MALIGNANT NEOPLASM OF LOWER BUCCAL 
SULCUS 
2 




B555.00 MALIGNANT NEOPLASM OF LOWER LIMB NOS 2 
B35zz00 MALIGNANT NEOPLASM OF MALE BREAST NOS 2 
B326500 MALIGNANT MELANOMA OF THUMB 2 
B1zz.00 MALIGNANT NEOPLASM OF DIGESTIVE TRACT 
AND PERITONEUM NOS 
2 
B332.00 MALIGNANT NEOPLASM SKIN OF EAR AND 
EXTERNAL AURICULAR CANAL 
2 
ZV10019 [V]PERSONAL HISTORY OF MALIGNANT 
NEOPLASM OF TONGUE 
2 
B335900 MALIGNANT NEOPLASM OF PERIANAL SKIN 2 
Byu1300 [X] MALIGNANT NEOPLASM /ILL-DEFINED SITES 
WITHIN DIGESTIVE SYSTEM 
2 
B013z00 MALIGNANT NEOPLASM OF VENTRAL TONGUE 
SURFACE NOS 
2 
B601400 LYMPHOSARCOMA OF LYMPH NODES OF 
AXILLA AND UPPER LIMB 
2 
B323500 MALIGNANT MELANOMA OF TEMPLE 2 
B51..11 CEREBRAL TUMOUR - MALIGNANT 2 
B226.00 MESOTHELIOMA 2 
B0...00 MALIGNANT NEOPLASM OF LIP, ORAL CAVITY 
AND PHARYNX 
2 
B26..00 MALIGNANT NEOPLASM, OVERLAP LESION OF 
RESPIRATORY & INTRATHORACIC ORGANS 
2 
B220z00 MALIGNANT NEOPLASM OF TRACHEA NOS 2 
B62z500 UNSPECIFIED MALIGNANT NEOPLASM 
LYMPHOID/HISTIOCYTIC NODES INGUINAL/LEG 
2 
B616400 HODGKIN'S LYMPHOCYTIC DEPLETION LYMPH 
NODES AXILLA AND ARM 
2 
B611.00 HODGKIN'S GRANULOMA 2 
B16..00 MALIGNANT NEOPLASM GALLBLADDER AND 





B553100 MALIGNANT NEOPLASM OF PRESACRAL 
REGION 
2 
B332z00 MALIGNANT NEOPLASM SKIN OF EAR AND 
EXTERNAL AURICULAR CANAL NOS 
2 
B333200 MALIGNANT NEOPLASM OF SKIN OF EYEBROW 2 
B2z0.00 MALIGNANT NEOPLASM OF UPPER 
RESPIRATORY TRACT, PART UNSPECIFIED 
2 
B501z00 MALIGNANT NEOPLASM OF ORBIT NOS 2 
B300500 MALIGNANT NEOPLASM OF ORBITAL BONE 2 
B521z00 MALIGNANT NEOPLASM OF CEREBRAL 
MENINGES NOS 
2 
B624200 LEUKAEMIC RETICULOENDOTHELIOSIS OF 
INTRATHORACIC LYMPH NODES 
2 
B305.00 MALIGNANT NEOPLASM OF HAND BONES 2 
B315.00 MALIGNANT NEOPLASM OF CONNECTIVE AND 
SOFT TISSUE OF PELVIS 
2 
B615300 HODGKIN'S MIXED CELLULARITY OF INTRA-
ABDOMINAL LYMPH NODES 
2 
B200300 MALIGNANT NEOPLASM OF VESTIBULE OF 
NOSE 
2 
ZV10417 [V]PERSONAL HISTORY OF MALIGNANT 
NEOPLASM OF UTERINE BODY 
2 
B060.00 MALIGNANT NEOPLASM OF TONSIL 2 
B627C00 FOLLICULAR NON-HODGKIN'S LYMPHOMA 2 
B136.00 MALIGNANT NEOPLASM OF ASCENDING COLON 2 
B221.00 MALIGNANT NEOPLASM OF MAIN BRONCHUS 2 
B615400 HODGKIN'S MIXED CELLULARITY OF LYMPH 
NODES OF AXILLA AND ARM 
2 
B00..00 MALIGNANT NEOPLASM OF LIP 2 
B003000 MALIGNANT NEOPLASM OF LOWER LIP, 
BUCCAL ASPECT 
2 




B303z00 MALIGNANT NEOPLASM OF RIB, STERNUM AND 
CLAVICLE NOS 
2 
B131.00 MALIGNANT NEOPLASM OF TRANSVERSE 
COLON 
2 
Byu5700 [X]MALIGNANT NEOPLASM OF PERITONEUM, 
UNSPECIFIED 
2 
B010000 MALIGNANT NEOPLASM OF BASE OF TONGUE 
DORSAL SURFACE 
2 
B305400 MALIGNANT NEOPLASM OF CARPAL BONE - 
TRAPEZIUM 
2 
B141.11 CARCINOMA OF RECTUM 2 
Byu3.00 [X]MALIGNANT NEOPLASM OF BONE AND 
ARTICULAR CARTILAGE 
2 
B060z00 MALIGNANT NEOPLASM TONSIL NOS 2 
B336500 MALIGNANT NEOPLASM OF SKIN OF THUMB 2 
B300.00 MALIGNANT NEOPLASM OF BONES OF SKULL 
AND FACE 
2 
B625400 LETTERER-SIWE DISEASE OF LYMPH NODES OF 
AXILLA AND ARM 
2 
B624800 LEUKAEMIC RETICULOEND OF LYMPH NODES 
OF MULTIPLE SITES 
2 
B626800 MAST CELL MALIGNANCY OF LYMPH NODES OF 
MULTIPLE SITES 
2 
Byu3100 [X]MALIGNANT NEOPLASM/BONES??? 
CARTILAGE/LIMB, UNSPECIFIC 
2 
B006.00 MALIGNANT NEOPLASM OF OVERLAPPING 
LESION OF LIP 
2 
ZV10413 [V]PERSONAL HISTORY MALIGNANT 
NEOPLASM - MALE GENITAL ORGAN 
2 
ZV10113 [V]PERSONAL HISTORY OF MALIGNANT 





ZV10014 [V]PERSONAL HISTORY OF MALIGNANT 
NEOPLASM OF LARGE INTESTINE 
2 
B62x500 MALIGNANT IMMUNOPROLIFERATIVE SMALL 
INTESTINAL DISEASE 
2 
B470z00 MALIGNANT NEOPLASM OF UNDESCENDED 
TESTIS NOS 
2 
ByuD600 [X]OTHER MYELOID LEUKAEMIA 2 
B616700 HODGKIN'S DISEASE, LYMPHOCYTIC 
DEPLETION OF SPLEEN 
2 
B306200 MALIGNANT NEOPLASM OF PUBIS 2 
B613800 HODGKIN'S, LYMPHOCYTIC-HISTIOCYTIC PRED 
OF MULTIPLE SITES 
2 
B520200 MALIGNANT NEOPLASM OF ACOUSTIC NERVE 2 
B621800 MYCOSIS FUNGOIDES OF LYMPH NODES OF 
MULTIPLE SITES 
2 
B62z800 UNSPECIFIED MALIGNANT NEOPLASM 
LYMPHOID/HISTIOCYTIC OF MULTIPLE SITES 
2 
B622300 SEZARY'S DISEASE OF INTRA-ABDOMINAL 
LYMPH NODES 
2 
B18yz00 MALIGNANT NEOPLASM OF SPECIFIED PARTS 
OF PERITONEUM NOS 
2 
B626.00 MALIGNANT MAST CELL TUMOURS 2 
B324000 MALIGNANT MELANOMA OF SCALP 2 
B621000 MYCOSIS FUNGOIDES OF UNSPECIFIED SITE 2 
B121.00 MALIGNANT NEOPLASM OF JEJUNUM 2 
B1z1000 ANGIOSARCOMA OF SPLEEN 2 
B480.00 MALIGNANT NEOPLASM OF PREPUCE 
(FORESKIN) 
2 
B332100 MALIGNANT NEOPLASM OF SKIN OF EXTERNAL 
AUDITORY MEATUS 
2 
B601.00 LYMPHOSARCOMA 2 




B170.00 MALIGNANT NEOPLASM OF HEAD OF 
PANCREAS 
2 
B325000 MALIGNANT MELANOMA OF AXILLA 2 
B02..00 MALIGNANT NEOPLASM OF MAJOR SALIVARY 
GLANDS 
2 
B051300 MALIGNANT NEOPLASM OF LOWER LABIAL 
SULCUS 
2 
B307.00 MALIGNANT NEOPLASM OF LONG BONES OF 
LEG 
2 
ZV10600 [V]PERSONAL HISTORY OF LEUKAEMIA 2 
B124.00 MALIGNANT NEOPLASM, OVERLAPPING LESION 
OF SMALL INTESTINE 
2 
B611800 HODGKIN'S GRANULOMA OF LYMPH NODES OF 
MULTIPLE SITES 
2 
B614800 HODGKIN'S NODULAR SCLEROSIS OF LYMPH 
NODES OF MULTIPLE SITES 
2 
B62z400 UNSPECIFIED MALIGNANT NEOPLASM 
LYMPHOID/HISTIOCYTIC LYMPH NODE 
AXILLA/ARM 
2 
ZV10212 [V]PERSONAL HISTORY OF MALIGNANT 
NEOPLASM OF LARYNX 
2 
B45y.00 MALIGNANT NEOPLASM OF OTHER SPECIFIED 
FEMALE GENITAL ORGAN 
2 
B007.00 MALIGNANT NEOPLASM OF LIP, UNSPECIFIED 2 
B512z00 MALIGNANT NEOPLASM OF TEMPORAL LOBE 
NOS 
2 
B310400 MALIGNANT NEOPLASM OF TARSUS OF EYELID 2 
B13z.11 COLONIC CANCER 2 
B623800 MALIGNANT HISTIOCYTOSIS OF LYMPH NODES 
OF MULTIPLE SITES 
2 
Byu7100 [X]MALIGNANT NEOPLASM/OTHER SPECIFIED 





B051200 MALIGNANT NEOPLASM OF UPPER LABIAL 
SULCUS 
2 
B430100 MALIGNANT NEOPLASM OF FUNDUS OF 
CORPUS UTERI 
2 
B610500 HODGKIN'S PARA-GRANULOMA LYMPH NODES 
INGUINAL REGION AND LEG 
2 
B223.00 MALIGNANT NEOPLASM OF MIDDLE LOBE, 
BRONCHUS OR LUNG 
2 
B545100 MALIGNANT NEOPLASM OF AORTIC BODY 2 
B08z.00 MALIGNANT NEOPLASM OF HYPOPHARYNX 
NOS 
2 
B152.00 MALIGNANT NEOPLASM OF LIVER 
UNSPECIFIED 
2 
B1...00 MALIGNANT NEOPLASM OF DIGESTIVE 
ORGANS AND PERITONEUM 
2 
B323400 MALIGNANT MELANOMA OF EXTERNAL 
SURFACE OF NOSE 
2 
B615z00 HODGKIN'S DISEASE, MIXED CELLULARITY NOS 2 
B613200 HODGKIN'S, LYMPHOCYTIC-HISTIOCYTIC PRED 
INTRATHORACIC NODES 
2 
B322100 MALIGNANT MELANOMA OF EXTERNAL 
AUDITORY MEATUS 
2 
B321.00 MALIGNANT MELANOMA OF EYELID 
INCLUDING CANTHUS 
2 
B651200 CHRONIC NEUTROPHILIC LEUKAEMIA 2 
Byu..00 [X]ADDITIONAL NEOPLASM CLASSIFICATION 
TERMS 
2 
Byu2000 [X]MALIGNANT NEOPLASM OF BRONCHUS OR 
LUNG, UNSPECIFIED 
2 
B6y1.11 MEGAKARYOCYTIC MYELOSCLEROSIS 2 






B215.00 MALIGNANT NEOPLASM OF EPIGLOTTIS NOS 2 
B0z0.00 MALIGNANT NEOPLASM OF PHARYNX 
UNSPECIFIED 
2 
ByuD800 [X]OTHER SPECIFIED LEUKAEMIAS 2 
B671.00 CHRONIC ERYTHRAEMIA 2 
B624100 LEUKAEMIC RETICULOEND OF LYMPH NODES 
OF HEAD, FACE AND NECK 
2 
B541.00 MALIGNANT NEOPLASM OF PARATHYROID 
GLAND 
2 
B545.00 MALIGNANT NEOPLASM OF AORTIC BODY AND 
OTHER PARAGANGLIA 
2 
ZV10613 [V]PERSONAL HISTORY OF MYELOID 
LEUKAEMIA 
2 
B470200 SEMINOMA OF UNDESCENDED TESTIS 2 
B626600 MAST CELL MALIGNANCY OF INTRAPELVIC 
LYMPH NODES 
2 
ByuA000 [X]MALIGNANT NEOPLASM/OTHER AND 
UNSPECIFIED CRANIAL NERVES 
2 
B6z0.00 KAPOSI'S SARCOMA OF LYMPH NODES 2 
B674.00 ACUTE PANMYELOSIS 2 
B614400 HODGKIN'S NODULAR SCLEROSIS OF LYMPH 
NODES OF AXILLA AND ARM 
2 
B312z00 MALIGNANT NEOPLASM CONNECTIVE AND 
SOFT TISSUE HIP AND LEG NOS 
2 
B06y000 MALIGNANT NEOPLASM OF BRANCHIAL CLEFT 2 
B602400 BURKITT'S LYMPHOMA OF LYMPH NODES OF 
AXILLA AND UPPER LIMB 
2 
B494.00 MALIGNANT NEOPLASM OF POSTERIOR WALL 
OF URINARY BLADDER 
2 
B335600 MALIGNANT NEOPLASM OF SKIN OF PERINEUM 2 
B45..00 MALIGNANT NEOPLASM OF OTHER AND 





B336300 MALIGNANT NEOPLASM OF SKIN OF HAND 2 
B470300 TERATOMA OF UNDESCENDED TESTIS 2 
B3...12 SARCOMA OF BONE AND CONNECTIVE TISSUE 2 
B62y700 MALIGNANT LYMPHOMA NOS OF SPLEEN 2 
B134.00 MALIGNANT NEOPLASM OF CAECUM 2 
B510200 MALIGNANT NEOPLASM OF CORPUS STRIATUM 2 
ZV10512 [V]PERSONAL HISTORY OF MALIGNANT 
NEOPLASM OF KIDNEY 
2 
B615.00 HODGKIN'S DISEASE, MIXED CELLULARITY 2 
Byu5500 [X]MAL NEOPLASM/OVERLAP LES/PERIPHERAL 
NERVE SYSTEM 
2 
B48y.00 MALIGNANT NEOPLASM OF OTHER MALE 
GENITAL ORGAN 
2 
B051000 MALIGNANT NEOPLASM OF UPPER BUCCAL 
SULCUS 
2 
B062000 MALIGNANT NEOPLASM OF FAUCIAL PILLAR 2 
B503.00 MALIGNANT NEOPLASM OF CONJUNCTIVA 2 
ByuD400 [X]OTHER MALIGNANT 
IMMUNOPROLIFERATIVE DISEASES 
2 
B610.00 HODGKIN'S PARAGRANULOMA 2 
Byu5900 [X]MALIGNANT NEOPLASM/CONNECTIVE SOFT 
TISSUE, UNSPECIFIED 
2 
B220000 MALIGNANT NEOPLASM OF CARTILAGE OF 
TRACHEA 
2 
B305300 MALIGNANT NEOPLASM OF CARPAL BONE - 
PISIFORM 
2 
B54z.00 MALIGNANT NEOPLASM OF ENDOCRINE GLAND 
OR RELATED STRUCTURE NOS 
2 
B13y.00 MALIGNANT NEOPLASM OF OTHER SPECIFIED 
SITES OF COLON 
2 




B40..00 MALIGNANT NEOPLASM OF UTERUS, PART 
UNSPECIFIED 
2 
B001100 MALIGNANT NEOPLASM OF LOWER LIP, 
LIPSTICK AREA 
2 
B51y.00 MALIGNANT NEOPLASM OF OTHER PARTS OF 
BRAIN 
2 
B545000 MALIGNANT NEOPLASM OF GLOMUS JUGULAR 2 
B312300 MALIGNANT NEOPLASM OF CONNECTIVE AND 
SOFT TISSUE OF LOWER LEG 
2 
B12y.00 MALIGNANT NEOPLASM OF OTHER SPECIFIED 
SITE SMALL INTESTINE 
2 
B602z00 BURKITT'S LYMPHOMA NOS 2 
B160.00 MALIGNANT NEOPLASM OF GALLBLADDER 2 
B520000 MALIGNANT NEOPLASM OF OLFACTORY BULB 2 
B13..00 MALIGNANT NEOPLASM OF COLON 2 
B542.00 MALIGNANT NEOPLASM PITUITARY GLAND 
AND CRANIO-PHARYNGEAL DUCT 
2 
B335300 MALIGNANT NEOPLASM OF SKIN OF 
ABDOMINAL WALL 
2 
B52X.00 MALIGNANT NEOPLASM OF MENINGES, 
UNSPECIFIED 
2 
B333.00 MALIGNANT NEOPLASM SKIN OF OTHER AND 
UNSPECIFIED PARTS FACE 
2 
B110111 MALIGNANT NEOPLASM OF GASTRO-
OESOPHAGEAL JUNCTION 
2 
B306300 MALIGNANT NEOPLASM OF SACRAL VERTEBRA 2 
B481.00 MALIGNANT NEOPLASM OF GLANS PENIS 2 
B61z800 HODGKIN'S DISEASE NOS OF LYMPH NODES OF 
MULTIPLE SITES 
2 
B62y200 MALIGNANT LYMPHOMA NOS OF 





B507z00 MALIGNANT NEOPLASM OF LACRIMAL DUCT 
NOS 
2 
B612z00 HODGKIN'S SARCOMA NOS 2 
B18y500 MALIGNANT NEOPLASM OF PELVIC 
PERITONEUM 
2 
B602700 BURKITT'S LYMPHOMA OF SPLEEN 2 
B614z00 HODGKIN'S DISEASE, NODULAR SCLEROSIS NOS 2 
B073100 MALIGNANT NEOPLASM OF NASOPHARYNGEAL 
SOFT PALATE SURFACE 
2 
B616500 HODGKIN'S LYMPHOCYTIC DEPLETION LYMPH 
NODES INGUINAL AND LEG 
2 
B334.00 MALIGNANT NEOPLASM OF SCALP AND SKIN 
OF NECK 
2 
B620700 NODULAR LYMPHOMA OF SPLEEN 2 
B61z700 HODGKIN'S DISEASE NOS OF SPLEEN 2 
B64yz00 OTHER LYMPHOID LEUKAEMIA NOS 2 
B612700 HODGKIN'S SARCOMA OF SPLEEN 2 
B551z00 MALIGNANT NEOPLASM OF THORAX NOS 2 
B610300 HODGKIN'S PARA-GRANULOMA OF INTRA-
ABDOMINAL LYMPH NODES 
2 
ZV10211 [V]PERSONAL HISTORY OF MALIGNANT 
NEOPLASM - ACCESSORY SINUS 
2 
B180z00 MALIGNANT NEOPLASM OF 
RETROPERITONEUM NOS 
2 
B304100 MALIGNANT NEOPLASM OF ACROMION 2 
B627W00 UNSPECIFIED B-CELL NON-HODGKIN'S 
LYMPHOMA 
2 
B081.00 MALIGNANT NEOPLASM OF PYRIFORM SINUS 2 
B512.00 MALIGNANT NEOPLASM OF TEMPORAL LOBE 2 






B213300 MALIGNANT NEOPLASM OF THYROID 
CARTILAGE 
2 
ZV10612 [V]PERSONAL HISTORY OF MONOCYTIC 
LEUKAEMIA 
2 
B627100 FOLLICULAR NON-HODG MIXED SML CLEAVD & 
LGE CELL LYMPHOMA 
2 
B084.00 MALIGNANT NEOPLASM, OVERLAPPING LESION 
OF HYPOPHARYNX 
2 
B491.00 MALIGNANT NEOPLASM OF DOME OF URINARY 
BLADDER 
2 
B522.00 MALIGNANT NEOPLASM OF SPINAL CORD 2 
B312600 MALIGNANT NEOPLASM OF CONNECTIVE AND 
SOFT TISSUE OF GREAT TOE 
2 
B308800 MALIGNANT NEOPLASM OF FIRST 
METATARSAL BONE 
2 
B308z00 MALIGNANT NEOPLASM OF SHORT BONES OF 
LEG NOS 
2 
B309.00 MALIGNANT NEOPLASM, OVERLAP LES BONE 
AND ARTIC CART OF LIMBS 
2 
B313000 MALIGNANT NEOPLASM OF CONNECTIVE AND 
SOFT TISSUE OF AXILLA 
2 
B18y300 MALIGNANT NEOPLASM OF OMENTUM 2 
B47z.12 TERATOMA OF TESTIS 2 
B62xX00 OTHER AND UNSPECIFIC PERIPHERAL & 
CUTANEOUS T-CELL LYMPHOMAS 
2 
B303300 MALIGNANT NEOPLASM OF COSTAL 
CARTILAGE 
2 
B451000 MALIGNANT NEOPLASM OF GREATER 
VESTIBULAR (BARTHOLIN'S) GLAND 
2 






B627000 FOLLICULAR NON-HODGKIN'S SMALL CLEAVED 
CELL LYMPHOMA 
2 
B331.00 MALIGNANT NEOPLASM OF EYELID INCLUDING 
CANTHUS 
2 
B33..15 MALIGNANT NEOPLASM OF SWEAT GLAND 2 
B327700 MALIGNANT MELANOMA OF FOOT 2 
B304z00 MALIGNANT NEOPLASM OF SCAPULA AND 
LONG BONES OF UPPER ARM NOS 
2 
Byu8200 [X]MALIGNANT NEOPLASM OF MALE GENITAL 
ORGAN, UNSPECIFIED 
2 
B610z00 HODGKIN'S PARA-GRANULOMA NOS 2 
B055100 MALIGNANT NEOPLASM OF ROOF OF MOUTH 2 
B600z00 RETICULOSARCOMA NOS 2 
B336400 MALIGNANT NEOPLASM OF SKIN OF FINGER 2 
Byu7000 [X]MALIGNANT NEOPLASM OF UTERINE 
ADNEXA, UNSPECIFIED 
2 
B105.00 MALIGNANT NEOPLASM OF LOWER THIRD OF 
OESOPHAGUS 
2 
B470.00 MALIGNANT NEOPLASM OF UNDESCENDED 
TESTIS 
2 
B616600 HODGKIN'S LYMPHOCYTIC DEPLETION OF 
INTRAPELVIC LYMPH NODES 
2 
B66y.00 OTHER MONOCYTIC LEUKAEMIA 2 
B11yz00 MALIGNANT NEOPLASM OF OTHER SPECIFIED 
SITE OF STOMACH NOS 
2 
B23..00 MALIGNANT NEOPLASM OF PLEURA 2 
B602500 BURKITT'S LYMPHOMA OF LYMPH NODES OF 
INGUINAL REGION AND LEG 
2 
B060200 MALIGNANT NEOPLASM OF OVERLAPPING 
LESION OF TONSIL 
2 






B614300 HODGKIN'S NODULAR SCLEROSIS OF INTRA-
ABDOMINAL LYMPH NODES 
2 
B004.00 MALIGNANT NEOPLASM OF LIP UNSPECIFIED, 
INNER ASPECT 
2 
B511.00 MALIGNANT NEOPLASM OF FRONTAL LOBE 2 
B336000 MALIGNANT NEOPLASM OF SKIN OF SHOULDER 2 
B61z100 HODGKIN'S DISEASE NOS OF LYMPH NODES OF 
HEAD, FACE AND NECK 
2 
B221z00 MALIGNANT NEOPLASM OF MAIN BRONCHUS 
NOS 
2 
B43y.00 MALIGNANT NEOPLASM OF OTHER SITE OF 
UTERINE BODY 
2 
B00..11 CARCINOMA OF LIP 2 
B33..14 MALIGNANT NEOPLASM OF SEBACEOUS 
GLAND 
2 
B305C00 MALIGNANT NEOPLASM OF FIFTH 
METACARPAL BONE 
2 
B614.00 HODGKIN'S DISEASE, NODULAR SCLEROSIS 2 
B172.00 MALIGNANT NEOPLASM OF TAIL OF PANCREAS 2 
B59zX00 KAPOSI'S SARCOMA, UNSPECIFIED 2 
B150300 HEPATOCELLULAR CARCINOMA 2 
B611100 HODGKIN'S GRANULOMA OF LYMPH NODES OF 
HEAD, FACE AND NECK 
2 
B621600 MYCOSIS FUNGOIDES OF INTRAPELVIC LYMPH 
NODES 
2 
B015.00 MALIGNANT NEOPLASM OF TONGUE, 
JUNCTIONAL ZONE 
2 
B213z00 MALIGNANT NEOPLASM OF LARYNGEAL 
CARTILAGE NOS 
2 
B04..00 MALIGNANT NEOPLASM OF FLOOR OF MOUTH 2 
B331100 MALIGNANT NEOPLASM OF UPPER EYELID 2 




B6y0.00 MYELOPROLIFERATIVE DISORDER 2 
B624500 LEUKAEMIC RETICULOEND OF LYMPH NODES 
INGUINAL REGION AND LEG 
2 
B012.00 MALIGNANT NEOPLASM OF TONGUE, TIP AND 
LATERAL BORDER 
2 
B305A00 MALIGNANT NEOPLASM OF THIRD 
METACARPAL BONE 
2 
B33..00 OTHER MALIGNANT NEOPLASM OF SKIN 2 
ByuA200 [X]MALIGNANT NEOPLASM OF MENINGES, 
UNSPECIFIED 
2 
B640.00 ACUTE LYMPHOID LEUKAEMIA 2 




B614000 HODGKIN'S DISEASE, NODULAR SCLEROSIS OF 
UNSPECIFIED SITE 
2 
B010.11 MALIGNANT NEOPLASM OF POSTERIOR THIRD 
OF TONGUE 
2 
B48yz00 MALIGNANT NEOPLASM OF OTHER MALE 
GENITAL ORGAN NOS 
2 
B510z00 MALIGNANT NEOPLASM OF CEREBRUM NOS 2 
B053.00 MALIGNANT NEOPLASM OF SOFT PALATE 2 
B311.00 MALIGNANT NEOPLASM CONNECTIVE AND 
SOFT TISSUE UPPER LIMB/SHOULDER 
2 
B083.00 MALIGNANT NEOPLASM OF POSTERIOR 
PHARYNX 
2 
B550100 MALIGNANT NEOPLASM OF CHEEK NOS 2 
ZV10013 [V]PERSONAL HISTORY OF MALIGNANT 
NEOPLASM OF INTESTINE 
2 
B135.00 MALIGNANT NEOPLASM OF APPENDIX 2 






B151z00 MALIGNANT NEOPLASM OF INTRAHEPATIC 
BILE DUCTS NOS 
2 
B65y.00 OTHER MYELOID LEUKAEMIA 2 
B64..11 LYMPHATIC LEUKAEMIA 2 
B151300 MALIGNANT NEOPLASM OF INTRAHEPATIC 
CANALICULI 
2 
B01..00 MALIGNANT NEOPLASM OF TONGUE 2 
B074.00 MALIGNANT NEOPLASM, OVERLAPPING LESION 
OF NASOPHARYNX 
2 
B110z00 MALIGNANT NEOPLASM OF CARDIA OF 
STOMACH NOS 
2 
B326200 MALIGNANT MELANOMA OF FOREARM 2 
B308300 MALIGNANT NEOPLASM OF MEDIAL 
CUNEIFORM 
2 
B122.00 MALIGNANT NEOPLASM OF ILEUM 2 
B064000 MALIGNANT NEOPLASM OF EPIGLOTTIS, FREE 
BORDER 
2 
B017.00 MALIGNANT OVERLAPPING LESION OF TONGUE 2 
B2zz.00 MALIGNANT NEOPLASM OF RESPIRATORY 
TRACT NOS 
2 
ZV10300 [V]PERSONAL HISTORY OF MALIGNANT 
NEOPLASM OF BREAST 
2 
B651.00 CHRONIC MYELOID LEUKAEMIA 2 
B300400 MALIGNANT NEOPLASM OF OCCIPITAL BONE 2 
B32y.00 MALIGNANT MELANOMA OF OTHER SPECIFIED 
SKIN SITE 
2 
B44y.00 MALIGNANT NEOPLASM OF OTHER SITE OF 
UTERINE ADNEXA 
2 
B10y.00 MALIGNANT NEOPLASM OF OTHER SPECIFIED 
PART OF OESOPHAGUS 
2 




B00z000 MALIGNANT NEOPLASM OF LIP, UNSPECIFIED, 
EXTERNAL 
2 
B210.00 MALIGNANT NEOPLASM OF GLOTTIS 2 
B162.00 MALIGNANT NEOPLASM OF AMPULLA OF 
VATER 
2 
B206.00 MALIGNANT NEOPLASM, OVERLAPPING LESION 
OF ACCESSORY SINUSES 
2 
B110000 MALIGNANT NEOPLASM OF CARDIAC ORIFICE 
OF STOMACH 
2 
B11y.00 MALIGNANT NEOPLASM OF OTHER SPECIFIED 
SITE OF STOMACH 
2 
B306400 MALIGNANT NEOPLASM OF COCCYGEAL 
VERTEBRA 
2 
B325z00 MALIGNANT MELANOMA OF TRUNK, 
EXCLUDING SCROTUM, NOS 
2 
B300100 MALIGNANT NEOPLASM OF FRONTAL BONE 2 
B300300 MALIGNANT NEOPLASM OF NASAL BONE 2 
ZV10711 [V]PERSONAL HISTORY OF HODGKIN'S DISEASE 2 
B142.11 ANAL CARCINOMA 2 
B305500 MALIGNANT NEOPLASM OF CARPAL BONE - 
TRAPEZOID 
2 
B308400 MALIGNANT NEOPLASM OF INTERMEDIATE 
CUNEIFORM 
2 
B551.00 MALIGNANT NEOPLASM OF THORAX 2 
B4...11 CARCINOMA OF GENITOURINARY ORGAN 2 
B500.00 MALIGNANT NEOPLASM EYEBALL EXCL 
CONJUNCTIVA, CORNEA, RETINA, CHOROID 
2 
B314.00 MALIGNANT NEOPLASM OF CONNECTIVE AND 
SOFT TISSUE OF ABDOMEN 
2 
B335800 MALIGNANT NEOPLASM OF SKIN OF BUTTOCK 2 




B312500 MALIGNANT NEOPLASM OF CONNECTIVE AND 
SOFT TISSUE OF TOE 
2 
B305900 MALIGNANT NEOPLASM OF SECOND 
METACARPAL BONE 
2 
B325400 MALIGNANT MELANOMA OF PERIANAL SKIN 2 
B484.00 MALIGNANT NEOPLASM OF EPIDIDYMIS 2 
B48y100 MALIGNANT NEOPLASM OF TUNICA VAGINALIS 2 
B60y.00 OTHER SPECIFIED RETICULOSARCOMA OR 
LYMPHOSARCOMA 
2 
B624700 LEUKAEMIC RETICULOENDOTHELIOSIS OF 
SPLEEN 
2 
B142.00 MALIGNANT NEOPLASM OF ANAL CANAL 2 
B300A00 MALIGNANT NEOPLASM OF MAXILLA 2 
Byu4200 [X]OTHER MALIGNANT NEOPLASM/SKIN OF 
OTHER PARTS OF FACE 
2 
B336100 MALIGNANT NEOPLASM OF SKIN OF UPPER 
ARM 
2 
ZV10015 [V]PERSONAL HISTORY OF MALIGNANT 
NEOPLASM OF LIVER 
2 
B47..00 MALIGNANT NEOPLASM OF TESTIS 2 
B611400 HODGKIN'S GRANULOMA OF LYMPH NODES OF 
AXILLA AND UPPER LIMB 
2 
B4A4.00 MALIGNANT NEOPLASM OF PARAURETHRAL 
GLANDS 
2 
B515z00 MALIGNANT NEOPLASM OF CEREBRAL 
VENTRICLE NOS 
2 
B332200 MALIGNANT NEOPLASM OF PINNA NEC 2 
B540100 MALIGNANT NEOPLASM OF ADRENAL 
MEDULLA 
2 
B300900 MALIGNANT NEOPLASM OF ZYGOMATIC BONE 2 






B1z0.00 MALIGNANT NEOPLASM OF INTESTINAL 
TRACT, PART UNSPECIFIED 
2 
B161300 MALIGNANT NEOPLASM OF SPHINCTER OF 
ODDI 
2 
B002100 MALIGNANT NEOPLASM OF UPPER LIP, 
FRENULUM 
2 
B621700 MYCOSIS FUNGOIDES OF SPLEEN 2 
B542z00 MALIGNANT NEOPLASM PITUITARY GLAND OR 
CRANIO-PHARYNGEAL DUCT NOS 
2 
Bz...00 NEOPLASMS NOS 2 
B151100 MALIGNANT NEOPLASM OF INTERLOBULAR 
BILIARY CANALS 
2 
B601300 LYMPHOSARCOMA OF INTRA-ABDOMINAL 
LYMPH NODES 
2 
B112.00 MALIGNANT NEOPLASM OF PYLORIC ANTRUM 
OF STOMACH 
2 
B507000 MALIGNANT NEOPLASM OF LACRIMAL SAC 2 
B623500 MALIGNANT HISTIOCYTOSIS OF LYMPH NODES 
INGUINAL AND LEG 
2 
B2zy.00 MALIGNANT NEOPLASM OF OTHER SITE OF 
RESPIRATORY TRACT 
2 
B055.00 MALIGNANT NEOPLASM OF PALATE 
UNSPECIFIED 
2 
B630100 SOLITARY MYELOMA 2 
B672.11 THROMBOCYTIC LEUKAEMIA 2 
B016.00 MALIGNANT NEOPLASM OF LINGUAL TONSIL 2 
B002.00 MALIGNANT NEOPLASM OF UPPER LIP, INNER 
ASPECT 
2 
B613000 HODGKIN'S, LYMPHOCYTIC-HISTIOCYTIC 
PREDOMINANCE UNSPECIFIC SITE 
2 






B622200 SEZARY'S DISEASE OF INTRATHORACIC LYMPH 
NODES 
2 
B115.00 MALIGNANT NEOPLASM OF LESSER CURVE OF 
STOMACH UNSPECIFIED 
2 
B505.00 MALIGNANT NEOPLASM OF RETINA 2 
B130.00 MALIGNANT NEOPLASM OF HEPATIC FLEXURE 
OF COLON 
2 
B692.00 SUBACUTE MYELOMONOCYTIC LEUKAEMIA 2 
B1z0.11 CANCER OF BOWEL 2 
B601100 LYMPHOSARCOMA OF LYMPH NODES OF HEAD, 
FACE AND NECK 
2 
B493.00 MALIGNANT NEOPLASM OF ANTERIOR WALL 
OF URINARY BLADDER 
2 
B6...11 MALIGNANT NEOPLASM OF HISTIOCYTIC 
TISSUE 
2 
B62yz00 MALIGNANT LYMPHOMA NOS 2 
B641.11 CHRONIC LYMPHATIC LEUKAEMIA 2 
B243.00 MALIGNANT NEOPLASM OF POSTERIOR 
MEDIASTINUM 
2 
B625800 LETTERER-SIWE DISEASE OF LYMPH NODES OF 
MULTIPLE SITES 
2 
B33X.00 MALIGNANT NEOPLASM OVERLAPPING LESION 
OF SKIN 
2 
B161211 CARCINOMA COMMON BILE DUCT 2 
B613700 HODGKIN'S, LYMPHOCYTIC-HISTIOCYTIC 
PREDOMINANCE OF SPLEEN 
2 
B623400 MALIGNANT HISTIOCYTOSIS OF LYMPH NODES 
OF AXILLA AND ARM 
2 
B612200 HODGKIN'S SARCOMA OF INTRATHORACIC 
LYMPH NODES 
2 






B1z1z00 MALIGNANT NEOPLASM OF SPLEEN NOS 2 
B673.00 MAST CELL LEUKAEMIA 2 
B4A0000 HYPERNEPHROMA 2 
ByuD100 [X]OTHER TYPES OF FOLLICULAR NON-
HODGKIN'S LYMPHOMA 
2 
B453.00 MALIGNANT NEOPLASM OF CLITORIS 2 
B47z.11 SEMINOMA OF TESTIS 2 
B623200 MALIGNANT HISTIOCYTOSIS OF 
INTRATHORACIC LYMPH NODES 
2 
B15z.00 MALIGNANT NEOPLASM OF LIVER AND 
INTRAHEPATIC BILE DUCTS NOS 
2 
B627.00 NON - HODGKIN'S LYMPHOMA 2 
B07y.00 MALIGNANT NEOPLASM OF OTHER SPECIFIED 
SITE OF NASOPHARYNX 
2 
B600500 RETICULOSARCOMA OF LYMPH NODES OF 
INGUINAL REGION AND LEG 
2 
B470100 MALIGNANT NEOPLASM OF RETAINED TESTIS 2 
B611500 HODGKIN'S GRANULOMA LYMPH NODES OF 
INGUINAL REGION AND LEG 
2 
B520.00 MALIGNANT NEOPLASM OF CRANIAL NERVES 2 
B14z.00 MALIGNANT NEOPLASM 
RECTUM,RECTOSIGMOID JUNCTION AND ANUS 
NOS 
2 
B151400 MALIGNANT NEOPLASM OF INTRAHEPATIC 
GALL DUCT 
2 
B16z.00 MALIGNANT NEOPLASM 
GALLBLADDER/EXTRAHEPATIC BILE DUCTS 
NOS 
2 
B241200 MALIGNANT NEOPLASM OF MYOCARDIUM 2 
ByuA300 [X] MALIGNANT NEOPLASM, OVERLAP LESION 





B057.00 OVERLAPPING LESION OF OTHER AND 
UNSPECIFIED PARTS OF MOUTH 
2 
B302000 MALIGNANT NEOPLASM OF CERVICAL 
VERTEBRA 
2 
B524200 MALIGNANT NEOPLASM OF PERIPHERAL 
NERVE OF LOW LIMB, INCL HIP 
2 
ZV10611 [V]PERSONAL HISTORY OF LYMPHOID 
LEUKAEMIA 
2 
B051z00 MALIGNANT NEOPLASM OF VESTIBULE OF 
MOUTH NOS 
2 
B050.00 MALIGNANT NEOPLASM OF CHEEK MUCOSA 2 
B161100 MALIGNANT NEOPLASM OF HEPATIC DUCT 2 
B66yz00 OTHER MONOCYTIC LEUKAEMIA NOS 2 
B325300 MALIGNANT MELANOMA OF GROIN 2 
B336.00 MALIGNANT NEOPLASM OF SKIN OF UPPER 
LIMB AND SHOULDER 
2 
ByuD500 [X]OTHER LYMPHOID LEUKAEMIA 2 
B116.00 MALIGNANT NEOPLASM OF GREATER CURVE 
OF STOMACH UNSPECIFIED 
2 
B41yz00 MALIGNANT NEOPLASM OF OTHER SITE OF 
CERVIX NOS 
2 
B003200 MALIGNANT NEOPLASM OF LOWER LIP, 
MUCOSA 
2 
B4A1100 MALIGNANT NEOPLASM OF URETEROPELVIC 
JUNCTION 
2 
B510.00 MALIGNANT NEOPLASM CEREBRUM 
(EXCLUDING LOBES AND VENTRICLES) 
2 
B151.00 MALIGNANT NEOPLASM OF INTRAHEPATIC 
BILE DUCTS 
2 
B200.00 MALIGNANT NEOPLASM OF NASAL CAVITIES 2 






B111z00 MALIGNANT NEOPLASM OF PYLORUS OF 
STOMACH NOS 
2 
B553200 MALIGNANT NEOPLASM OF SACROCOCCYGEAL 
REGION 
2 
B241z00 MALIGNANT NEOPLASM OF HEART NOS 2 
B440.11 CANCER OF OVARY 2 
B34z.00 MALIGNANT NEOPLASM OF FEMALE BREAST 
NOS 
2 
B542100 MALIGNANT NEOPLASM OF 
CRANIOPHARYNGEAL DUCT 
2 
Byu3000 [X]MAL NEOPLASM/OVERLAP LESION/BONE 
CARTILAGE/LIMB 
2 
B622400 SEZARY'S DISEASE OF LYMPH NODES OF 
AXILLA AND UPPER LIMB 
2 
B625z00 LETTERER-SIWE DISEASE NOS 2 
1959CC MALIGNANT NEOPLASM HAND 2 
B3z..00 MALIGNANT NEOPLASM OF BONE, 
CONNECTIVE TISSUE, SKIN AND BREAST NOS 
2 
B515000 MALIGNANT NEOPLASM OF CHOROID PLEXUS 2 
B653.00 MYELOID SARCOMA 2 
B222.11 PANCOAST'S SYNDROME 2 
B62x600 TRUE HISTIOCYTIC LYMPHOMA 2 
B616300 HODGKIN'S LYMPHOCYTIC DEPLETION INTRA-
ABDOMINAL LYMPH NODES 
2 
B600800 RETICULOSARCOMA OF LYMPH NODES OF 
MULTIPLE SITES 
2 
B624.11 LEUKAEMIC RETICULOENDOTHELIOSIS 2 
B4A0.00 MALIGNANT NEOPLASM OF KIDNEY 
PARENCHYMA 
2 
B07..00 MALIGNANT NEOPLASM OF NASOPHARYNX 2 




B615700 HODGKIN'S DISEASE, MIXED CELLULARITY OF 
SPLEEN 
2 
B324z00 MALIGNANT MELANOMA OF SCALP AND NECK 
NOS 
2 
B601z00 LYMPHOSARCOMA NOS 2 
B653100 GRANULOCYTIC SARCOMA 2 
Byu5300 [X]KAPOSI'S SARCOMA, UNSPECIFIED 2 
ZV10415 [V]PERSONAL HISTORY OF MALIGNANT 
NEOPLASM OF PROSTATE 
2 
B05z000 KAPOSI'S SARCOMA OF PALATE 2 
B61z200 HODGKIN'S DISEASE NOS OF INTRATHORACIC 
LYMPH NODES 
2 
B307200 MALIGNANT NEOPLASM OF TIBIA 2 
B627X00 DIFFUSE NON-HODGKIN'S LYMPHOMA, 
UNSPECIFIED 
2 
ZV10y12 [V]PERSONAL HISTORY OF MALIGNANT 
NEOPLASM OF BRAIN 
2 
B621200 MYCOSIS FUNGOIDES OF INTRATHORACIC 
LYMPH NODES 
2 
B300800 MALIGNANT NEOPLASM OF TEMPORAL BONE 2 
B214.00 MALIGNANT NEOPLASM, OVERLAPPING LESION 
OF LARYNX 
2 
B200200 MALIGNANT NEOPLASM OF SEPTUM OF NOSE 2 
B306000 MALIGNANT NEOPLASM OF ILIUM 2 
B48y000 MALIGNANT NEOPLASM OF SEMINAL VESICLE 2 
B06..00 MALIGNANT NEOPLASM OF OROPHARYNX 2 
B55..00 MALIGNANT NEOPLASM OF OTHER AND ILL-
DEFINED SITES 
2 
B350000 MALIGNANT NEOPLASM OF NIPPLE OF MALE 
BREAST 
2 
B31y.00 MALIGNANT NEOPLASM CONNECTIVE AND 





Byu8000 [X]MALIGNANT NEOPLASM/OTHER SPECIFIED 
MALE GENITAL ORGANS 
2 
B613500 HODGKIN'S, LYMPHOCYTIC-HISTIOCYTIC PRED 
INGUINAL AND LEG 
2 
B312.00 MALIGNANT NEOPLASM OF CONNECTIVE AND 
SOFT TISSUE OF HIP AND LEG 
2 
B613600 HODGKIN'S, LYMPHOCYTIC-HISTIOCYTIC PRED 
INTRAPELVIC NODES 
2 
B550000 MALIGNANT NEOPLASM OF HEAD NOS 2 
B071100 MALIGNANT NEOPLASM OF PHARYNGEAL 
TONSIL 
2 
B05y.00 MALIGNANT NEOPLASM OF OTHER SPECIFIED 
MOUTH PARTS 
2 
B44..00 MALIGNANT NEOPLASM OF OVARY AND OTHER 
UTERINE ADNEXA 
2 
B0z2.00 MALIGNANT NEOPLASM OF 
LARYNGOPHARYNX 
2 
B432.00 MALIGNANT NEOPLASM OF OVERLAPPING 
LESION OF CORPUS UTERI 
2 
B20z.00 MALIGNANT NEOPLASM OF ACCESSORY SINUS 
NOS 
2 
ZV10z00 [V]PERSONAL HISTORY OF UNSPECIFIED 
MALIGNANT NEOPLASM 
2 
ZV10y15 [V]PERSONAL HISTORY OF MALIGNANT 
NEOPLASM OF THYROID 
2 
B14y.00 MALIGNANT NEOPLASM OTHER SITE RECTUM, 
RECTOSIGMOID JUNCTION AND ANUS 
2 
B171.00 MALIGNANT NEOPLASM OF BODY OF 
PANCREAS 
2 
B624600 LEUKAEMIC RETICULOENDOTHELIOSIS OF 
INTRAPELVIC LYMPH NODES 
2 




B64z.00 LYMPHOID LEUKAEMIA NOS 2 
B201300 MALIGNANT NEOPLASM OF MASTOID AIR 
CELLS 
2 
B614200 HODGKIN'S NODULAR SCLEROSIS OF 
INTRATHORACIC LYMPH NODES 
2 
B543.00 MALIGNANT NEOPLASM OF PINEAL GLAND 2 
B151200 MALIGNANT NEOPLASM OF INTRAHEPATIC 
BILIARY PASSAGES 
2 
B551100 MALIGNANT NEOPLASM OF CHEST WALL NOS 2 
B524500 MALIGNANT NEOPLASM OF PERIPHERAL 
NERVE OF PELVIS 
2 
B623.00 MALIGNANT HISTIOCYTOSIS 2 
B610000 HODGKIN'S PARA-GRANULOMA OF 
UNSPECIFIED SITE 
2 
B614700 HODGKIN'S DISEASE, NODULAR SCLEROSIS OF 
SPLEEN 
2 
B4A..11 RENAL MALIGNANT NEOPLASM 2 
B550500 MALIGNANT NEOPLASM OF 
SUPRACLAVICULAR FOSSA NOS 
2 
B624000 LEUKAEMIC RETICULOENDOTHELIOSIS OF 
UNSPECIFIED SITES 
2 
B320.00 MALIGNANT MELANOMA OF LIP 2 
B08y.00 MALIGNANT NEOPLASM OF OTHER SPECIFIED 
HYPOPHARYNGEAL SITE 
2 
B62y800 MALIGNANT LYMPHOMA NOS OF LYMPH 
NODES OF MULTIPLE SITES 
2 
B340000 MALIGNANT NEOPLASM OF NIPPLE OF FEMALE 
BREAST 
2 
B625100 LETTERER-SIWE DISEASE OF LYMPH NODES OF 
HEAD, FACE AND NECK 
2 
B323200 MALIGNANT MELANOMA OF EYEBROW 2 




B34..11 CANCER FEMALE BREAST 2 
B525.00 MALIGNANT NEOPLASM OF CAUDA EQUINA 2 
B66..11 HISTIOCYTIC LEUKAEMIA 2 
B18y200 MALIGNANT NEOPLASM OF MESORECTUM 2 
B4Ay000 MALIGNANT NEOPLASM OF OVERLAPPING 
LESION OF URINARY ORGANS 
2 
B224000 MALIGNANT NEOPLASM OF LOWER LOBE 
BRONCHUS 
2 
B31z.00 MALIGNANT NEOPLASM OF CONNECTIVE AND 
SOFT TISSUE, SITE NOS 
2 
B311400 MALIGNANT NEOPLASM OF CONNECTIVE AND 
SOFT TISSUE OF FINGER 
2 
B323z00 MALIGNANT MELANOMA OF FACE NOS 2 
B333400 MALIGNANT NEOPLASM OF SKIN OF NOSE 
(EXTERNAL) 
2 
B073200 MALIGNANT NEOPLASM POSTERIOR MARGIN 
NASAL SEPTUM AND CHOANAE 
2 
B313200 MALIGNANT NEOPLASM OF GREAT VESSELS 2 
B052.00 MALIGNANT NEOPLASM OF HARD PALATE 2 
B305200 MALIGNANT NEOPLASM OF CARPAL BONE - 
TRIQUETRUM 
2 
B343.00 MALIGNANT NEOPLASM OF LOWER-INNER 
QUADRANT OF FEMALE BREAST 
2 
B62zz11 IMMUNOPROLIFERATIVE NEOPLASM 2 
B602100 BURKITT'S LYMPHOMA OF LYMPH NODES OF 
HEAD, FACE AND NECK 
2 
B521100 MALIGNANT NEOPLASM OF CEREBRAL 
ARACHNOID MATER 
2 
B35z.00 MALIGNANT NEOPLASM OF OTHER SITE OF 
MALE BREAST 
2 






B611300 HODGKIN'S GRANULOMA OF INTRA-
ABDOMINAL LYMPH NODES 
2 
B021.00 MALIGNANT NEOPLASM OF SUBMANDIBULAR 
GLAND 
2 
B031.00 MALIGNANT NEOPLASM OF LOWER GUM 2 
B324.00 MALIGNANT MELANOMA OF SCALP AND NECK 2 
B451z00 MALIGNANT NEOPLASM OF LABIA MAJORA 
NOS 
2 
B34yz00 MALIGNANT NEOPLASM OF OTHER SITE OF 
FEMALE BREAST NOS 
2 
B15..00 MALIGNANT NEOPLASM OF LIVER AND 
INTRAHEPATIC BILE DUCTS 
2 
B308500 MALIGNANT NEOPLASM OF LATERAL 
CUNEIFORM 
2 
B202.00 MALIGNANT NEOPLASM OF MAXILLARY SINUS 2 
B613400 HODGKIN'S, LYMPHOCYTIC-HISTIOCYTIC PRED 
AXILLA AND ARM 
2 
B614600 HODGKIN'S NODULAR SCLEROSIS OF 
INTRAPELVIC LYMPH NODES 
2 
ZV10213 [V]PERSONAL HISTORY OF MALIGNANT 
NEOPLASM OF MIDDLE EAR 
2 
Moderate to severe liver disease 
G852300 OESOPHAGEAL VARICES IN ALCOHOLIC 
CIRRHOSIS OF THE LIVER 
3 
J62z.00 LIVER ABSCESS AND CHRONIC LIVER DISEASE 
CAUSING SEQUELAE NOS 
3 
G851.00 OESOPHAGEAL VARICES WITHOUT BLEEDING 3 
Gyu9400 [X]OESOPHAGEAL VARICES IN DISEASES 
CLASSIFIED ELSEWHERE 
3 
J62y.00 OTHER SEQUELAE OF CHRONIC LIVER DISEASE 3 






J624.00 HEPATORENAL SYNDROME 3 
G850.00 OESOPHAGEAL VARICES WITH BLEEDING 3 
G852.00 OESOPHAGEAL VARICES IN DISEASES EC 3 
J622.00 HEPATIC COMA 3 
G858.00 OESOPHAGEAL VARICES NOS 3 
G85..11 OESOPHAGEAL VARICES 3 
J623.00 PORTAL HYPERTENSION 3 
G852200 OESOPHAGEAL VARICES IN CIRRHOSIS OF THE 
LIVER 
3 
A704z00 OTHER SPECIFIED VIRAL HEPATITIS WITH 
HEPATIC COMA NOS 
3 
760F300 RIGID OESOPHAGOSCOPIC INJECTION 
SCLEROTHERAPY OESOPH VARICES 
3 
G852100 OESOPHAGEAL VARICES WITHOUT BLEEDING 
IN DISEASES EC 
3 
G852z00 OESOPHAGEAL VARICES IN DISEASES EC NOS 3 
Metastatic tumour 
B561400 SECONDARY AND UNSPECIFIED MALIGNANT 
NEOPLASM POST MEDIASTINAL LYMPH NODES 
6 
B58y900 SECONDARY MALIGNANT NEOPLASM OF 
TONGUE 
6 
B5y..00 MALIGNANT NEOPLASM OF OTHER AND 
UNSPECIFIED SITE OS 
6 
B562300 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM COMMON ILIAC LYMPH NODES 
6 
B563300 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM PECTORAL LYMPH NODES 
6 
B575.00 SECONDARY MALIGNANT NEOPLASM OF 
LARGE INTESTINE AND RECTUM 
6 






B58y300 SECONDARY MALIGNANT NEOPLASM OF 
VAGINA 
6 
B5z..00 MALIGNANT NEOPLASM OF OTHER AND 
UNSPECIFIED SITE NOS 
6 
B58y411 SECONDARY CANCER OF THE VULVA 6 
B564200 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM POPLITEAL LYMPH NODES 
6 
B58y600 SECONDARY MALIGNANT NEOPLASM OF 
TESTIS 
6 
B586.00 SECONDARY MALIGNANT NEOPLASM OF 
OVARY 
6 
B573.00 SECONDARY MALIGNANT NEOPLASM OF 
OTHER RESPIRATORY ORGANS 
6 
B593.00 PRIMARY MALIGNANT NEOPLASM OF 
UNKNOWN SITE 
6 
B58..00 SECONDARY MALIGNANT NEOPLASM OF 
OTHER SPECIFIED SITES 
6 
B581200 SECONDARY MALIGNANT NEOPLASM OF 
URETHRA 
6 
B563100 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM SUPRATROCHLEAR LYMPH NODES 
6 
B56..11 LYMPH NODE METASTASES 6 
B574200 SECONDARY MALIGNANT NEOPLASM OF ILEUM 6 
ByuC.00 [X]MALIGNANT NEOPLASM OF ILL-DEFINED, 
SECONDARY AND UNSPECIFIC 
6 
B58y800 SECONDARY MALIGNANT NEOPLASM OF 
EPIDIDYMIS AND VAS DEFERENS 
6 
B561300 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM ANT MEDIASTINAL LYMPH NODES 
6 
B58yz00 SECONDARY MALIGNANT NEOPLASM OF 





B574z00 SECONDARY MALIGNANT NEOPLASM OF 
SMALL INTESTINE OR DUODENUM NOS 
6 
B560500 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM SUBMANDIBULAR LYMPH NODES 
6 
B562.00 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM INTRA-ABDOMINAL LYMPH NODES 
6 
B562000 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM COELIAC LYMPH NODES 
6 
B576z00 SECONDARY MALIGNANT NEOPLASM OF 
RETROPERITONEUM OR PERITONEUM NOS 
6 
B561800 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM BRONCHOPULMONARY LYMPH 
NODES 
6 
B560700 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM SUBMENTAL LYMPH NODES 
6 
B562100 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM SUPERFICIAL MESENTERIC LN 
6 
B56..00 SECONDARY AND UNSPECIFIED MALIGNANT 
NEOPLASM OF LYMPH NODES 
6 
B574000 SECONDARY MALIGNANT NEOPLASM OF 
DUODENUM 
6 
B564000 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM SUPERFICIAL INGUINAL LN 
6 
B582100 SECONDARY MALIGNANT NEOPLASM OF SKIN 
OF FACE 
6 
B577.11 LIVER METASTASES 6 
B564100 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM DEEP INGUINAL LYMPH NODES 
6 
B574100 SECONDARY MALIGNANT NEOPLASM OF 
JEJUNUM 
6 
B56y.00 SECONDARY AND UNSPECIFIC MALIGNANT 





B590.11 CARCINOMATOSIS 6 
B582000 SECONDARY MALIGNANT NEOPLASM OF SKIN 
OF HEAD 
6 
B583z00 SECONDARY MALIGNANT NEOPLASM OF BRAIN 
OR SPINAL CORD NOS 
6 
B576.00 SECONDARY MALIGNANT NEOPLASM OF 
RETROPERITONEUM AND PERITONEUM 
6 
B153.00 SECONDARY MALIGNANT NEOPLASM OF LIVER 6 
B565.00 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM INTRAPELVIC LYMPH NODES 
6 
B563z00 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM AXILLA AND UPPER LIMB LN NOS 
6 
B58y.00 SECONDARY MALIGNANT NEOPLASM OF 
OTHER SPECIFIED SITES 
6 
B572.00 SECONDARY MALIGNANT NEOPLASM OF 
PLEURA 
6 
B57..12 SECONDARY CARCINOMA OF RESPIRATORY 
AND/OR DIGESTIVE SYSTEMS 
6 
B560100 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM MASTOID LYMPH NODES 
6 
B582300 SECONDARY MALIGNANT NEOPLASM OF SKIN 
OF TRUNK 
6 
B57..00 SECONDARY MALIGNANT NEOPLASM OF 
RESPIRATORY AND DIGESTIVE SYSTEMS 
6 
B561200 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM DIAPHRAGMATIC LYMPH NODES 
6 
B592.00 MALIGNANT NEOPLASMS OF INDEPENDENT 
(PRIMARY) MULTIPLE SITES 
6 
B582500 SECONDARY MALIGNANT NEOPLASM OF SKIN 
OF HIP AND LEG 
6 






B560200 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM SUPERFICIAL CERVICAL LN 
6 
B583100 SECONDARY MALIGNANT NEOPLASM OF 
SPINAL CORD 
6 
B59z.00 MALIGNANT NEOPLASM OF UNSPECIFIED SITE 
NOS 
6 
B561600 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM TRACHEOBRONCHIAL LN 
6 
B564.00 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM INGUINAL AND LOWER LIMB LN 
6 
B576000 SECONDARY MALIGNANT NEOPLASM OF 
RETROPERITONEUM 
6 
B560000 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM OF SUPERFICIAL PAROTID LN 
6 
B561700 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM INFERIOR TRACHEOBRONCHIAL LN 
6 
B563.00 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM AXILLA AND UPPER LIMB LN 
6 
B592X00 KAPOSI'S SARCOMA OF MULTIPLE ORGANS 6 
B58y500 SECONDARY MALIGNANT NEOPLASM OF 
PROSTATE 
6 
B58y200 SECONDARY MALIGNANT NEOPLASM OF 
CERVIX UTERI 
6 
B58y211 SECONDARY CANCER OF THE CERVIX 6 
B57z.00 SECONDARY MALIGNANT NEOPLASM OF 
RESPIRATORY OR DIGESTIVE SYSTEM NOS 
6 
B582400 SECONDARY MALIGNANT NEOPLASM OF SKIN 
OF SHOULDER AND ARM 
6 
B587.00 SECONDARY MALIGNANT NEOPLASM OF 
ADRENAL GLAND 
6 






B581.00 SECONDARY MALIGNANT NEOPLASM OF 
OTHER URINARY ORGANS 
6 
B58y000 SECONDARY MALIGNANT NEOPLASM OF 
BREAST 
6 
B590.00 DISSEMINATED MALIGNANCY NOS 6 
B57..11 METASTASES OF RESPIRATORY AND/OR 
DIGESTIVE SYSTEMS 
6 
B58y700 SECONDARY MALIGNANT NEOPLASM OF PENIS 6 
B565200 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM CIRCUMFLEX ILIAC LN 
6 
B58y400 SECONDARY MALIGNANT NEOPLASM OF 
VULVA 
6 
B575000 SECONDARY MALIGNANT NEOPLASM OF 
COLON 
6 
B561000 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM INTERNAL MAMMARY LYMPH 
NODES 
6 
B583000 SECONDARY MALIGNANT NEOPLASM OF BRAIN 6 
B58y100 SECONDARY MALIGNANT NEOPLASM OF 
UTERUS 
6 
B565300 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM SACRAL LYMPH NODES 
6 
B582z00 SECONDARY MALIGNANT NEOPLASM OF SKIN 
NOS 
6 
B565100 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM INFERIOR EPIGASTRIC LN 
6 
B582600 SECONDARY MALIGNANT NEOPLASM OF SKIN 
OF BREAST 
6 
B585000 PATHOLOGICAL FRACTURE DUE TO 
METASTATIC BONE DISEASE 
6 
ByuC100 [X]MALIGNANT NEOPLASM/OVERLAP 





B560600 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM OF FACIAL LYMPH NODES 
6 
B560900 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM DEEP CERVICAL LN 
6 
ByuC700 [X]SECONDARY MALIGNANT NEOPLASM OF 
OTHER SPECIFIED SITES 
6 
B562z00 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM INTRA-ABDOMINAL LN NOS 
6 
B571.00 SECONDARY MALIGNANT NEOPLASM OF 
MEDIASTINUM 
6 
B560800 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM ANTERIOR CERVICAL LN 
6 
B580.00 SECONDARY MALIGNANT NEOPLASM OF 
KIDNEY 
6 
B563000 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM AXILLARY LYMPH NODES 
6 
B560.00 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM LYMPH NODES HEAD/FACE/NECK 
6 
ByuC800 [X]MALIGNANT NEOPLASM WITHOUT 
SPECIFICATION OF SITE 
6 
B560z00 SECONDARY UNSPECIFIC MALIGNANT 
NEOPLASM LYMPH NODES HEAD/FACE/NECK 
NOS 
6 
B575z00 SECONDARY MALIGNANT NEOPLASM OF 
LARGE INTESTINE OR RECTUM NOS 
6 
B583200 CEREBRAL METASTASIS 6 
ByuC500 [X]2NDRY MALIGNANT NEOPLASM/BLADDER 
URINARY ORGANS 
6 
B570.00 SECONDARY MALIGNANT NEOPLASM OF LUNG 6 
B58z.00 SECONDARY MALIGNANT NEOPLASM OF 
OTHER SPECIFIED SITE NOS 
6 




B56z.00 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM LYMPH NODES NOS 
6 
B565000 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM INTERNAL ILIAC LYMPH NODES 
6 
B591.00 OTHER MALIGNANT NEOPLASM NOS 6 
ByuC400 [X]SECONDARY MALIGNANT 
NEOPLASM/OTHER DIGESTIVE ORGANS 
6 
B563200 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM INFRACLAVICULAR LYMPH NODES 
6 
B564z00 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM OF INGUINAL AND LEG LN NOS 
6 
ByuC300 [X]SECONDARY MALIGNANT 
NEOPLASM/OTHER RESPIRATORY ORGANS 
6 
B582.00 SECONDARY MALIGNANT NEOPLASM OF SKIN 6 
B581z00 SECONDARY MALIGNANT NEOPLASM OF 
OTHER URINARY ORGAN NOS 
6 
B561100 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM INTERCOSTAL LYMPH NODES 
6 
B581000 SECONDARY MALIGNANT NEOPLASM OF 
URETER 
6 
B585.00 SECONDARY MALIGNANT NEOPLASM OF BONE 
AND BONE MARROW 
6 
B565z00 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM INTRAPELVIC LN NOS 
6 
B562400 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM EXTERNAL ILIAC LYMPH NODES 
6 
B583.00 SECONDARY MALIGNANT NEOPLASM OF BRAIN 
AND SPINAL CORD 
6 
B561.00 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM INTRATHORACIC LYMPH NODES 
6 




B574.00 SECONDARY MALIGNANT NEOPLASM OF 
SMALL INTESTINE AND DUODENUM 
6 
B594.00 SECONDARY MALIGNANT NEOPLASM OF 
UNKNOWN SITE 
6 
B584.00 SECONDARY MALIGNANT NEOPLASM OF 
OTHER PART OF NERVOUS SYSTEM 
6 
B562200 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM INFERIOR MESENTERIC LN 
6 
B58..11 SECONDARY CARCINOMA OF OTHER SPECIFIED 
SITES 
6 
ByuC200 [X]2NDRY MALIGNANT NEOPLASM LYMPH 
NODES/MULTI REGIONS 
6 
B57y.00 SECONDARY MALIGNANT NEOPLASM OF 
OTHER DIGESTIVE ORGAN 
6 
B59..00 MALIGNANT NEOPLASM OF UNSPECIFIED SITE 6 
B561900 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM PULMONARY LYMPH NODES 
6 
B561z00 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM INTRATHORACIC LN NOS 
6 
B561500 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM PARATRACHEAL LYMPH NODES 
6 
B565400 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM OBTURATOR LYMPH NODES 
6 
ByuC600 [X]2NDRY MALIGNANT NEOPLASM/OTHER 
PARTS/NERVOUS SYSTEM 
6 
B560400 SECONDARY AND UNSPECIFIC MALIGNANT 
NEOPLASM DEEP PAROTID LYMPH NODES 
6 
B576100 SECONDARY MALIGNANT NEOPLASM OF 
PERITONEUM 
6 
B560300 SECONDARY AND UNSPECIFIC MALIGNANT 






A788W00 HIV DISEASE RESULTING IN UNSPECIFIED 
MALIGNANT NEOPLASM 
6 
A788V00 HIV DISEASE RESULTING IN MULTIPLE 
DISEASES CE 
6 
AyuC.00 [X]HUMAN IMMUNODEFICIENCY VIRUS 
DISEASE 
6 
A789000 HIV DISEASE RESULTING IN MYCOBACTERIAL 
INFECTION 
6 
A788400 HUMAN IMMUNODEFICIENCY VIRUS WITH 
NEUROLOGICAL DISEASE 
6 
AyuC600 [X]HIV DISEASE RESULTING IN OTHER NON-
HODGKIN'S LYMPHOMA 
6 
A788X00 HIV DISEASE RESULTING/ UNSPECIFIC 
INFECTIOUS DISEASE 
6 
A788z00 ACQUIRED HUMAN IMMUNODEFICIENCY VIRUS 
INFECTION SYNDROME NOS 
6 
AyuC900 [X]HIV DISEASE RESULTING IN UNSPECIFIED 
MALIGNANT NEOPLASM 
6 
AyuC300 [X]HIV DISEASE RESULTING IN MULTIPLE 
INFECTIONS 
6 
A789200 HIV DISEASE RESULTING IN CANDIDIASIS 6 
A788500 HUMAN IMMUNODEFICIENCY VIRUS WITH 
SECONDARY INFECTION 
6 
AyuC000 [X]HIV DISEASE RESULTING IN OTHER 
BACTERIAL INFECTIONS 
6 
AyuCD00 [X]UNSPECIFIED HUMAN IMMUNODEFICIENCY 
VIRUS [HIV] DISEASE 
6 
AyuCC00 [X]HIV DISEASE RESULTING IN OTHER 
SPECIFIED CONDITIONS 
6 






AyuC200 [X]HIV DISEASE RESULTING IN OTHER 
MYCOSES 
6 
A789900 HIV DISEASE RESULTING IN LYMPHOID 
INTERSTITIAL PNEUMONITIS 
6 
A789.00 HUMAN IMMUNODEFICIENCY VIRUS 
RESULTING IN OTHER DISEASE 
6 
A789A00 HIV DISEASE RESULTING IN WASTING 
SYNDROME 
6 
AyuC100 [X]HIV DISEASE RESULTING IN OTHER VIRAL 
INFECTIONS 
6 
A788300 HUMAN IMMUNODEFICIENCY VIRUS WITH 
CONSTITUTIONAL DISEASE 
6 
A788.00 ACQUIRED IMMUNE DEFICIENCY SYNDROME 6 
AyuCB00 [X]HIV DISEASE RESULT/HAEMATOLOGICAL 
ABNORMS, NEC 
6 
A789100 HIV DISEASE RESULTING IN 
CYTOMEGALOVIRAL DISEASE 
6 
A789500 HIV DISEASE RESULTING IN KAPOSI'S SARCOMA 6 
A788200 HIV INFECTION WITH PERSISTENT 
GENERALISED LYMPHADENOPATHY 
6 
A788U00 HIV DISEASE RESULT/HAEMATOLOGICAL 
ABNORMS,NEC 
6 
A788y00 HUMAN IMMUNODEFICIENCY VIRUS WITH 
OTHER CLINICAL FINDINGS 
6 
A788600 HUMAN IMMUNODEFICIENCY VIRUS WITH 
SECONDARY CANCERS 
6 
A789300 HIV DISEASE RESULTING IN PNEUMOCYSTIS 
CARINII PNEUMONIA 
6 






A789X00 HIV DIS RESULT/OTHER MALIGNANT 
NEOPLASM / LYMPHOID, HEMATOPOIETIC 
TISSUE  
6 
AyuC700 [X]HIV DISSIEASE RESULT/OTHER MALIGNANT 
NEOPLASM / LYMPHOID, HEMATOPOIETIC 
TISSUE 
6 
A788100 ASYMPTOMATIC HUMAN IMMUNODEFICIENCY 
VIRUS INFECTION 
6 
AyuC800 [X]HIV DISEASE RESULTING IN OTHER 
MALIGNANT NEOPLASMS 
6 
AyuC400 [X]HIV DISEASE RESULTING/OTHER INFECTIOUS 
DISEASES 
6 
A789400 HIV DISEASE RESULTING IN MULTIPLE 
INFECTIONS 
6 
A789800 HIV DISEASE RESULTING IN MULTIPLE 
MALIGNANT NEOPLASMS 
6 








Appendix 9-8. Inhaled corticosteroids (ICS) codes 
95964996 BETAMETHASONE VALERATE 
100MICROGRAMS/ACTUATION 
99887998 BETAMETHASONE VALERATE 
100MICROGRAMS/ACTUATION 
85830998 BECLOMETASONE CFC FREE 
50MICROGRAMS/ACTUATION 
87986997 BECLOMETASONE EXTRAFINE PARTICLE CFC/FREE 
B/ACT 100MICROGRAMS/ACTUATION 
87986998 BECLOMETASONE EXTRAFINE PARTICLE CFC/FREE 
B/ACT 50MICROGRAMS/ACTUATION 
87988997 BECLOMETASONE EXTRAFINE PARTICLE CFC/FREE 
B/ACT 100MICROGRAMS/ACTUATION 
87988998 BECLOMETASONE EXTRAFINE PARTICLE CFC/FREE 
B/ACT 50MICROGRAMS/ACTUATION 
88832998 BECLOMETASONE BREATH ACT 
250MICROGRAMS/ACTUATION 
88833997 BECLOMETASONE BREATH ACT 
100MICROGRAMS/ACTUATION 
86569998 BECLOMETASONE DRY POWDER 
200MICROGRAMS/ACTUATION 
87173998 BECLOMETASONE EXTRAFINE PARTICLE CFC/FREE 
B/ACT 100MICROGRAMS/ACTUATION 
88305998 BUDESONIDE + FORMOTEROL DRY POWDER 
100MICROGRAMS + 6MICROGRAMS/ACTUATION 
88434996 BECLOMETASONE DRY POWDER 
250MICROGRAMS/ACTUATION 
88434997 BECLOMETASONE DRY POWDER 
100MICROGRAMS/ACTUATION 





91088996 BECLOMETASONE DRY POWDER 
400MICROGRAMS/ACTUATION 
91088997 BECLOMETASONE DRY POWDER 
200MICROGRAMS/ACTUATION 
91088998 BECLOMETASONE DRY POWDER 
100MICROGRAMS/ACTUATION 
91363996 BECLOMETASONE DRY POWDER 
100MICROGRAMS/ACTUATION 
92285996 BECLOMETASONE DRY POWDER 
400MICROGRAMS/ACTUATION 
92285997 BECLOMETASONE DRY POWDER 
200MICROGRAMS/ACTUATION 
92285998 BECLOMETASONE DRY POWDER 
250MICROGRAMS/ACTUATION 
93066997 BECLOMETASONE BREATH ACT 
100MICROGRAMS/ACTUATION 
93066998 BECLOMETASONE BREATH ACT 
50MICROGRAMS/ACTUATION 
96626989 BECLOMETASONE 100MICROGRAMS/ACTUATION 
85823998 BECLOMETASONE CFC FREE 
250MICROGRAMS/ACTUATION 
85824998 BECLOMETASONE CFC FREE 
200MICROGRAMS/ACTUATION 
85825998 BECLOMETASONE CFC FREE 
100MICROGRAMS/ACTUATION 
85826998 BECLOMETASONE CFC FREE 
50MICROGRAMS/ACTUATION 
85827998 BECLOMETASONE CFC FREE 
250MICROGRAMS/ACTUATION 
85828998 BECLOMETASONE CFC FREE 
200MICROGRAMS/ACTUATION 




84873998 BECLOMETASONE POWDER 400MICROGRAMS 
84875998 BECLOMETASONE POWDER 200MICROGRAMS 
84877998 BECLOMETASONE POWDER 200MICROGRAMS 
84879998 BECLOMETASONE POWDER 100MICROGRAMS 
84881998 BECLOMETASONE POWDER 100MICROGRAMS 
94847996 BECLOMETASONE DISC 400MICROGRAMS 
94847997 BECLOMETASONE DISC 200MICROGRAMS 
94847998 BECLOMETASONE DISC 100MICROGRAMS 
97517998 BECLOMETASONE DISC 400MICROGRAMS 
84869998 BECLOMETASONE POWDER BLISTERS REF 
400MICROGRAMS 
84872998 BECLOMETASONE POWDER BLISTERS REF 
400MICROGRAMS 
84874998 BECLOMETASONE POWDER BLISTERS REF 
200MICROGRAMS 
84876998 BECLOMETASONE POWDER BLISTERS REF 
200MICROGRAMS 
84878998 BECLOMETASONE POWDER BLISTERS REF 
100MICROGRAMS 
84880998 BECLOMETASONE POWDER BLISTERS REF 
100MICROGRAMS 
93620992 BECLOMETHASONE DIPROPRIONATE CART 200 MCG 
93621992 BECLOMETHASONE DIPROPRIONATE CART 100 MCG 
94456996 BECLOMETASONE DISC 400MICROGRAMS 
94456997 BECLOMETASONE DISC 200MICROGRAMS 
94456998 BECLOMETASONE DISC 100MICROGRAMS 
94557996 BECLOMETASONE 400MICROGRAMS/ACTUATION 
94558996 BECLOMETASONE  400MICROGRAMS 
94558997 BECLOMETASONE 200MICROGRAMS 
94558998 BECLOMETASONE 100MICROGRAMS 
94849997 SALBUTAMOL + BECLOMETASONE CAPS 




94849998 SALBUTAMOL + BECLOMETASONE CAPS 
400MICROGRAMS + 200MICROGRAMS 
94941996 SALBUTAMOL + BECLOMETASONE CAPS 
200MICROGRAMS + 100MICROGRAMS 
94941997 SALBUTAMOL + BECLOMETASONE CAPS 
400MICROGRAMS + 200MICROGRAMS 
95983996 BECLOMETASONE + SALBUTAMOL CAPS 
100MICROGRAMS + 200MICROGRAMS 
95983997 BECLOMETASONE + SALBUTAMOL CAPS 
200MICROGRAMS + 400MICROGRAMS 
96027990 BECLOMETASONE 400MICROGRAMS 
96028990 BECLOMETASONE 200MICROGRAMS 
96029990 BECLOMETASONE 100MICROGRAMS 
98590996 BECLOMETASONE 400MICROGRAMS 
98590997 BECLOMETASONE 200MICROGRAMS 
98590998 BECLOMETASONE 100MICROGRAMS 
83447998 BECLOMETASONE BREATH ACT 
250MICROGRAMS/ACTUATION 
84238998 BECLOMETASONE EXTRAFINE PARTICLE + 
FORMOTEROL CFC FREE 100MICROGRAMS + 
6MICROGRAMS/ACTUATION 
84239998 BECLOMETASONE EXTRAFINE PARTICLE + 
FORMOTEROL CFC FREE100MICROGRAMS + 
6MICROGRAMS/ACTUATION 
85829998 BECLOMETASONE CFC FREE 
100MICROGRAMS/ACTUATION 
87990997 BECLOMETASONE EXTRAFINE PARTICLE CFC FREE 
100MICROGRAMS/ACTUATION 
87990998 BECLOMETASONE EXTRAFINE PARTICLE CFC FREE 
50MICROGRAMS/ACTUATION 





87991998 BECLOMETASONE EXTRAFINE PARTICLE CFC FREE 
50MICROGRAMS/ACTUATION 
89862996 BECLOMETASONE 250MICROGRAMS/ACTUATION 
89862997 BECLOMETASONE 100MICROGRAMS/ACTUATION 
89862998 BECLOMETASONE 50MICROGRAMS/ACTUATION 
90588998 BECLOMETASONE 200MICROGRAMS/ACTUATION 
91363997 BECLOMETASONE DRY POWDER 
50MICROGRAMS/ACTUATION 
91403996 BECLOMETASONE BREATH ACT 
250MICROGRAMS/ACTUATION 
91403997 BECLOMETASONE BREATH ACT 
100MICROGRAMS/ACTUATION 
91403998 BECLOMETASONE BREATH ACT 
50MICROGRAMS/ACTUATION 
92836990 BECLOMETASONE 50MICROGRAMS/ACTUATION 
92837990 BECLOMETASONE 250MICROGRAMS/ACTUATION 
92838990 BECLOMETASONE 100MICROGRAMS/ACTUATION 
93066996 BECLOMETASONE BREATH ACT 
250MICROGRAMS/ACTUATION 
94557997 BECLOMETASONE 200MICROGRAMS/ACTUATION 
94559996 BECLOMETASONE 100MICROGRAMS/ACTUATION 
94559997 BECLOMETASONE 50MICROGRAMS/ACTUATION 
94559998 BECLOMETASONE 250MICROGRAMS/ACTUATION 
94941998 SALBUTAMOL + BECLOMETASONE 100MCG + 50MCG 
95111998 BECLOMETASONE 200MICROGRAMS/ACTUATION 
95162990 BECLOMETASONE 250MICROGRAMS/ACTUATION 
95163990 BECLOMETASONE 100MICROGRAMS/ACTUATION 
95164990 BECLOMETASONE 50MICROGRAMS/ACTUATION 
95536990 BECLOMETASONE 200MICROGRAMS/ACTUATION 
95983998 BECLOMETASONE + SALBUTAMOL 50MICROGRAMS + 
100MICROGRAMS/INHALATION 




96131990 BECLOMETASONE 100MICROGRAMS/ACTUATION 
96132990 BECLOMETASONE 50MICROGRAMS/ACTUATION 
96626988 BECLOMETASONE 250MICROGRAMS/ACTUATION 
96626990 BECLOMETASONE 50MICROGRAMS/ACTUATION 
96935988 BECLOMETASONE 250MICROGRAMS/ACTUATION 
96935989 BECLOMETASONE 100MICROGRAMS/ACTUATION 
96935990 BECLOMETASONE 50MICROGRAMS/ACTUATION 
97006988 BECLOMETASONE 250MICROGRAMS/ACTUATION 
97006989 BECLOMETASONE 100MICROGRAMS/ACTUATION 
97006990 BECLOMETASONE 50MICROGRAMS/ACTUATION 
97255988 BECLOMETASONE 100MICROGRAMS/ACTUATION 
97255989 BECLOMETASONE 50MICROGRAMS/ACTUATION 
97255990 BECLOMETASONE 250MICROGRAMS/ACTUATION 
97698998 BECLOMETASONE 100MICROGRAMS/ACTUATION 
97872996 BECLOMETASONE 250MICROGRAMS/ACTUATION 
97872997 BECLOMETASONE 100MICROGRAMS/ACTUATION 
97872998 BECLOMETASONE 50MICROGRAMS/ACTUATION 
98288998 BECLOMETASONE 250MICROGRAMS/ACTUATION 
98332996 BECLOMETASONE BREATH ACT 
100MICROGRAMS/ACTUATION 
98332997 BECLOMETASONE BREATH ACT 
250MICROGRAMS/ACTUATION 
98332998 BECLOMETASONE BREATH ACT 
50MICROGRAMS/ACTUATION 
98580998 SALBUTAMOL + BECLOMETASONE 100MCG + 50MCG 
99910998 BECLOMETASONE 50MICROGRAMS/ACTUATION 
99914998 BECLOMETASONE 250MICROGRAMS/ACTUATION 
99965997 BECLOMETASONE 100MICROGRAMS/ACTUATION 
99965998 BECLOMETASONE 50MICROGRAMS/ACTUATION 
99914997 BECLOMETASONE 250MICROGRAMS/ACTUATION 
94557998 BECLOMETASONE NEB SUSP 50MICROGRAMS/ML 




88833998 BECLOMETASONE BREATH ACT 
50MICROGRAMS/ACTUATION 
86195998 BUDESONIDE DRY POWDER 
400MICROGRAMS/ACTUATION 
86196998 BUDESONIDE DRY POWDER 
200MICROGRAMS/ACTUATION 
86197998 BUDESONIDE DRY POWDER 
100MICROGRAMS/ACTUATION 
87174998 BECLOMETASONE EXTRAFINE PARTICLE CFC/FREE 
B/ACT 50MICROGRAMS/ACTUATION 
91493998 BUDESONIDE + FORMOTEROL DRY POWDER 
400MICROGRAMS + 12MICROGRAMS/ACTUATION 
92411998 BUDESONIDE + FORMOTEROL DRY POWDER 
400MICROGRAMS + 12MICROGRAMS/ACTUATION 
93302998 BUDESONIDE 400MICROGRAMS/ACTUATION 
93303996 BUDESONIDE DRY POWDER 
100MICROGRAMS/ACTUATION 
93303997 BUDESONIDE DRY POWDER 
400MICROGRAMS/ACTUATION 
93303998 BUDESONIDE DRY POWDER 
200MICROGRAMS/ACTUATION 
95938996 BUDESONIDE 100MICROGRAMS/ACTUATION 
98887996 BUDESONIDE DRY POWDER 
100MICROGRAMS/ACTUATION 
98887997 BUDESONIDE DRY POWDER 
400MICROGRAMS/ACTUATION 
98887998 BUDESONIDE DRY POWDER 
200MICROGRAMS/ACTUATION 
83268998 BUDESONIDE CFC FREE 200MICROGRAMS 
83269998 BUDESONIDE CFC FREE 100MICROGRAMS 
83306998 BUDESONIDE CFC FREE 200MICROGRAMS 




82890998 BUDESONIDE DRY POWDER CART REF 
400MICROGRAMS 
82891998 BUDESONIDE DRY POWDER 400MICROGRAMS 
88156998 BUDESONIDE 200MICROGRAMS 
89121998 BUDESONIDE  400MICROGRAMS 
95982990 BUDESONIDE  400MICROGRAMS 
95983990 BUDESONIDE 200MICROGRAMS 
85036998 BUDESONIDE DRY POWDER CART REF 
200MICROGRAMS 
85037998 BUDESONIDE DRY POWDER 200MICROGRAMS 
85045998 BUDESONIDE DRY POWDER 200MICROGRAMS 
87438998 BUDESONIDE REFILLABLE BREATH ACT POWDER 
200MICROGRAMS/ACTUATION 
95526992 PULMICORT COMPLETE 50 MCG INH 
95528992 PULMICORT COMPLETE 200 MCG INH 
95938997 BUDESONIDE 50MICROGRAMS/ACTUATION 
95938998 BUDESONIDE 200MICROGRAMS/ACTUATION 
98595998 BUDESONIDE 50MICROGRAMS/ACTUATION 
98596998 BUDESONIDE 200MICROGRAMS/ACTUATION 
93302996 BUDESONIDE REFILL CANISTER 
50MICROGRAMS/ACTUATION 
95527992 PULMICORT REFIL 50 MG INH 
98595997 BUDESONIDE REFILL CANISTER 
50MICROGRAMS/ACTUATION 
93546990 BUDESONIDE NEB SUSP 1MG/2ML 
93547990 BUDESONIDE NEB SUSP 0.5MG/2ML 
93555990 BUDESONIDE NEB SUSP 0.5MG/2ML 
95492997 BUDESONIDE NEB SUSP 1MG/2ML 
95492998 BUDESONIDE NEB SUSP 0.5MG/2ML 
95493997 BUDESONIDE NEB SUSP 1MG/2ML 




87439998 BUDESONIDE REFILLABLE BREATH ACT POWDER 
200MICROGRAMS/ACTUATION 
88305997 BUDESONIDE + FORMOTEROL DRY POWDER 
200MICROGRAMS + 6MICROGRAMS/ACTUATION 
90394997 BUDESONIDE + FORMOTEROL DRY POWDER 
200MICROGRAMS + 6MICROGRAMS/ACTUATION 
90394998 BUDESONIDE + FORMOTEROL DRY POWDER 
100MICROGRAMS + 6MICROGRAMS/ACTUATION 
87062998 CICLESONIDE CFC FREE 160MICROGRAMS/ACTUATION 
87063998 CICLESONIDE CFC FREE 80MICROGRAMS/ACTUATION 
87065998 CICLESONIDE CFC FREE 160MICROGRAMS/ACTUATION 
87069998 CICLESONIDE CFC FREE 80MICROGRAMS/ACTUATION 
84751998 FLUTICASONE POWDER 500 MICROGRAMS 
84753998 FLUTICASONE POWDER 500 MICROGRAMS 
84755998 FLUTICASONE POWDER 250MICROGRAMS 
84757998 FLUTICASONE POWDER 250MICROGRAMS 
84760998 FLUTICASONE POWDER 100MICROGRAMS 
84763998 FLUTICASONE POWDER 100MICROGRAMS 
84768998 FLUTICASONE POWDER 50MICROGRAMS 
84771998 FLUTICASONE POWDER 50MICROGRAMS 
96041992 FLIXOTIDE DISKHALER-COMMUNITY PACK 50 MCG 
96884992 FLIXOTIDE DISKHALER-COMMUNITY PACK 250 MCG 
96885992 FLIXOTIDE DISKHALER-COMMUNITY PACK 100 MCG 
84750998 FLUTICASONE POWDER BLISTERS REF 500 
MICROGRAMS 
84752998 FLUTICASONE POWDER BLISTERS REF 500 
MICROGRAMS 
84754998 FLUTICASONE POWDER BLISTERS REF 
250MICROGRAMS 





84759998 FLUTICASONE POWDER BLISTERS REF 
100MICROGRAMS 
84762998 FLUTICASONE POWDER BLISTERS REF 
100MICROGRAMS 
84767998 FLUTICASONE POWDER BLISTERS REF 
50MICROGRAMS 
84770998 FLUTICASONE POWDER BLISTERS REF 
50MICROGRAMS 
92843998 FLUTICASONE DISC 500MICROGRAMS 
92844998 FLUTICASONE DISC 500MICROGRAMS 
93056996 FLUTICASONE DISC 250MICROGRAMS 
93056997 FLUTICASONE DISC 100MICROGRAMS 
93056998 FLUTICASONE DISC 50MICROGRAMS 
93057996 FLUTICASONE DISC 250MICROGRAMS 
93057997 FLUTICASONE DISC 100MICROGRAMS 
93057998 FLUTICASONE DISC 50MICROGRAMS 
82254998 FLUTICASONE DRY POWDER 
500MICROGRAMS/INHALATION 
82255998 FLUTICASONE DRY POWDER 
250MICROGRAMS/INHALATION 
82257998 FLUTICASONE DRY POWDER 
100MICROGRAMS/INHALATION 
82258998 FLUTICASONE DRY POWDER 
50MICROGRAMS/INHALATION 
87979998 SALMETEROL + FLUTICASONE CFC FREE 
25MICROGRAMS + 50MICROGRAMS/ACTUATION 
87980996 SALMETEROL + FLUTICASONE CFC FREE 
25MICROGRAMS + 250MICROGRAMS/ACTUATION 
87980997 SALMETEROL + FLUTICASONE CFC FREE 
25MICROGRAMS + 125MICROGRAMS/ACTUATION 
87980998 SALMETEROL + FLUTICASONE CFC FREE 




88522998 SALMETEROL + FLUTICASONE DRY POWDER 
50MICROGRAMS + 100MICROGRAMS/INHALATION 
88524996 FLUTICASONE + SALMETEROL DRY POWDER 
500MICROGRAMS + 50MICROGRAMS/INHALATION 
88524997 FLUTICASONE + SALMETEROL DRY POWDER 
250MICROGRAMS + 50MICROGRAMS/INHALATION 
88524998 FLUTICASONE + SALMETEROL DRY POWDER 
100MICROGRAMS + 50MICROGRAMS/INHALATION 
88525996 SALMETEROL + FLUTICASONE DRY POWDER 
50MICROGRAMS+ 500MICROGRAMS/INHALATION 
88525997 SALMETEROL + FLUTICASONE DRY POWDER 
50MICROGRAMS + 250MICROGRAMS/INHALATION 
88525998 SALMETEROL + FLUTICASONE DRY POWDER 
50MICROGRAMS + 100MICROGRAMS/INHALATION 
91322997 FLUTICASONE DRY POWDER 
500MICROGRAMS/INHALATION 
91322998 FLUTICASONE DRY POWDER 
250MICROGRAMS/INHALATION 
91334997 FLUTICASONE DRY POWDER 
500MICROGRAMS/INHALATION 
91334998 FLUTICASONE DRY POWDER 
250MICROGRAMS/INHALATION 
91348998 SALMETEROL + FLUTICASONE DRY POWDER 
50MICROGRAMS + 250MICROGRAMS/INHALATION 
91547998 SALMETEROL + FLUTICASONE CFC FREE 
25MICROGRAMS + 125MICROGRAMS/ACTUATION 
91619996 FLUTICASONE CFC FREE 50MICROGRAMS/ACTUATION 
91619997 FLUTICASONE CFC FREE 
250MICROGRAMS/ACTUATION 





92199998 SALMETEROL + FLUTICASONE DRY POWDER 
50MICROGRAMS+ 500MICROGRAMS/INHALATION 
92473996 FLUTICASONE CFC FREE 50MICROGRAMS/ACTUATION 
92473997 FLUTICASONE CFC FREE 
250MICROGRAMS/ACTUATION 
92473998 FLUTICASONE CFC FREE 
125MICROGRAMS/ACTUATION 
92842996 FLUTICASONE DRY POWDER 
100MICROGRAMS/INHALATION 
92842997 FLUTICASONE DRY POWDER 
50MICROGRAMS/INHALATION 
92842998 FLUTICASONE 250MICROGRAMS/ACTUATION 
92845996 FLUTICASONE DRY POWDER 
100MICROGRAMS/INHALATION 
92845997 FLUTICASONE DRY POWDER 
50MICROGRAMS/INHALATION 
92845998 FLUTICASONE 250MICROGRAMS/ACTUATION 
92899996 FLUTICASONE 125MICROGRAMS/ACTUATION 
92899997 FLUTICASONE 50MICROGRAMS/ACTUATION 
92899998 FLUTICASONE 25MICROGRAMS/ACTUATION 
92900996 FLUTICASONE 125MICROGRAMS/ACTUATION 
92900997 FLUTICASONE 50MICROGRAMS/ACTUATION 
92900998 FLUTICASONE 25MICROGRAMS/ACTUATION 
93983996 FLUTICASONE + SALMETEROL CFC FREE 
250MICROGRAMS + 25MICROGRAMS/ACTUATION 
93983997 FLUTICASONE + SALMETEROL CFC FREE 
125MICROGRAMS + 25MICROGRAMS/ACTUATION 
93983998 FLUTICASONE + SALMETEROL CFC FREE 
50MICROGRAMS + 25MICROGRAMS/ACTUATION 
94625998 SALMETEROL + FLUTICASONE CFC FREE 




97672997 FLUTICASONE UNIT DOSE NEB SUSP 
500MICROGRAMS/2ML 
97672998 FLUTICASONE UNIT DOSE NEB SUSP 2MG/2ML 
97680997 FLUTICASONE UNIT DOSE NEB SUSP 
500MICROGRAMS/2ML 
97680998 FLUTICASONE UNIT DOSE NEB SUSP 2MG/2ML 
88727998 MOMETASONE FUROATE DRY POWDER 
200MICROGRAMS/ACTUATION 
89229998 MOMETASONE FUROATE DRY POWDER 
400MICROGRAMS/ACTUATION 
90758998 MOMETASONE FUROATE DRY POWDER 
200MICROGRAMS/ACTUATION 







Appendix 9-9. Cerebrovascular disease codes  
Code Description  
1477.00 H/O: CEREBROVASCULAR DISEASE 
14A7.00 H/O: CVA/STROKE 
14A7.11 H/O: CVA 
14A7.12 H/O: STROKE 
14AF.00 H/O SUBARACHNOID HAEMORRHAGE 
14AK.00 H/O: STROKE IN LAST YEAR 
662M.00 STROKE MONITORING 
7A23.00 CEREBRAL ARTERY AND CIRCLE OF WILLIS 
ANEURYSM OPERATIONS 
7A23.11 CEREBRAL ARTERY ANEURYSM OPERATIONS 
7A23000 EXCISION OF ANEURYSM OF CEREBRAL ARTERY 
7A23200 CLIPPING OF ANEURYSM OF CEREBRAL ARTERY 
7A23400 LIGATION OF ANEURYSM OF CEREBRAL ARTERY NEC 
7A23600 OBLITERATION OF ANEURYSM OF CEREBRAL ARTERY 
NEC 
7A23y00 OPERATION ON CEREBRAL ARTERY/ CIRCLE OF 
WILLIS ANEURYSM OS 
7A23z00 OPERATION ON CEREBRAL ARTERY/ CIRCLE OF 
WILLIS ANEURYSM NOS 
7A24.00 OTHER OPEN OPERATIONS ON CEREBRAL ARTERY OR 
CIRCLE OF WILLIS 
7A24.11 OTHER OPEN OPERATIONS ON CEREBRAL ARTERY 
7A24000 RECONSTRUCTION OF CEREBRAL ARTERY 
7A24200 ANASTOMOSIS OF CEREBRAL ARTERY 
7A24400 OPEN EMBOLECTOMY OF CEREBRAL ARTERY 
7A24600 OPEN EMBOLISATION OF CEREBRAL ARTERY 
7A24y00 OTHER OPEN OPERATION ON CEREBRAL 
ARTERY/CIRCLE OF WILLIS OS 
7A24z00 OTHER OPEN OPERATION ON CEREBRAL 




7A25.00 TRANSLUMINAL OPERATIONS ON CEREBRAL ARTERY/ 
CIRCLE OF WILLIS 
7A25000 PERCUTANEOUS TRANSLUMINAL EMBOLISATION OF 
CEREBRAL ARTERY 
7A25200 EMBOLISATION OF CEREBRAL ARTERY NEC 
7A25400 ARTERIOGRAPHY OF CEREBRAL ARTERY 
7A25y00 TRANSLUMINAL OPERATION ON CEREBRAL 
ART/CIRCLE OF WILLIS OS 
7A25z00 TRANSLUMINAL OPERATION ON CEREBRAL 
ART/CIRCLE OF WILLIS NOS 
E030400 ACUTE CONFUSIONAL STATE, OF CEREBROVASCULAR 
ORIGIN 
E031400 SUBACUTE CONFUSIONAL STATE, OF 
CEREBROVASCULAR ORIGIN 
F11x200 CEREBRAL DEGENERATION DUE TO 
CEREBROVASCULAR DISEASE 
Fyu5500 [X]OTHER TRANSNT CEREBRAL ISCHAEMIC 
ATTACKS+RELATED SYNDROMS 
Fyu5600 [X]OTHER LACUNAR SYNDROMES 
Fyu5700 [X]OTHER VASCULAR SYNDROMS/BRAIN IN 
CEREBROVASCULR DISEASES 
G6...00 CEREBROVASCULAR DISEASE 
G60..00 SUBARACHNOID HAEMORRHAGE 
G600.00 RUPTURED BERRY ANEURYSM 
G601.00 SUBARACHNOID HAEMORRHAGE FROM CAROTID 
SIPHON AND BIFURCATION 
G602.00 SUBARACHNOID HAEMORRHAGE FROM MIDDLE 
CEREBRAL ARTERY 
G603.00 SUBARACHNOID HAEMORRHAGE FROM ANTERIOR 
COMMUNICATING ARTERY 





G605.00 SUBARACHNOID HAEMORRHAGE FROM BASILAR 
ARTERY 
G606.00 SUBARACHNOID HAEMORRHAGE FROM VERTEBRAL 
ARTERY 
G60X.00 SUBARACHNOID HAEMORRH FROM INTRACRANIAL 
ARTERY, UNSPECIF 
G60z.00 SUBARACHNOID HAEMORRHAGE NOS 
G61..00 INTRACEREBRAL HAEMORRHAGE 
G61..11 CVA - CEREBROVASCULAR ACCID DUE TO 
INTRACEREBRAL HAEMORRHAGE 
G61..12 STROKE DUE TO INTRACEREBRAL HAEMORRHAGE 
G610.00 CORTICAL HAEMORRHAGE 
G611.00 INTERNAL CAPSULE HAEMORRHAGE 
G612.00 BASAL NUCLEUS HAEMORRHAGE 
G613.00 CEREBELLAR HAEMORRHAGE 
G614.00 PONTINE HAEMORRHAGE 
G615.00 BULBAR HAEMORRHAGE 
G616.00 EXTERNAL CAPSULE HAEMORRHAGE 
G617.00 INTRACEREBRAL HAEMORRHAGE, 
INTRAVENTRICULAR 
G618.00 INTRACEREBRAL HAEMORRHAGE, MULTIPLE 
LOCALIZED 
G619.00 LOBAR CEREBRAL HAEMORRHAGE 
G61X.00 INTRACEREBRAL HAEMORRHAGE IN HEMISPHERE, 
UNSPECIFIED 
G61X000 LEFT SIDED INTRACEREBRAL HAEMORRHAGE, 
UNSPECIFIED 
G61X100 RIGHT SIDED INTRACEREBRAL HAEMORRHAGE, 
UNSPECIFIED 
G61z.00 INTRACEREBRAL HAEMORRHAGE NOS 





G620.00 EXTRADURAL HAEMORRHAGE - NONTRAUMATIC 
G621.00 SUBDURAL HAEMORRHAGE - NONTRAUMATIC 
G622.00 SUBDURAL HAEMATOMA - NONTRAUMATIC 
G62z.00 INTRACRANIAL HAEMORRHAGE NOS 
G63..00 PRECEREBRAL ARTERIAL OCCLUSION 
G63..11 INFARCTION - PRECEREBRAL 
G63..12 STENOSIS OF PRECEREBRAL ARTERIES 
G630.00 BASILAR ARTERY OCCLUSION 
G631.00 CAROTID ARTERY OCCLUSION 
G631.11 STENOSIS, CAROTID ARTERY 
G631.12 THROMBOSIS, CAROTID ARTERY 
G633.00 MULTIPLE AND BILATERAL PRECEREBRAL ARTERIAL 
OCCLUSION 
G634.00 CAROTID ARTERY STENOSIS 
G63y.00 OTHER PRECEREBRAL ARTERY OCCLUSION 
G63y000 CEREBRAL INFARCT DUE TO THROMBOSIS OF 
PRECEREBRAL ARTERIES 
G63y100 CEREBRAL INFARCTION DUE TO EMBOLISM OF 
PRECEREBRAL ARTERIES 
G63z.00 PRECEREBRAL ARTERY OCCLUSION NOS 
G64..00 CEREBRAL ARTERIAL OCCLUSION 
G64..11 CVA - CEREBRAL ARTERY OCCLUSION 
G64..12 INFARCTION - CEREBRAL 
G64..13 STROKE DUE TO CEREBRAL ARTERIAL OCCLUSION 
G640.00 CEREBRAL THROMBOSIS 
G640000 CEREBRAL INFARCTION DUE TO THROMBOSIS OF 
CEREBRAL ARTERIES 
G641.00 CEREBRAL EMBOLISM 
G641.11 CEREBRAL EMBOLUS 
G641000 CEREBRAL INFARCTION DUE TO EMBOLISM OF 
CEREBRAL ARTERIES 




G64z.12 CEREBELLAR INFARCTION 
G64z100 WALLENBERG SYNDROME 
G64z111 LATERAL MEDULLARY SYNDROME 
G64z200 LEFT SIDED CEREBRAL INFARCTION 
G64z300 RIGHT SIDED CEREBRAL INFARCTION 
G65..00 TRANSIENT CEREBRAL ISCHAEMIA 
G65..12 TRANSIENT ISCHAEMIC ATTACK 
G65..13 VERTEBRO-BASILAR INSUFFICIENCY 
G650.00 BASILAR ARTERY SYNDROME 
G650.11 INSUFFICIENCY - BASILAR ARTERY 
G651.00 VERTEBRAL ARTERY SYNDROME 
G651000 VERTEBRO-BASILAR ARTERY SYNDROME 
G652.00 SUBCLAVIAN STEAL SYNDROME 
G653.00 CAROTID ARTERY SYNDROME HEMISPHERIC 
G654.00 MULTIPLE AND BILATERAL PRECEREBRAL ARTERY 
SYNDROMES 
G655.00 TRANSIENT GLOBAL AMNESIA 
G65y.00 OTHER TRANSIENT CEREBRAL ISCHAEMIA 
G65z.00 TRANSIENT CEREBRAL ISCHAEMIA NOS 
G65z000 IMPENDING CEREBRAL ISCHAEMIA 
G65z100 INTERMITTENT CEREBRAL ISCHAEMIA 
G65zz00 TRANSIENT CEREBRAL ISCHAEMIA NOS 
G66..00 STROKE AND CEREBROVASCULAR ACCIDENT 
UNSPECIFIED 
G66..11 CVA UNSPECIFIED 
G66..12 STROKE UNSPECIFIED 
G66..13 CVA - CEREBROVASCULAR ACCIDENT UNSPECIFIED 
G660.00 MIDDLE CEREBRAL ARTERY SYNDROME 
G661.00 ANTERIOR CEREBRAL ARTERY SYNDROME 
G662.00 POSTERIOR CEREBRAL ARTERY SYNDROME 
G663.00 BRAIN STEM STROKE SYNDROME 




G665.00 PURE MOTOR LACUNAR SYNDROME 
G666.00 PURE SENSORY LACUNAR SYNDROME 
G667.00 LEFT SIDED CVA 
G668.00 RIGHT SIDED CVA 
G67..00 OTHER CEREBROVASCULAR DISEASE 
G670.00 CEREBRAL ATHEROSCLEROSIS 
G670.11 PRECEREBRAL ATHEROSCLEROSIS 
G671.00 GENERALISED ISCHAEMIC CEREBROVASCULAR 
DISEASE NOS 
G671000 ACUTE CEREBROVASCULAR INSUFFICIENCY NOS 
G671100 CHRONIC CEREBRAL ISCHAEMIA 
G671z00 GENERALISED ISCHAEMIC CEREBROVASCULAR 
DISEASE NOS 
G673.00 CEREBRAL ANEURYSM, NONRUPTURED 
G673000 DISSECTION OF CEREBRAL ARTERIES, NONRUPTURED 
G674.00 CEREBRAL ARTERITIS 
G675.00 MOYAMOYA DISEASE 
G676.00 NONPYOGENIC VENOUS SINUS THROMBOSIS 
G676000 CEREB INFARCT DUE CEREBRAL VENOUS 
THROMBOSIS, NONPYOGENIC 
G677.00 OCCLUSION/STENOSIS CEREBRAL ARTS NOT RESULT 
CEREBRAL INFARCT 
G677000 OCCLUSION AND STENOSIS OF MIDDLE CEREBRAL 
ARTERY 
G677100 OCCLUSION AND STENOSIS OF ANTERIOR CEREBRAL 
ARTERY 
G677200 OCCLUSION AND STENOSIS OF POSTERIOR CEREBRAL 
ARTERY 
G677300 OCCLUSION AND STENOSIS OF CEREBELLAR 
ARTERIES 





G679.00 SMALL VESSEL CEREBROVASCULAR DISEASE 
G67y.00 OTHER CEREBROVASCULAR DISEASE  
G67z.00 OTHER CEREBROVASCULAR DISEASE 
G68..00 LATE EFFECTS OF CEREBROVASCULAR DISEASE 
G680.00 SEQUELAE OF SUBARACHNOID HAEMORRHAGE 
G681.00 SEQUELAE OF INTRACEREBRAL HAEMORRHAGE 
G682.00 SEQUELAE OF OTHER NONTRAUMATIC 
INTRACRANIAL HAEMORRHAGE 
G683.00 SEQUELAE OF CEREBRAL INFARCTION 
G68W.00 SEQUELAE/OTHER + UNSPECIFIED 
CEREBROVASCULAR DISEASES 
G68X.00 SEQUELAE OF STROKE,NOT SPECFD AS H'MORRHAGE 
OR INFARCTION 
G6W..00 CEREB INFARCT DUE UNSP OCCLUS/STENOS 
PRECEREBR ARTERIES 
G6X..00 CEREBRL INFARCTN DUE/UNSPCF OCCLUSN OR 
STEN/CEREBRL ARTRS 
G6y..00 OTHER SPECIFIED CEREBROVASCULAR DISEASE 
G6z..00 CEREBROVASCULAR DISEASE NOS 
Gyu6.00 CEREBROVASCULAR DISEASES 
Gyu6000 SUBARACHNOID HAEMORRHAGE FROM OTHER 
INTRACRANIAL ARTERIES 
Gyu6100 OTHER SUBARACHNOID HAEMORRHAGE 
Gyu6200 OTHER INTRACEREBRAL HAEMORRHAGE 
Gyu6300 CEREBRL INFARCTN DUE/UNSPCF OCCLUSN OR 
STEN/CEREBRL ARTRS 
Gyu6400 OTHER CEREBRAL INFARCTION 
Gyu6500 OCCLUSION AND STENOSIS OF OTHER PRECEREBRAL 
ARTERIES 
Gyu6600 OCCLUSION AND STENOSIS OF OTHER CEREBRAL 
ARTERIES 




Gyu6800 CEREBRAL ARTERITIS IN INFECTIOUS AND PARASITIC 
DISEASES 
Gyu6900 CEREBRAL ARTERITIS IN OTHER DISEASES CE 
Gyu6A00 OTHER CEREBROVASCULAR DISORDERS IN DISEASES 
CE 
Gyu6B00 SEQUELAE OF OTHER NONTRAUMATIC 
INTRACRANIAL HAEMORRHAGE 
Gyu6C00 SEQUELAE OF STROKE, NOT SPECFD AS H'MORRHAGE 
OR INFARCTION 
Gyu6D00 SEQUELAE/OTHER + UNSPECIFIED 
CEREBROVASCULAR DISEASES 
Gyu6E00 SUBARACHNOID HAEMORRH FROM INTRACRANIAL 
ARTERY, UNSPECIF 
Gyu6F00 INTRACEREBRAL HAEMORRHAGE IN HEMISPHERE, 
UNSPECIFIED 
Gyu6G00 CEREB INFARCT DUE UNSP OCCLUS/STENOS 
PRECEREBR ARTERIES 
L417.00 OBSTETRIC CEREBRAL VENOUS THROMBOSIS 
L417000 CEREBRAL VENOUS THROMBOSIS IN PREGNANCY 
L417100 CEREBRAL VENOUS THROMBOSIS IN THE 
PUERPERIUM 
L440.00 CEREBROVASCULAR DISORDERS IN THE PUERPERIUM 
L440.11 CVA- CEREBROVASCULAR ACCIDENT IN THE 
PUERPERIUM 
L440.12 STROKE IN THE PUERPERIUM 
L440000 PUERPERAL CEREBROVASCULAR DISORDER 
UNSPECIFIED 
L440100 PUERPERAL CEREBROVASCULAR DISORDER - 
DELIVERED 
L440200 PUERPERAL CEREBROVASCULAR DISORDER - 




L440300 PUERPERAL CEREBROVASCULAR DISORDER WITH 
ANTENATAL COMP 
L440400 PUERPERAL CEREBROVASCULAR DISORDER WITH 
POSTNATAL COMP 
L440z00 PUERPERAL CEREBROVASCULAR DISORDER NOS 
P7y0.00 CEREBROVASCULAR SYSTEM ANOMALIES 
P7y0100 CONGENITAL CEREBRAL ARTERIOVENOUS 
ANEURYSM 
P7y0112 CONGENITAL CEREBRAL ARTERIOVENOUS 
MALFORMATION 
P7y0300 CONGENITAL STRICTURE OF CEREBRAL ARTERY 
P7y0y00 OTHER SPECIFIED CEREBROVASCULAR ANOMALY 
P7y0z00 CEREBROVASCULAR SYSTEM ANOMALY NOS 
Pyu2C00 [X]OTHER MALFORMATIONS OF PRECEREBRAL 
VESSELS 
Pyu2D00 [X]OTHER MALFORMATIONS OF CEREBRAL VESSELS 
S62..00 CEREBRAL HAEMORRHAGE FOLLOWING INJURY 
S62..11 EXTRADURAL HAEMORRHAGE FOLLOWING INJURY 
S62..12 SUBARACHNOID HAEMORRHAGE FOLLOWING INJURY 
S62..13 SUBDURAL HAEMORRHAGE FOLLOWING INJURY 
S62..14 TRAUMATIC CEREBRAL HAEMORRHAGE 
S620.00 CLOSED TRAUMATIC SUBARACHNOID 
HAEMORRHAGE 
S620.11 MIDDLE MENINGEAL HAEMMORHAGE FOLLOWING 
INJURY 
S620000 SUBARACHNOID H'GE INJ NO OPEN INTRACRAN 
WOUND + UNSPEC CONSC 
S620100 SUBARACHNOID H'GE INJ NO OPEN INTRACRAN 
WND+NO LOSS CONSC 
S620200 SUBARACHNOID H'GE INJ NO OPEN INTRACRAN 




S620300 SUBARACHNOID H'GE INJ NO OPEN INTRACRAN 
WOUND + 1-24HR LOC 
S620400 SUBARACHNOID H'GE INJ NO OPEN INTRACRAN 
WND+>24 LOC+RECOVERY 
S620500 SUBARACH H'GE INJ NO OPEN INTRACRAN 
WND+>24HRS LOC-RESTORED 
S620600 SUBARACH H'GE INJ NO OPEN INTRACRAN WND+LOC 
UNSPEC DURATION 
S620z00 SUBARACH H'GE INJ NO OPEN INTRACRAN WND + 
CONCUSSION UNSPEC 
S621.00 OPEN TRAUMATIC SUBARACHNOID HAEMORRHAGE 
S621000 SUBARACHNOID H'GE INJ + OPEN INTRACRAN WOUND 
+ UNSPEC CONSC 
S621100 SUBARACHNOID H'GE INJ + OPEN INTRACRANIAL 
WOUND + NO LOC 
S621200 SUBARACHNOID H'GE INJ + OPEN INTRACRAN 
WOUND+<1HR LOSS CONSC 
S621300 SUBARACHNOID H'GE INJ + OPEN INTRACRAN WND+1-
24HR LOSS CONSC 
S621400 SUBARACH H'GE INJ + OPEN INTRACRAN WND +>24HR 
LOC + RECOVERY 
S621500 SUBARACH H'GE INJ + OPEN INTRACRAN WND+>24HR 
LOC -RESTORED 
S621600 SUBARACH H'GE INJ + OPEN INTRACRAN WND+LOC 
UNSPEC DURATION 
S621z00 SUBARACHNOID H'GE INJ + OPEN INTRACRAN 
WND+CONCUSSION UNSPEC 
S622.00 CLOSED TRAUMATIC SUBDURAL HAEMORRHAGE 
S622000 SUBDURAL H'GE INJ NO OPEN INTRACRANIAL WND + 
UNSPEC CONSC 
S622100 SUBDURAL H'GE INJ NO OPEN INTRACRANIAL 




S622200 SUBDURAL H'GE INJ NO OPEN INTRACRANIAL 
WOUND+<1HR LOSS CONSC 
S622300 SUBDURAL H'GE INJ NO OPEN INTRACRAN WND+1-
24HR LOSS CONSC 
S622400 SUBDURAL H'GE INJ NO OPEN INTRACRANIAL 
WND+>24 LOC +RECOVERY 
S622500 SUBDURAL H'GE INJ NO OPEN INTRACRAN 
WND+>24HR LOC -RESTORED 
S622600 SUBDURAL H'GE INJ NO OPEN INTRACRAN WND+LOC 
UNSPEC DURATION 
S622z00 SUBDURAL H'GE INJ NO OPEN INTRACRAN 
WOUND+CONCUSSION UNSPEC 
S623.00 OPEN TRAUMATIC SUBDURAL HAEMORRHAGE 
S623000 SUBDURAL H'GE INJ + OPEN INTRACRANIAL WOUND + 
UNSPEC CONSC 
S623100 SUBDURAL H'GE INJ + OPEN INTRACRANIAL 
WOUND+NO LOSS CONSC 
S623200 SUBDURAL H'GE INJ + OPEN INTRACRANIAL 
WOUND+<1HR LOSS CONSC 
S623300 SUBDURAL H'GE INJ + OPEN INTRACRANIAL WND+1-
24HR LOSS CONSC 
S623400 SUBDURAL H'GE INJ + OPEN INTRACRAN 
WOUND+>24HR LOC +RECOVERY 
S623500 SUBDURAL H'GE INJ + OPEN INTRACRAN WND+>24HR 
LOC -RESTORED 
S623600 SUBDURAL H'GE INJ + OPEN INTRACRAN WND+LOC 
UNSPEC DURATION 
S623z00 SUBDURAL H'GE INJ + OPEN INTRACRANIAL 
WND+CONCUSSION UNSPEC 
S624.00 CLOSED TRAUMATIC EXTRADURAL HAEMORRHAGE 
S624000 EXTRADURAL H'GE INJ NO OPEN INTRACRANIAL WND 




S624100 EXTRADURAL H'GE INJ NO OPEN INTRACRANIAL WND 
+ NO LOSS CONSC 
S624200 EXTRADURAL H'GE INJ NO OPEN INTRACRANIAL 
WND+<1HR LOSS CONSC 
S624300 EXTRADURAL H'GE INJ NO OPEN INTRACRAN WND+1-
24HR LOSS CONSC 
S624400 EXTRADURAL H'GE INJ NO OPEN INTRACRAN 
WND+>24HR LOC+RECOVERY 
S624500 EXTRADURAL H'GE INJ NO OPEN INTRACRAN 
WND+>24HR LOC-RESTORED 
S624600 EXTRADURAL H'GE INJ NO OPEN INTRACRA WND+LOC 
UNSPEC DURATION 
S624z00 EXTRADURAL H'GE INJ NO OPEN INTRACRAN 
WND+CONCUSSION UNSPEC 
S625.00 OPEN TRAUMATIC EXTRADURAL HAEMORRHAGE 
S625000 EXTRADURAL H'GE INJ + OPEN INTRACRANIAL WND + 
UNSPEC CONSC 
S625100 EXTRADURAL H'GE INJ + OPEN INTRACRANIAL 
WOUND+NO LOSS CONSC 
S625200 EXTRADURAL H'GE INJ + OPEN INTRACRANIAL 
WND+<1HR LOSS CONSC 
S625300 EXTRADURAL H'GE INJ + OPEN INTRACRAN WND+1-
24HR LOSS CONSC 
S625400 EXTRADURAL H'GE INJ + OPEN INTRACRAN 
WND+>24HR LOC+RECOVERY 
S625500 EXTRADURAL H'GE INJ + OPEN INTRACRAN 
WND+>24HR LOC -RESTORED 
S625600 EXTRADURAL H'GE INJ + OPEN INTRACRAN WND+LOC 
UNSPEC DURATION 
S625z00 EXTRADURAL H'GE INJ + OPEN INTRACRAN 
WND+CONCUSSION UNSPEC 




S628.00 TRAUMATIC SUBDURAL HAEMORRHAGE 
S629.00 TRAUMATIC SUBDURAL HAEMATOMA 
S629000 TRAUMATIC SUBDURAL HAEMATOMA WITHOUT OPEN 
INTRACRANIAL WOUND 
S629100 TRAUMATIC SUBDURAL HAEMATOMA WITH OPEN 
INTRACRANIAL WOUND 
S62A.00 TRAUMATIC EXTRADURAL HAEMATOMA 
S62A000 TRAUMATIC EXTRADURAL HAEMAT WITHOUT OPEN 
INTRACRANIAL WOUND 
S62A100 TRAUMATIC EXTRADURAL HAEMATOMA WITH OPEN 
INTRACRANIAL WOUND 
S62z.00 CEREBRAL HAEMORRHAGE FOLLOWING INJURY NOS 
S63..00 OTHER CEREBRAL HAEMORRHAGE FOLLOWING 
INJURY 
S630.00 OTHER CEREBRAL H'GE AFTER INJURY NO OPEN 
INTRACRANIAL WOUND 
S630.12 INTRACRANIAL HAEMATOMA FOLLOWING INJURY 
S630000 OTH CEREBRAL H'GE INJ NO OPEN INTRACRAN 
WND+UNSPEC CONSC 
S630100 OTH CEREBRAL H'GE INJ NO OPEN INTRACRANIAL 
WND+NO LOSS CONSC 
S630200 OTH CEREBRAL H'GE INJ NO OPEN INTRACRAN 
WND+<1HR LOSS CONSC 
S630300 OTH CEREBRAL H'GE INJ NO OPEN INTRACRAN 
WND+1-24HR LOC 
S630400 OTH CEREB H'GE INJ NO OPEN INTRACRAN 
WND+>24HR LOC +RECOVERY 
S630500 OTH CEREB H'GE INJ NO OPEN INTRACRAN 
WND+>24HR LOC -RESTORED 





S630z00 OTH CEREB H'GE INJ NO OPEN INTRACRAN 
WND+CONCUSSION UNSPEC 
S631.00 OTHER CEREBRAL H'GE AFTER INJURY + OPEN 
INTRACRANIAL WOUND 
S631000 OTH CEREBRAL H'GE INJ + OPEN INTRACRAN WND + 
UNSPEC CONSC 
S631100 OTH CEREBRAL H'GE INJ + OPEN INTRACRANIAL 
WND+NO LOSS CONSC 
S631200 OTH CEREBRAL H'GE INJ + OPEN INTRACRAN 
WND+<1HR LOSS CONSC 
S631300 OTH CEREBRAL H'GE INJ + OPEN INTRACRAN WND+1-
24HR LOSS CONSC 
S631400 OTH CEREB H'GE INJ + OPEN INTRACRAN WND+>24HR 
LOC + RECOVERY 
S631500 OTH CEREB H'GE INJ + OPEN INTRACRAN WND+>24HR 
LOC -RESTORED 
S631600 OTH CEREB H'GE INJ + OPEN INTRACRAN WND+LOC 
UNSPEC DURATION 
S631z00 OTH CEREB H'GE INJ + OPEN INTRACRAN 
WND+CONCUSSION UNSPEC 
S63z.00 OTHER CEREBRAL HAEMORRHAGE FOLLOWING 
INJURY NOS 
ZV12511 PERSONAL HISTORY OF STROKE 







Appendix 9-10. Cardiovascular (CV) disease codes 
Code Description  
14A..00 H/O: CARDIOVASCULAR DISEASE 
14AH.00 H/O: MYOCARDIAL INFARCTION IN LAST YEAR 
G3...00 ISCHAEMIC HEART DISEASE 
G3...11 ARTERIOSCLEROTIC HEART DISEASE 
G3...12 ATHEROSCLEROTIC HEART DISEASE 
G3...13 IHD - ISCHAEMIC HEART DISEASE 
G30..00 ACUTE MYOCARDIAL INFARCTION 
G30..11 ATTACK - HEART 
G30..12 CORONARY THROMBOSIS 
G30..13 CARDIAC RUPTURE FOLLOWING MYOCARDIAL 
INFARCTION (MI) 
G30..14 HEART ATTACK 
G30..15 MI - ACUTE MYOCARDIAL INFARCTION 
G30..16 THROMBOSIS - CORONARY 
G30..17 SILENT MYOCARDIAL INFARCTION 
G300.00 ACUTE ANTEROLATERAL INFARCTION 
G301.00 OTHER SPECIFIED ANTERIOR MYOCARDIAL 
INFARCTION 
G301000 ACUTE ANTEROAPICAL INFARCTION 
G301100 ACUTE ANTEROSEPTAL INFARCTION 
G301z00 ANTERIOR MYOCARDIAL INFARCTION NOS 
G302.00 ACUTE INFEROLATERAL INFARCTION 
G303.00 ACUTE INFEROPOSTERIOR INFARCTION 
G304.00 POSTERIOR MYOCARDIAL INFARCTION NOS 
G305.00 LATERAL MYOCARDIAL INFARCTION NOS 
G306.00 TRUE POSTERIOR MYOCARDIAL INFARCTION 
G307.00 ACUTE SUBENDOCARDIAL INFARCTION 
G307000 ACUTE NON-Q WAVE INFARCTION 





G308.00 INFERIOR MYOCARDIAL INFARCTION NOS 
G309.00 ACUTE Q-WAVE INFARCT 
G30A.00 MURAL THROMBOSIS 
G30B.00 ACUTE POSTEROLATERAL MYOCARDIAL INFARCTION 
G30X.00 ACUTE TRANSMURAL MYOCARDIAL INFARCTION OF 
UNSPECIFIC SITE 
G30X000 ACUTE ST SEGMENT ELEVATION MYOCARDIAL 
INFARCTION 
G30y.00 OTHER ACUTE MYOCARDIAL INFARCTION 
G30y000 ACUTE ATRIAL INFARCTION 
G30y200 ACUTE SEPTAL INFARCTION 
G30yz00 OTHER ACUTE MYOCARDIAL INFARCTION NOS 
G30z.00 ACUTE MYOCARDIAL INFARCTION NOS 
G311.11 CRESCENDO ANGINA 
G311.13 UNSTABLE ANGINA 
G311.14 ANGINA AT REST 
G311100 UNSTABLE ANGINA 
G311200 ANGINA AT REST 
G311300 REFRACTORY ANGINA 
G311400 WORSENING ANGINA 
G311500 ACUTE CORONARY SYNDROME 
G312.00 CORONARY THROMBOSIS NOT RESULTING IN 
MYOCARDIAL INFARCTION 
G31y.00 OTHER ACUTE AND SUBACUTE ISCHAEMIC HEART 
DISEASE 
G31y000 ACUTE CORONARY INSUFFICIENCY 
G32..00 OLD MYOCARDIAL INFARCTION 
G33..00 ANGINA PECTORIS 
G33z.00 ANGINA PECTORIS NOS 
G33z300 ANGINA ON EFFORT 
G33z400 ISCHAEMIC CHEST PAIN 




G33zz00 ANGINA PECTORIS NOS 
G340.00 CORONARY ATHEROSCLEROSIS 
G340.11 TRIPLE VESSEL DISEASE OF THE HEART 
G340.12 CORONARY ARTERY DISEASE 
G340000 SINGLE CORONARY VESSEL DISEASE 
G340100 DOUBLE CORONARY VESSEL DISEASE 
G343.00 ISCHAEMIC CARDIOMYOPATHY 
G34z000 ASYMPTOMATIC CORONARY HEART DISEASE 
G3z..00 ISCHAEMIC HEART DISEASE NOS 
G70y011 CAROTID ARTERY DISEASE 
G32..11 HEALED MYOCARDIAL INFARCTION 
G32..12 PERSONAL HISTORY OF MYOCARDIAL INFARCTION 
G211100 BENIGN HYPERTENSIVE HEART DISEASE WITH CCF 
G21z100 HYPERTENSIVE HEART DISEASE NOS WITH CCF 
G232.00 HYPERTENSIVE HEART & RENAL DIS WITH 
(CONGESTIVE) HEART FAILURE 
G234.00 HYPERTENSIVE HEART & RENAL DIS 
+BOTH(CONGESTIVE)HEART AND RENAL FAIL 
G343.00 ISCHAEMIC CARDIOMYOPATHY 
G55..00 CARDIOMYOPATHY 
G550.00 ENDOMYOCARDIAL FIBROSIS 
G58..00 HEART FAILURE 
G58..11 CARDIAC FAILURE 
G580.00 CONGESTIVE HEART FAILURE 
G580.11 CONGESTIVE CARDIAC FAILURE 
G580.14 BIVENTRICULAR FAILURE 
G580000 ACUTE CONGESTIVE HEART FAILURE 
G580100 CHRONIC CONGESTIVE HEART FAILURE 
G580200 DECOMPENSATED CARDIAC FAILURE 
G580300 COMPENSATED CARDIAC FAILURE 
G581.00 LEFT VENTRICULAR FAILURE 




G581.13 IMPAIRED LEFT VENTRICULAR FUNCTION 
G581000 ACUTE LEFT VENTRICULAR FAILURE 
G582.00 ACUTE HEART FAILURE 
G58z.00 HEART FAILURE NOS 
G58z.12 CARDIAC FAILURE NOS 
1O1..00 HEART FAILURE CONFIRMED 
8B29.00 CARDIAC FAILURE THERAPY 
8CL3.00 HEART FAILURE CARE PLAN DISCUSSED WITH 
PATIENT 
8H2S.00 ADMIT HEART FAILURE EMERGENCY 
G554000 CONGESTIVE CARDIOMYOPATHY 
G631.11 STENOSIS, CAROTID ARTERY 
G634.00 CAROTID ARTERY STENOSIS 
G65z.00 TRANSIENT CEREBRAL ISCHAEMIA NOS 
G70z.00 ARTERIOSCLEROTIC VASCULAR DISEASE NOS 
G73..00 OTHER PERIPHERAL VASCULAR DISEASE 
G73..11 PERIPHERAL ISCHAEMIC VASCULAR DISEASE 
G73..12 ISCHAEMIA OF LEGS 
G73..13 PERIPHERAL ISCHAEMIA 
G732.00 PERIPHERAL GANGRENE 
G732000 GANGRENE OF TOE 
G732100 GANGRENE OF FOOT 
G73yz00 OTHER SPECIFIED PERIPHERAL VASCULAR DISEASE 
NOS 
G734.00 PERIPHERAL ARTERIAL DISEASE 
G73z.00 PERIPHERAL VASCULAR DISEASE NOS 
G73z000 INTERMITTENT CLAUDICATION 
G73z011 CLAUDICATION 
G73zz00 PERIPHERAL VASCULAR DISEASE NOS 
G71z.00 AORTIC ANEURYSM 





7A14.11 AORTIC ANEURYSM REPAIR 
14NB.00 H/O: PERIPHERAL VASCULAR DISEASE PROCEDURE 
G71..00 AORTIC ANEURYSM 
G713.11 RUPTURED ABDOMINAL AORTIC ANEURYSM 
Gyu7400 OTHER SPECIFIED PERIPHERAL VASCULAR DISEASES 
G3...11 ARTERIOSCLEROTIC HEART DISEASE 
G309.00  ACUTE Q-WAVE INFARCT 
G30y100 ACUTE PAPILLARY MUSCLE INFARCTION 
G31..00 OTHER ACUTE AND SUBACUTE ISCHAEMIC HEART 
DISEASE 
G311.00 PREINFARCTION SYNDROME 
G311.12 IMPENDING INFARCTION 
G311000 MYOCARDIAL INFARCTION ABORTED 
G311011 MI - MYOCARDIAL INFARCTION ABORTED 
G311100  UNSTABLE ANGINA 
G311z00 PREINFARCTION SYNDROME NOS 
G31y100 MICROINFARCTION OF HEART 
G31y200 SUBENDOCARDIAL ISCHAEMIA 
G31y300 TRANSIENT MYOCARDIAL ISCHAEMIA 
G31yz00 OTHER ACUTE AND SUBACUTE ISCHAEMIC HEART 
DISEASE NOS 
G33z100 STENOCARDIA 
G330.00 ANGINA DECUBITUS  
 G33z000 STATUS ANGINOSUS 
G330z00 ANGINA DECUBITUS NOS 
G330000 NOCTURNAL ANGINA 
 G33zz00 ANGINA PECTORIS NOS 
G33z200 SYNCOPE ANGINOSA  
G33z500 POST INFARCT ANGINA 
G33z600 NEW ONSET ANGINA 
G34..00 OTHER CHRONIC ISCHAEMIC HEART DISEASE 




G344.00 SILENT MYOCARDIAL ISCHAEMIA 
G34y.00 OTHER SPECIFIED CHRONIC ISCHAEMIC HEART 
DISEASE 
G34y000 CHRONIC CORONARY INSUFFICIENCY 
G34y100 CHRONIC MYOCARDIAL ISCHAEMIA 
G34yz00 OTHER SPECIFIED CHRONIC ISCHAEMIC HEART 
DISEASE NOS 
G34z.00 OTHER CHRONIC ISCHAEMIC HEART DISEASE NOS 
G35..00 SUBSEQUENT MYOCARDIAL INFARCTION 
G350.00 SUBSEQUENT MYOCARDIAL INFARCTION OF 
ANTERIOR WALL 
G351.00 SUBSEQUENT MYOCARDIAL INFARCTION OF INFERIOR 
WALL 
G353.00 SUBSEQUENT MYOCARDIAL INFARCTION OF OTHER 
SITES 
G35X.00 SUBSEQUENT MYOCARDIAL INFARCTION OF 
UNSPECIFIED SITE 
G360.00 HAEMOPERICARDIUM/CURRENT COMP FOLOW ACUT 
MYOCARD INFARCT 
G362.00 VENTRIC SEPTAL DEFECT/CURR COMP FOL ACUT 
MYOCARDAL INFARCTN 
G363.00 RUPTURE CARDIAC WALL W'OUT 
HAEMOPERICARD/CUR COMP FOL AC MI 
G364.00 RUPTURE CHORDAE TENDINAE/CURR COMP FOL 
ACUTE MI 
G365.00 RUPTURE PAPILLARY MUSCLE/CURR COMP FOL ACUTE 
MI 
G38..00 POSTOPERATIVE MYOCARDIAL INFARCTION 
G380.00 POSTOPERATIVE TRANSMURAL MYOCARDIAL 
INFARCTION ANTERIOR WALL 
G381.00 POSTOPERATIVE TRANSMURAL MYOCARDIAL 




G382.00 POSTOPERATIVE TRANSMURAL MYOCARDIAL 
INFARCTION OTHER SITES 
G383.00 POSTOPERATIVE TRANSMURAL MYOCARDIAL 
INFARCTION UNSPECIFIC SITE  
G38z.00 POSTOPERATIVE MYOCARDIAL INFARCTION, 
UNSPECIFIED 
G39..00 CORONARY MICROVASCULAR DISEASE 
G3y..00 OTHER SPECIFIED ISCHAEMIC HEART DISEASE 
G574011 CARDIAC ARREST-VENTRICULAR FIBRILLATION 
G575.00 CARDIAC ARREST 
G575.11 CARDIO-RESPIRATORY ARREST 
Gyu3.00 [X]ISCHAEMIC HEART DISEASES 
Gyu3000 [X]OTHER FORMS OF ANGINA PECTORIS 
Gyu3200 [X]OTHER FORMS OF ACUTE ISCHAEMIC HEART 
DISEASE  
G384.00 POSTOPERATIVE SUBENDOCARDIAL MYOCARDIAL 
INFARCTION 
Gyu3300 [X]OTHER FORMS OF CHRONIC ISCHAEMIC HEART 
DISEASE   
Gyu3500 [X]SUBSEQUENT MYOCARDIAL INFARCTION OF 
OTHER SITES 
Gyu3400 [X]ACUTE TRANSMURAL MYOCARDIAL INFARCTION 
OF UNSPECIFIC SITE 
 Gyu3600 [X]SUBSEQUENT MYOCARDIAL INFARCTION OF 
UNSPECIFIED SITE 
Fyu5500 [X]OTHER TRANSIT CEREBRAL ISCHAEMIC ATTACKS + 
RELATED SYNDROMES 
G657.00 CAROTID TERRITORY TRANSIENT ISCHAEMIC ATTACK 







Appendix 9-11. Depression codes 
146D.00 H/O: MANIC DEPRESSIVE DISORDER 
1B17.00 DEPRESSED 
62T1.00 PUERPERAL DEPRESSION 
8BK0.00 DEPRESSION MANAGEMENT PROGRAMME 
8CAa.00 PATIENT GIVEN ADVICE ABOUT MANAGEMENT OF 
DEPRESSION 
8HHq.00 REFERRAL FOR GUIDED SELF-HELP FOR DEPRESSION 
9H90.00 DEPRESSION ANNUAL REVIEW 
9H91.00 DEPRESSION MEDICATION REVIEW 
9H92.00 DEPRESSION INTERIM REVIEW 
9HA0.00 ON DEPRESSION REGISTER 
9k4..00 DEPRESSION - ENHANCED SERVICES ADMINISTRATION 
9k40.00 DEPRESSION - ENHANCED SERVICE COMPLETED 
9kQ..00 ON FULL DOSE LONG TERM TREATMENT DEPRESSION  
E001300 PRESENILE DEMENTIA WITH DEPRESSION 
E002.00 SENILE DEMENTIA WITH DEPRESSIVE OR PARANOID 
FEATURES 
E002100 SENILE DEMENTIA WITH DEPRESSION 
E002z00 SENILE DEMENTIA WITH DEPRESSIVE OR PARANOID 
FEATURES 
E004300 ARTERIOSCLEROTIC DEMENTIA WITH DEPRESSION 
E11..12 DEPRESSIVE PSYCHOSES 
E112.00 SINGLE MAJOR DEPRESSIVE EPISODE 
E112.11 AGITATED DEPRESSION 
E112.12 ENDOGENOUS DEPRESSION FIRST EPISODE 
E112.13 ENDOGENOUS DEPRESSION FIRST EPISODE 
E112.14 ENDOGENOUS DEPRESSION 
E112000 SINGLE MAJOR DEPRESSIVE EPISODE, UNSPECIFIED 
E112100 SINGLE MAJOR DEPRESSIVE EPISODE, MILD 




E112300 SINGLE MAJOR DEPRESSIVE EPISODE, SEVERE, 
WITHOUT PSYCHOSIS 
E112400 SINGLE MAJOR DEPRESSIVE EPISODE, SEVERE, WITH 
PSYCHOSIS 
E112500 SINGLE MAJOR DEPRESSIVE EPISODE, PARTIAL OR 
UNSPECIFIC REMISSION 
E112600 SINGLE MAJOR DEPRESSIVE EPISODE, IN FULL 
REMISSION 
E112z00 SINGLE MAJOR DEPRESSIVE EPISODE NOS 
E113.00 RECURRENT MAJOR DEPRESSIVE EPISODE 
E113.11 ENDOGENOUS DEPRESSION - RECURRENT 
E113000 RECURRENT MAJOR DEPRESSIVE EPISODES, 
UNSPECIFIED 
E113100 RECURRENT MAJOR DEPRESSIVE EPISODES, MILD 
E113200 RECURRENT MAJOR DEPRESSIVE EPISODES, MODERATE 
E113300 RECURRENT MAJOR DEPRESSIVE EPISODES, SEVERE, 
NO PSYCHOSIS 
E113400 RECURRENT MAJOR DEPRESSIVE EPISODES, SEVERE, 
WITH PSYCHOSIS 
E113500 RECURRENT MAJOR DEPRESSIVE EPISODES, 
PARTIAL/UNSPECIFIC REMISSION 
E113600 RECURRENT MAJOR DEPRESSIVE EPISODES, IN FULL 
REMISSION 
E113700 RECURRENT DEPRESSION 
E113z00 RECURRENT MAJOR DEPRESSIVE EPISODE NOS 
E114.11 MANIC-DEPRESSIVE - NOW MANIC 
E115.00 BIPOLAR AFFECTIVE DISORDER, CURRENTLY 
DEPRESSED 
E115.11 MANIC-DEPRESSIVE - NOW DEPRESSED 





E115100 BIPOLAR AFFECTIVE DISORDER, CURRENTLY 
DEPRESSED, MILD 
E115200 BIPOLAR AFFECTIVE DISORDER, CURRENTLY 
DEPRESSED, MODERATE 
E115300 BIPOLAR AFFECT DISORDER, NOW DEPRESSED, SEVERE, 
NO PSYCHOSIS 
E115600 BIPOLAR AFFECTIVE DISORDER, NOW DEPRESSED, IN 
FULL REMISSION 
E115z00 BIPOLAR AFFECTIVE DISORDER, CURRENTLY 
DEPRESSED 
E11y.00 OTHER AND UNSPECIFIED MANIC-DEPRESSIVE 
PSYCHOSES 
E11y000 UNSPECIFIED MANIC-DEPRESSIVE PSYCHOSES 
E11y200 ATYPICAL DEPRESSIVE DISORDER 
E11y300 OTHER MIXED MANIC-DEPRESSIVE PSYCHOSES 
E11yz00 OTHER AND UNSPECIFIED MANIC-DEPRESSIVE 
PSYCHOSES 
E11z200 MASKED DEPRESSION 
E130.00 REACTIVE DEPRESSIVE PSYCHOSIS 
E130.11 PSYCHOTIC REACTIVE DEPRESSION 
E135.00 AGITATED DEPRESSION 
E200300 ANXIETY WITH DEPRESSION 
E204.00 NEUROTIC DEPRESSION REACTIVE TYPE 
E204.11 POSTNATAL DEPRESSION 
E211200 DEPRESSIVE PERSONALITY DISORDER 
E290.00 BRIEF DEPRESSIVE REACTION 
E290z00 BRIEF DEPRESSIVE REACTION NOS 
E291.00 PROLONGED DEPRESSIVE REACTION 
E2B..00 DEPRESSIVE DISORDER NEC 
E2B0.00 DEPRESSIVE DISORDER NEC 
E2B1.00 CHRONIC DEPRESSION 




Eu20400 POST-SCHIZOPHRENIC DEPRESSION 
Eu32.00 DEPRESSIVE EPISODE 
Eu32.11 SINGLE EPISODE OF DEPRESSIVE REACTION 
Eu32.12 SINGLE EPISODE OF PSYCHOGENIC DEPRESSION 
Eu32.13 SINGLE EPISODE OF REACTIVE DEPRESSION 
Eu32000 MILD DEPRESSIVE EPISODE 
Eu32100 MODERATE DEPRESSIVE EPISODE 
Eu32200 SEVERE DEPRESSIVE EPISODE WITHOUT PSYCHOTIC 
SYMPTOMS 
Eu32211 SINGLE EPISODE AGITATED DEPRESSION WITHOUT 
PSYCHOTIC SYMPTOMS 
Eu32212 SINGLE EPISODE MAJOR DEPRESSION WITHOUT 
PSYCHOTIC SYMPTOMS 
Eu32213 SINGLE EPISODE VITAL DEPRESSION WITHOUT  
PSYCHOTIC SYMPTOMS 
Eu32300 SEVERE DEPRESSIVE EPISODE WITH PSYCHOTIC 
SYMPTOMS 
Eu32311 SINGLE EPISODE OF MAJOR DEPRESSION AND 
PSYCHOTIC SYMPTOMS 
Eu32312 SINGLE EPISODE OF PSYCHOGENIC DEPRESSIVE 
PSYCHOSIS 
Eu32313 SINGLE EPISODE OF PSYCHOTIC DEPRESSION 
Eu32314 SINGLE EPISODE OF REACTIVE DEPRESSIVE PSYCHOSIS 
Eu32400 MILD DEPRESSION 
Eu32500 MAJOR DEPRESSION, MILD 
Eu32600 MAJOR DEPRESSION, MODERATELY SEVERE 
Eu32700 MAJOR DEPRESSION, SEVERE WITHOUT PSYCHOTIC 
SYMPTOMS 
Eu32800 MAJOR DEPRESSION, SEVERE WITH PSYCHOTIC 
SYMPTOMS 
Eu32y00 OTHER DEPRESSIVE EPISODES 




Eu32y12 SINGLE EPISODE OF MASKED DEPRESSION NOS 
Eu32z00 DEPRESSIVE EPISODE, UNSPECIFIED 
Eu32z11 DEPRESSION  
Eu32z12 DEPRESSIVE DISORDER NOS 
Eu32z13 PROLONGED SINGLE EPISODE OF REACTIVE 
DEPRESSION 
Eu32z14 REACTIVE DEPRESSION 
Eu33.00 RECURRENT DEPRESSIVE DISORDER 
Eu33.11 RECURRENT EPISODES OF DEPRESSIVE REACTION 
Eu33.12 RECURRENT EPISODES OF PSYCHOGENIC DEPRESSION 
Eu33.13 RECURRENT EPISODES OF REACTIVE DEPRESSION 
Eu33.14 SEASONAL DEPRESSIVE DISORDER 
Eu33000 RECURRENT DEPRESSIVE DISORDER, CURRENT 
EPISODE MILD 
Eu33100 RECURRENT DEPRESSIVE DISORDER, CURRENT 
EPISODE MODERATE 
Eu33200 RECURRENT DEPRESS DISORDER CUR EPI SEVERE 
WITHOUT PSYCHOTIC SYMPTOMS 
Eu33211 ENDOGENOUS DEPRESSION WITHOUT PSYCHOTIC 
SYMPTOMS 
Eu33212 MAJOR DEPRESSION, RECURRENT WITHOUT 
PSYCHOTIC SYMPTOMS 
Eu33213 MANIC-DEPRESS PSYCHOSIS, DEPRESSED PSYCHOTIC 
SYMPTOMS 
Eu33300 RECURRENT DEPRESS DISORDER CUR EPI SEVERE WITH 
PSYCHOTIC SYMPTOMS 
Eu33311 ENDOGENOUS DEPRESSION WITH PSYCHOTIC 
SYMPTOMS 
Eu33312 MANIC-DEPRESS PSYCHOSIS, DEPRESSED TYPE + 
PSYCHOTIC SYMPTOMS 





Eu33315 RECURRENT SEVERE EPISODES OF PSYCHOTIC 
DEPRESSION 
Eu33316 RECURRENT SEVERE EPISODES/REACTIVE DEPRESSIVE 
PSYCHOSIS 
Eu33400 RECURRENT DEPRESSIVE DISORDER, CURRENTLY IN 
REMISSION 
Eu33y00 OTHER RECURRENT DEPRESSIVE DISORDERS 
Eu33z00 RECURRENT DEPRESSIVE DISORDER, UNSPECIFIED 
Eu34.00 PERSISTENT MOOD AFFECTIVE DISORDERS 
Eu34111 DEPRESSIVE NEUROSIS 
Eu34112 DEPRESSIVE PERSONALITY DISORDER 
Eu34113 NEUROTIC DEPRESSION 
Eu34114 PERSISTENT ANXIETY DEPRESSION 
Eu34z00 PERSISTENT MOOD AFFECTIVE DISORDER, 
UNSPECIFIED 
Eu3y111 RECURRENT BRIEF DEPRESSIVE EPISODES 
Eu41200 MIXED ANXIETY AND DEPRESSIVE DISORDER 
Eu41211 MILD ANXIETY DEPRESSION 
Eu53011 POSTNATAL DEPRESSION 
Eu53012 POSTPARTUM DEPRESSION 
Eu92000 DEPRESSIVE CONDUCT DISORDER 






Appendix 9-12. Antidepression codes 
Selective Serotonin Reuptake Inhibitor (SSRI) 
86222020 CIPRALEX 10MG TABLETS  
90873020 CIPRALEX 10MG/ML ORAL DROPS  
55602020 CIPRALEX 20MG TABLETS 
97171020 CIPRALEX 20MG/ML ORAL DROPS  
87526020 CIPRALEX 5MG TABLETS  
79421020 CIPRAMIL 10MG TABLETS  
79420020 CIPRAMIL 20MG TABLETS  
79422020 CIPRAMIL 40MG TABLETS  
77312020 CIPRAMIL 40MG/ML DROPS  
65254020 CITALOPRAM 10MG TABLET  
79463020 CITALOPRAM 10MG TABLETS 
87251998 CITALOPRAM 10MG TABLETS 
91380997 CITALOPRAM 10MG TABLETS 
91395997 CITALOPRAM 10MG TABLETS 
93948990 CITALOPRAM 10MG TABLETS 
93994990 CITALOPRAM 10MG TABLETS 
94895990 CITALOPRAM 10MG TABLETS 
95271990 CITALOPRAM 10MG TABLETS 
95335990 CITALOPRAM 10MG TABLETS 
95421990 CITALOPRAM 10MG TABLETS 
95633990 CITALOPRAM 10MG TABLETS 
95668990 CITALOPRAM 10MG TABLETS 
95705990 CITALOPRAM 10MG TABLETS 
95995979 CITALOPRAM 10MG TABLETS 
65376020 CITALOPRAM 10MG TABLETS  
67890020 CITALOPRAM 10MG TABLETS  
71373020 CITALOPRAM 10MG TABLETS  
66451020 CITALOPRAM 10MG TABLETS  
71225020 CITALOPRAM 10MG TABLETS  




71214020 CITALOPRAM 10MG TABLETS  
65125020 CITALOPRAM 10MG TABLETS  
68042020 CITALOPRAM 10MG TABLETS  
66149020 CITALOPRAM 10MG TABLETS  
69605979 CITALOPRAM 10MG/5ML ORAL SUSPENSION 
69606979 CITALOPRAM 10MG/5ML ORAL SUSPENSION 
65257020 CITALOPRAM 20MG TABLET  
79462020 CITALOPRAM 20MG TABLETS 
91380998 CITALOPRAM 20MG TABLETS 
91395998 CITALOPRAM 20MG TABLETS 
93996990 CITALOPRAM 20MG TABLETS 
94894990 CITALOPRAM 20MG TABLETS 
94937990 CITALOPRAM 20MG TABLETS 
95270990 CITALOPRAM 20MG TABLETS 
95334990 CITALOPRAM 20MG TABLETS 
95420990 CITALOPRAM 20MG TABLETS 
95632990 CITALOPRAM 20MG TABLETS 
95667990 CITALOPRAM 20MG TABLETS 
95704990 CITALOPRAM 20MG TABLETS 
65381020 CITALOPRAM 20MG TABLETS  
67893020 CITALOPRAM 20MG TABLETS  
71376020 CITALOPRAM 20MG TABLETS  
38526020 CITALOPRAM 20MG TABLETS  
66454020 CITALOPRAM 20MG TABLETS  
66685020 CITALOPRAM 20MG TABLETS  
65128020 CITALOPRAM 20MG TABLETS  
68045020 CITALOPRAM 20MG TABLETS  
66152020 CITALOPRAM 20MG TABLETS  
69604979 CITALOPRAM 20MG/5ML ORAL SUSPENSION 
65262020 CITALOPRAM 40MG TABLET  
79464020 CITALOPRAM 40MG TABLETS 




91395996 CITALOPRAM 40MG TABLETS 
94880990 CITALOPRAM 40MG TABLETS 
94893990 CITALOPRAM 40MG TABLETS 
94936990 CITALOPRAM 40MG TABLETS 
95269990 CITALOPRAM 40MG TABLETS 
95333990 CITALOPRAM 40MG TABLETS 
95418990 CITALOPRAM 40MG TABLETS 
95631990 CITALOPRAM 40MG TABLETS 
95666990 CITALOPRAM 40MG TABLETS 
95703990 CITALOPRAM 40MG TABLETS 
65386020 CITALOPRAM 40MG TABLETS  
67898020 CITALOPRAM 40MG TABLETS  
66459020 CITALOPRAM 40MG TABLETS  
66688020 CITALOPRAM 40MG TABLETS  
65131020 CITALOPRAM 40MG TABLETS  
68049020 CITALOPRAM 40MG TABLETS  
66160020 CITALOPRAM 40MG TABLETS  
92172998 CITALOPRAM 40MG/ML ORAL DROPS 
77306020 CITALOPRAM 40MG/ML ORAL DROPS SUGAR FREE 
92174998 CITALOPRAM 40MG/ML ORAL DROPS SUGAR FREE 
78768020 ESCITALOPRAM 10MG TABLETS 
88285998 ESCITALOPRAM 10MG TABLETS 
91671998 ESCITALOPRAM 10MG TABLETS 
85970998 ESCITALOPRAM 10MG/ML ORAL DROPS 
85971998 ESCITALOPRAM 10MG/ML ORAL DROPS SUGAR FREE 
90871020 ESCITALOPRAM 10MG/ML ORAL DROPS SUGAR FREE 
53823020 ESCITALOPRAM 20MG TABLETS 
98088998 ESCITALOPRAM 20MG TABLETS 
98561998 ESCITALOPRAM 20MG TABLETS 
82790998 ESCITALOPRAM 20MG/ML ORAL DROPS 
82791998 ESCITALOPRAM 20MG/ML ORAL DROPS SUGAR FREE 




87524020 ESCITALOPRAM 5MG TABLETS 
87662998 ESCITALOPRAM 5MG TABLETS 
87663998 ESCITALOPRAM 5MG TABLETS 
62074020 FAVERIN 100MG TABLETS  
62073020 FAVERIN 50MG TABLETS  
49680020 FELICIUM 20MG CAPSULES  
82367998 FLUOXETINE 10MG TABLETS 
98001020 FLUOXETINE 10MG TABLETS 
74425020 FLUOXETINE 20MG CAPSULE 
69654020 FLUOXETINE 20MG CAPSULES 
90159998 FLUOXETINE 20MG CAPSULES 
90814998 FLUOXETINE 20MG CAPSULES 
93066990 FLUOXETINE 20MG CAPSULES 
93905990 FLUOXETINE 20MG CAPSULES 
94447998 FLUOXETINE 20MG CAPSULES 
94490998 FLUOXETINE 20MG CAPSULES 
95388990 FLUOXETINE 20MG CAPSULES 
96162979 FLUOXETINE 20MG CAPSULES 
96168979 FLUOXETINE 20MG CAPSULES 
96272990 FLUOXETINE 20MG CAPSULES 
96281990 FLUOXETINE 20MG CAPSULES 
96606990 FLUOXETINE 20MG CAPSULES 
96644990 FLUOXETINE 20MG CAPSULES 
96647990 FLUOXETINE 20MG CAPSULES 
96651990 FLUOXETINE 20MG CAPSULES 
96654990 FLUOXETINE 20MG CAPSULES 
96659990 FLUOXETINE 20MG CAPSULES 
96674990 FLUOXETINE 20MG CAPSULES 
96709990 FLUOXETINE 20MG CAPSULES 
96729990 FLUOXETINE 20MG CAPSULES 
99592998 FLUOXETINE 20MG CAPSULES 




61452020 FLUOXETINE 20MG CAPSULES  
62975020 FLUOXETINE 20MG CAPSULES  
61409020 FLUOXETINE 20MG CAPSULES  
61455020 FLUOXETINE 20MG CAPSULES  
61167020 FLUOXETINE 20MG CAPSULES  
61420020 FLUOXETINE 20MG CAPSULES  
63016020 FLUOXETINE 20MG CAPSULES  
61387020 FLUOXETINE 20MG CAPSULES  
61319020 FLUOXETINE 20MG CAPSULES  
66273020 FLUOXETINE 20MG CAPSULES  
61439020 FLUOXETINE 20MG CAPSULES  
61616020 FLUOXETINE 20MG CAPSULES  
90766998 FLUOXETINE 20MG/5ML ORAL LIQ 
94490997 FLUOXETINE 20MG/5ML ORAL LIQ 
69655020 FLUOXETINE 20MG/5ML ORAL SOLUTION 
91928990 FLUOXETINE 20MG/5ML ORAL SOLUTION 
94447997 FLUOXETINE 20MG/5ML ORAL SOLUTION 
95426990 FLUOXETINE 20MG/5ML ORAL SOLUTION 
95813990 FLUOXETINE 20MG/5ML ORAL SOLUTION 
95820990 FLUOXETINE 20MG/5ML ORAL SOLUTION 
64717020 FLUOXETINE 20MG/5ML ORAL SOLUTION  
66129020 FLUOXETINE 20MG/5ML ORAL SOLUTION  
64692020 FLUOXETINE 20MG/5ML ORAL SOLUTION  
84403998 FLUOXETINE 20MG/5ML ORAL SOLUTION SUGAR FREE 
84436998 FLUOXETINE 20MG/5ML ORAL SOLUTION SUGAR FREE 
93984020 FLUOXETINE 20MG/5ML ORAL SOLUTION SUGAR FREE 
69656020 FLUOXETINE 60MG CAPSULES 
94447996 FLUOXETINE 60MG CAPSULES 
94490996 FLUOXETINE 60MG CAPSULES 
95610990 FLUOXETINE 60MG CAPSULES 
65464020 FLUOXETINE 60MG CAPSULES  




96345989 FLUVOXAMINE 100MG TABLETS 
96493997 FLUVOXAMINE 100MG TABLETS 
96810989 FLUVOXAMINE 100MG TABLETS 
66244020 FLUVOXAMINE 100MG TABLETS  
62693020 FLUVOXAMINE 100MG TABLETS  
60735020 FLUVOXAMINE 100MG TABLETS  
62069020 FLUVOXAMINE 50MG TABLETS 
96493998 FLUVOXAMINE 50MG TABLETS 
96492997 FLUVOXAMINE MALEATE 100MG TABS 
96492998 FLUVOXAMINE MALEATE 50MG TABS 
74047020 LUSTRAL 100MG TABLETS  
74046020 LUSTRAL 50MG TABLETS  
80679020 OXACTIN 20MG CAPSULES  
54495979 PAROXETINE 10MG TABLETS 
84807998 PAROXETINE 10MG TABLETS 
85382998 PAROXETINE 10MG TABLETS 
92043020 PAROXETINE 10MG TABLETS 
72934020 PAROXETINE 10MG/5ML ORAL SUSPENSION SUGAR 
FREE 
93490996 PAROXETINE 10MG/5ML ORAL SUSPENSION SUGAR 
FREE 
93489996 PAROXETINE 10MG/5ML S/F LIQ 
72932020 PAROXETINE 20MG TABLETS 
93489998 PAROXETINE 20MG TABLETS 
93490998 PAROXETINE 20MG TABLETS 
95051990 PAROXETINE 20MG TABLETS 
95332990 PAROXETINE 20MG TABLETS 
95350990 PAROXETINE 20MG TABLETS 
95578990 PAROXETINE 20MG TABLETS 
96087990 PAROXETINE 20MG TABLETS 
66464020 PAROXETINE 20MG TABLETS  




66399020 PAROXETINE 20MG TABLETS  
69754020 PAROXETINE 20MG TABLETS  
63703020 PAROXETINE 20MG TABLETS  
72933020 PAROXETINE 30MG TABLETS 
93487990 PAROXETINE 30MG TABLETS 
93489997 PAROXETINE 30MG TABLETS 
93490997 PAROXETINE 30MG TABLETS 
95007990 PAROXETINE 30MG TABLETS 
95028990 PAROXETINE 30MG TABLETS 
67650020 PAROXETINE 30MG TABLETS  
67575020 PAROXETINE 30MG TABLETS  
88346020 PAXORAN 10MG TABLET  
88348020 PAXORAN 20MG TABLET  
69506020 PROZAC 20MG CAPSULES  
69507020 PROZAC 20MG/5ML LIQUID  
69508020 PROZAC 60MG CAPSULES  
93918020 PROZEP 20MG/5ML ORAL SOLUTION  
80777020 PROZIT 20MG/5ML ORAL SOLUTION  
82055020 RANFLUTIN 20MG CAPSULES  
93187020 SEROXAT 10MG TABLETS  
72937020 SEROXAT 20MG TABLETS  
72939020 SEROXAT 20MG/10ML LIQUID  
72938020 SEROXAT 30MG TABLETS  
74051020 SERTRALINE 100MG TABLETS 
92729990 SERTRALINE 100MG TABLETS 
93173997 SERTRALINE 100MG TABLETS 
93174997 SERTRALINE 100MG TABLETS 
93732990 SERTRALINE 100MG TABLETS 
93842990 SERTRALINE 100MG TABLETS 
72095020 SERTRALINE 100MG TABLETS  
20738020 SERTRALINE 100MG/5ML ORAL SUSPENSION 




66187979 SERTRALINE 150MG/5ML ORAL SUSPENSION 
33816020 SERTRALINE 25MG/5ML ORAL SUSPENSION 
66183979 SERTRALINE 25MG/5ML ORAL SUSPENSION 
74050020 SERTRALINE 50MG TABLETS 
92728990 SERTRALINE 50MG TABLETS 
93173998 SERTRALINE 50MG TABLETS 
93174998 SERTRALINE 50MG TABLETS 
93694990 SERTRALINE 50MG TABLETS 
93749990 SERTRALINE 50MG TABLETS 
71725020 SERTRALINE 50MG TABLETS  
72034020 SERTRALINE 50MG TABLETS  
75620020 SERTRALINE 50MG TABLETS  
86159998 SERTRALINE 50MG/5ML ORAL SUSPENSION 
90497020 SERTRALINE 50MG/5ML ORAL SUSPENSION 
Serotonin–norepinephrine reuptake inhibitor (SNRI) 
3977020 ALVENTA XL 150MG CAPSULES  
3966020 ALVENTA XL 75MG CAPSULES  
88849020 CYMBALTA 30MG GASTRO-RESISTANT CAPSULES  
88851020 CYMBALTA 60MG GASTRO-RESISTANT CAPSULES  
98863020 DEPEFEX XL 150MG CAPSULES  
98861020 DEPEFEX XL 75MG CAPSULES  
87335998 DULOXETINE 20MG G/R CAPSULES 
87337998 DULOXETINE 20MG GASTRO-RESISTANT CAPSULES 
86997998 DULOXETINE 30MG G/R CAPSULES 
86999998 DULOXETINE 30MG GASTRO-RESISTANT CAPSULES 
88845020 DULOXETINE 30MG GASTRO-RESISTANT CAPSULES 
87334998 DULOXETINE 40MG G/R CAPSULES 
87336998 DULOXETINE 40MG GASTRO-RESISTANT CAPSULES 
86996998 DULOXETINE 60MG G/R CAPSULES 
86998998 DULOXETINE 60MG GASTRO-RESISTANT CAPSULES 
88847020 DULOXETINE 60MG GASTRO-RESISTANT CAPSULES 




84961020 EDRONAX 4MG TABLETS  
48376020 EFEXOR 37.5MG TABLETS  
48377020 EFEXOR 75MG TABLETS  
85164020 EFEXOR XL 150MG CAPSULES  
3970020 EFEXOR XL 150MG CAPSULES  
85163020 EFEXOR XL 75MG CAPSULES  
97351020 FORAVEN XL 75MG CAPSULES  
97656020 RANFAXINE XL 75MG CAPSULES  
84955020 REBOXETINE 4MG TABLETS 
88836998 REBOXETINE 4MG TABLETS 
88838998 REBOXETINE 4MG TABLETS 
96241020 RODOMEL XL 150MG CAPSULES  
96239020 RODOMEL XL 75MG CAPSULES  
96331020 TARDCAPS XL 150MG CAPSULES  
96329020 TARDCAPS XL 75MG CAPSULES  
97030020 VALDOXAN 25MG TABLETS  
97005020 VENAXX XL 150MG CAPSULES  
97003020 VENAXX XL 75MG CAPSULES  
3976020 VENLABLUE XL 150MG CAPSULES  
3965020 VENLABLUE XL 75MG CAPSULES  
82190998 VENLAFAXINE 150MG M/R CAPSULES 
82874998 VENLAFAXINE 150MG M/R CAPSULES 
83114998 VENLAFAXINE 150MG M/R CAPSULES 
83149998 VENLAFAXINE 150MG M/R CAPSULES 
83204998 VENLAFAXINE 150MG M/R CAPSULES 
83217998 VENLAFAXINE 150MG M/R CAPSULES 
83264998 VENLAFAXINE 150MG M/R CAPSULES 
88755997 VENLAFAXINE 150MG M/R CAPSULES 
96022979 VENLAFAXINE 150MG M/R CAPSULES 
96029979 VENLAFAXINE 150MG M/R CAPSULES 
52165979 VENLAFAXINE 150MG M/R TABLETS 




82962998 VENLAFAXINE 150MG M/R TABLETS 
83157998 VENLAFAXINE 150MG M/R TABLETS 
81749998 VENLAFAXINE 150MG MODIFIED-RELEASE CAPSULES 
81929998 VENLAFAXINE 150MG MODIFIED-RELEASE CAPSULES 
83074998 VENLAFAXINE 150MG MODIFIED-RELEASE CAPSULES 
83145998 VENLAFAXINE 150MG MODIFIED-RELEASE CAPSULES 
85109020 VENLAFAXINE 150MG MODIFIED-RELEASE CAPSULES 
88776997 VENLAFAXINE 150MG MODIFIED-RELEASE CAPSULES 
96023979 VENLAFAXINE 150MG MODIFIED-RELEASE CAPSULES 
96616020 VENLAFAXINE 150MG MODIFIED-RELEASE CAPSULES  
83159998 VENLAFAXINE 150MG MODIFIED-RELEASE TABLETS 
96447020 VENLAFAXINE 150MG MODIFIED-RELEASE TABLETS 
35355020 VENLAFAXINE 150MG/5ML ORAL SOLUTION 
82959998 VENLAFAXINE 225MG M/R TABLETS 
82961998 VENLAFAXINE 225MG MODIFIED-RELEASE TABLETS 
96838020 VENLAFAXINE 225MG MODIFIED-RELEASE TABLETS 
81505998 VENLAFAXINE 37.5MG M/R TABLETS 
79303978 VENLAFAXINE 37.5MG MODIFIED-RELEASE CAPSULES 
79304978 VENLAFAXINE 37.5MG MODIFIED-RELEASE CAPSULES 
81506998 VENLAFAXINE 37.5MG MODIFIED-RELEASE TABLETS 
99679020 VENLAFAXINE 37.5MG MODIFIED-RELEASE TABLETS 
54686020 VENLAFAXINE 37.5MG TABLETS 
83163998 VENLAFAXINE 37.5MG TABLETS 
98336998 VENLAFAXINE 37.5MG TABLETS 
99896998 VENLAFAXINE 37.5MG TABLETS 
3942020 VENLAFAXINE 37.5MG TABLETS  
35357020 VENLAFAXINE 37.5MG/5ML ORAL SOLUTION 
64642979 VENLAFAXINE 37.5MG/5ML ORAL SOLUTION 
86431998 VENLAFAXINE 37.5MG/5ML ORAL SUSPENSION 
89954020 VENLAFAXINE 37.5MG/5ML ORAL SUSPENSION 
98336996 VENLAFAXINE 50MG TABLETS 




82191998 VENLAFAXINE 75MG M/R CAPSULES 
82875998 VENLAFAXINE 75MG M/R CAPSULES 
83115998 VENLAFAXINE 75MG M/R CAPSULES 
83150998 VENLAFAXINE 75MG M/R CAPSULES 
83205998 VENLAFAXINE 75MG M/R CAPSULES 
83218998 VENLAFAXINE 75MG M/R CAPSULES 
83265998 VENLAFAXINE 75MG M/R CAPSULES 
88755998 VENLAFAXINE 75MG M/R CAPSULES 
96033979 VENLAFAXINE 75MG M/R CAPSULES 
80023978 VENLAFAXINE 75MG M/R TABLETS 
82963998 VENLAFAXINE 75MG M/R TABLETS 
83158998 VENLAFAXINE 75MG M/R TABLETS 
83162998 VENLAFAXINE 75MG M/R TABLETS 
81750998 VENLAFAXINE 75MG MODIFIED-RELEASE CAPSULES 
81930998 VENLAFAXINE 75MG MODIFIED-RELEASE CAPSULES 
82540998 VENLAFAXINE 75MG MODIFIED-RELEASE CAPSULES 
83075998 VENLAFAXINE 75MG MODIFIED-RELEASE CAPSULES 
83146998 VENLAFAXINE 75MG MODIFIED-RELEASE CAPSULES 
85108020 VENLAFAXINE 75MG MODIFIED-RELEASE CAPSULES 
88776998 VENLAFAXINE 75MG MODIFIED-RELEASE CAPSULES 
96034979 VENLAFAXINE 75MG MODIFIED-RELEASE CAPSULES 
96614020 VENLAFAXINE 75MG MODIFIED-RELEASE CAPSULES  
83160998 VENLAFAXINE 75MG MODIFIED-RELEASE TABLETS 
96445020 VENLAFAXINE 75MG MODIFIED-RELEASE TABLETS 
54687020 VENLAFAXINE 75MG TABLETS 
98336997 VENLAFAXINE 75MG TABLETS 
99896997 VENLAFAXINE 75MG TABLETS 
35359020 VENLAFAXINE 75MG/5ML ORAL SOLUTION 
64640979 VENLAFAXINE 75MG/5ML ORAL SOLUTION 
96836020 VENLALIC XL 150MG TABLETS  
96841020 VENLALIC XL 225MG TABLETS  




96834020 VENLALIC XL 75MG TABLETS  
99210020 VENLANEO XL 150MG CAPSULES  
99208020 VENLANEO XL 75MG CAPSULES  
96357020 VENSIR XL 150MG CAPSULES  
96355020 VENSIR XL 75MG CAPSULES  
96536020 VEXARIN XL 150MG CAPSULES  
96534020 VEXARIN XL 75MG CAPSULES  
96439020 VIEPAX 37.5MG TABLETS  
96441020 VIEPAX 75MG TABLETS  
96451020 VIEPAX XL 150MG TABLETS  
96449020 VIEPAX XL 75MG TABLETS  
Tricyclic (TCA) 
55355020 ALLEGRON 10MG TABLETS  
55356020 ALLEGRON 25MG TABLETS 
99824992 AMITRIPTYLINE 100 MG TAB 
98129998 AMITRIPTYLINE 100MG/10ML  
94703998 AMITRIPTYLINE 10MG / PERPHENAZINE 2MG TABLETS 
48490020 AMITRIPTYLINE 10MG TABLET  
48533020 AMITRIPTYLINE 10MG TABLET 
58949020 AMITRIPTYLINE 10MG TABLETS 
97223998 AMITRIPTYLINE 10MG TABLETS 
98130998 AMITRIPTYLINE 10MG TABLETS 
98150998 AMITRIPTYLINE 10MG TABLETS 
99861990 AMITRIPTYLINE 10MG TABLETS 
99863990 AMITRIPTYLINE 10MG TABLETS 
99864990 AMITRIPTYLINE 10MG TABLETS 
99866990 AMITRIPTYLINE 10MG TABLETS 
99868990 AMITRIPTYLINE 10MG TABLETS 
99869990 AMITRIPTYLINE 10MG TABLETS 
99870990 AMITRIPTYLINE 10MG TABLETS 
99871990 AMITRIPTYLINE 10MG TABLETS 




48507020 AMITRIPTYLINE 10MG TABLETS  
48522020 AMITRIPTYLINE 10MG TABLETS  
48516020 AMITRIPTYLINE 10MG TABLETS  
48479020 AMITRIPTYLINE 10MG TABLETS  
48484020 AMITRIPTYLINE 10MG TABLETS  
81085998 AMITRIPTYLINE 10MG/5ML ORAL SOLUTION 
55688020 AMITRIPTYLINE 10MG/5ML ORAL SOLUTION  
81084998 AMITRIPTYLINE 10MG/5ML ORAL SUSPENSION 
75331020 AMITRIPTYLINE 10MG/5ML SUGAR FREE ORAL 
SOLUTION 
92808996 AMITRIPTYLINE 10MG/5ML SUGAR FREE ORAL 
SOLUTION 
98067988 AMITRIPTYLINE 10MG/5ML SUGAR FREE ORAL 
SOLUTION 
98128998 AMITRIPTYLINE 10MG/5ML SUGAR FREE ORAL 
SOLUTION 
60229020 AMITRIPTYLINE 10MG/ML INJECTION 
96924998 AMITRIPTYLINE 10MG/ML INJECTION 
68724020 AMITRIPTYLINE 12.5MG / CHLORDIAZEPOXIDE 5MG 
CAPSULES 
94704998 AMITRIPTYLINE 12.5MG / CHLORDIAZEPOXIDE 5MG 
CAPSULES 
99826992 AMITRIPTYLINE 200 MG TAB 
68725020 AMITRIPTYLINE 25MG / CHLORDIAZEPOXIDE 10MG 
CAPSULES 
94704997 AMITRIPTYLINE 25MG / CHLORDIAZEPOXIDE 10MG 
CAPSULES 
98343998 AMITRIPTYLINE 25MG / CHLORDIAZEPOXIDE 10MG 
CAPSULES 
68729020 AMITRIPTYLINE 25MG / PERPHENAZINE 2MG TABLETS 
94703997 AMITRIPTYLINE 25MG / PERPHENAZINE 2MG TABLETS 




96925998 AMITRIPTYLINE 25MG MODIFIED-RELEASE CAPSULES 
48492020 AMITRIPTYLINE 25MG TABLET  
48502020 AMITRIPTYLINE 25MG TABLET  
48513020 AMITRIPTYLINE 25MG TABLET  
48528020 AMITRIPTYLINE 25MG TABLET  
48534020 AMITRIPTYLINE 25MG TABLET  
58950020 AMITRIPTYLINE 25MG TABLETS 
94076990 AMITRIPTYLINE 25MG TABLETS 
94771990 AMITRIPTYLINE 25MG TABLETS 
97223997 AMITRIPTYLINE 25MG TABLETS 
98130997 AMITRIPTYLINE 25MG TABLETS 
98150997 AMITRIPTYLINE 25MG TABLETS 
99861989 AMITRIPTYLINE 25MG TABLETS 
99863989 AMITRIPTYLINE 25MG TABLETS 
99864989 AMITRIPTYLINE 25MG TABLETS 
99865990 AMITRIPTYLINE 25MG TABLETS 
99866989 AMITRIPTYLINE 25MG TABLETS 
99867989 AMITRIPTYLINE 25MG TABLETS 
99868989 AMITRIPTYLINE 25MG TABLETS 
99869988 AMITRIPTYLINE 25MG TABLETS 
99870989 AMITRIPTYLINE 25MG TABLETS 
99871989 AMITRIPTYLINE 25MG TABLETS 
48497020 AMITRIPTYLINE 25MG TABLETS  
48508020 AMITRIPTYLINE 25MG TABLETS  
70948020 AMITRIPTYLINE 25MG TABLETS  
48523020 AMITRIPTYLINE 25MG TABLETS  
48517020 AMITRIPTYLINE 25MG TABLETS  
48480020 AMITRIPTYLINE 25MG TABLETS  
48485020 AMITRIPTYLINE 25MG TABLETS  





92808997 AMITRIPTYLINE 25MG/5ML ORAL SOLUTION SUGAR 
FREE 
98067990 AMITRIPTYLINE 25MG/5ML ORAL SOLUTION SUGAR 
FREE 
55686020 AMITRIPTYLINE 25MG/5ML ORAL SOLUTION SUGAR 
FREE  
99825992 AMITRIPTYLINE 300 MG TAB 
98138997 AMITRIPTYLINE 50MG M/R CAPS 
96925997 AMITRIPTYLINE 50MG MODIFIED-RELEASE CAPSULES 
48491020 AMITRIPTYLINE 50MG TABLET  
58951020 AMITRIPTYLINE 50MG TABLETS 
97223996 AMITRIPTYLINE 50MG TABLETS 
98130996 AMITRIPTYLINE 50MG TABLETS 
98150996 AMITRIPTYLINE 50MG TABLETS 
99863988 AMITRIPTYLINE 50MG TABLETS 
99864988 AMITRIPTYLINE 50MG TABLETS 
99866988 AMITRIPTYLINE 50MG TABLETS 
99868988 AMITRIPTYLINE 50MG TABLETS 
99869989 AMITRIPTYLINE 50MG TABLETS 
99870988 AMITRIPTYLINE 50MG TABLETS 
99871988 AMITRIPTYLINE 50MG TABLETS 
48498020 AMITRIPTYLINE 50MG TABLETS  
48509020 AMITRIPTYLINE 50MG TABLETS  
48524020 AMITRIPTYLINE 50MG TABLETS  
48518020 AMITRIPTYLINE 50MG TABLETS  
48481020 AMITRIPTYLINE 50MG TABLETS  
48486020 AMITRIPTYLINE 50MG TABLETS  
75329020 AMITRIPTYLINE 50MG/5ML ORAL SOLUTION SUGAR 
FREE 





98067989 AMITRIPTYLINE 50MG/5ML ORAL SOLUTION SUGAR 
FREE 
55687020 AMITRIPTYLINE 50MG/5ML ORAL SOLUTION SUGAR 
FREE  
94067992 AMITRIPTYLINE 75 MG TAB 
98129997 AMITRIPTYLINE 75MG M/R CAPS 
60224020 AMITRIPTYLINE 75MG MODIFIED-RELEASE CAPSULES 
96925996 AMITRIPTYLINE 75MG MODIFIED-RELEASE CAPSULES 
92481020 AMITRIPTYLINE ORAL SOLUTION 
96891992 AMITRIPTYLINE S/F 25 MG/5ML  
55386020 ANAFRANIL 10MG CAPSULES  
55387020 ANAFRANIL 25MG CAPSULES  
55392020 ANAFRANIL 25MG/5ML SYRUP  
55388020 ANAFRANIL 50MG CAPSULES  
55396020 ANAFRANIL SR 75MG TABLETS  
61463020 CLOMIPRAMINE 10MG CAPSULES 
96640998 CLOMIPRAMINE 10MG CAPSULES 
97548990 CLOMIPRAMINE 10MG CAPSULES 
98340990 CLOMIPRAMINE 10MG CAPSULES 
99297990 CLOMIPRAMINE 10MG CAPSULES 
50946020 CLOMIPRAMINE 10MG CAPSULES  
57824020 CLOMIPRAMINE 10MG CAPSULES  
54669020 CLOMIPRAMINE 10MG CAPSULES  
97167992 CLOMIPRAMINE 25 MG TAB 
61464020 CLOMIPRAMINE 25MG CAPSULES 
96640997 CLOMIPRAMINE 25MG CAPSULES 
97548989 CLOMIPRAMINE 25MG CAPSULES 
97773989 CLOMIPRAMINE 25MG CAPSULES 
98340989 CLOMIPRAMINE 25MG CAPSULES 
99297989 CLOMIPRAMINE 25MG CAPSULES 
50947020 CLOMIPRAMINE 25MG CAPSULES  




54670020 CLOMIPRAMINE 25MG CAPSULES  
61469020 CLOMIPRAMINE 25MG/5ML ORAL SOLUTION 
96639998 CLOMIPRAMINE 25MG/5ML ORAL SOLUTION 
61465020 CLOMIPRAMINE 50MG CAPSULES 
96640996 CLOMIPRAMINE 50MG CAPSULES 
96901988 CLOMIPRAMINE 50MG CAPSULES 
97548988 CLOMIPRAMINE 50MG CAPSULES 
98340988 CLOMIPRAMINE 50MG CAPSULES 
99297988 CLOMIPRAMINE 50MG CAPSULES 
50948020 CLOMIPRAMINE 50MG CAPSULES  
57826020 CLOMIPRAMINE 50MG CAPSULES 
19451020 CLOMIPRAMINE 50MG/5ML ORAL SOLUTION 
80548979 CLOMIPRAMINE 50MG/5ML ORAL SOLUTION 
83878998 CLOMIPRAMINE 50MG/5ML ORAL SUSPENSION 
95021020 CLOMIPRAMINE 50MG/5ML ORAL SUSPENSION 
61473020 CLOMIPRAMINE 75MG MODIFIED-RELEASE TABLETS 
96638998 CLOMIPRAMINE 75MG MODIFIED-RELEASE TABLETS 
93360992 CLOMIPRAMINE HCL 10MG CAPSULES 
98144998 CLOMIPRAMINE HCL 10MG CAPSULES 
98144997 CLOMIPRAMINE HCL 25MG CAPSULES 
96637998 CLOMIPRAMINE HCL 25MG/2ML  
99794992 CLOMIPRAMINE HCL 25MG/2ML  
98143998 CLOMIPRAMINE HCL 25MG/5ML SYR 
93358992 CLOMIPRAMINE HCL 50MG CAPSULES 
98144996 CLOMIPRAMINE HCL 50MG CAPSULES 
98142998 CLOMIPRAMINE HCL 75MG M/R TABS 
62833020 DOSULEPIN 25MG CAPSULES 
94801990 DOSULEPIN 25MG CAPSULES 
96158990 DOSULEPIN 25MG CAPSULES 
96311998 DOSULEPIN 25MG CAPSULES 
96467990 DOSULEPIN 25MG CAPSULES 




96964990 DOSULEPIN 25MG CAPSULES 
97762990 DOSULEPIN 25MG CAPSULES 
98351989 DOSULEPIN 25MG CAPSULES 
98563989 DOSULEPIN 25MG CAPSULES 
98783990 DOSULEPIN 25MG CAPSULES 
99614990 DOSULEPIN 25MG CAPSULES 
49588020 DOSULEPIN 25MG CAPSULES  
56942020 DOSULEPIN 25MG CAPSULES  
68380020 DOSULEPIN 25MG CAPSULES  
60464020 DOSULEPIN 25MG CAPSULES  
53818020 DOSULEPIN 25MG CAPSULES  
63443020 DOSULEPIN 25MG CAPSULES  
66765020 DOSULEPIN 25MG CAPSULES  
62179020 DOSULEPIN 25MG CAPSULES  
54621020 DOSULEPIN 25MG CAPSULES  
54728020 DOSULEPIN 25MG/5ML MIXTURE 
98327997 DOSULEPIN 25MG/5ML MIXTURE 
19725020 DOSULEPIN 25MG/5ML ORAL SOLUTION 
80274979 DOSULEPIN 25MG/5ML ORAL SOLUTION 
55642020 DOSULEPIN 25MG/5ML ORAL SOLUTION  
62835020 DOSULEPIN 25MG/5ML ORAL SOLUTION SUGAR FREE 
96311996 DOSULEPIN 25MG/5ML ORAL SOLUTION SUGAR FREE 
98078990 DOSULEPIN 25MG/5ML ORAL SOLUTION SUGAR FREE 
62834020 DOSULEPIN 75MG TABLETS 
94800990 DOSULEPIN 75MG TABLETS 
96311997 DOSULEPIN 75MG TABLETS 
96868989 DOSULEPIN 75MG TABLETS 
97762989 DOSULEPIN 75MG TABLETS 
98351990 DOSULEPIN 75MG TABLETS 
98563990 DOSULEPIN 75MG TABLETS 
99614989 DOSULEPIN 75MG TABLETS 




56943020 DOSULEPIN 75MG TABLETS  
68383020 DOSULEPIN 75MG TABLETS  
60465020 DOSULEPIN 75MG TABLETS  
53817020 DOSULEPIN 75MG TABLETS  
54620020 DOSULEPIN 75MG TABLETS  
80278979 DOSULEPIN 75MG/5ML ORAL SOLUTION 
54727020 DOSULEPIN 75MG/5ML ORAL SOLUTION SUGAR FREE 
98078989 DOSULEPIN 75MG/5ML ORAL SOLUTION SUGAR FREE 
98327998 DOSULEPIN 75MG/5ML ORAL SOLUTION SUGAR FREE 
88906998 DOSULEPIN 25MG CAPSULES 
97722998 DOSULEPIN 25MG CAPSULES 
97818998 DOSULEPIN 25MG CAPSULES 
98126998 DOSULEPIN 25MG CAPSULES 
88906997 DOSULEPIN 75MG TABLETS 
97722997 DOSULEPIN 75MG TABLETS 
97818997 DOSULEPIN 75MG TABLETS 
98126997 DOSULEPIN 75MG TABLETS 
56698020 DOTHAPAX 25 CAPSULES  
56699020 DOTHAPAX 75 TABLETS  
62850020 DOXEPIN 10MG CAPSULES 
96308998 DOXEPIN 10MG CAPSULES 
98124998 DOXEPIN 10MG CAPSULES 
62851020 DOXEPIN 25MG CAPSULES 
85172998 DOXEPIN 25MG CAPSULES 
96308997 DOXEPIN 25MG CAPSULES 
98124997 DOXEPIN 25MG CAPSULES 
83206998 DOXEPIN 25MG/5ML ORAL SUSPENSION 
96353020 DOXEPIN 25MG/5ML ORAL SUSPENSION 
89407998 DOXEPIN 5% CREAM 
62852020 DOXEPIN 50MG CAPSULES 
85171998 DOXEPIN 50MG CAPSULES 




98124996 DOXEPIN 50MG CAPSULES 
80210979 DOXEPIN 50MG/5ML ORAL SOLUTION 
62857020 DOXEPIN 75MG CAPSULES 
96307998 DOXEPIN 75MG CAPSULES 
98123998 DOXEPIN 75MG CAPSULES 
88747998 DOXEPIN HYDROCHLORIDE  
94795998 DOXEPIN HYDROCHLORIDE  
96687992 IMIPRAMINE 100 MG TAB 
59429020 IMIPRAMINE 10MG TABLETS 
97112998 IMIPRAMINE 10MG TABLETS 
99554990 IMIPRAMINE 10MG TABLETS 
99555990 IMIPRAMINE 10MG TABLETS 
49845020 IMIPRAMINE 10MG TABLETS  
49841020 IMIPRAMINE 10MG TABLETS  
68803020 IMIPRAMINE 10MG TABLETS  
97091998 IMIPRAMINE 10MG TABS 
95155992 IMIPRAMINE 25 MG CAP 
49838020 IMIPRAMINE 25MG TABLET  
59430020 IMIPRAMINE 25MG TABLETS 
97112997 IMIPRAMINE 25MG TABLETS 
98140997 IMIPRAMINE 25MG TABLETS 
98149990 IMIPRAMINE 25MG TABLETS 
99554989 IMIPRAMINE 25MG TABLETS 
99555989 IMIPRAMINE 25MG TABLETS 
99556989 IMIPRAMINE 25MG TABLETS 
49846020 IMIPRAMINE 25MG TABLETS  
49842020 IMIPRAMINE 25MG TABLETS  
55369020 IMIPRAMINE 25MG TABLETS  
96130998 IMIPRAMINE 25MG/5ML ORAL SOLUTION 
62948979 IMIPRAMINE 25MG/5ML ORAL SOLUTION SUGAR FREE 
82432998 IMIPRAMINE 25MG/5ML ORAL SOLUTION SUGAR FREE 




95156992 IMIPRAMINE 50 MG TAB 
95154992 IMIPRAMINE 75 MG TAB 
98140998 IMIPRAMINE 10MG TABLETS 
97593992 IMIPRAMINE 12.5 MG  
98140996 IMIPRAMINE  
85437998 IMIPRAMINE  
64034020 LOFEPRAMINE 70MG TABLETS 
95999998 LOFEPRAMINE 70MG TABLETS 
96793990 LOFEPRAMINE 70MG TABLETS 
96963990 LOFEPRAMINE 70MG TABLETS 
97142990 LOFEPRAMINE 70MG TABLETS 
97192990 LOFEPRAMINE 70MG TABLETS 
97743990 LOFEPRAMINE 70MG TABLETS 
97861990 LOFEPRAMINE 70MG TABLETS 
98132998 LOFEPRAMINE 70MG TABLETS 
59084020 LOFEPRAMINE 70MG TABLETS  
57022020 LOFEPRAMINE 70MG TABLETS  
56517020 LOFEPRAMINE 70MG TABLETS  
60055020 LOFEPRAMINE 70MG TABLETS  
67063979 LOFEPRAMINE 70MG 
55646020 LOFEPRAMINE 70MG 
64035020 LOFEPRAMINE 70MG 
95999997 LOFEPRAMINE 70MG 
98077990 LOFEPRAMINE 70MG 
89205998 LOFEPRAMINE 70MG 
94249992 NORTRIPTYLINE 10 MG ELI 
94630998 NORTRIPTYLINE 10MG / FLUPHENAZINE 
500MICROGRAM TABLETS 
95695998 NORTRIPTYLINE 10MG CAPSULE 
98154998 NORTRIPTYLINE 10MG CAPSULES 
65153020 NORTRIPTYLINE 10MG TABLETS 




96248979 NORTRIPTYLINE 10MG TABLETS 
98152998 NORTRIPTYLINE 10MG TABLETS 
95695996 NORTRIPTYLINE 10MG/5ML LIQUID 
98154996 NORTRIPTYLINE 10MG/5ML LIQUID 
95695997 NORTRIPTYLINE 25MG CAPSULE 
98154997 NORTRIPTYLINE 25MG CAPSULES 
65154020 NORTRIPTYLINE 25MG TABLETS 
95696997 NORTRIPTYLINE 25MG TABLETS 
98152997 NORTRIPTYLINE 25MG TABLETS 
77778020 NORTRIPTYLINE 25MG TABLETS  
94630997 NORTRIPTYLINE 30MG / FLUPHENAZINE 1.5MG TABLETS 
67280020 TRIMIPRAMINE 10MG TABLETS 
93841990 TRIMIPRAMINE 10MG TABLETS 
95107998 TRIMIPRAMINE 10MG TABLETS 
98136998 TRIMIPRAMINE 10MG TABLETS 
71733020 TRIMIPRAMINE 10MG TABLETS  
67281020 TRIMIPRAMINE 25MG TABLETS 
93840990 TRIMIPRAMINE 25MG TABLETS 
95107997 TRIMIPRAMINE 25MG TABLETS 
98136997 TRIMIPRAMINE 25MG TABLETS 
71736020 TRIMIPRAMINE 25MG TABLETS  
98212992 TRIMIPRAMINE 50 MG TAB 
67282020 TRIMIPRAMINE 50MG CAPSULES 
93839990 TRIMIPRAMINE 50MG CAPSULES 
95107996 TRIMIPRAMINE 50MG CAPSULES 
98136996 TRIMIPRAMINE 50MG CAPSULES 
55440020 TRYPTIZOL 10MG TABLET  
55450020 TRYPTIZOL 10MG/5ML SUGAR FREE ORAL SOLUTION  
55445020 TRYPTIZOL 10MG/ML INJECTION  
55441020 TRYPTIZOL 25MG TABLET  
55442020 TRYPTIZOL 50MG TABLET  




Monoamine oxidase inhibitors (MAOIs) 
96105998 ISOCARBOXAZID 10MG TABLETS 
97169990 ISOCARBOXAZID 10MG TABLETS 
99450998 ISOCARBOXAZID 10MG TABLETS 
71994020 MANERIX 150MG TABLETS  
71995020 MANERIX 300MG TABLETS  
50286020 MARPLAN 10MG TABLET  
93749998 MOCLOBEMIDE 150MG TABLETS 
93759998 MOCLOBEMIDE 150MG TABLETS 
96061990 MOCLOBEMIDE 150MG TABLETS 
93749997 MOCLOBEMIDE 300MG TABLETS 
93759997 MOCLOBEMIDE 300MG TABLETS 
50620020 NARDIL 15MG TABLETS  
51010020 PARNATE 10MG TABLET  
51013020 PARSTELIN TABLET  
65635020 PHENELZINE 15MG TABLETS 
95560998 PHENELZINE 15MG TABLETS 
99377998 PHENELZINE 15MG TABLETS 
95144998 TRANYLCYPROMINE 10MG TABLETS 
95665990 TRANYLCYPROMINE 10MG TABLETS 
99281998 TRANYLCYPROMINE 10MG TABLETS 
95143998 TRANYLCYPROMINE WITH TRIFLUOPERAZINE TABLET 







Appendix 9-13.Pneumonia codes 
A022200 SALMONELLA PNEUMONIA 
A116.00                     TUBERCULOUS PNEUMONIA 
A203.00 PRIMARY PNEUMONIC PLAGUE 
A204.00 SECONDARY PNEUMONIC PLAGUE 
A205.00 PNEUMONIC PLAGUE, UNSPECIFIED 
A380300 SEPTICAEMIA DUE TO STREPTOCOCCUS 
PNEUMONIAE  
A3BXA00 MYCOPLASMA PNEUMONIAE 
A3BXB00 KLEBSIELLA PNEUMONIAE 
A54x400 HERPES SIMPLEX PNEUMONIA 
A551.00 POST-MEASLES PNEUMONIA 
A730.00 ORNITHOSIS WITH PNEUMONIA 
A789300 HIV DISEASE RESULTING IN PNEUMOCYSTIS CARINII 
PNEUMONIA 
A789311 HIV DISEASE RESULTING IN PNEUMOCYSTIS 
JIROVECII PNEUMONIA 
A789900 HIV DISEASE RESULTING IN LYMPHOID 
INTERSTITIAL PNEUMONITIS 
AB24.11 PNEUMONIA  
AB40500 HISTOPLASMA CAPSULATUM WITH PNEUMONIA 
AB41500 HISTOPLASMA DUBOISII WITH PNEUMONIA 
AyuK900 MYCOPLASMA PNEUMONIAE 
AyuKA00 KLEBSIELLA PNEUMONIAE/CAUSE/DISEASE 
CLASSIFIED /OTHER CHAPTERS 
H060A00 ACUTE BRONCHITIS DUE TO MYCOPLASMA 
PNEUMONIA 
H062.00                ACUTE LOWER RESPIRATORY TRACT INFECTION 
H06z112 ACUTE LOWER RESPIRATORY TRACT INFECTION 
H2...00 PNEUMONIA AND INFLUENZA 
H20..00 VIRAL PNEUMONIA 




H200.00 PNEUMONIA DUE TO ADENOVIRUS 
H201.00 PNEUMONIA DUE TO RESPIRATORY SYNCYTIAL 
VIRUS 
H202.00 PNEUMONIA DUE TO PARAINFLUENZA VIRUS 
H203.00 PNEUMONIA DUE TO HUMAN METAPNEUMOVIRUS 
H20y.00 VIRAL PNEUMONIA 
H20z.00 VIRAL PNEUMONIA  
H21..00 LOBAR (PNEUMOCOCCAL) PNEUMONIA 
H22..00 OTHER BACTERIAL PNEUMONIA 
H22..11 CHEST INFECTION - OTHER BACTERIAL PNEUMONIA 
H220.00                                    PNEUMONIA DUE TO KLEBSIELLA PNEUMONIA  
H221.00 PNEUMONIA DUE TO PSEUDOMONAS 
H222.00 PNEUMONIA DUE TO HAEMOPHILUS INFLUENZA 
H222.11 PNEUMONIA DUE TO HAEMOPHILUS INFLUENZA 
H223.00 PNEUMONIA DUE TO STREPTOCOCCUS 
H223000 PNEUMONIA DUE TO STREPTOCOCCUS, GROUP B 
H224.00 PNEUMONIA DUE TO STAPHYLOCOCCUS 
H22y.00 PNEUMONIA DUE TO OTHER SPECIFIED BACTERIA 
H22y000 PNEUMONIA DUE TO ESCHERICHIA COLI 
H22y011 E. COLI PNEUMONIA 
H22y100 PNEUMONIA DUE TO PROTEUS 
H22y200 PNEUMONIA - LEGIONELLA 
H22yX00 PNEUMONIA DUE TO OTHER AEROBIC GRAM-
NEGATIVE BACTERIA 
H22yz00 PNEUMONIA DUE TO BACTERIA NOS 
H22z.00 BACTERIAL PNEUMONIA NOS 
H23..00 PNEUMONIA DUE TO OTHER SPECIFIED ORGANISMS 
H23..11 CHEST INFECTION - PNEUMONIA ORGANISM 
H230.00 PNEUMONIA DUE TO EATON’S AGENT 
H231.00 PNEUMONIA DUE TO MYCOPLASMA PNEUMONIA 





H233.00 CHLAMYDIAL PNEUMONIA 
H23z.00 PNEUMONIA DUE TO SPECIFIED ORGANISM NOS 
H24..00 PNEUMONIA WITH INFECTIOUS DISEASES EC 
H240.00 PNEUMONIA WITH MEASLES 
H241.00 PNEUMONIA WITH CYTOMEGALIC INCLUSION 
DISEASE 
H242.00 PNEUMONIA WITH ORNITHOSIS 
H243.00 PNEUMONIA WITH WHOOPING COUGH 
H243.11 PNEUMONIA WITH PERTUSSIS 
H244.00 PNEUMONIA WITH TULARAEMIA 
H246.00 PNEUMONIA WITH ASPERGILLOSIS 
H247.00 PNEUMONIA WITH OTHER SYSTEMIC MYCOSES 
H247000 PNEUMONIA WITH CANDIDIASIS 
H247100 PNEUMONIA WITH COCCIDIOIDOMYCOSIS 
H247z00 PNEUMONIA WITH SYSTEMIC MYCOSIS  
H24y.00 PNEUMONIA WITH OTHER INFECTIOUS DISEASES EC 
H24y000 PNEUMONIA WITH ACTINOMYCOSIS 
H24y100 PNEUMONIA WITH NOCARDIOSIS 
H24y200 PNEUMONIA WITH PNEUMOCYSTIS CARINII 
H24y300 PNEUMONIA WITH Q-FEVER 
H24y400 PNEUMONIA WITH SALMONELLOSIS 
H24y500 PNEUMONIA WITH TOXOPLASMOSIS 
H24y600 PNEUMONIA WITH TYPHOID FEVER 
H24y700 PNEUMONIA WITH VARICELLA 
H24yz00 PNEUMONIA WITH OTHER INFECTIOUS DISEASES EC 
NOS 
H24z.00 PNEUMONIA WITH INFECTIOUS DISEASES EC NOS 
H25..00 BRONCHOPNEUMONIA DUE TO UNSPECIFIED 
ORGANISM 
H25..11 CHEST INFECTION - UNSPECIFIED 
BRONCHOPNEUMONIA 




H26..11 CHEST INFECTION - PNEUMONIA DUE TO 
UNSPECIFIED ORGANISM 
H260.00 LOBAR PNEUMONIA DUE TO UNSPECIFIED 
ORGANISM 
H260000 LUNG CONSOLIDATION 
H261.00 BASAL PNEUMONIA DUE TO UNSPECIFIED ORGANISM 
H262.00 POSTOPERATIVE PNEUMONIA 
H270.00 INFLUENZA WITH PNEUMONIA 
H270.11 CHEST INFECTION - INFLUENZA WITH PNEUMONIA 
H270000 INFLUENZA WITH BRONCHOPNEUMONIA 
H270100 INFLUENZA WITH PNEUMONIA, INFLUENZA VIRUS 
IDENTIFIED 
H270z00 INFLUENZA WITH PNEUMONIA 
H28..00 ATYPICAL PNEUMONIA 
H2B..00 COMMUNITY-ACQUIRED PNEUMONIA 
H2C..00 HOSPITAL ACQUIRED PNEUMONIA 
H2y..00 OTHER SPECIFIED PNEUMONIA OR INFLUENZA 
H2z..00 PNEUMONIA OR INFLUENZA  
H47..00 PNEUMONITIS DUE TO INHALATION OF SOLIDS OR 
LIQUIDS 
H47..11 ASPIRATION PNEUMONITIS 
H470.00 PNEUMONITIS DUE TO INHALATION OF FOOD OR 
VOMITUS 
H470.11 ASPIRATION PNEUMONIA 
H470000 PNEUMONITIS DUE TO INHALATION OF 
REGURGITATED FOOD 
H470300 PNEUMONITIS DUE TO INHALATION OF VOMITUS 
H470311 VOMIT INHALATION PNEUMONITIS 
H470312 ASPIRATION PNEUMONIA DUE TO VOMIT 





H471.00 PNEUMONITIS DUE TO INHALATION OF OIL OR 
ESSENCE 
H510900 PNEUMOCOCCAL PLEURISY 
H511000 PNEUMOCOCCAL PLEURISY WITH EFFUSION 
H530200 GANGRENOUS PNEUMONIA 
H530300 ABSCESS OF LUNG WITH PNEUMONIA 
H540000 HYPOSTATIC PNEUMONIA 
H540100 HYPOSTATIC BRONCHOPNEUMONIA 
H564.00 BRONCHIOLITIS OBLITERANS ORGANISING 
PNEUMONIA 
H56y100 INTERSTITIAL PNEUMONIA 
H571.00 RHEUMATIC PNEUMONIA 
Hyu0800 OTHER VIRAL PNEUMONIA 
Hyu0900 PNEUMONIA DUE TO OTHER AEROBIC GRAM-
NEGATIVE BACTERIA 
Hyu0A00 OTHER BACTERIAL PNEUMONIA 
Hyu0B00 PNEUMONIA DUE TO OTHER SPECIFIED INFECTIOUS 
ORGANISMS 
Hyu0C00 PNEUMONIA IN BACTERIAL DISEASES CLASSIFIED 
ELSEWHERE 
Hyu0D00 PNEUMONIA IN VIRAL DISEASES CLASSIFIED 
ELSEWHERE 
Hyu0G00 PNEUMONIA IN OTHER DISEASES CLASSIFIED 
ELSEWHERE 
Hyu0H00 OTHER PNEUMONIA, ORGANISM UNSPECIFIED 
SP13100 OTHER ASPIRATION PNEUMONIA AS A 






Appendix 9-14. COPD exacerbation algorithm codes 
Lower Respiratory tract infection  
H06z011 CHEST INFECTION 
H060.00 ACUTE BRONCHITIS 
H27..00 INFLUENZA 
H061.00 ACUTE BRONCHIOLITIS 
H060w00 ACUTE VIRAL BRONCHITIS UNSPECIFIED 
H27z.11 FLU LIKE ILLNESS 
H07..00 CHEST COLD 
H06z000 CHEST INFECTION NOS 
H06z100 LOWER RESPIRATORY TRACT INFECTION 
H27z.12 INFLUENZA LIKE ILLNESS 
H060.11 ACUTE WHEEZY BRONCHITIS 
H062.00 ACUTE LOWER RESPIRATORY TRACT INFECTION 
H061400 OBLITERATING FIBROUS BRONCHIOLITIS 
16L..00 INFLUENZA-LIKE SYMPTOMS 
H060600 ACUTE PNEUMOCOCCAL BRONCHITIS 
H060300 ACUTE PURULENT BRONCHITIS 
H27y100 INFLUENZA WITH GASTROINTESTINAL TRACT 
INVOLVEMENT 
H271000 INFLUENZA WITH LARYNGITIS 
H27z.00 INFLUENZA 
H061200 ACUTE BRONCHIOLITIS WITH BRONCHOSPASM 
H30..11 CHEST INFECTION - UNSPECIFIED BRONCHITIS 
H061z00 ACUTE BRONCHIOLITIS 
H061500 ACUTE BRONCHIOLITIS DUE TO RESPIRATORY 
SYNCYTIAL VIRUS 
H060z00 ACUTE BRONCHITIS  
H3y0.00 CHRONIC OBSTRUCT PULMONARY DIS WITH ACUTE 
LOWER RESPIRATORY INFECTION 
H060400 ACUTE CROUPOUS BRONCHITIS 




H271z00 INFLUENZA WITH RESPIRATORY MANIFESTATIONS 
NOS 
H24..11 CHEST INFECTION WITH INFECTIOUS DISEASE EC 
H060x00 ACUTE BACTERIAL BRONCHITIS UNSPECIFIED 
H312300 BRONCHIOLITIS OBLITERANS 
H060C00 ACUTE BRONCHITIS DUE TO PARAINFLUENZA VIRUS 
H271100 INFLUENZA WITH PHARYNGITIS 
H06..00 ACUTE BRONCHITIS AND BRONCHIOLITIS 
H27yz00 INFLUENZA WITH OTHER MANIFESTATIONS NOS 
H06z112 ACUTE LOWER RESPIRATORY TRACT INFECTION 
H06z.00 ACUTE BRONCHITIS OR BRONCHIOLITIS NOS 
H061100 ACUTE OBLITERATING BRONCHIOLITIS 
H060700 ACUTE STREPTOCOCCAL BRONCHITIS 
H271.00 INFLUENZA WITH OTHER RESPIRATORY 
MANIFESTATION 
H27y000 INFLUENZA WITH ENCEPHALOPATHY 
H27y.00 INFLUENZA WITH OTHER MANIFESTATIONS 
H060D00 ACUTE BRONCHITIS DUE TO RESPIRATORY 
SYNCYTIAL VIRUS 
H060900 ACUTE NEISSERIA CATARRHALIS BRONCHITIS 
H061000 ACUTE CAPILLARY BRONCHIOLITIS 
43jQ.00 AVIAN INFLUENZA VIRUS NUCLEIC ACID DETECTION 
H060E00 ACUTE BRONCHITIS DUE TO RHINOVIRUS 
H060F00 ACUTE BRONCHITIS DUE TO ECHOVIRUS 
H061600 ACUTE BRONCHIOLITIS DUE TO OTHER SPECIFIED 
ORGANISMS 
Hyu1.00 [X]OTHER ACUTE LOWER RESPIRATORY INFECTIONS 
H061300 ACUTE EXUDATIVE BRONCHIOLITIS 
H060200 ACUTE PSEUDOMEMBRANOUS BRONCHITIS 
Hyu1000 [X]ACUTE BRONCHITIS DUE TO OTHER SPECIFIED 
ORGANISMS 




H060B00 ACUTE BRONCHITIS DUE TO COXSACKIEVIRUS 
43jx.00 PARAINFLUENZA TYPE 1 NUCLEIC ACID DETECTION 
43jy.00 PARAINFLUENZA TYPE 2 NUCLEIC ACID DETECTION 
H29..00 AVIAN INFLUENZA 
4JU5.00 INFLUENZA B VIRUS DETECTED 
4JU2.00 INFLUENZA H3 VIRUS DETECTED 
4JU0.00 INFLUENZA H1 VIRUS DETECTED 
4JUF.00 HUMAN PARAINFLUENZA VIRUS DETECTED 
4JU4.00 INFLUENZA A VIRUS, OTHER OR UNTYPED STRAIN 
DETECTED 
Hyu0700 [X]INFLUENZA + OTHER MANIFESTATIONS, VIRUS 
NOT IDENTIFIED 
Hyu0600 [X]INFLUENZA + OTHER RESPIRATORY 
MANIFESTATIONS, VIRUS NOT IDENTIFIED 
Hyu0500 [X]INFLUENZA + OTHER MANIFESTATIONS, 
INFLUENZA VIRUS IDENTIFIED 
H2A..11 INFLUENZA A (H1N1) SWINE FLU 
1W0..00 POSSIBLE INFLUENZA A VIRUS H1N1 SUBTYPE 
1J72.11 SUSPECTED SWINE INFLUENZA 
1J72.00 SUSPECTED INFLUENZA A VIRUS SUBTYPE H1N1 
INFECTION 
H2A..00 INFLUENZA DUE TO INFLUENZA A VIRUS SUBTYPE 
H1N1 
4J3L.00 INFLUENZA A VIRUS H1N1 SUBTYPE DETECTED 
4JU3.00 INFLUENZA H5 VIRUS DETECTED 
Hyu0400 [X]FLU + OTHER RESPIRATORY MANIFESTATIONS, 
‘FLU VIRUS IDENTIFIED 
Hyu1100 [X]ACUTE BRONCHIOLITIS DUE TO OTHER SPECIFIED 
ORGANISMS 
H060100 ACUTE MEMBRANOUS BRONCHITIS 
4JU1.00 INFLUENZA H2 VIRUS DETECTED 




H312200 ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE 
AIRWAYS DISEASE 
H3y1.00 CHRON OBSTRUCT PULMONARY DISSEASE WITH 
ACUTE EXACERBATION, UNSPECIFIED 
Antibiotics 
88556998 AMOXICILLIN CAPS 250MG 
89177998 AMOXICILLIN CAPS 250MG 
92456990 AMOXICILLIN CAPS 250MG 
93372998 AMOXICILLIN CAPS 250MG 
93377998 AMOXICILLIN CAPS 250MG 
93407998 AMOXICILLIN CAPS 250MG 
93465998 AMOXICILLIN CAPS 250MG 
94074990 AMOXICILLIN CAPS 250MG 
94699998 AMOXICILLIN CAPS 250MG 
95225990 AMOXICILLIN CAPS 250MG 
96239998 AMOXICILLIN CAPS 250MG 
96307990 AMOXICILLIN CAPS 250MG 
96313998 AMOXICILLIN CAPS 250MG 
96383990 AMOXICILLIN CAPS 250MG 
96931990 AMOXICILLIN CAPS 250MG 
96990990 AMOXICILLIN CAPS 250MG 
97050990 AMOXICILLIN CAPS 250MG 
97131998 AMOXICILLIN CAPS 250MG 
97133990 AMOXICILLIN CAPS 250MG 
97790990 AMOXICILLIN CAPS 250MG 
97808998 AMOXICILLIN CAPS 250MG 
98803990 AMOXICILLIN CAPS 250MG 
99836990 AMOXICILLIN CAPS 250MG 
99837990 AMOXICILLIN CAPS 250MG 
99838990 AMOXICILLIN CAPS 250MG 
99839990 AMOXICILLIN CAPS 250MG 




99842990 AMOXICILLIN CAPS 250MG 
99843990 AMOXICILLIN CAPS 250MG 
99844990 AMOXICILLIN CAPS 250MG 
99845990 AMOXICILLIN CAPS 250MG 
99848990 AMOXICILLIN CAPS 250MG 
99849988 AMOXICILLIN CAPS 250MG 
99962998 AMOXICILLIN CAPS 250MG 
88556997 AMOXICILLIN CAPS 500MG 
89177997 AMOXICILLIN CAPS 500MG 
92455990 AMOXICILLIN CAPS 500MG 
93372997 AMOXICILLIN CAPS 500MG 
93377997 AMOXICILLIN CAPS 500MG 
93407997 AMOXICILLIN CAPS 500MG 
93465997 AMOXICILLIN CAPS 500MG 
94073990 AMOXICILLIN CAPS 500MG 
94699997 AMOXICILLIN CAPS 500MG 
95224990 AMOXICILLIN CAPS 500MG 
96239997 AMOXICILLIN CAPS 500MG 
96307989 AMOXICILLIN CAPS 500MG 
96313997 AMOXICILLIN CAPS 500MG 
96383989 AMOXICILLIN CAPS 500MG 
96931989 AMOXICILLIN CAPS 500MG 
96990989 AMOXICILLIN CAPS 500MG 
97050989 AMOXICILLIN CAPS 500MG 
97131997 AMOXICILLIN CAPS 500MG 
98334990 AMOXICILLIN CAPS 500MG 
98803989 AMOXICILLIN CAPS 500MG 
99836989 AMOXICILLIN CAPS 500MG 
99837989 AMOXICILLIN CAPS 500MG 
99838989 AMOXICILLIN CAPS 500MG 
99839989 AMOXICILLIN CAPS 500MG 




99841989 AMOXICILLIN CAPS 500MG 
99842989 AMOXICILLIN CAPS 500MG 
99843989 AMOXICILLIN CAPS 500MG 
99844989 AMOXICILLIN CAPS 500MG 
99845989 AMOXICILLIN CAPS 500MG 
99846990 AMOXICILLIN CAPS 500MG 
99848989 AMOXICILLIN CAPS 500MG 
99962997 AMOXICILLIN CAPS 500MG 
96944998 AMOXICILLIN TAB 500MG 
99962996 AMOXICILLIN TAB 500MG 
88557996 AMOXICILLIN SF ORAL SUSP 125MG/5ML 
89889998 AMOXICILLIN SF ORAL SUSP 125MG/5ML 
93041990 AMOXICILLIN SF ORAL SUSP 125MG/5ML 
93372996 AMOXICILLIN SF ORAL SUSP 125MG/5ML 
93377996 AMOXICILLIN SF ORAL SUSP 125MG/5ML 
93407996 AMOXICILLIN SF ORAL SUSP 125MG/5ML 
93592990 AMOXICILLIN SF ORAL SUSP 125MG/5ML 
94792998 AMOXICILLIN SF ORAL SUSP 125MG/5ML 
96928989 AMOXICILLIN SF ORAL SUSP 125MG/5ML 
97133989 AMOXICILLIN SF ORAL SUSP 125MG/5ML 
97790988 AMOXICILLIN SF ORAL SUSP 125MG/5ML 
97868998 AMOXICILLIN SF ORAL SUSP 125MG/5ML 
98334989 AMOXICILLIN SF ORAL SUSP 125MG/5ML 
99831989 AMOXICILLIN SF ORAL SUSP 125MG/5ML 
99832989 AMOXICILLIN SF ORAL SUSP 125MG/5ML 
99838988 AMOXICILLIN SF ORAL SUSP 125MG/5ML 
88382998 AMOXICILLIN SF ORAL SUSP 250MG/5ML 
89889997 AMOXICILLIN SF ORAL SUSP 250MG/5ML 
93040990 AMOXICILLIN SF ORAL SUSP 250MG/5ML 
93375998 AMOXICILLIN SF ORAL SUSP 250MG/5ML 
93404998 AMOXICILLIN SF ORAL SUSP 250MG/5ML 




93591990 AMOXICILLIN SF ORAL SUSP 250MG/5ML 
94792997 AMOXICILLIN SF ORAL SUSP 250MG/5ML 
96928988 AMOXICILLIN SF ORAL SUSP 250MG/5ML 
97133988 AMOXICILLIN SF ORAL SUSP 250MG/5ML 
97789990 AMOXICILLIN SF ORAL SUSP 250MG/5ML 
97868997 AMOXICILLIN SF ORAL SUSP 250MG/5ML 
98334988 AMOXICILLIN SF ORAL SUSP 250MG/5ML 
99828990 AMOXICILLIN SF ORAL SUSP 250MG/5ML 
99831988 AMOXICILLIN SF ORAL SUSP 250MG/5ML 
99832988 AMOXICILLIN SF ORAL SUSP 250MG/5ML 
95086996 AMOXICILLIN SF POWDER 125MG 
99830988 AMOXICILLIN SF POWDER 125MG 
96156990 AMOXICILLIN SF POWDER 3G 
96943998 AMOXICILLIN SF POWDER 3G 
97790989 AMOXICILLIN SF POWDER 3G 
97956990 AMOXICILLIN SF POWDER 3G 
98673998 AMOXICILLIN SF POWDER 3G 
99830989 AMOXICILLIN SF POWDER 3G 
96944996 AMOXICILLIN SF POWDER 750MG 
97868996 AMOXICILLIN SF POWDER 750MG 
95077998 AMOXICILLIN SOL TAB 375MG 
95086998 AMOXICILLIN SOL TAB 375MG 
95077997 AMOXICILLIN SOL TAB 750MG 
95086997 AMOXICILLIN SOL TAB 750MG 
88557998 AMOXICILLIN SYRUP 125MG/5ML 
93465996 AMOXICILLIN SYRUP 125MG/5ML 
94071990 AMOXICILLIN SYRUP 125MG/5ML 
94699996 AMOXICILLIN SYRUP 125MG/5ML 
94794998 AMOXICILLIN SYRUP 125MG/5ML 
96239996 AMOXICILLIN SYRUP 125MG/5ML 
96307988 AMOXICILLIN SYRUP 125MG/5ML 




96383988 AMOXICILLIN SYRUP 125MG/5ML 
96931988 AMOXICILLIN SYRUP 125MG/5ML 
97808997 AMOXICILLIN SYRUP 125MG/5ML 
98803988 AMOXICILLIN SYRUP 125MG/5ML 
99836988 AMOXICILLIN SYRUP 125MG/5ML 
99837988 AMOXICILLIN SYRUP 125MG/5ML 
99839988 AMOXICILLIN SYRUP 125MG/5ML 
99840989 AMOXICILLIN SYRUP 125MG/5ML 
99841988 AMOXICILLIN SYRUP 125MG/5ML 
99842988 AMOXICILLIN SYRUP 125MG/5ML 
99843988 AMOXICILLIN SYRUP 125MG/5ML 
99844988 AMOXICILLIN SYRUP 125MG/5ML 
99845988 AMOXICILLIN SYRUP 125MG/5ML 
99846989 AMOXICILLIN SYRUP 125MG/5ML 
99848988 AMOXICILLIN SYRUP 125MG/5ML 
99849990 AMOXICILLIN SYRUP 125MG/5ML 
88557997 AMOXICILLIN SYRUP 250MG/5ML 
93466998 AMOXICILLIN SYRUP 250MG/5ML 
94070990 AMOXICILLIN SYRUP 250MG/5ML 
94698998 AMOXICILLIN SYRUP 250MG/5ML 
94794997 AMOXICILLIN SYRUP 250MG/5ML 
96255998 AMOXICILLIN SYRUP 250MG/5ML 
96306990 AMOXICILLIN SYRUP 250MG/5ML 
96365998 AMOXICILLIN SYRUP 250MG/5ML 
96377990 AMOXICILLIN SYRUP 250MG/5ML 
96928990 AMOXICILLIN SYRUP 250MG/5ML 
96965990 AMOXICILLIN SYRUP 250MG/5ML 
98779990 AMOXICILLIN SYRUP 250MG/5ML 
99827990 AMOXICILLIN SYRUP 250MG/5ML 
99829990 AMOXICILLIN SYRUP 250MG/5ML 
99830990 AMOXICILLIN SYRUP 250MG/5ML 




99832990 AMOXICILLIN SYRUP 250MG/5ML 
99833990 AMOXICILLIN SYRUP 250MG/5ML 
99834990 AMOXICILLIN SYRUP 250MG/5ML 
99840988 AMOXICILLIN SYRUP 250MG/5ML 
99846988 AMOXICILLIN SYRUP 250MG/5ML 
99847990 AMOXICILLIN SYRUP 250MG/5ML 
99849989 AMOXICILLIN SYRUP 250MG/5ML 
96092992 AMOXYCILLIN FIZTAB 125 MG TAB 
96822992 AMOXYCILLIN FIZTAB 250 MG TAB 
88245998 CEFACLOR CAPS 250MG 
89452998 CEFACLOR CAPS 250MG 
94648990 CEFACLOR CAPS 250MG 
96856998 CEFACLOR CAPS 250MG 
96925990 CEFACLOR CAPS 250MG 
97035988 CEFACLOR CAPS 250MG 
97694990 CEFACLOR CAPS 250MG 
97696990 CEFACLOR CAPS 250MG 
97840990 CEFACLOR CAPS 250MG 
99741998 CEFACLOR CAPS 250MG 
85949998 CEFACLOR CAPS 500MG 
88245997 CEFACLOR CAPS 500MG 
89452997 CEFACLOR CAPS 500MG 
94647990 CEFACLOR CAPS 500MG 
94870998 CEFACLOR CAPS 500MG 
94873998 CEFACLOR CAPS 500MG 
96925989 CEFACLOR CAPS 500MG 
97038990 CEFACLOR CAPS 500MG 
97694989 CEFACLOR CAPS 500MG 
97696989 CEFACLOR CAPS 500MG 
97840989 CEFACLOR CAPS 500MG 
85952998 CEFACLOR TAB 375MG 




93901997 CEFACLOR TAB 375MG 
94791998 CEFACLOR TAB 375MG 
96639990 CEFACLOR TAB 375MG 
96923989 CEFACLOR TAB 375MG 
93901998 CEFACLOR TAB 500MG 
94791997 CEFACLOR TAB 500MG 
89452996 CEFACLOR SF SUSP 125MG/5ML 
94301990 CEFACLOR SF SUSP 125MG/5ML 
94873997 CEFACLOR SF SUSP 125MG/5ML 
96925988 CEFACLOR SF SUSP 125MG/5ML 
97035989 CEFACLOR SF SUSP 125MG/5ML 
97696988 CEFACLOR SF SUSP 125MG/5ML 
88818998 CEFACLOR SF SUSP 250MG/5ML 
94300990 CEFACLOR SF SUSP 250MG/5ML 
94873996 CEFACLOR SF SUSP 250MG/5ML 
96923990 CEFACLOR SF SUSP 250MG/5ML 
97035990 CEFACLOR SF SUSP 250MG/5ML 
97542990 CEFACLOR SF SUSP 250MG/5ML 
85951998 CEFACLOR SUSP 125MG/5ML 
88245996 CEFACLOR SUSP 125MG/5ML 
96224990 CEFACLOR SUSP 125MG/5ML 
96856997 CEFACLOR SUSP 125MG/5ML 
97328998 CEFACLOR SUSP 125MG/5ML 
97694988 CEFACLOR SUSP 125MG/5ML 
97840988 CEFACLOR SUSP 125MG/5ML 
99741997 CEFACLOR SUSP 125MG/5ML 
85950998 CEFACLOR SUSP 250MG/5ML 
88222998 CEFACLOR SUSP 250MG/5ML 
96215990 CEFACLOR SUSP 250MG/5ML 
96856996 CEFACLOR SUSP 250MG/5ML 
97328997 CEFACLOR SUSP 250MG/5ML 




97839990 CEFACLOR SUSP 250MG/5ML 
99741996 CEFACLOR SUSP 250MG/5ML 
82664998 CEFALEXIN CAPS 250MG 
85946998 CEFALEXIN CAPS 250MG 
90029998 CEFALEXIN CAPS 250MG 
92076996 CEFALEXIN CAPS 250MG 
93529998 CEFALEXIN CAPS 250MG 
94174990 CEFALEXIN CAPS 250MG 
94646990 CEFALEXIN CAPS 250MG 
94730996 CEFALEXIN CAPS 250MG 
96433989 CEFALEXIN CAPS 250MG 
96911988 CEFALEXIN CAPS 250MG 
97171990 CEFALEXIN CAPS 250MG 
97859989 CEFALEXIN CAPS 250MG 
97888996 CEFALEXIN CAPS 250MG 
97991988 CEFALEXIN CAPS 250MG 
98015989 CEFALEXIN CAPS 250MG 
98195990 CEFALEXIN CAPS 250MG 
98638990 CEFALEXIN CAPS 250MG 
99699990 CEFALEXIN CAPS 250MG 
99700990 CEFALEXIN CAPS 250MG 
99701988 CEFALEXIN CAPS 250MG 
82663998 CEFALEXIN CAPS 500MG 
85945998 CEFALEXIN CAPS 500MG 
90029997 CEFALEXIN CAPS 500MG 
92077998 CEFALEXIN CAPS 500MG 
93529997 CEFALEXIN CAPS 500MG 
94173990 CEFALEXIN CAPS 500MG 
94645990 CEFALEXIN CAPS 500MG 
94729998 CEFALEXIN CAPS 500MG 
96433988 CEFALEXIN CAPS 500MG 




97171989 CEFALEXIN CAPS 500MG 
97859988 CEFALEXIN CAPS 500MG 
97887998 CEFALEXIN CAPS 500MG 
97990990 CEFALEXIN CAPS 500MG 
98195989 CEFALEXIN CAPS 500MG 
98638989 CEFALEXIN CAPS 500MG 
99255990 CEFALEXIN CAPS 500MG 
99699989 CEFALEXIN CAPS 500MG 
99700989 CEFALEXIN CAPS 500MG 
94728998 CEFALEXIN CHEWABLE TAB 250MG 
96837996 CEFALEXIN CHEWABLE TAB 250MG 
82662998 CEFALEXIN ORAL SUSP 125MG/5ML 
85944998 CEFALEXIN ORAL SUSP 125MG/5ML 
90028998 CEFALEXIN ORAL SUSP 125MG/5ML 
92077997 CEFALEXIN ORAL SUSP 125MG/5ML 
93104990 CEFALEXIN ORAL SUSP 125MG/5ML 
94644990 CEFALEXIN ORAL SUSP 125MG/5ML 
94729997 CEFALEXIN ORAL SUSP 125MG/5ML 
96435988 CEFALEXIN ORAL SUSP 125MG/5ML 
96836998 CEFALEXIN ORAL SUSP 125MG/5ML 
96909989 CEFALEXIN ORAL SUSP 125MG/5ML 
97171988 CEFALEXIN ORAL SUSP 125MG/5ML 
97778989 CEFALEXIN ORAL SUSP 125MG/5ML 
97886997 CEFALEXIN ORAL SUSP 125MG/5ML 
97887997 CEFALEXIN ORAL SUSP 125MG/5ML 
97990989 CEFALEXIN ORAL SUSP 125MG/5ML 
98635989 CEFALEXIN ORAL SUSP 125MG/5ML 
99698989 CEFALEXIN ORAL SUSP 125MG/5ML 
82661998 CEFALEXIN ORAL SUSP 250MG/5ML 
85943998 CEFALEXIN ORAL SUSP 250MG/5ML 
90028997 CEFALEXIN ORAL SUSP 250MG/5ML 




93103990 CEFALEXIN ORAL SUSP 250MG/5ML 
94643990 CEFALEXIN ORAL SUSP 250MG/5ML 
94729996 CEFALEXIN ORAL SUSP 250MG/5ML 
96277990 CEFALEXIN ORAL SUSP 250MG/5ML 
96433990 CEFALEXIN ORAL SUSP 250MG/5ML 
96836997 CEFALEXIN ORAL SUSP 250MG/5ML 
96909988 CEFALEXIN ORAL SUSP 250MG/5ML 
97778988 CEFALEXIN ORAL SUSP 250MG/5ML 
97886996 CEFALEXIN ORAL SUSP 250MG/5ML 
97887996 CEFALEXIN ORAL SUSP 250MG/5ML 
97990988 CEFALEXIN ORAL SUSP 250MG/5ML 
98195988 CEFALEXIN ORAL SUSP 250MG/5ML 
98635988 CEFALEXIN ORAL SUSP 250MG/5ML 
99698988 CEFALEXIN ORAL SUSP 250MG/5ML 
82660998 CEFALEXIN ORAL SUSP 500MG/5ML 
96836996 CEFALEXIN ORAL SUSP 500MG/5ML 
97886998 CEFALEXIN ORAL SUSP 500MG/5ML 
87657998 CEFALEXIN SF ORAL SUSP 125MG/5ML 
97237990 CEFALEXIN SF ORAL SUSP 125MG/5ML 
87658998 CEFALEXIN SF ORAL SUSP 250MG/5ML 
97237989 CEFALEXIN SF ORAL SUSP 250MG/5ML 
96835998 CEFALEXIN SUSP 125MG/5ML 
96835997 CEFALEXIN SUSP 250MG/5ML 
93533998 CEFALEXIN TABS 1G 
93534998 CEFALEXIN TABS 1G 
82666998 CEFALEXIN TABS 250MG 
85948998 CEFALEXIN TABS 250MG 
92076998 CEFALEXIN TABS 250MG 
93102990 CEFALEXIN TABS 250MG 
94642990 CEFALEXIN TABS 250MG 
94730998 CEFALEXIN TABS 250MG 




96435990 CEFALEXIN TABS 250MG 
96837998 CEFALEXIN TABS 250MG 
96911990 CEFALEXIN TABS 250MG 
97859990 CEFALEXIN TABS 250MG 
97888998 CEFALEXIN TABS 250MG 
97991990 CEFALEXIN TABS 250MG 
98010990 CEFALEXIN TABS 250MG 
98015990 CEFALEXIN TABS 250MG 
98141990 CEFALEXIN TABS 250MG 
98638988 CEFALEXIN TABS 250MG 
99699988 CEFALEXIN TABS 250MG 
99701990 CEFALEXIN TABS 250MG 
82665998 CEFALEXIN TABS 500MG 
85947998 CEFALEXIN TABS 500MG 
90029996 CEFALEXIN TABS 500MG 
92076997 CEFALEXIN TABS 500MG 
93101990 CEFALEXIN TABS 500MG 
94622990 CEFALEXIN TABS 500MG 
94641990 CEFALEXIN TABS 500MG 
94730997 CEFALEXIN TABS 500MG 
96435989 CEFALEXIN TABS 500MG 
96837997 CEFALEXIN TABS 500MG 
96911989 CEFALEXIN TABS 500MG 
97778990 CEFALEXIN TABS 500MG 
97888997 CEFALEXIN TABS 500MG 
97991989 CEFALEXIN TABS 500MG 
98635990 CEFALEXIN TABS 500MG 
99698990 CEFALEXIN TABS 500MG 
99700988 CEFALEXIN TABS 500MG 
99701989 CEFALEXIN TABS 500MG 
96681998 CHLORTETRACYCLINE CAPS 250MG 




95828992 CHLORTETRACYCLINE HCL SYR 
84350998 CIPROFLOXACIN ORAL LIQUID 
93079996 CIPROFLOXACIN SUSP 250MG/5ML 
93080996 CIPROFLOXACIN SUSP 250MG/5ML 
93079997 CIPROFLOXACIN TABS 100MG 
93080997 CIPROFLOXACIN TABS 100MG 
94268990 CIPROFLOXACIN TABS 100MG 
95686990 CIPROFLOXACIN TABS 100MG 
95804990 CIPROFLOXACIN TABS 100MG 
95824990 CIPROFLOXACIN TABS 100MG 
95949990 CIPROFLOXACIN TABS 100MG 
96033990 CIPROFLOXACIN TABS 100MG 
96045990 CIPROFLOXACIN TABS 100MG 
93830990 CIPROFLOXACIN TABS 250MG 
94024990 CIPROFLOXACIN TABS 250MG 
94607990 CIPROFLOXACIN TABS 250MG 
94692990 CIPROFLOXACIN TABS 250MG 
94912998 CIPROFLOXACIN TABS 250MG 
94913998 CIPROFLOXACIN TABS 250MG 
95212990 CIPROFLOXACIN TABS 250MG 
95430990 CIPROFLOXACIN TABS 250MG 
95629990 CIPROFLOXACIN TABS 250MG 
95823990 CIPROFLOXACIN TABS 250MG 
95867990 CIPROFLOXACIN TABS 250MG 
95948990 CIPROFLOXACIN TABS 250MG 
96024990 CIPROFLOXACIN TABS 250MG 
96032990 CIPROFLOXACIN TABS 250MG 
96044990 CIPROFLOXACIN TABS 250MG 
96049990 CIPROFLOXACIN TABS 250MG 
96052990 CIPROFLOXACIN TABS 250MG 
96058990 CIPROFLOXACIN TABS 250MG 




94023990 CIPROFLOXACIN TABS 500MG 
94606990 CIPROFLOXACIN TABS 500MG 
94691990 CIPROFLOXACIN TABS 500MG 
94912996 CIPROFLOXACIN TABS 500MG 
94913996 CIPROFLOXACIN TABS 500MG 
95131990 CIPROFLOXACIN TABS 500MG 
95211990 CIPROFLOXACIN TABS 500MG 
95429990 CIPROFLOXACIN TABS 500MG 
95628990 CIPROFLOXACIN TABS 500MG 
95822990 CIPROFLOXACIN TABS 500MG 
95866990 CIPROFLOXACIN TABS 500MG 
95947990 CIPROFLOXACIN TABS 500MG 
96023990 CIPROFLOXACIN TABS 500MG 
96031990 CIPROFLOXACIN TABS 500MG 
96043990 CIPROFLOXACIN TABS 500MG 
96048990 CIPROFLOXACIN TABS 500MG 
96051990 CIPROFLOXACIN TABS 500MG 
96057990 CIPROFLOXACIN TABS 500MG 
96066990 CIPROFLOXACIN TABS 500MG 
93079998 CIPROFLOXACIN TABS 750MG 
93080998 CIPROFLOXACIN TABS 750MG 
94267990 CIPROFLOXACIN TABS 750MG 
94653990 CIPROFLOXACIN TABS 750MG 
95132990 CIPROFLOXACIN TABS 750MG 
95181990 CIPROFLOXACIN TABS 750MG 
95210990 CIPROFLOXACIN TABS 750MG 
95627990 CIPROFLOXACIN TABS 750MG 
95821990 CIPROFLOXACIN TABS 750MG 
95865990 CIPROFLOXACIN TABS 750MG 
95946990 CIPROFLOXACIN TABS 750MG 
96022990 CIPROFLOXACIN TABS 750MG 




96042990 CIPROFLOXACIN TABS 750MG 
96047990 CIPROFLOXACIN TABS 750MG 
96050990 CIPROFLOXACIN TABS 750MG 
96056990 CIPROFLOXACIN TABS 750MG 
88378998 CLARITHROMYCIN GRANS FOR SUSP 250MG/SACHET 
92495997 CLARITHROMYCIN GRANS FOR SUSP 250MG/SACHET 
89246998 CLARITHROMYCIN TAB 500MG 
92495998 CLARITHROMYCIN TAB 500MG 
86475998 CLARITHROMYCIN ORAL SUSP GRANULES 
125MG/STRAW 
86478998 CLARITHROMYCIN ORAL SUSP GRANULES 
125MG/STRAW 
86474998 CLARITHROMYCIN ORAL SUSP GRANULES 
187.5MG/STRAW 
86477998 CLARITHROMYCIN ORAL SUSP GRANULES 
187.5MG/STRAW 
86473998 CLARITHROMYCIN ORAL SUSP GRANULES 
250MG/STRAW 
86476998 CLARITHROMYCIN ORAL SUSP GRANULES 
250MG/STRAW 
92632990 CLARITHROMYCIN TABS 250MG 
94185990 CLARITHROMYCIN TABS 250MG 
94505990 CLARITHROMYCIN TABS 250MG 
94530990 CLARITHROMYCIN TABS 250MG 
94530998 CLARITHROMYCIN TABS 250MG 
94531998 CLARITHROMYCIN TABS 250MG 
94542990 CLARITHROMYCIN TABS 250MG 
94551990 CLARITHROMYCIN TABS 250MG 
92631990 CLARITHROMYCIN TABS 500MG 
94370990 CLARITHROMYCIN TABS 500MG 
94504990 CLARITHROMYCIN TABS 500MG 




94530996 CLARITHROMYCIN TABS 500MG 
94531996 CLARITHROMYCIN TABS 500MG 
94541990 CLARITHROMYCIN TABS 500MG 
94550990 CLARITHROMYCIN TABS 500MG 
96660997 CLAVULANIC ACID + AMOXICILLIN TAB 
86034998 CLAVULANIC ACID + AMOXICILLIN ORAL SUSP 31MG 
+ 125 
86036998 CLAVULANIC ACID + AMOXICILLIN ORAL SUSP 62MG 
+ 250 
96660996 CLAVULANIC ACID + AMOXICILLIN SF SUSP 31MG + 
125MG 
97708996 CLAVULANIC ACID + AMOXICILLIN SF SUSP 57MG + 
400MG 
97708998 CLAVULANIC ACID + AMOXICILLIN SF SUSP 62MG + 
250MG 
95076998 CLAVULANIC ACID + AMOXICILLIN SUSP 62MG + 
125MG/5M 
96660998 CLAVULANIC ACID + AMOXICILLIN TABS 125MG + 
250MG 
97708997 CLAVULANIC ACID + AMOXICILLIN TABS 
125MG+500MG 
96635998 CLOMOCYCLINE CAPS 170MG 
96636998 CLOMOCYCLINE CAPS 170MG 
93225997 CO-AMOXICLAV TAB 250MG+125MG 
99927997 CO-AMOXICLAV TAB 250MG+125MG 
86055998 CO-AMOXICLAV ORAL SUSP 125MG + 31MG/5ML 
95315990 CO-AMOXICLAV ORAL SUSP 125MG + 31MG/5ML 
86056998 CO-AMOXICLAV ORAL SUSP 250MG + 62MG/5ML 
95314990 CO-AMOXICLAV ORAL SUSP 250MG + 62MG/5ML 
92340996 CO-AMOXICLAV SF SUSP 125MG + 31MG/5ML 
92396990 CO-AMOXICLAV SF SUSP 125MG + 31MG/5ML 




94026990 CO-AMOXICLAV SF SUSP 125MG + 31MG/5ML 
95040990 CO-AMOXICLAV SF SUSP 125MG + 31MG/5ML 
96539988 CO-AMOXICLAV SF SUSP 125MG + 31MG/5ML 
96731989 CO-AMOXICLAV SF SUSP 125MG + 31MG/5ML 
96975988 CO-AMOXICLAV SF SUSP 125MG + 31MG/5ML 
97010988 CO-AMOXICLAV SF SUSP 125MG + 31MG/5ML 
98363998 CO-AMOXICLAV SF SUSP 125MG + 31MG/5ML 
92339998 CO-AMOXICLAV SF SUSP 250MG + 62MG/5ML 
92395990 CO-AMOXICLAV SF SUSP 250MG + 62MG/5ML 
93224998 CO-AMOXICLAV SF SUSP 250MG + 62MG/5ML 
94025990 CO-AMOXICLAV SF SUSP 250MG + 62MG/5ML 
95039990 CO-AMOXICLAV SF SUSP 250MG + 62MG/5ML 
95586990 CO-AMOXICLAV SF SUSP 250MG + 62MG/5ML 
96538990 CO-AMOXICLAV SF SUSP 250MG + 62MG/5ML 
96731988 CO-AMOXICLAV SF SUSP 250MG + 62MG/5ML 
96974990 CO-AMOXICLAV SF SUSP 250MG + 62MG/5ML 
97009990 CO-AMOXICLAV SF SUSP 250MG + 62MG/5ML 
98364998 CO-AMOXICLAV SF SUSP 250MG + 62MG/5ML 
91014998 CO-AMOXICLAV SF SUSP 400MG + 57MG/5ML 
92125990 CO-AMOXICLAV SF SUSP 400MG + 57MG/5ML 
93224996 CO-AMOXICLAV SF SUSP 400MG + 57MG/5ML 
88536998 CO-AMOXICLAV TABS 250MG+125MG 
92340998 CO-AMOXICLAV TABS 250MG+125MG 
93225998 CO-AMOXICLAV TABS 250MG+125MG 
94027990 CO-AMOXICLAV TABS 250MG+125MG 
95872990 CO-AMOXICLAV TABS 250MG+125MG 
96137990 CO-AMOXICLAV TABS 250MG+125MG 
96189990 CO-AMOXICLAV TABS 250MG+125MG 
96343990 CO-AMOXICLAV TABS 250MG+125MG 
96539990 CO-AMOXICLAV TABS 250MG+125MG 
96637990 CO-AMOXICLAV TABS 250MG+125MG 




96975990 CO-AMOXICLAV TABS 250MG+125MG 
97010990 CO-AMOXICLAV TABS 250MG+125MG 
99927998 CO-AMOXICLAV TABS 250MG+125MG 
92340997 CO-AMOXICLAV TABS 500MG+125MG 
93224997 CO-AMOXICLAV TABS 500MG+125MG 
95070990 CO-AMOXICLAV TABS 500MG+125MG 
95585990 CO-AMOXICLAV TABS 500MG+125MG 
95618990 CO-AMOXICLAV TABS 500MG+125MG 
96391990 CO-AMOXICLAV TABS 500MG+125MG 
96539989 CO-AMOXICLAV TABS 500MG+125MG 
96637989 CO-AMOXICLAV TABS 500MG+125MG 
96975989 CO-AMOXICLAV TABS 500MG+125MG 
97010989 CO-AMOXICLAV TABS 500MG+125MG 
99110998 CO-AMOXICLAV TABS 500MG+125MG 
93484992 CYCLODOX CAP 100 MG 
96447998 DEMECLOCYCLINE + CHLORTETRACYCLINE & 
TETRACYCLINE 
97246992 DEMIX 100 MG CAP 
88431998 DOXYCYCLINE (AS HYCLATE) CAPS 100MG 
92362998 DOXYCYCLINE (AS HYCLATE) CAPS 100MG 
92775990 DOXYCYCLINE (AS HYCLATE) CAPS 100MG 
92856998 DOXYCYCLINE (AS HYCLATE) CAPS 100MG 
93923998 DOXYCYCLINE (AS HYCLATE) CAPS 100MG 
96089990 DOXYCYCLINE (AS HYCLATE) CAPS 100MG 
96305997 DOXYCYCLINE (AS HYCLATE) CAPS 100MG 
96354990 DOXYCYCLINE (AS HYCLATE) CAPS 100MG 
97051990 DOXYCYCLINE (AS HYCLATE) CAPS 100MG 
97121990 DOXYCYCLINE (AS HYCLATE) CAPS 100MG 
97209989 DOXYCYCLINE (AS HYCLATE) CAPS 100MG 
97711998 DOXYCYCLINE (AS HYCLATE) CAPS 100MG 
97761989 DOXYCYCLINE (AS HYCLATE) CAPS 100MG 




98352990 DOXYCYCLINE (AS HYCLATE) CAPS 100MG 
98601989 DOXYCYCLINE (AS HYCLATE) CAPS 100MG 
98969998 DOXYCYCLINE (AS HYCLATE) CAPS 100MG 
99101998 DOXYCYCLINE (AS HYCLATE) CAPS 100MG 
99613990 DOXYCYCLINE (AS HYCLATE) CAPS 100MG 
92556998 DOXYCYCLINE (AS HYCLATE) CAPS 20MG 
96304997 DOXYCYCLINE (AS HYCLATE) CAPS 20MG 
92613998 DOXYCYCLINE (AS HYCLATE) CAPS 50MG 
92774990 DOXYCYCLINE (AS HYCLATE) CAPS 50MG 
92856997 DOXYCYCLINE (AS HYCLATE) CAPS 50MG 
96202990 DOXYCYCLINE (AS HYCLATE) CAPS 50MG 
97121989 DOXYCYCLINE (AS HYCLATE) CAPS 50MG 
97209990 DOXYCYCLINE (AS HYCLATE) CAPS 50MG 
97247990 DOXYCYCLINE (AS HYCLATE) CAPS 50MG 
97753998 DOXYCYCLINE (AS HYCLATE) CAPS 50MG 
97761990 DOXYCYCLINE (AS HYCLATE) CAPS 50MG 
98352989 DOXYCYCLINE (AS HYCLATE) CAPS 50MG 
98601990 DOXYCYCLINE (AS HYCLATE) CAPS 50MG 
99101997 DOXYCYCLINE (AS HYCLATE) CAPS 50MG 
99613989 DOXYCYCLINE (AS HYCLATE) CAPS 50MG 
96305998 DOXYCYCLINE (AS HYCLATE) TAB 100MG 
84948998 DOXYCYCLINE (AS HYCLATE) ORAL LIQUID 
96304998 DOXYCYCLINE (AS HYCLATE) SYRUP 50MG/5ML 
98969996 DOXYCYCLINE (AS HYCLATE) SYRUP 50MG/5ML 
96282990 DOXYCYCLINE (AS HYCLATE) TABS 100MG 
96305996 DOXYCYCLINE (AS HYCLATE) TABS 100MG 
97913998 DOXYCYCLINE (AS HYCLATE) TABS 100MG 
89467998 DOXYCYCLINE (AS HYCLATE) TABS 20MG 
90801998 DOXYCYCLINE (AS HYCLATE) TABS 20MG 
91630998 DOXYCYCLINE MONOHYDRATE TAB 100MG 
98231998 DOXYCYCLINE MONOHYDRATE TAB 100MG 




82730998 DOXYCYCLINE MONOHYDRATE CAP 40MG 
82732998 DOXYCYCLINE MONOHYDRATE CAP 40MG 
94457992 ERYCEN 125 MG SUS 
94153992 ERYCEN 250 MG SUS 
94977992 ERYMAX 500 MG CAP 
93003992 ERYMIN 250 MG/5ML SUS 
96230992 ERYTHROCIN 100 MG SYR 
97379992 ERYTHROCIN 125 MG SYR 
97380992 ERYTHROCIN 250 250 MG TAB 
97378992 ERYTHROCIN A 1 GM TAB 
97381992 ERYTHROCIN B-PACK 10 FILMTABS 500 MG TAB 
96229992 ERYTHROMYCIN 100 MG SYR 
96648992 ERYTHROMYCIN 12 MG SYR 
97375992 ERYTHROMYCIN 250 MG MIX 
94980992 ERYTHROMYCIN 500 MG CAP 
87506998 ERYTHROMYCIN CAPS 250MG 
90844998 ERYTHROMYCIN CAPS 250MG 
92104998 ERYTHROMYCIN CAPS 250MG 
95920990 ERYTHROMYCIN CAPS 250MG 
95965990 ERYTHROMYCIN CAPS 250MG 
97118996 ERYTHROMYCIN CAPS 250MG 
97932998 ERYTHROMYCIN CAPS 250MG 
93914990 ERYTHROMYCIN TAB 250MG 
94358990 ERYTHROMYCIN TAB 250MG 
94426990 ERYTHROMYCIN TAB 250MG 
95305990 ERYTHROMYCIN TAB 250MG 
96352990 ERYTHROMYCIN TAB 250MG 
96373990 ERYTHROMYCIN TAB 250MG 
96786998 ERYTHROMYCIN TAB 250MG 
97096998 ERYTHROMYCIN TAB 250MG 
97118998 ERYTHROMYCIN TAB 250MG 




98166988 ERYTHROMYCIN TAB 250MG 
98353988 ERYTHROMYCIN TAB 250MG 
98559988 ERYTHROMYCIN TAB 250MG 
99103997 ERYTHROMYCIN TAB 250MG 
99435990 ERYTHROMYCIN TAB 250MG 
99540998 ERYTHROMYCIN TAB 250MG 
99604988 ERYTHROMYCIN TAB 250MG 
99605988 ERYTHROMYCIN TAB 250MG 
99607988 ERYTHROMYCIN TAB 250MG 
99681998 ERYTHROMYCIN TAB 250MG 
99683998 ERYTHROMYCIN TAB 250MG 
96786997 ERYTHROMYCIN TAB 500MG 
97118997 ERYTHROMYCIN TAB 500MG 
98166989 ERYTHROMYCIN TAB 500MG 
98345990 ERYTHROMYCIN TAB 500MG 
98558990 ERYTHROMYCIN TAB 500MG 
98752998 ERYTHROMYCIN TAB 500MG 
99103996 ERYTHROMYCIN TAB 500MG 
99210990 ERYTHROMYCIN TAB 500MG 
99433990 ERYTHROMYCIN TAB 500MG 
99434990 ERYTHROMYCIN TAB 500MG 
99435989 ERYTHROMYCIN TAB 500MG 
99542997 ERYTHROMYCIN TAB 500MG 
99683997 ERYTHROMYCIN TAB 500MG 
96785998 ERYTHROMYCIN ESTOLATE CAPS 250MG 
97757990 ERYTHROMYCIN ESTOLATE CAPS 250MG 
99542998 ERYTHROMYCIN ESTOLATE CAPS 250MG 
96785996 ERYTHROMYCIN ESTOLATE SUSP 125MG/5ML 
99542996 ERYTHROMYCIN ESTOLATE SUSP 125MG/5ML 
98846998 ERYTHROMYCIN ESTOLATE SUSP 250MG/5ML 
99541998 ERYTHROMYCIN ESTOLATE SUSP 250MG/5ML 




89421998 ERYTHROMYCIN ETHYLSUCCINATE (COATED) SF 
ORAL SUSP 
89423998 ERYTHROMYCIN ETHYLSUCCINATE (COATED) SF 
ORAL SUSP 
93147998 ERYTHROMYCIN ETHYLSUCCINATE  125MG 
99679997 ERYTHROMYCIN ETHYLSUCCINATE 125MG 
94819998 ERYTHROMYCIN ETHYLSUCCINATE  
94820998 ERYTHROMYCIN ETHYLSUCCINATE 
93147997 ERYTHROMYCIN ETHYLSUCCINATE 250MG 
99680997 ERYTHROMYCIN ETHYLSUCCINATE 250MG 
94820996 ERYTHROMYCIN ETHYLSUCCINATE 500MG 
98751997 ERYTHROMYCIN ETHYLSUCCINATE 500MG 
93316992 ERYTHROMYCIN ETHYLSUCCINATE SF 125 MG/5ML 
SUS 
96783998 ERYTHROMYCIN ETHYLSUCCINATE SF GRANS 250MG 
97519998 ERYTHROMYCIN ETHYLSUCCINATE SF GRANS 250MG 
83061998 ERYTHROMYCIN ETHYLSUCCINATE SF SUSP 
125MG/5ML 
90499998 ERYTHROMYCIN ETHYLSUCCINATE SF SUSP 
125MG/5ML 
92765990 ERYTHROMYCIN ETHYLSUCCINATE SF SUSP 
125MG/5ML 
94217990 ERYTHROMYCIN ETHYLSUCCINATE SF SUSP 
125MG/5ML 
94694990 ERYTHROMYCIN ETHYLSUCCINATE SF SUSP 
125MG/5ML 
96352989 ERYTHROMYCIN ETHYLSUCCINATE SF SUSP 
125MG/5ML 
96721988 ERYTHROMYCIN ETHYLSUCCINATE SF SUSP 
125MG/5ML 





97947989 ERYTHROMYCIN ETHYLSUCCINATE SF SUSP 
125MG/5ML 
98353989 ERYTHROMYCIN ETHYLSUCCINATE SF SUSP 
125MG/5ML 
99103998 ERYTHROMYCIN ETHYLSUCCINATE SF SUSP 
125MG/5ML 
99679996 ERYTHROMYCIN ETHYLSUCCINATE SF SUSP 
125MG/5ML 
83063998 ERYTHROMYCIN ETHYLSUCCINATE SF SUSP 
250MG/5ML 
90499997 ERYTHROMYCIN ETHYLSUCCINATE SF SUSP 
250MG/5ML 
92764990 ERYTHROMYCIN ETHYLSUCCINATE SF SUSP 
250MG/5ML 
94216990 ERYTHROMYCIN ETHYLSUCCINATE SF SUSP 
250MG/5ML 
94693990 ERYTHROMYCIN ETHYLSUCCINATE SF SUSP 
250MG/5ML 
96352988 ERYTHROMYCIN ETHYLSUCCINATE SF SUSP 
250MG/5ML 
96721990 ERYTHROMYCIN ETHYLSUCCINATE SF SUSP 
250MG/5ML 
96783996 ERYTHROMYCIN ETHYLSUCCINATE SF SUSP 
250MG/5ML 
97947988 ERYTHROMYCIN ETHYLSUCCINATE SF SUSP 
250MG/5ML 
98353990 ERYTHROMYCIN ETHYLSUCCINATE SF SUSP 
250MG/5ML 
99680996 ERYTHROMYCIN ETHYLSUCCINATE SF SUSP 
250MG/5ML 





90499996 ERYTHROMYCIN ETHYLSUCCINATE SF SUSP 
500MG/5ML 
90567998 ERYTHROMYCIN ETHYLSUCCINATE SF SUSP 
500MG/5ML 
92763990 ERYTHROMYCIN ETHYLSUCCINATE SF SUSP 
500MG/5ML 
94215990 ERYTHROMYCIN ETHYLSUCCINATE SF SUSP 
500MG/5ML 
96250990 ERYTHROMYCIN ETHYLSUCCINATE SF SUSP 
500MG/5ML 
96721989 ERYTHROMYCIN ETHYLSUCCINATE SF SUSP 
500MG/5ML 
97898990 ERYTHROMYCIN ETHYLSUCCINATE SF SUSP 
500MG/5ML 
98166990 ERYTHROMYCIN ETHYLSUCCINATE SF SUSP 
500MG/5ML 
98345989 ERYTHROMYCIN ETHYLSUCCINATE SF SUSP 
500MG/5ML 
98751996 ERYTHROMYCIN ETHYLSUCCINATE SF SUSP 
500MG/5ML 
88231998 ERYTHROMYCIN ETHYLSUCCINATE SUSP 125MG/5ML 
89630998 ERYTHROMYCIN ETHYLSUCCINATE SUSP 125MG/5ML 
94220990 ERYTHROMYCIN ETHYLSUCCINATE SUSP 125MG/5ML 
96177990 ERYTHROMYCIN ETHYLSUCCINATE SUSP 125MG/5ML 
96374990 ERYTHROMYCIN ETHYLSUCCINATE SUSP 125MG/5ML 
96784998 ERYTHROMYCIN ETHYLSUCCINATE SUSP 125MG/5ML 
97095998 ERYTHROMYCIN ETHYLSUCCINATE SUSP 125MG/5ML 
97119990 ERYTHROMYCIN ETHYLSUCCINATE SUSP 125MG/5ML 
97759989 ERYTHROMYCIN ETHYLSUCCINATE SUSP 125MG/5ML 
98557989 ERYTHROMYCIN ETHYLSUCCINATE SUSP 125MG/5ML 
98559990 ERYTHROMYCIN ETHYLSUCCINATE SUSP 125MG/5ML 




99605990 ERYTHROMYCIN ETHYLSUCCINATE SUSP 125MG/5ML 
99606990 ERYTHROMYCIN ETHYLSUCCINATE SUSP 125MG/5ML 
99607990 ERYTHROMYCIN ETHYLSUCCINATE SUSP 125MG/5ML 
99679998 ERYTHROMYCIN ETHYLSUCCINATE SUSP 125MG/5ML 
88231997 ERYTHROMYCIN ETHYLSUCCINATE SUSP 250MG/5ML 
89630997 ERYTHROMYCIN ETHYLSUCCINATE SUSP 250MG/5ML 
94219990 ERYTHROMYCIN ETHYLSUCCINATE SUSP 250MG/5ML 
96176990 ERYTHROMYCIN ETHYLSUCCINATE SUSP 250MG/5ML 
96374989 ERYTHROMYCIN ETHYLSUCCINATE SUSP 250MG/5ML 
96784997 ERYTHROMYCIN ETHYLSUCCINATE SUSP 250MG/5ML 
97095997 ERYTHROMYCIN ETHYLSUCCINATE SUSP 250MG/5ML 
97119989 ERYTHROMYCIN ETHYLSUCCINATE SUSP 250MG/5ML 
97360998 ERYTHROMYCIN ETHYLSUCCINATE SUSP 250MG/5ML 
97759988 ERYTHROMYCIN ETHYLSUCCINATE SUSP 250MG/5ML 
98557990 ERYTHROMYCIN ETHYLSUCCINATE SUSP 250MG/5ML 
98559989 ERYTHROMYCIN ETHYLSUCCINATE SUSP 250MG/5ML 
99604989 ERYTHROMYCIN ETHYLSUCCINATE SUSP 250MG/5ML 
99605989 ERYTHROMYCIN ETHYLSUCCINATE SUSP 250MG/5ML 
99606989 ERYTHROMYCIN ETHYLSUCCINATE SUSP 250MG/5ML 
99607989 ERYTHROMYCIN ETHYLSUCCINATE SUSP 250MG/5ML 
99680998 ERYTHROMYCIN ETHYLSUCCINATE SUSP 250MG/5ML 
89630996 ERYTHROMYCIN ETHYLSUCCINATE SUSP 500MG/5ML 
94218990 ERYTHROMYCIN ETHYLSUCCINATE SUSP 500MG/5ML 
96175990 ERYTHROMYCIN ETHYLSUCCINATE SUSP 500MG/5ML 
96374988 ERYTHROMYCIN ETHYLSUCCINATE SUSP 500MG/5ML 
96784996 ERYTHROMYCIN ETHYLSUCCINATE SUSP 500MG/5ML 
97095996 ERYTHROMYCIN ETHYLSUCCINATE SUSP 500MG/5ML 
97119988 ERYTHROMYCIN ETHYLSUCCINATE SUSP 500MG/5ML 
97757989 ERYTHROMYCIN ETHYLSUCCINATE SUSP 500MG/5ML 
97947990 ERYTHROMYCIN ETHYLSUCCINATE SUSP 500MG/5ML 
98557988 ERYTHROMYCIN ETHYLSUCCINATE SUSP 500MG/5ML 




99210989 ERYTHROMYCIN ETHYLSUCCINATE SUSP 500MG/5ML 
99212990 ERYTHROMYCIN ETHYLSUCCINATE SUSP 500MG/5ML 
99606988 ERYTHROMYCIN ETHYLSUCCINATE SUSP 500MG/5ML 
83064998 ERYTHROMYCIN ETHYLSUCCINATE TABS 500MG 
94819997 ERYTHROMYCIN ETHYLSUCCINATE TABS 500MG 
94820997 ERYTHROMYCIN ETHYLSUCCINATE TABS 500MG 
93317992 ERYTHROMYCIN SF 250 MG 
94495998 ERYTHROMYCIN SPRINKLE CAPS 125MG 
94496998 ERYTHROMYCIN SPRINKLE CAPS 125MG 
83066998 ERYTHROMYCIN STEARATE TABS 250MG 
96781998 ERYTHROMYCIN STEARATE TABS 250MG 
97361998 ERYTHROMYCIN STEARATE TABS 250MG 
99682998 ERYTHROMYCIN STEARATE TABS 250MG 
83065998 ERYTHROMYCIN STEARATE TABS 500MG 
96781997 ERYTHROMYCIN STEARATE TABS 500MG 
97361997 ERYTHROMYCIN STEARATE TABS 500MG 
98754998 ERYTHROMYCIN STEARATE TABS 500MG 
97117998 ERYTHROMYCIN SUSP 125MG/5ML 
97117997 ERYTHROMYCIN SUSP 250MG/5ML 
97117996 ERYTHROMYCIN SUSP 500MG/5ML 
94984992 ERYTHROPED 250 MG TAB 
94208992 KEFLEX-C 125 MG TAB 
94484992 KEFLEX-C 250 MG TAB 
88261998 LEVOFLOXACIN FC TAB 250MG 
88267998 LEVOFLOXACIN FC TAB 250MG 
88261997 LEVOFLOXACIN FC TAB 500MG 
88267997 LEVOFLOXACIN FC TAB 500MG 
89356998 MOXIFLOXACIN TABS 400MG 
89361998 MOXIFLOXACIN TABS 400MG 
96367992 NOVOBIOCIN/TETRACYCLINE 125 MG CAP 
97815992 NOVOBIOCIN/TETRACYCLINE 62.5 MG MIX 




95680996 NYSTATIN + TETRACYCLINE HCL SYRUP 
95680997 NYSTATIN + TETRACYCLINE HCL TABS 
91262998 OXYTETRACYCLINE + BROMHEXINE HCL CAPS 
250MG + 8MG 
99884998 OXYTETRACYCLINE + BROMHEXINE HCL CAPS 
250MG + 8MG 
97843992 OXYTETRACYCLINE 100 MG TAB 
97842992 OXYTETRACYCLINE 250 MG SYR 
95369992 OXYTETRACYCLINE 500 MG TAB 
95644998 OXYTETRACYCLINE CAPS 250MG 
97143998 OXYTETRACYCLINE CAPS 250MG 
99060997 OXYTETRACYCLINE CAPS 250MG 
83942998 OXYTETRACYCLINE ORAL LIQUID 
95640998 OXYTETRACYCLINE SYRUP 125MG/5ML 
95644997 OXYTETRACYCLINE SYRUP 125MG/5ML 
93938998 OXYTETRACYCLINE TABS 250MG 
94398990 OXYTETRACYCLINE TABS 250MG 
94446990 OXYTETRACYCLINE TABS 250MG 
94750990 OXYTETRACYCLINE TABS 250MG 
97144998 OXYTETRACYCLINE TABS 250MG 
97145998 OXYTETRACYCLINE TABS 250MG 
97146998 OXYTETRACYCLINE TABS 250MG 
97154998 OXYTETRACYCLINE TABS 250MG 
97732990 OXYTETRACYCLINE TABS 250MG 
98456998 OXYTETRACYCLINE TABS 250MG 
98462990 OXYTETRACYCLINE TABS 250MG 
98463990 OXYTETRACYCLINE TABS 250MG 
98464990 OXYTETRACYCLINE TABS 250MG 
99060998 OXYTETRACYCLINE TABS 250MG 
99478990 OXYTETRACYCLINE TABS 250MG 
99479990 OXYTETRACYCLINE TABS 250MG 




99895998 OXYTETRACYCLINE TABS 250MG 
96779992 TERRAMYCIN SYR 
96826992 TETRACHEL 200 MG TAB 
95190998 TETRACYCLINE + AMPHOTERACIN SYRUP 
98795998 TETRACYCLINE + AMPHOTERACIN SYRUP 
92481998 TETRACYCLINE + CHLORTETRACYCLINE & 
DEMECLOCYCLINE 
95192998 TETRACYCLINE + CHLORTETRACYCLINE & 
DEMECLOCYCLINE 
99767998 TETRACYCLINE + CHLORTETRACYCLINE & 
DEMECLOCYCLINE 
95191997 TETRACYCLINE + NYSTATIN CAPS 
99382998 TETRACYCLINE + NYSTATIN CAPS 
96781992 TETRACYCLINE 500 MG CAP 
96485992 TETRACYCLINE 500 MG TAB 
93837998 TETRACYCLINE CAPS 250MG 
95193998 TETRACYCLINE CAPS 250MG 
95196997 TETRACYCLINE CAPS 250MG 
97142998 TETRACYCLINE CAPS 250MG 
98323998 TETRACYCLINE CAPS 250MG 
98341997 TETRACYCLINE CAPS 250MG 
98612990 TETRACYCLINE CAPS 250MG 
99053998 TETRACYCLINE CAPS 250MG 
99055997 TETRACYCLINE CAPS 250MG 
99056998 TETRACYCLINE CAPS 250MG 
95194998 TETRACYCLINE CAP 250MG 
97892998 TETRACYCLINE CAP 250MG 
95196996 TETRACYCLINE 
98341996 TETRACYCLINE  
93837997 TETRACYCLINE SYRUP 125MG/5ML 
95196998 TETRACYCLINE SYRUP 125MG/5ML 




98323997 TETRACYCLINE SYRUP 125MG/5ML 
96989990 TETRACYCLINE TABS 250MG 
97142997 TETRACYCLINE TABS 250MG 
97153998 TETRACYCLINE TABS 250MG 
98341998 TETRACYCLINE TABS 250MG 
98405990 TETRACYCLINE TABS 250MG 
99043990 TETRACYCLINE TABS 250MG 
99055998 TETRACYCLINE TABS 250MG 
99354990 TETRACYCLINE TABS 250MG 
99355990 TETRACYCLINE TABS 250MG 
99356990 TETRACYCLINE TABS 250MG 
Oral Corticosteroids (OCS) 
95492992 PREDNISOLONE 10 MG TAB 
88912979 PREDNISOLONE 10MG/5ML ORAL SOLUTION 
96411992 PREDNISOLONE 15 MG TAB 
88905979 PREDNISOLONE 15MG/5ML ORAL SUSPENSION 
97155998 PREDNISOLONE 1MG TABLETS 
98456988 PREDNISOLONE 1MG TABLETS 
99425990 PREDNISOLONE 1MG TABLETS 
99228998 PREDNISOLONE 1MG TABLETS 
99423990 PREDNISOLONE 1MG TABLETS 
98514998 PREDNISOLONE 1MG TABLETS 
99100990 PREDNISOLONE 1MG TABLETS 
96361990 PREDNISOLONE 1MG TABLETS 
95594990 PREDNISOLONE 1MG TABLETS 
95493992 PREDNISOLONE 2 MG TAB 
98562998 PREDNISOLONE 2.5MG E/C TABLETS 
93912998 PREDNISOLONE 2.5MG GASTRO-RESISTANT TABLETS 
99423988 PREDNISOLONE 2.5MG GASTRO-RESISTANT TABLETS 
97726990 PREDNISOLONE 2.5MG GASTRO-RESISTANT TABLETS 
99099990 PREDNISOLONE 2.5MG GASTRO-RESISTANT TABLETS 




91648990 PREDNISOLONE 2.5MG GASTRO-RESISTANT TABLETS 
95417998 PREDNISOLONE 2.5MG TABLET 
66092979 PREDNISOLONE 2.5MG/5ML ORAL SUSPENSION 
66090979 PREDNISOLONE 20MG/5ML ORAL SOLUTION 
66088979 PREDNISOLONE 20MG/5ML ORAL SUSPENSION 
95417997 PREDNISOLONE 25MG TABLETS 
97436998 PREDNISOLONE 25MG TABLETS 
95912990 PREDNISOLONE 25MG TABLETS 
66084979 PREDNISOLONE 25MG/5ML ORAL SUSPENSION 
96744992 PREDNISOLONE 4 MG TAB 
93912997 PREDNISOLONE 5 MG GASTRO-RESISTANT TABLET 
96409992 PREDNISOLONE 50 MG TAB 
93912996 PREDNISOLONE 50MG TABLETS 
98562997 PREDNISOLONE 5MG E/C TABLETS 
83565978 PREDNISOLONE 5MG E/C TABLETS 
95417996 PREDNISOLONE 5MG GASTRO-RESISTANT TABLETS 
98455990 PREDNISOLONE 5MG GASTRO-RESISTANT TABLETS 
99425988 PREDNISOLONE 5MG GASTRO-RESISTANT TABLETS 
99099989 PREDNISOLONE 5MG GASTRO-RESISTANT TABLETS 
97101989 PREDNISOLONE 5MG GASTRO-RESISTANT TABLETS 
98456989 PREDNISOLONE 5MG GASTRO-RESISTANT TABLETS 
99226998 PREDNISOLONE 5MG SOL TABLETS 
95487992 PREDNISOLONE 5MG SOL TABLETS 
93075998 PREDNISOLONE 5MG SOLUBLE TABLETS 
96577990 PREDNISOLONE 5MG SOLUBLE TABLETS 
91788990 PREDNISOLONE 5MG SOLUBLE TABLETS 
97155997 PREDNISOLONE 5MG TABLETS 
99228997 PREDNISOLONE 5MG TABLETS 
98107990 PREDNISOLONE 5MG TABLETS 
99425989 PREDNISOLONE 5MG TABLETS 
99423989 PREDNISOLONE 5MG TABLETS 




99100989 PREDNISOLONE 5MG TABLETS 
95593990 PREDNISOLONE 5MG TABLETS 
99424989 PREDNISOLONE 5MG TABLETS 
97929990 PREDNISOLONE 5MG TABLETS 
96361989 PREDNISOLONE 5MG TABLETS 
98514997 PREDNISOLONE 5MG TABLETS 
99099988 PREDNISOLONE 5MG TABLETS 
65924979 PREDNISOLONE 5MG/5ML ORAL SOLUTION 
95484992 PREDNISOLONE E/C 1 MG TAB 
Cough and Sputum 
171..00 COUGH 
1719.00 CHESTY COUGH 
1719.11 BRONCHIAL COUGH 
R062.00 [D]COUGH 
1716.00 PRODUCTIVE COUGH NOS 
171..11 C/O - COUGH 
1717.00 NIGHT COUGH PRESENT 
1716.11 COUGHING UP PHLEGM 
171C.00 MORNING COUGH 
173B.00 NOCTURNAL COUGH / WHEEZE 
1712.00 DRY COUGH 
1713.00 PRODUCTIVE COUGH -CLEAR SPUTUM 
171Z.00 COUGH SYMPTOM NOS 
1715.00 PRODUCTIVE COUGH-YELLOW SPUTUM 
1714.00 PRODUCTIVE COUGH -GREEN SPUTUM 
R063000 [D]COUGH WITH HAEMORRHAGE 
171F.00 COUGH WITH FEVER 
171H.00 DIFFICULTY IN COUGHING UP SPUTUM 
171D.00 EVENING COUGH 
1D87.00 COUGH AGGRAVATES SYMPTOM 
4I2G.00 COUGH SWAB 




4JF5.00 SPUTUM SENT FOR C/S 
41D4.00 SPUTUM SAMPLE OBTAINED 
R153100 [D]POSITIVE CULTURE FINDINGS IN SPUTUM 
171..12 SPUTUM - SYMPTOM 
H060300 ACUTE PURULENT BRONCHITIS 
4E4..00 SPUTUM CULTURE 
4E3..00 SPUTUM MICROSCOPY 
4E2A.00 SPUTUM APPEARANCE 
4E3Z.12 SPUTUM APPEARS INFECTED 
R064100 [D]SPUTUM ABNORMAL - COLOUR 
4E13.00 SPUTUM EXAMINATION: ABNORMAL 
Z691.11 SPUTUM CLEARANCE 
R064000 [D]SPUTUM ABNORMAL - AMOUNT 
4E3Z.00 SPUTUM MICROSCOPY NOS 
R064z00 [D]ABNORMAL SPUTUM NOS 
4E23.00 SPUTUM: MUCOPURULENT 
4E28.00 YELLOW SPUTUM 
4E11.00 SPUTUM SENT FOR EXAMINATION 
R064300 [D]ABNORMAL SPUTUM - TENACIOUS 
4E29.00 GREEN SPUTUM 
4E3Z.11 SPUTUM EVIDENCE OF INFECTION 
Breathlessness  
R060D00 [D]BREATHLESSNESS 
R060800 [D]SHORTNESS OF BREATH 
173..00 BREATHLESSNESS 
R060600 [D]RESPIRATORY DISTRESS 
173C.00 SHORT OF BREATH ON EXERTION 
Q30..00 RESPIRATORY DISTRESS SYNDROME 
1738.00 DIFFICULTY BREATHING 
R060A00 [D]DYSPNOEA 
1739.00 SHORTNESS OF BREATH 




173..13 SHORTNESS OF BREATH SYMPTOM 
173..12 DYSPNOEA - SYMPTOM 
1732.00 BREATHLESS - MODERATE EXERTION 
1736.00 PAROXYSMAL NOCTURNAL DYSPNOEA 
2322.00 O/E - DYSPNOEA 
2324.00 O/E - RESPIRATORY DISTRESS 
1735.00 BREATHLESS - LYING FLAT 
1733.00 BREATHLESS - MILD EXERTION 
R060700 [D]RESPIRATORY INSUFFICIENCY 
173D.00 NOCTURNAL DYSPNOEA 
173Z.00 BREATHLESSNESS NOS 
173F.00 SHORT OF BREATH DRESSING/UNDRESSING 
173G.00 BREATHLESS - STRENUOUS EXERTION 
1734.00 BREATHLESS - AT REST 
 
